


THE UNIVERSITY OF CHICAGO PRESS

(10) International Publication Number
WO 02/081646 A2

[Continued on next page]

[illegible]

Pool sequencing of PSMA 281-310 digested for 60 min by Proteasome

WO 02/081646 A2

(57) Abstract: Disclosed herein are polypeptides, including epitopes, clusters, and antigens. Also disclosed are compositions that include said polypeptides and methods for their use.

BEST AVAILABLE COPY

WO 02/081646 A2



(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

EPITOPE SEQUENCESBackground of the InventionField of the Invention

5 The present invention generally relates to peptides, and nucleic acids encoding peptides, that are useful epitopes of target-associated antigens. More specifically, the invention relates to epitopes that have a high affinity for MHC class I and that are produced by target-specific proteasomes.

Description of the Related ArtNeoplasia and the Immune System

10 The neoplastic disease state commonly known as cancer is thought to result generally from a single cell growing out of control. The uncontrolled growth state typically results from a multi-step process in which a series of cellular systems fail, resulting in the genesis of a neoplastic cell. The resulting neoplastic cell rapidly reproduces itself, forms one or more tumors, and eventually may cause the death of the host.

15 Because the progenitor of the neoplastic cell shares the host's genetic material, neoplastic cells are largely unassailed by the host's immune system. During immune surveillance, the process in which the host's immune system surveys and localizes foreign materials, a neoplastic cell will appear to the host's immune surveillance machinery as a "self" cell.

Viruses and the Immune System

20 In contrast to cancer cells, virus infection involves the expression of clearly non-self antigens. As a result, many virus infections are successfully dealt with by the immune system with minimal clinical sequela. Moreover, it has been possible to develop effective vaccines for many of those infections that do cause serious disease. A variety of vaccine approaches have been used successfully to combat various diseases. These approaches include subunit vaccines consisting of
25 individual proteins produced through recombinant DNA technology. Notwithstanding these advances, the selection and effective administration of minimal epitopes for use as viral vaccines has remained problematic.

In addition to the difficulties involved in epitope selection stands the problem of viruses that have evolved the capability of evading a host's immune system. Many viruses, especially
30 viruses that establish persistent infections, such as members of the herpes and pox virus families, produce immunomodulatory molecules that permit the virus to evade the host's immune system. The effects of these immunomodulatory molecules on antigen presentation may be overcome by the targeting of select epitopes for administration as immunogenic compositions. To better understand the interaction of neoplastic cells and virally infected cells with the host's immune
35 system, a discussion of the system's components follows below.

The immune system functions to discriminate molecules endogenous to an organism ("self" molecules) from material exogenous or foreign to the organism ("non-self" molecules). The immune system has two types of adaptive responses to foreign bodies based on the components that mediate the response: a humoral response and a cell-mediated response. The humoral response is mediated by antibodies, while the cell-mediated response involves cells classified as lymphocytes. Recent anticancer and antiviral strategies have focused on mobilizing the host immune system as a means of anticancer or antiviral treatment or therapy.

The immune system functions in three phases to protect the host from foreign bodies: the cognitive phase, the activation phase, and the effector phase. In the cognitive phase, the immune system recognizes and signals the presence of a foreign antigen or invader in the body. The foreign antigen can be, for example, a cell surface marker from a neoplastic cell or a viral protein. Once the system is aware of an invading body, antigen specific cells of the immune system proliferate and differentiate in response to the invader-triggered signals. The last stage is the effector stage in which the effector cells of the immune system respond to and neutralize the detected invader.

An array of effector cells implements an immune response to an invader. One type of effector cell, the B cell, generates antibodies targeted against foreign antigens encountered by the host. In combination with the complement system, antibodies direct the destruction of cells or organisms bearing the targeted antigen. Another type of effector cell is the natural killer cell (NK cell), a type of lymphocyte having the capacity to spontaneously recognize and destroy a variety of virus infected cells as well as malignant cell types. The method used by NK cells to recognize target cells is poorly understood.

Another type of effector cell, the T cell, has members classified into three subcategories, each playing a different role in the immune response. Helper T cells secrete cytokines which stimulate the proliferation of other cells necessary for mounting an effective immune response, while suppressor T cells down-regulate the immune response. A third category of T cell, the cytotoxic T cell (CTL), is capable of directly lysing a targeted cell presenting a foreign antigen on its surface.

The Major Histocompatibility Complex and T Cell Target Recognition

T cells are antigen-specific immune cells that function in response to specific antigen signals. B lymphocytes and the antibodies they produce are also antigen-specific entities. However, unlike B lymphocytes, T cells do not respond to antigens in a free or soluble form. For a T cell to respond to an antigen, it requires the antigen to be processed to peptides which are then bound to a presenting structure encoded in the major histocompatibility complex (MHC). This requirement is called "MHC restriction" and it is the mechanism by which T cells differentiate "self" from "non-self" cells. If an antigen is not displayed by a recognizable MHC molecule, the T cell will not recognize and act on the antigen signal. T cells specific for a peptide bound to a recognizable MHC

molecule bind to these MHC-peptide complexes and proceed to the next stages of the immune response.

5 There are two types of MHC, class I MHC and class II MHC. T Helper cells (CD4⁺) predominately interact with class II MHC proteins while cytolytic T cells (CD8⁺) predominately interact with class I MHC proteins. Both classes of MHC protein are transmembrane proteins with a majority of their structure on the external surface of the cell. Additionally, both classes of MHC proteins have a peptide binding cleft on their external portions. It is in this cleft that small fragments of proteins, endogenous or foreign, are bound and presented to the extracellular environment.

10 Cells called "professional antigen presenting cells" (pAPCs) display antigens to T cells using the MHC proteins but additionally express various co-stimulatory molecules depending on the particular state of differentiation/activation of the pAPC. When T cells, specific for the peptide bound to a recognizable MHC protein, bind to these MHC-peptide complexes on pAPCs, the specific co-stimulatory molecules that act upon the T cell direct the path of differentiation/activation taken by the T cell. That is, the co-stimulation molecules affect how the T cell will act on antigenic signals in
15 future encounters as it proceeds to the next stages of the immune response.

As discussed above, neoplastic cells are largely ignored by the immune system. A great deal of effort is now being expended in an attempt to harness a host's immune system to aid in combating the presence of neoplastic cells in a host. One such area of research involves the formulation of anticancer vaccines.

20 Anticancer Vaccines

Among the various weapons available to an oncologist in the battle against cancer is the immune system of the patient. Work has been done in various attempts to cause the immune system to combat cancer or neoplastic diseases. Unfortunately, the results to date have been largely disappointing. One area of particular interest involves the generation and use of anticancer
25 vaccines.

To generate a vaccine or other immunogenic composition, it is necessary to introduce to a subject an antigen or epitope against which an immune response may be mounted. Although neoplastic cells are derived from and therefore are substantially identical to normal cells on a genetic level, many neoplastic cells are known to present tumor-associated antigens (TuAAs). In
30 theory, these antigens could be used by a subject's immune system to recognize these antigens and attack the neoplastic cells. In reality, however, neoplastic cells generally appear to be ignored by the host's immune system.

A number of different strategies have been developed in an attempt to generate vaccines with activity against neoplastic cells. These strategies include the use of tumor-associated antigens
35 as immunogens. For example, U.S. Patent No. 5,993,828, describes a method for producing an

immune response against a particular subunit of the Urinary Tumor Associated Antigen by administering to a subject an effective dose of a composition comprising inactivated tumor cells having the Urinary Tumor Associated Antigen on the cell surface and at least one tumor associated antigen selected from the group consisting of GM-2, GD-2, Fetal Antigen and Melanoma Associated Antigen. Accordingly, this patent describes using whole, inactivated tumor cells as the immunogen in an anticancer vaccine.

Another strategy used with anticancer vaccines involves administering a composition containing isolated tumor antigens. In one approach, MAGE-A1 antigenic peptides were used as an immunogen. (See Chaux, P., *et al.*, "Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by *In Vitro* Stimulation with Dendritic Cells Transduced with MAGE-A1," J. Immunol., 163(5):2928-2936 (1999)). There have been several therapeutic trials using MAGE-A1 peptides for vaccination, although the effectiveness of the vaccination regimes was limited. The results of some of these trials are discussed in Vose, J.M., "Tumor Antigens Recognized by T Lymphocytes," 10th European Cancer Conference, Day 2, Sept. 14, 1999.

In another example of tumor associated antigens used as vaccines, Scheinberg, *et al.* treated 12 chronic myelogenous leukemia (CML) patients already receiving interferon (IFN) or hydroxyurea with 5 injections of class I-associated bcr-abl peptides with a helper peptide plus the adjuvant QS-21. Scheinberg, D.A., *et al.*, "BCR-ABL Breakpoint Derived Oncogene Fusion Peptide Vaccines Generate Specific Immune Responses in Patients with Chronic Myelogenous Leukemia (CML) [Abstract 1665], American Society of Clinical Oncology 35th Annual Meeting, Atlanta (1999). Proliferative and delayed type hypersensitivity (DTH) T cell responses indicative of T-helper activity were elicited, but no cytolytic killer T cell activity was observed within the fresh blood samples.

Additional examples of attempts to identify TuAAs for use as vaccines are seen in the recent work of Cebon, *et al.* and Scheibenbogen, *et al.* Cebon, *et al.* immunized patients with metastatic melanoma using intradermally administered MART-1₂₆₋₃₅ peptide with IL-12 in increasing doses given either subcutaneously or intravenously. Of the first 15 patients, 1 complete remission, 1 partial remission, and 1 mixed response were noted. Immune assays for T cell generation included DTH, which was seen in patients with or without IL-12. Positive CTL assays were seen in patients with evidence of clinical benefit, but not in patients without tumor regression. Cebon, *et al.*, "Phase I Studies of Immunization with Melan-A and IL-12 in HLA A2+ Positive Patients with Stage III and IV Malignant Melanoma," [Abstract 1671], American Society of Clinical Oncology 35th Annual Meeting, Atlanta (1999).

Scheibenbogen, *et al.* immunized 18 patients with 4 HLA class I restricted tyrosinase peptides, 16 with metastatic melanoma and 2 adjuvant patients. Scheibenbogen, *et al.*,

“Vaccination with Tyrosinase peptides and GM-CSF in Metastatic Melanoma: a Phase II Trial,” [Abstract 1680], American Society of Clinical Oncology 35th Annual Meeting, Atlanta (1999). Increased CTL activity was observed in 4/15 patients, 2 adjuvant patients, and 2 patients with evidence of tumor regression. As in the trial by Cebon, *et al.*, patients with progressive disease did not show boosted immunity. In spite of the various efforts expended to date to generate efficacious anticancer vaccines, no such composition has yet been developed.

Antiviral Vaccines

Vaccine strategies to protect against viral diseases have had many successes. Perhaps the most notable of these is the progress that has been made against the disease small pox, which has been driven to extinction. The success of the polio vaccine is of a similar magnitude.

Viral vaccines can be grouped into three classifications: live attenuated virus vaccines, such as vaccinia for small pox, the Sabin poliovirus vaccine, and measles mumps and rubella; whole killed or inactivated virus vaccines, such as the Salk poliovirus vaccine, hepatitis A virus vaccine and the typical influenza virus vaccines; and subunit vaccines, such as hepatitis B. Due to their lack of a complete viral genome, subunit vaccines offer a greater degree of safety than those based on whole viruses.

The paradigm of a successful subunit vaccine is the recombinant hepatitis B vaccine based on the viruses envelope protein. Despite much academic interest in pushing the reductionist subunit concept beyond single proteins to individual epitopes, the efforts have yet to bear much fruit. Viral vaccine research has also concentrated on the induction of an antibody response although cellular responses also occur. However, many of the subunit formulations are particularly poor at generating a CTL response.

Summary of the Invention

Previous methods of priming professional antigen presenting cells (pAPCs) to display target cell epitopes have relied simply on causing the pAPCs to express target-associated antigens (TAAs), or epitopes of those antigens which are thought to have a high affinity for MHC I molecules. However, the proteasomal processing of such antigens results in presentation of epitopes on the pAPC that do not correspond to the epitopes present on the target cells.

Using the knowledge that an effective cellular immune response requires that pAPCs present the same epitope that is presented by the target cells, the present invention provides epitopes that have a high affinity for MHC I, and that correspond to the processing specificity of the housekeeping proteasome, which is active in peripheral cells. These epitopes thus correspond to those presented on target cells. The use of such epitopes in vaccines can activate the cellular immune response to recognize the correctly processed TAA and can result in removal of target cells that present such epitopes. In some embodiments, the housekeeping epitopes provided herein

can be used in combination with immune epitopes, generating a cellular immune response that is competent to attack target cells both before and after interferon induction. In other embodiments the epitopes are useful in the diagnosis and monitoring of the target-associated disease and in the generation of immunological reagents for such purposes.

5 Embodiments of the invention relate to isolated epitopes, and antigens or polypeptides that comprise the epitopes. Preferred embodiments include an epitope or antigen having the sequence as disclosed in Table 1. Other embodiments can include an epitope cluster comprising a polypeptide from Table 1. Further, embodiments include a polypeptide having substantial similarity to the already mentioned epitopes, polypeptides, antigens, or clusters. Other preferred
10 embodiments include a polypeptide having functional similarity to any of the above. Still further embodiments relate to a nucleic acid encoding the polypeptide of any of the epitopes, clusters, antigens, and polypeptides from Table 1 and mentioned herein. For purposes of the following summary, discussions of other embodiments of the invention, when making reference to "the epitope," or "the epitopes" may refer without limitation to all of the foregoing forms of the epitope.

15 The epitope can be immunologically active. The polypeptide comprising the epitope can be less than about 30 amino acids in length, more preferably, the polypeptide is 8 to 10 amino acids in length, for example. Substantial or functional similarity can include addition of at least one amino acid, for example, and the at least one additional amino acid can be at an N-terminus of the polypeptide. The substantial or functional similarity can include a substitution of at least one
20 amino acid.

 The epitope, cluster, or polypeptide comprising the same can have affinity to an HLA-A2 molecule. The affinity can be determined by an assay of binding, by an assay of restriction of epitope recognition, by a prediction algorithm, and the like. The epitope, cluster, or polypeptide comprising the same can have affinity to an HLA-B7, HLA-B51 molecule, and the like.

25 In preferred embodiments the polypeptide can be a housekeeping epitope. The epitope or polypeptide can correspond to an epitope displayed on a tumor cell, to an epitope displayed on a neovasculature cell, and the like. The epitope or polypeptide can be an immune epitope. The epitope, cluster and/or polypeptide can be a nucleic acid.

 Other embodiments relate to pharmaceutical compositions comprising the polypeptides,
30 including an epitope from Table 1, a cluster, or a polypeptide comprising the same, and a pharmaceutically acceptable adjuvant, carrier, diluent, excipient, and the like. The adjuvant can be a polynucleotide. The polynucleotide can include a dinucleotide, which can be CpG, for example. The adjuvant can be encoded by a polynucleotide. The adjuvant can be a cytokine and the cytokine can be, for example, GM-CSF.

The pharmaceutical compositions can further include a professional antigen-presenting cell (pAPC). The pAPC can be a dendritic cell, for example. The pharmaceutical composition can further include a second epitope. The second epitope can be a polypeptide, a nucleic acid, a housekeeping epitope, an immune epitope, and the like.

5 Still further embodiments relate to pharmaceutical compositions that include any of the nucleic acids discussed herein, including those that encode polypeptides that comprise epitopes or antigens from Table 1. Such compositions can include a pharmaceutically acceptable adjuvant, carrier, diluent, excipient, and the like.

10 Other embodiments relate to recombinant constructs that include such a nucleic acid as described herein, including those that encode polypeptides that comprise epitopes or antigens from Table 1. The constructs can further include a plasmid, a viral vector, an artificial chromosome, and the like. The construct can further include a sequence encoding at least one feature, such as for example, a second epitope, an IRES, an ISS, an NIS, a ubiquitin, and the like.

15 Further embodiments relate to purified antibodies that specifically bind to at least one of the epitopes in Table 1. Other embodiments relate to purified antibodies that specifically bind to a peptide-MHC protein complex comprising an epitope disclosed in Table 1 or any other suitable epitope. The antibody from any embodiment can be a monoclonal antibody or a polyclonal antibody.

20 Still other embodiments relate to multimeric MHC-peptide complexes that include an epitope, such as, for example, an epitope disclosed in Table 1. Also, contemplated are antibodies specific for the complexes.

25 Embodiments relate to isolated T cells expressing a T cell receptor specific for an MHC-peptide complex. The complex can include an epitope, such as, for example, an epitope disclosed in Table 1. The T cell can be produced by an *in vitro* immunization and can be isolated from an immunized animal. Embodiments relate to T cell clones, including cloned T cells, such as those discussed above. Embodiments also relate to polyclonal population of T cells. Such populations can include a T cell, as described above, for example.

30 Still further embodiments relate to pharmaceutical compositions that include a T cell, such as those described above, for example, and a pharmaceutically acceptable adjuvant, carrier, diluent, excipient, and the like.

35 Embodiments of the invention relate to isolated protein molecules comprising the binding domain of a T cell receptor specific for an MHC-peptide complex. The complex can include an epitope as disclosed in Table 1. The protein can be multivalent. Other embodiments relate to isolated nucleic acids encoding such proteins. Still further embodiments relate to recombinant constructs that include such nucleic acids.

Other embodiments of the invention relate to host cells expressing a recombinant construct as described herein, including constructs encoding an epitope, cluster or polypeptide comprising the same, disclosed in Table 1, for example. The host cell can be a dendritic cell, macrophage, tumor cell, tumor-derived cell, a bacterium, fungus, protozoan, and the like. Embodiments also
5 relate to pharmaceutical compositions that include a host cell, such as those discussed herein, and a pharmaceutically acceptable adjuvant, carrier, diluent, excipient, and the like.

Still other embodiments relate to vaccines or immunotherapeutic compositions that include at least one component, such as, for example, an epitope disclosed in Table 1 or otherwise described herein; a cluster that includes such an epitope, an antigen or polypeptide that includes
10 such an epitope; a composition as described above and herein; a construct as described above and herein, a T cell, or a host cell as described above and herein.

Further embodiments relate to methods of treating an animal. The methods can include administering to an animal a pharmaceutical composition, such as, a vaccine or immunotherapeutic composition, including those disclosed above and herein. The administering step can include a
15 mode of delivery, such as, for example, transdermal, intranodal, perinodal, oral, intravenous, intradermal, intramuscular, intraperitoneal, mucosal, aerosol inhalation, instillation, and the like. The method can further include a step of assaying to determine a characteristic indicative of a state of a target cell or target cells. The method can include a first assaying step and a second assaying step, wherein the first assaying step precedes the administering step, and wherein the second
20 assaying step follows the administering step. The method can further include a step of comparing the characteristic determined in the first assaying step with the characteristic determined in the second assaying step to obtain a result. The result can be for example, evidence of an immune response, a diminution in number of target cells, a loss of mass or size of a tumor comprising target cells, a decrease in number or concentration of an intracellular parasite infecting target cells, and
25 the like.

Embodiments relate to methods of evaluating immunogenicity of a vaccine or immunotherapeutic composition. The methods can include administering to an animal a vaccine or immunotherapeutic, such as those described above and elsewhere herein, and evaluating immunogenicity based on a characteristic of the animal. The animal can be HLA-transgenic.

30 Other embodiments relate to methods of evaluating immunogenicity that include *in vitro* stimulation of a T cell with the vaccine or immunotherapeutic composition, such as those described above and elsewhere herein, and evaluating immunogenicity based on a characteristic of the T cell. The stimulation can be a primary stimulation.

Still further embodiments relate to methods of making a passive/adoptive
35 immunotherapeutic. The methods can include combining a T cell or a host cell, such as those

described above and elsewhere herein, with a pharmaceutically acceptable adjuvant, carrier, diluent, excipient, and the like.

5 Other embodiments relate to methods of determining specific T cell frequency, and can include the step of contacting T cells with a MHC-peptide complex comprising an epitope disclosed in Table 1, or a complex comprising a cluster or antigen comprising such an epitope. The contacting step can include at least one feature, such as, for example, immunization, restimulation, detection, enumeration, and the like. The method can further include ELISPOT analysis, limiting dilution analysis, flow cytometry, in situ hybridization, the polymerase chain reaction, any combination thereof, and the like.

10 Embodiments relate to methods of evaluating immunologic response. The methods can include the above-described methods of determining specific T cell frequency carried out prior to and subsequent to an immunization step.

15 Other embodiments relate to methods of evaluating immunologic response. The methods can include determining frequency, cytokine production, or cytolytic activity of T cells, prior to and subsequent to a step of stimulation with MHC-peptide complexes comprising an epitope, such as, for example an epitope from Table 1, a cluster or a polypeptide comprising such an epitope.

20 Further embodiments relate to methods of diagnosing a disease. The methods can include contacting a subject tissue with at least one component, including, for example, a T cell, a host cell, an antibody, a protein, including those described above and elsewhere herein; and diagnosing the disease based on a characteristic of the tissue or of the component. The contacting step can take place *in vivo* or *in vitro*, for example.

25 Still other embodiments relate to methods of making a vaccine. The methods can include combining at least one component, an epitope, a composition, a construct, a T cell, a host cell; including any of those described above and elsewhere herein, with a pharmaceutically acceptable adjuvant, carrier, diluent, excipient, and the like.

Embodiments relate to computer readable media having recorded thereon the sequence of any one of SEQ ID NOS: 1 -602, in a machine having a hardware or software that calculates the physical, biochemical, immunologic, molecular genetic properties of a molecule embodying said sequence, and the like.

30 Still other embodiments relate to methods of treating an animal. The methods can include combining the method of treating an animal that includes administering to the animal a vaccine or immunotherapeutic composition, such as described above and elsewhere herein, combined with at least one mode of treatment, including, for example, radiation therapy, chemotherapy, biochemotherapy, surgery, and the like.

Further embodiments relate to isolated polypeptides that include an epitope cluster. In preferred embodiments the cluster can be from a target-associated antigen having the sequence as disclosed in any one of Tables 25-44, wherein the amino acid sequence includes not more than about 80% of the amino acid sequence of the antigen.

5 Other embodiments relate to vaccines or immunotherapeutic products that include an isolated peptide as described above and elsewhere herein. Still other embodiments relate to isolated polynucleotides encoding a polypeptide as described above and elsewhere herein. Other embodiments relate vaccines or immunotherapeutic products that include these polynucleotides. The polynucleotide can be DNA, RNA, and the like.

10 Still further embodiments relate to kits comprising a delivery device and any of the embodiments mentioned above and elsewhere herein. The delivery device can be a catheter, a syringe, an internal or external pump, a reservoir, an inhaler, microinjector, a patch, and any other like device suitable for any route of delivery. As mentioned, the kit, in addition to the delivery device also includes any of the embodiments disclosed herein. For example, without limitations,
15 the kit can include an isolated epitope, a polypeptide, a cluster, a nucleic acid, an antigen, a pharmaceutical composition that includes any of the foregoing, an antibody, a T cell, a T cell receptor, an epitope-MHC complex, a vaccine, an immunotherapeutic, and the like. The kit can also include items such as detailed instructions for use and any other like item.

Brief Description of the Drawings

20 Figure 1 is a sequence alignment of NY-ESO-1 and several similar protein sequences.

Figure 2 graphically represents a plasmid vaccine backbone useful for delivering nucleic acid-encoded epitopes.

Figures 3A and 3B are FACS profiles showing results of HLA-A2 binding assays for tyrosinase₂₀₇₋₂₁₅ and tyrosinase₂₀₈₋₂₁₆.

25 Figure 3C shows cytolytic activity against a tyrosinase epitope by human CTL induced by *in vitro* immunization.

Figure 4 is a T=120 min. time point mass spectrum of the fragments produced by proteasomal cleavage of SSX-2₃₁₋₆₈.

Figure 5 shows a binding curve for HLA-A2:SSX-2₄₁₋₄₉ with controls.

30 Figure 6 shows specific lysis of SSX-2₄₁₋₄₉-pulsed targets by CTL from SSX-2₄₁₋₄₉-immunized HLA-A2 transgenic mice.

Figure 7A, B, and C show results of N-terminal pool sequencing of a T=60 min. time point aliquot of the PSMA₁₆₃₋₁₉₂ proteasomal digest.

35 Figure 8 shows binding curves for HLA-A2:PSMA₁₆₈₋₁₇₇ and HLA-A2:PSMA₂₈₈₋₂₉₇ with controls.

Figure 9 shows results of N-terminal pool sequencing of a T=60 min. time point aliquot of the PSMA₂₈₁₋₃₁₀ proteasomal digest.

Figure 10 shows binding curves for HLA-A2:PSMA₄₆₁₋₄₆₉, HLA-A2:PSMA₄₆₀₋₄₆₉, and HLA-A2:PSMA₆₆₃₋₆₇₁, with controls.

5 Figure 11 shows the results of a γ -IFN-based ELISPOT assay detecting PSMA₄₆₃₋₄₇₁-reactive HLA-A1⁺ CD8⁺ T cells.

Figure 12 shows blocking of reactivity of the T cells used in figure 10 by anti-HLA-A1 mAb, demonstrating HLA-A1-restricted recognition.

Figure 13 shows a binding curve for HLA-A2:PSMA₆₆₃₋₆₇₁, with controls.

10 Figure 14 shows a binding curve for HLA-A2:PSMA₆₆₂₋₆₇₁, with controls.

Figure 15. Comparison of anti-peptide CTL responses following immunization with various doses of DNA by different routes of injection.

Figure 16. Growth of transplanted gp33 expressing tumor in mice immunized by i.ln. injection of gp33 epitope-expressing, or control, plasmid.

15 Figure 17. Amount of plasmid DNA detected by real-time PCR in injected or draining lymph nodes at various times after i.ln. of i.m. injection, respectively.

Detailed Description of the Preferred Embodiment

Definitions

20 Unless otherwise clear from the context of the use of a term herein, the following listed terms shall generally have the indicated meanings for purposes of this description.

PROFESSIONAL ANTIGEN-PRESENTING CELL (pAPC) – a cell that possesses T cell costimulatory molecules and is able to induce a T cell response. Well characterized pAPCs include dendritic cells, B cells, and macrophages.

PERIPHERAL CELL – a cell that is not a pAPC.

25 HOUSEKEEPING PROTEASOME – a proteasome normally active in peripheral cells, and generally not present or not strongly active in pAPCs.

IMMUNE PROTEASOME – a proteasome normally active in pAPCs; the immune proteasome is also active in some peripheral cells in infected tissues.

30 EPITOPE – a molecule or substance capable of stimulating an immune response. In preferred embodiments, epitopes according to this definition include but are not necessarily limited to a polypeptide and a nucleic acid encoding a polypeptide, wherein the polypeptide is capable of stimulating an immune response. In other preferred embodiments, epitopes according to this definition include but are not necessarily limited to peptides presented on the surface of cells, the peptides being non-covalently bound to the binding cleft of class I MHC, such that they can
35 interact with T cell receptors.

MHC EPITOPE – a polypeptide having a known or predicted binding affinity for a mammalian class I or class II major histocompatibility complex (MHC) molecule.

HOUSEKEEPING EPITOPE – In a preferred embodiment, a housekeeping epitope is defined as a polypeptide fragment that is an MHC epitope, and that is displayed on a cell in which housekeeping proteasomes are predominantly active. In another preferred embodiment, a housekeeping epitope is defined as a polypeptide containing a housekeeping epitope according to the foregoing definition, that is flanked by one to several additional amino acids. In another preferred embodiment, a housekeeping epitope is defined as a nucleic acid that encodes a housekeeping epitope according to the foregoing definitions.

IMMUNE EPITOPE – In a preferred embodiment, an immune epitope is defined as a polypeptide fragment that is an MHC epitope, and that is displayed on a cell in which immune proteasomes are predominantly active. In another preferred embodiment, an immune epitope is defined as a polypeptide containing an immune epitope according to the foregoing definition, that is flanked by one to several additional amino acids. In another preferred embodiment, an immune epitope is defined as a polypeptide including an epitope cluster sequence, having at least two polypeptide sequences having a known or predicted affinity for a class I MHC. In yet another preferred embodiment, an immune epitope is defined as a nucleic acid that encodes an immune epitope according to any of the foregoing definitions.

TARGET CELL – a cell to be targeted by the vaccines and methods of the invention. Examples of target cells according to this definition include but are not necessarily limited to: a neoplastic cell and a cell harboring an intracellular parasite, such as, for example, a virus, a bacterium, or a protozoan.

TARGET-ASSOCIATED ANTIGEN (TAA) – a protein or polypeptide present in a target cell.

TUMOR-ASSOCIATED ANTIGENS (TuAA) – a TAA, wherein the target cell is a neoplastic cell.

HLA EPITOPE – a polypeptide having a known or predicted binding affinity for a human class I or class II HLA complex molecule.

ANTIBODY – a natural immunoglobulin (Ig), poly- or monoclonal, or any molecule composed in whole or in part of an Ig binding domain, whether derived biochemically or by use of recombinant DNA. Examples include *inter alia*, F(ab), single chain Fv, and Ig variable region-phage coat protein fusions.

ENCODE – an open-ended term such that a nucleic acid encoding a particular amino acid sequence can consist of codons specifying that (poly)peptide, but can also comprise additional

sequences either translatable, or for the control of transcription, translation, or replication, or to facilitate manipulation of some host nucleic acid construct.

SUBSTANTIAL SIMILARITY – this term is used to refer to sequences that differ from a reference sequence in an inconsequential way as judged by examination of the sequence. Nucleic acid sequences encoding the same amino acid sequence are substantially similar despite differences in degenerate positions or modest differences in length or composition of any non-coding regions. Amino acid sequences differing only by conservative substitution or minor length variations are substantially similar. Additionally, amino acid sequences comprising housekeeping epitopes that differ in the number of N-terminal flanking residues, or immune epitopes and epitope clusters that differ in the number of flanking residues at either terminus, are substantially similar. Nucleic acids that encode substantially similar amino acid sequences are themselves also substantially similar.

FUNCTIONAL SIMILARITY – this term is used to refer to sequences that differ from a reference sequence in an inconsequential way as judged by examination of a biological or biochemical property, although the sequences may not be substantially similar. For example, two nucleic acids can be useful as hybridization probes for the same sequence but encode differing amino acid sequences. Two peptides that induce cross-reactive CTL responses are functionally similar even if they differ by non-conservative amino acid substitutions (and thus do not meet the substantial similarity definition). Pairs of antibodies, or TCRs, that recognize the same epitope can be functionally similar to each other despite whatever structural differences exist. In testing for functional similarity of immunogenicity one would generally immunize with the “altered” antigen and test the ability of the elicited response (Ab, CTL, cytokine production, etc.) to recognize the target antigen. Accordingly, two sequences may be designed to differ in certain respects while retaining the same function. Such designed sequence variants are among the embodiments of the present invention.

Table 1A. SEQ ID NOS.* including epitopes in Examples 1-7, 13.

SEQ ID NO	IDENTITY	SEQUENCE
1	Tyr 207-216	FLPWHRLFL
2	Tyrosinase protein	Accession number*: P14679
3	SSX-2 protein	Accession number: NP_003138
4	PSMA protein	Accession number: NP_004467
5	Tyrosinase cDNA	Accession number: NM_000372
6	SSX-2 cDNA	Accession number: NM_003147
7	PSMA cDNA	Accession number: NM_004476
8	Tyr 207-215	FLPWHRLFL
9	Tyr 208-216	LPWHRLFL

10	SSX-2 31-68	YFSKEEWEKMKASEKIFYVYMKRKYEAMTKLGFKATLP
11	SSX-2 32-40	FSKEEWEKM
12	SSX-2 39-47	KMKASEKIF
13	SSX-2 40-48	MKASEKIFY
14	SSX-2 39-48	KMKASEKIFY
15	SSX-2 41-49	KASEKIFYV
16	SSX-2 40-49	MKASEKIFYV
17	SSX-2 41-50	KASEKIFYVY
18	SSX-2 42-49	ASEKIFYVY
19	SSX-2 53-61	RKYEAMTKL
20	SSX-2 52-61	KRKYEAMTKL
21	SSX-2 54-63	KYEAMTKLGF
22	SSX-2 55-63	YEAMTKLGF
23	SSX-2 56-63	EAMTKLGF
24	HBV18-27	FLPSDYFPSV
25	HLA-B44 binder	AEMGKYSFY
26	SSX-1 41-49	KYSEKISYV
27	SSX-3 41-49	KVSEKIVYV
28	SSX-4 41-49	KSSEKIVYV
29	SSX-5 41-49	KASEKIIVY
30	PSMA163-192	AFSPQGMPEGDLVYVNYARTEDFFKLERDM
31	PSMA 168-190	GMPEGDLVYVNYARTEDFFKLER
32	PSMA 169-177	MPEGDLVYV
33	PSMA 168-177	GMPEGDLVYV
34	PSMA 168-176	GMPEGDLVY
35	PSMA 167-176	QGMPEGDLVY
36	PSMA 169-176	MPEGDLVY
37	PSMA 171-179	EGDLVYVNY
38	PSMA 170-179	PEGDLVYVNY
39	PSMA 174-183	LVYVNYARTE
40	PSMA 177-185	VNYARTEDF
41	PSMA 176-185	YVNYARTEDF
42	PSMA 178-186	NYARTEDFF
43	PSMA 179-186	YARTEDFF
44	PSMA 181-189	RTEDFFKLE
45	PSMA 281-310	RGIAEAVGLPSIPVHPIGYYDAQKLLEKMG
46	PSMA 283-307	IAEAVGLPSIPVHPIGYYDAQKLLE
47	PSMA 289-297	LPSIPVHPI
48	PSMA 288-297	GLPSIPVHPI
49	PSMA 297-305	IGYYDAQKL
50	PSMA 296-305	PIGYYDAQKL

51	PSMA 291-299	SIPVHPIGY
52	PSMA 290-299	PSIPVHPIGY
53	PSMA 292-299	IPVHPIGY
54	PSMA 299-307	YYDAQKLE
55	PSMA454-481	SSIEGNYTLRVDCTPLMYSLVHLTKEL
56	PSMA 456-464	IEGNYTLRV
57	PSMA 455-464	SIEGNYTLRV
58	PSMA 457-464	EGNYTLRV
59	PSMA 461-469	TLRVDCTPL
60	PSMA 460-469	YTLRVDCTPL
61	PSMA 462-470	LRVDCTPLM
62	PSMA 463-471	RVDCTPLMY
63	PSMA 462-471	LRVDCTPLMY
64	PSMA653-687	FDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFY
65	PSMA 660-681	VLRMMNDQLMFLERAFIDPLGL
66	PSMA 663-671	MMNDQLMFL
67	PSMA 662-671	RMMNDQLMFL
68	PSMA 662-670	RMMNDQLMF
69	Tyr 1-17	MLLAVLYCLLWSFQTSA

Table 1B. SEQ ID NOS.* including epitopes in Examples 14 and 15.

SEQ ID NO	IDENTITY	SEQUENCE
70	GP100 protein ²	**Accession number: P40967
71	MAGE-1 protein	Accession number: P43355
72	MAGE-2 protein	Accession number: P43356
73	MAGE-3 protein	Accession number: P43357
74	NY-ESO-1 protein	Accession number: P78358
75	LAGE-1a protein	Accession number: CAA11116
76	LAGE-1b protein	Accession number: CAA11117
77	PRAME protein	Accession number: NP 006106
78	PSA protein	Accession number: P07288
79	PSCA protein	Accession number: O43653
80	GP100 cds	Accession number: U20093
81	MAGE-1 cds	Accession number: M77481
82	MAGE-2 cds	Accession number: L18920
83	MAGE-3 cds	Accession number: U03735
84	NY-ESO-1 cDNA	Accession number: U87459
85	PRAME cDNA	Accession number: NM_006115
86	PSA cDNA	Accession number: NM_001648
87	PSCA cDNA	Accession number: AF043498
88	GP100 630-638	LPHSSSHWL
89	GP100 629-638	QLPHSSSHWL

90	GP100 614-622	LIYRRRLMK
91	GP100 613-622	SLIYRRRLMK
92	GP100 615-622	TYRRRLMK
93	GP100 630-638	LPHSSSHWL
94	GP100 629-638	QLPHSSSHWL
95	MAGE-1 95-102	ESLFRAVI
96	MAGE-1 93-102	ILESFRVI
97	MAGE-1 93-101	ILESFRV
98	MAGE-1 92-101	CILESFRV
99	MAGE-1 92-100	CILESFR
100	MAGE-1 263-271	EFLWGPRAL
101	MAGE-1 264-271	FLWGPRAL
102	MAGE-1 264-273	FLWGPRALAE
103	MAGE-1 265-274	LWGPRALAE
104	MAGE-1 268-276	PRALAETSY
105	MAGE-1 267-276	GPRALAETSY
106	MAGE-1 269-277	RALAETSYV
107	MAGE-1 271-279	LAETSYVKV
108	MAGE-1 270-279	ALAETSYVKV
109	MAGE-1 272-280	AETSYVKVL
110	MAGE-1 271-280	LAETSYVKVL
111	MAGE-1 274-282	TSYVKVLEY
112	MAGE-1 273-282	ETSYVKVLEY
113	MAGE-1 278-286	KVLEYVIKV
114	MAGE-1 168-177	SYVLVTCLGL
115	MAGE-1 169-177	YVLVTCLGL
116	MAGE-1 170-177	VLVTCLGL
117	MAGE-1 240-248	TQDLVQEKY
118	MAGE-1 239-248	LTQDLVQEKY
119	MAGE-1 232-240	YGEPKLLT
120	MAGE-1 243-251	LVQEKYLEY
121	MAGE-1 242-251	DLVQEKYLEY
122	MAGE-1 230-238	SAYGEPKRL
123	MAGE-1 278-286	KVLEYVIKV
124	MAGE-1 277-286	VKVLEYVIKV
125	MAGE-1 276-284	YVKVLEYVI
126	MAGE-1 274-282	TSYVKVLEY
127	MAGE-1 273-282	ETSYVKVLEY
128	MAGE-1 283-291	VIKVSARVR
129	MAGE-1 282-291	YVIKVSARVR
130	MAGE-2 115-122	ELVHFLLL
131	MAGE-2 113-122	MVELVHFLLL

132	MAGE-2 109-116	ISRKMVEL
133	MAGE-2 108-116	AISRKMVEL
134	MAGE-2 107-116	AAISRKMVEL
135	MAGE-2 112-120	KMVELVHFL
136	MAGE-2 109-117	ISRKMVELV
137	MAGE-2 108-117	AISRKMVELV
138	MAGE-2 116-124	LVHFLLLKY
139	MAGE-2 115-124	ELVHFLLLKY
140	MAGE-2 111-119	RKMVELVHF
141	MAGE-2 158-166	LQLVFGIEV
142	MAGE-2 157-166	YLQLVFGIEV
143	MAGE-2 159-167	QLVFGIEVV
144	MAGE-2 158-167	LQLVFGIEVV
145	MAGE-2 164-172	IEVVVEVPI
146	MAGE-2 163-172	GIEVVVEVPI
147	MAGE-2 162-170	FGIEVVVEVV
148	MAGE-2 154-162	ASEYLQLVF
149	MAGE-2 153-162	KASEYLQLVF
150	MAGE-2 218-225	EEKIWEEL
151	MAGE-2 216-225	APEEKIWEEL
152	MAGE-2 216-223	APEEKIWE
153	MAGE-2 220-228	KIWEELSML
154	MAGE-2 219-228	EKIWEELSML
155	MAGE-2 271-278	FLWGPRAL
156	MAGE-2 271-279	FLWGPRALI
157	MAGE-2 278-286	LIETSYVKV
158	MAGE-2 277-286	ALIETSYVKV
159	MAGE-2 276-284	RALIETSYV
160	MAGE-2 279-287	IETSYVKVL
161	MAGE-2 278-287	LIETSYVKVL
162	MAGE-3 271-278	FLWGPRAL
163	MAGE-3 270-278	EFLWGPRAL
164	MAGE-3 271-279	FLWGPRALV
165	MAGE-3 276-284	RALVETSYV
166	MAGE-3 272-280	LWGPRALVE
167	MAGE-3 271-280	FLWGPRALVE
168	MAGE-3 27 2-281	LWGPRALVET
169	NY-ESO-1 82-90	GPESRLLEF
170	NY-ESO-1 83-91	PESRLLEFY
171	NY-ESO-1 82-91	GPESRLLEFY
172	NY-ESO-1 84-92	ESRLLEFYL
173	NY-ESO-1 86-94	RLLEFYLAM

174	NY-ESO-1 88-96	LEFYLAMPF
175	NY-ESO-1 87-96	LLEFYLAMPF
176	NY-ESO-1 93-102	AMPFATPMEA
177	NY-ESO-1 94-102	MPFATPMEA
178	NY-ESO-1 115-123	PLPVPGVLL
179	NY-ESO-1 114-123	PPLPVPGVLL
180	NY-ESO-1 116-123	LPVPGVLL
181	NY-ESO-1 103-112	ELARRSLAQD
182	NY-ESO-1 118-126	VPGVLLKEF
183	NY-ESO-1 117-126	PVPGVLLKEF
184	NY-ESO-1 116-123	LPVPGVLL
185	NY-ESO-1 127-135	TVSGNILT
186	NY-ESO-1 126-135	FTVSGNILT
187	NY-ESO-1 120-128	GVLLKEFTV
188	NY-ESO-1 121-130	VLLKEFTVSG
189	NY-ESO-1 122-130	LLKEFTVSG
190	NY-ESO-1 118-126	VPGVLLKEF
191	NY-ESO-1 117-126	PVPGVLLKEF
192	NY-ESO-1 139-147	AADHRQLQL
193	NY-ESO-1 148-156	SISSCLQQL
194	NY-ESO-1 147-156	LSISSCLQQL
195	NY-ESO-1 138-147	TAADHRQLQL
196	NY-ESO-1 161-169	WITQCFLPV
197	NY-ESO-1 157-165	SLLMWITQC
198	NY-ESO-1 150-158	SSCLQQLSL
199	NY-ESO-1 154-162	QQLSLLMWI
200	NY-ESO-1 151-159	SCLQQLSLL
201	NY-ESO-1 150-159	SSCLQQLSLL
202	NY-ESO-1 163-171	TQCFLPVFL
203	NY-ESO-1 162-171	ITQCFLPVFL
204	PRAME 219-227	PMQDIKMIL
205	PRAME 218-227	MPMQDIKMIL
206	PRAME 428-436	QHLIGLSNL
207	PRAME 427-436	LQHLIGLSNL
208	PRAME 429-436	HLIGLSNL
209	PRAME 431-439	IGLSNLTHV
210	PRAME 430-439	LIGLSNLTHV
211	PSA 53-61	VLVHPQWVL
212	PSA 52-61	GVLVHPQWVL
213	PSA 52-60	GVLVHPQWV
214	PSA 59-67	WVLTAACHCI
215	PSA 54-63	LVHPQWVLTA

216	PSA 53-62	VLVHPQWVLT
217	PSA 54-62	LVHPQWVLT
218	PSA 66-73	CIRNKSVI
219	PSA 65-73	HCIRNKSVI
220	PSA 56-64	HPQWVLTAA
221	PSA 63-72	AAHCIRNKSV
222	PSCA 116-123	LLWGPQGQL
223	PSCA 115-123	LLLWGPQGQL
224	PSCA 114-123	GLLLWGPQGQL
225	PSCA 99-107	ALQPAAAIL
226	PSCA 98-107	HALQPAAAIL
227	Tyr 128-137	APEKDKFFAY
228	Tyr 129-137	PEKDKFFAY
229	Tyr 130-138	EKDKFFAYL
230	Tyr 131-138	KDKFFAYL
231	Tyr 205-213	PAFLPWHRL
232	Tyr 204-213	APAFLPWHRL
233	Tyr 214-223	FLLRWEQEIQ
234	Tyr 212-220	RLFLLRWEQ
235	Tyr 191-200	GSEIWRDIDF
236	Tyr 192-200	SEIWRDIDF
237	Tyr 473-481	RIWSWLLGA
238	Tyr 476-484	SWLLGAAMV
239	Tyr 477-486	WLLGAAMVGA
240	Tyr 478-486	LLGAAMVGA
241	PSMA 4-12	LLHETDSAV
242	PSMA 13-21	ATARRPRWL
243	PSMA 53-61	TPKHNMKAF
244	PSMA 64-73	ELKAENIKKF
245	PSMA 69-77	NIKKFLH ¹ NF
246	PSMA 68-77	ENIKKFLH ¹ NF
247	PSMA 220-228	AGAKGVILY
248	PSMA 468-477	PLMYSLVHNL
249	PSMA 469-477	LMYSLVHNL
250	PSMA 463-471	RVDCTPLMY
251	PSMA 465-473	DCTPLMYSL
252	PSMA 507-515	SGMPRISKL
253	PSMA 506-515	FSGMPRISKL
254	NY-ESO-1 136-163	RLTAADHRQLQLSISSCLQLSLLMWIT
255	NY-ESO-1 150-177	SSCLQLSLLMWITQCFLPVFLAQPPSG

¹ This H was reported as Y in the SWISSPROT database.

The amino acid at position 274 may be Pro or Leu depending upon the database. The particular analysis presented herein used the Pro.

Table 1C. SEQ ID NOS.* including epitopes in Example14.

5

SEQ ID NO.	IDENTITY	SEQUENCE
256	Mage-1 125-132	KAEMLESV
257	Mage-1 124-132	TKAEMLESV
258	Mage-1 123-132	VTKAEMLESV
259	Mage-1 128-136	MLESVIKNY
260	Mage-1 127-136	EMLESVIKNY
261	Mage-1 125-133	KAEMLESVI
262	Mage-1 146-153	KASESLQL
263	Mage-1 145-153	GKASESLQL
264	Mage-1 147-155	ASESLQLVF
265	Mage-1 153-161	LVFGIDVKE
266	Mage-1 114-121	LLKYRARE
267	Mage-1 106-113	VADLVGFL
268	Mage-1 105-113	KVADLVGFL
269	Mage-1 107-115	ADLVGFLLL
270	Mage-1 106-115	VADLVGFLLL
271	Mage-1 114-123	LLKYRAREPV
272	Mage-3 278-286	LVETSYVKV
273	Mage-3 277-286	ALVETSYVKV
274	Mage-3 285-293	KVLHHMVKI
275	Mage-3 283-291	YVKVLHHMV
276	Mage-3 275-283	PRALVETSY
277	Mage-3 274-283	GPRALVETSY
278	Mage-3 278-287	LVETSYVKVL
279	ED-B 4'-5	TIPEVPQL
280	ED-B 5'-5	DTIPEVPQL
281	ED-B 1-10	EVPQLTDLSF
282	ED-B 23-30	TPLNSSTI
283	ED-B 18-25	IGLRWTPL
284	ED-B 17-25	SIGLRWTPL
285	ED-B 25-33	LNSSTIIGY
286	ED-B 24-33	PLNSSTIIGY
287	ED-B 23-31	TPLNSSTII
288	ED-B 31-38	IGYRITVV
289	ED-B 30-38	IIGYRITVV
290	ED-B 29-38	TIIGYRITVV
291	ED-B 31-39	IGYRITVVA
292	ED-B 30-39	IIGYRITVVA
293	CEA 184-191	SLPVSPRL
294	CEA 183-191	QSLPVSPRL
295	CEA 186-193	PVSPRLQL
296	CEA 185-193	LPVSPRLQL
297	CEA 184-193	SLPVSPRLQL
298	CEA 185-192	LPVSPRLQ
299	CEA 192-200	QLSNGNRTL

300	CEA 191-200	LQLSNGNRTL
301	CEA 179-187	WVNNQSLPV
302	CEA 186-194	PVSPRLQLS
303	CEA 362-369	SLPVSPRL
304	CEA 361-369	QSLPVSPRL
305	CEA 364-371	PVSPRLQL
306	CEA 363-371	LPVSPRLQL
307	CEA 362-371	SLPVSPRLQL
308	CEA 363-370	LPVSPRLQ
309	CEA 370-378	QLSNDNRTL
310	CEA 369-378	LQLSNDNRTL
311	CEA 357-365	WVNNQSLPV
312	CEA 360-368	NQSLPVSPR
313	CEA 540-547	SLPVSPRL
314	CEA 539-547	QSLPVSPRL
315	CEA 542-549	PVSPRLQL
316	CEA 541-549	LPVSPRLQL
317	CEA 540-549	SLPVSPRLQL
318	CEA 541-548	LPVSPRLQ
319	CEA 548-556	QLSNGNRTL
320	CEA 547-556	LQLSNGNRTL
321	CEA 535-543	WVNGQSLPV
322	CEA 533-541	LWWVNGQSL
323	CEA 532-541	YLWWVNGQSL
324	CEA 538-546	GQSLPVSPR
325	Her-2 30-37	DMKLRRLPA
326	Her-2 28-37	GTDMLRLPA
327	Her-2 42-49	HLDMLRHL
328	Her-2 41-49	THLDMLRHL
329	Her-2 40-49	ETHLDMLRHL
330	Her-2 36-43	PASPETHL
331	Her-2 35-43	LPASPETHL
332	Her-2 34-43	RLPASPETHL
333	Her-2 38-46	SPETHLDML
334	Her-2 37-46	ASPETHLDML
335	Her-2 42-50	HLDMLRHLY
336	Her-2 41-50	THLDMLRHLY
337	Her-2 719-726	ELRKVKVL
338	Her-2 718-726	TELRKVKVL
339	Her-2 717-726	ETELRKVKVL
340	Her-2 715-723	LKETELRKV
341	Her-2 714-723	ILKETELRKV
342	Her-2 712-720	MRILKETEL
343	Her-2 711-720	QMRILKETEL
344	Her-2 717-725	ETELRKVKV
345	Her-2 716-725	KETELRKVKV
346	Her-2 706-714	MPNQAQMRI
347	Her-2 705-714	AMPNQAQMRI
348	Her-2 706-715	MPNQAQMRL
349	HER-2 966-973	RPRFRELV

350	HER-2 965-973	CRPRFREL V
351	HER-2 968-976	RFREL VSEF
352	HER-2 967-976	PRFREL VSEF
353	HER-2 964-972	ECRPRFREL
354	NY-ESO-1 67-75	GAASGLNGC
355	NY-ESO-1 52-60	RASGPGGGA
356	NY-ESO-1 64-72	PHGGAASGL
357	NY-ESO-1 63-72	GPHGGAASGL
358	NY-ESO-1 60-69	APRGPHGGAA
359	PRAME 112-119	VRPRRWKL
360	PRAME 111-119	EVPRRWKL
361	PRAME 113-121	RPRRWKLQV
362	PRAME 114-122	PRRWKLQVL
363	PRAME 113-122	RPRRWKLQVL
364	PRAME 116-124	RWKLQVLDL
365	PRAME 115-124	RRWKLQVLDL
366	PRAME 174-182	PVEVLVDLF
367	PRAME 199-206	VKRKKNVL
368	PRAME 198-206	KVKRKKNVL
369	PRAME 197-206	EKVKRKKNVL
370	PRAME 198-205	KVKRKKNV
371	PRAME 201-208	RKKNVRL
372	PRAME 200-208	KRKKNVRL
373	PRAME 199-208	VKRKKNVRL
374	PRAME 189-196	DELFSYLI
375	PRAME 205-213	VLRLCCKKL
376	PRAME 204-213	NVRLCCKKL
377	PRAME 194-202	YLIEKVKRK
378	PRAME 74-81	QAWPFTCL
379	PRAME 73-81	VQAWPFTCL
380	PRAME 72-81	MVQAWPFTCL
381	PRAME 81-88	LPLGVLMK
382	PRAME 80-88	CLPLGVLMK
383	PRAME 79-88	TCLPLGVLMK
384	PRAME 84-92	GVLMMKGQHL
385	PRAME 81-89	LPLGVLMKG
386	PRAME 80-89	CLPLGVLMKG
387	PRAME 76-85	WPFTCLPLGV
388	PRAME 51-59	ELFPPLFMA
389	PRAME 49-57	PRELFPPLF
390	PRAME 48-57	LPRELFPPLF
391	PRAME 50-58	RELFPPLFM
392	PRAME 49-58	PRELFPPLFM
393	PSA 239-246	RPSLYTKV
394	PSA 238-246	ERPSLYTKV
395	PSA 236-243	LPERPSLY
396	PSA 235-243	ALPERPSLY
397	PSA 241-249	SLYTKVVHY
398	PSA 240-249	PSLYTKVVHY
399	PSA 239-247	RPSLYTKVV

400	PSMA 211-218	GNKVKNAQ
401	PSMA 202-209	IARYGKVF
402	PSMA 217-225	AQLAGAKGV
403	PSMA 207-215	KVFRGNKVK
404	PSMA 211-219	GNKVKNAQL
405	PSMA 269-277	TPGYPANEY
406	PSMA 268-277	LTPGYPANEY
407	PSMA 271-279	GYPANEYAY
408	PSMA 270-279	PGYPANEYAY
409	PSMA 266-274	DPLTPGYPA
410	PSMA 492-500	SLYESWTKK
411	PSMA 491-500	KSLYESWTKK
412	PSMA 486-494	EGFEGKSLY
413	PSMA 485-494	DEGFEGKSLY
414	PSMA 498-506	TKKSPSPEF
415	PSMA 497-506	WTKKSPSPEF
416	PSMA 492-501	SLYESWTKKS
417	PSMA 725-732	WGEVKRQI
418	PSMA 724-732	AWGEVKRQI
419	PSMA 723-732	KAWGEVKRQI
420	PSMA 723-730	KAWGEVKR
421	PSMA 722-730	SKAWGEVKR
422	PSMA 731-739	QIYVAAFTV
423	PSMA 733-741	YVAAFTVQA
424	PSMA 725-733	WGEVKRQIY
425	PSMA 727-735	EVKRQIYVA
426	PSMA 738-746	TVQAAAETL
427	PSMA 737-746	FTVQAAAETL
428	PSMA 729-737	KRQIYVAAF
429	PSMA 721-729	PSKA WGEVK
430	PSMA 723-731	KAWGEVKRQ
431	PSMA 100-108	WKEFGLDV
432	PSMA 99-108	QWKEFGLDV
433	PSMA 102-111	EFGLDSVELA
434	SCP-1 126-134	ELRQKESKL
435	SCP-1 125-134	AELRQKESKL
436	SCP-1 133-141	KLQENRKII
437	SCP-1 298-305	QLEEKTKL
438	SCP-1 297-305	NQLEEKTKL
439	SCP-1 288-296	LLEESRDV
440	SCP-1 287-296	FLLEESRDV
441	SCP-1 291-299	ESRDVQNQL
442	SCP-1 290-299	EESRDVQNQL
443	SCP-1 475-483	EKEVHDLEY
444	SCP-1 474-483	REKEVHDLEY
445	SCP-1 480-488	DLEYSYCHY
446	SCP-1 477-485	EVHDLEYSY
447	SCP-1 477-486	EVHDLEYSYC
448	SCP-1 502-509	KLSSKREL
449	SCP-1 508-515	ELKNTEYF

450	SCP-1 507-515	RELKNTEYF
451	SCP-1 496-503	KRGQRPKL
452	SCP-1 494-503	LPKRGQRPKL
453	SCP-1 509-517	LKNTEYFTL
454	SCP-1 508-517	ELKNTEYFTL
455	SCP-1 506-514	KRELKNTEY
456	SCP-1 502-510	KLSSKRELK
457	SCP-1 498-506	GQRPKLSSK
458	SCP-1 497-506	RGQRPKLSSK
459	SCP-1 500-508	RPKLSSKRE
460	SCP-1 573-580	LEYVREEL
461	SCP-1 572-580	ELEYVREEL
462	SCP-1 571-580	NELEYVREEL
463	SCP-1 579-587	ELKQKREDEV
464	SCP-1 575-583	YVREELKQK
465	SCP-1 632-640	QLNVYEIKV
466	SCP-1 630-638	SKQLNVYEI
467	SCP-1 628-636	AESKQLNVY
468	SCP-1 627-636	TAESKQLNVY
469	SCP-1 638-645	IKV NKLEL
470	SCP-1 637-645	EIKV NKLEL
471	SCP-1 636-645	YEIKV NKLEL
472	SCP-1 642-650	KLELELESA
473	SCP-1 635-643	VYEIKV NKL
474	SCP-1 634-643	NVYEIKV NKL
475	SCP-1 646-654	ELESAKQKF
476	SCP-1 642-650	KLELELESA
477	SCP-1 646-654	ELESAKQKF
478	SCP-1 771-778	KEK LKREA
479	SCP-1 777-785	EAKENTATL
480	SCP-1 776-785	REAKENTATL
481	SCP-1 773-782	KLKREAKENT
482	SCP-1 112-119	EAEKIKKW
483	SCP-1 101-109	GLSRVYSKL
484	SCP-1 100-109	EGLSRVYSKL
485	SCP-1 108-116	KLYKEAEKI
486	SCP-1 98-106	NSEGLSRVY
487	SCP-1 97-106	ENSEGLSRVY
488	SCP-1 102-110	LSRVYSKLY
489	SCP-1 101-110	GLSRVYSKLY
490	SCP-1 96-105	LENSEGLSRV
491	SCP-1 108-117	KLYKEAEKIK
492	SCP-1 949-956	REDRWAVI
493	SCP-1 948-956	MREDRWAVI
494	SCP-1 947-956	KMREDRWAVI
495	SCP-1 947-955	KMREDRWAV
496	SCP-1 934-942	TTPGSTLKF
497	SCP-1 933-942	LTPGSTLKF
498	SCP-1 937-945	GSTLKGAI
499	SCP-1 945-953	IRKMREDRW

500	SCP-1 236-243	RLEMHFKL
501	SCP-1 235-243	SRLEMHFKL
502	SCP-1 242-250	KLKEDYEKI
503	SCP-1 249-257	KIQHLEQEY
504	SCP-1 248-257	EKIQHLEQEY
505	SCP-1 233-242	ENSRLEMHF
506	SCP-1 236-245	RLEMHFKLKE
507	SCP-1 324-331	LEDIKVSL
508	SCP-1 323-331	ELEDIKVSL
509	SCP-1 322-331	KELEDIKVSL
510	SCP-1 320-327	LTKELEDI
511	SCP-1 319-327	HLTKELEDI
512	SCP-1 330-338	SLQRSVSTQ
513	SCP-1 321-329	TKELEDIKV
514	SCP-1 320-329	LTKELEDIKV
515	SCP-1 326-335	DIKVS LQRSV
516	SCP-1 281-288	KMKDLTFL
517	SCP-1 280-288	NKMKDLTFL
518	SCP-1 279-288	ENKMKDLTFL
519	SCP-1 288-296	LLEESRDKV
520	SCP-1 287-296	FLLEESRDKV
521	SCP-1 291-299	ESRDKVNQL
522	SCP-1 290-299	EESRDKVNQL
523	SCP-1 277-285	EKENMKDL
524	SCP-1 276-285	TEKENMKDL
525	SCP-1 279-287	ENKMKDLTF
526	SCP-1 218-225	IEKMITAF
527	SCP-1 217-225	NIEKMITAF
528	SCP-1 216-225	SNIEKMITAF
529	SCP-1 223-230	TAFEELRV
530	SCP-1 222-230	ITAFEELRV
531	SCP-1 221-230	MITAFEELRV
532	SCP-1 220-228	KMITAFEEL
533	SCP-1 219-228	EKMITAFEEL
534	SCP-1 227-235	ELRVQAENS
535	SCP-1 213-222	DLNSNIEKMI
536	SCP-1 837-844	WTSAKNTL
537	SCP-1 846-854	TPLPKAYTV
538	SCP-1 845-854	STPLPKAYTV
539	SCP-1 844-852	LSTPLPKAY
540	SCP-1 843-852	TLSTPLPKAY
541	SCP-1 842-850	NTLSTPLPK
542	SCP-1 841-850	KNTLSTPLPK
543	SCP-1 828-835	ISKDKRDY
544	SCP-1 826-835	HGISKDKRDY
545	SCP-1 832-840	KRDYLW TSA
546	SCP-1 829-838	SKDKRDYLWT
547	SCP-1 279-286	ENKMKDLT
548	SCP-1 260-268	EINDKEKQV
549	SCP-1 274-282	QITEKENKM

550	SCP-1 269-277	SLLLIQITE
551	SCP-1 453-460	FEKIAEEL
552	SCP-1 452-460	QFEKIAEEL
553	SCP-1 451-460	KQFEKIAEEL
554	SCP-1 449-456	DNKQFEKI
555	SCP-1 448-456	YDNKQFEKI
556	SCP-1 447-456	LYDNKQFEKI
557	SCP-1 440-447	LGEKETLL
558	SCP-1 439-447	VLGEKETLL
559	SCP-1 438-447	KVLGEKETLL
560	SCP-1 390-398	LLRTEQQL
561	SCP-1 389-398	ELLRTEQQL
562	SCP-1 393-401	TEQQRLNY
563	SCP-1 392-401	RTEQQRLNY
564	SCP-1 402-410	EDQLILTM
565	SCP-1 397-406	RLENYEDQLI
566	SCP-1 368-375	KARAAHSF
567	SCP-1 376-384	VVTEFETTV
568	SCP-1 375-384	FVVTEFETTV
569	SCP-1 377-385	VTEFETTV
570	SCP-1 376-385	VVTEFETTV
571	SCP-1 344-352	DLQIATNTI
572	SCP-1 347-355	IATNTICQL
573	SCP-1 346-355	QIATNTICQL
574	SSX4 57-65	VMTKLGFKY
575	SSX4 53-61	LNVEVMTKL
576	SSX4 52-61	KLNYEVMTKL
577	SSX4 66-74	TLPPFMRSK
578	SSX4 110-118	KIMPKKPAE
579	SSX4 103-112	SLQRIFPKIM
580	Tyr 463-471	YIKSYLEQA
581	Tyr 459-467	SFQDYIKSY
582	Tyr 458-467	DSFQDYIKSY
583	Tyr 507-514	LPEEKQPL
584	Tyr 506-514	QLPEEKQPL
585	Tyr 505-514	KQLPEEKQPL
586	Tyr 507-515	LPEEKQPLL
587	Tyr 506-515	QLPEEKQPLL
588	Tyr 497-505	SLLCRHKRK
589	ED-B domain of Fibronectin	EVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRI TVVAAGEGIPIFEDFVDSSVGYYTGTGLEPGID YDISVITLINGGESAPTTLTQQT
590	ED-B domain of Fibronectin with flanking sequence from Fibronectin	CTFDNLSPGLEYNVSVYTVKDDKESVPISDTIP EVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRI TVVAAGEGIPIFEDFVDSSVGYYTGTGLEPGID YDISVITLINGGESAPTTLTQQT AVPPPTDLRFTNIGPDTMRVTW
591	ED-B domain of Fibronectin cds	Accession number: X07717
592	CEA protein	Accession number: P06731
593	CEA cDNA	Accession number: NM_004363

594	Her2/Neu protein	Accession number: P04626
595	Her2/Neu cDNA	Accession number: M11730
596	SCP-1 protein	Accession number: Q15431
597	SCP-1 cDNA	Accession number: X95654
598	SSX-4 protein	Accession number: O60224
599	SSX-4 cDNA	Accession number: NM_005636

*Any of SEQ ID NOS. 1, 8, 9, 11-23, 26-29, 32-44, 47-54, 56-63, 66-68 88-253, and 256-588 can be useful as epitopes in any of the various embodiments of the invention. Any of SEQ ID NOS. 10, 30, 31, 45, 46, 55, 64, 65, 69, 254, and 255 can be useful as sequences containing epitopes or epitope clusters, as described in various embodiments of the invention.

5

**All accession numbers used here and throughout can be accessed through the NCBI databases, for example, through the Entrez seek and retrieval system on the world wide web.

Note that the following discussion sets forth the inventors' understanding of the operation of the invention. However, it is not intended that this discussion limit the patent to any particular theory of operation not set forth in the claims.

In pursuing the development of epitope vaccines others have generated lists of predicted epitopes based on MHC binding motifs. Such peptides can be immunogenic, but may not correspond to any naturally produced antigenic fragment. Therefore, whole antigen will not elicit a similar response or sensitize a target cell to cytolysis by CTL. Therefore such lists do not differentiate between those sequences that can be useful as vaccines and those that cannot. Efforts to determine which of these predicted epitopes are in fact naturally produced have often relied on screening their reactivity with tumor infiltrating lymphocytes (TIL). However, TIL are strongly biased to recognize immune epitopes whereas tumors (and chronically infected cells) will generally present housekeeping epitopes. Thus, unless the epitope is produced by both the housekeeping and immuno- proteasomes, the target cell will generally not be recognized by CTL induced with TIL-identified epitopes. The epitopes of the present invention, in contrast, are generated by the action of a specified proteasome, indicating that they can be naturally produced, and enabling their appropriate use. The importance of the distinction between housekeeping and immune epitopes to vaccine design is more fully set forth in PCT publication WO 01/82963A2.

The epitopes of the invention include or encode polypeptide fragments of TAAs that are precursors or products of proteasomal cleavage by a housekeeping or immune proteasome, and that contain or consist of a sequence having a known or predicted affinity for at least one allele of MHC I. In some embodiments, the epitopes include or encode a polypeptide of about 6 to 25 amino acids in length, preferably about 7 to 20 amino acids in length, more preferably about 8 to 15 amino acids in length, and still more preferably 9 or 10 amino acids in length. However, it is understood that the polypeptides can be larger as long as N-terminal trimming can produce the MHC epitope or that they do not contain sequences that cause the polypeptides to be directed away from the proteasome or to be destroyed by the proteasome. For immune epitopes, if the larger

peptides do not contain such sequences, they can be processed in the pAPC by the immune proteasome. Housekeeping epitopes may also be embedded in longer sequences provided that the sequence is adapted to facilitate liberation of the epitope's C-terminus by action of the immunoproteasome. The foregoing discussion has assumed that processing of longer epitopes proceeds through action of the immunoproteasome of the pAPC. However, processing can also be accomplished through the contrivance of some other mechanism, such as providing an exogenous protease activity and a sequence adapted so that action of the protease liberates the MHC epitope. The sequences of these epitopes can be subjected to computer analysis in order to calculate physical, biochemical, immunologic, or molecular genetic properties such as mass, isoelectric point, predicted mobility in electrophoresis, predicted binding to other MHC molecules, melting temperature of nucleic acid probes, reverse translations, similarity or homology to other sequences, and the like.

In constructing the polynucleotides encoding the polypeptide epitopes of the invention, the gene sequence of the associated TAA can be used, or the polynucleotide can be assembled from any of the corresponding codons. For a 10 amino acid epitope this can constitute on the order of 10^6 different sequences, depending on the particular amino acid composition. While large, this is a distinct and readily definable set representing a miniscule fraction of the $>10^{18}$ possible polynucleotides of this length, and thus in some embodiments, equivalents of a particular sequence disclosed herein encompass such distinct and readily definable variations on the listed sequence. In choosing a particular one of these sequences to use in a vaccine, considerations such as codon usage, self-complementarity, restriction sites, chemical stability, etc. can be used as will be apparent to one skilled in the art.

The invention contemplates producing peptide epitopes. Specifically these epitopes are derived from the sequence of a TAA, and have known or predicted affinity for at least one allele of MHC I. Such epitopes are typically identical to those produced on target cells or pAPCs.

Compositions Containing Active Epitopes

Embodiments of the present invention provide polypeptide compositions, including vaccines, therapeutics, diagnostics, pharmacological and pharmaceutical compositions. The various compositions include newly identified epitopes of TAAs, as well as variants of these epitopes. Other embodiments of the invention provide polynucleotides encoding the polypeptide epitopes of the invention. The invention further provides vectors for expression of the polypeptide epitopes for purification. In addition, the invention provides vectors for the expression of the polypeptide epitopes in an APC for use as an anti-tumor vaccine. Any of the epitopes or antigens, or nucleic acids encoding the same, from Table 1 can be used. Other embodiments relate to methods of making and using the various compositions.

A general architecture for a class I MHC-binding epitope can be described, and has been reviewed more extensively in Madden, D.R. *Annu. Rev. Immunol.* 13:587-622, 1995. Much of the binding energy arises from main chain contacts between conserved residues in the MHC molecule and the N- and C-termini of the peptide. Additional main chain contacts are made but vary among MHC alleles. Sequence specificity is conferred by side chain contacts of so-called anchor residues with pockets that, again, vary among MHC alleles. Anchor residues can be divided into primary and secondary. Primary anchor positions exhibit strong preferences for relatively well-defined sets of amino acid residues. Secondary positions show weaker and/or less well-defined preferences that can often be better described in terms of less favored, rather than more favored, residues. Additionally, residues in some secondary anchor positions are not always positioned to contact the pocket on the MHC molecule at all. Thus, a subset of peptides exists that bind to a particular MHC molecule and have a side chain-pocket contact at the position in question and another subset exists that show binding to the same MHC molecule that does not depend on the conformation the peptide assumes in the peptide-binding groove of the MHC molecule. The C-terminal residue (P_ω) is preferably a primary anchor residue. For many of the better studied HLA molecules (e.g. A2, A68, B27, B7, B35, and B53) the second position (P2) is also an anchor residue. However, central anchor residues have also been observed including P3 and P5 in HLA-B8, as well as P5 and P_{ω-3} in the murine MHC molecules H-2D^b and H-2K^b, respectively. Since more stable binding will generally improve immunogenicity, anchor residues are preferably conserved or optimized in the design of variants, regardless of their position.

Because the anchor residues are generally located near the ends of the epitope, the peptide can buckle upward out of the peptide-binding groove allowing some variation in length. Epitopes ranging from 8-11 amino acids have been found for HLA-A68, and up to 13 amino acids for HLA-A2. In addition to length variation between the anchor positions, single residue truncations and extensions have been reported and the N- and C-termini, respectively. Of the non-anchor residues, some point up out of the groove, making no contact with the MHC molecule but being available to contact the TCR, very often P1, P4, and P_{ω-1} for HLA-A2. Others of the non-anchor residues can become interposed between the upper edges of the peptide-binding groove and the TCR, contacting both. The exact positioning of these side chain residues, and thus their effects on binding, MHC fine conformation, and ultimately immunogenicity, are highly sequence dependent. For an epitope to be highly immunogenic it must not only promote stable enough TCR binding for activation to occur, but the TCR must also have a high enough off-rate that multiple TCR molecules can interact sequentially with the same peptide-MHC complex (Kalergis, A.M. et al., *Nature Immunol.* 2:229-234, 2001. Thus, without further information about the ternary complex,

both conservative and non-conservative substitutions at these positions merit consideration when designing variants.

The polypeptide epitope variants can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations. Variants can be derived from substitution, deletion or insertion of one or more amino acids as compared with the native sequence. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a threonine with a serine, for example. Such replacements are referred to as conservative amino acid replacements, and all appropriate conservative amino acid replacements are considered to be embodiments of one invention. Insertions or deletions can optionally be in the range of about 1 to 4, preferably 1 to 2, amino acids. It is generally preferable to maintain the "anchor positions" of the peptide which are responsible for binding to the MHC molecule in question. Indeed, immunogenicity of peptides can be improved in many cases by substituting more preferred residues at the anchor positions (Franco, et al., *Nature Immunology*, 1(2):145-150, 2000). Immunogenicity of a peptide can also often be improved by substituting bulkier amino acids for small amino acids found in non-anchor positions while maintaining sufficient cross-reactivity with the original epitope to constitute a useful vaccine. The variation allowed can be determined by routine insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the polypeptide epitope. Because the polypeptide epitope is often 9 amino acids, the substitutions preferably are made to the shortest active epitope, for example, an epitope of 9 amino acids.

Variants can also be made by adding any sequence onto the N-terminus of the polypeptide epitope variant. Such N-terminal additions can be from 1 amino acid up to at least 25 amino acids. Because peptide epitopes are often trimmed by N-terminal exopeptidases active in the pAPC, it is understood that variations in the added sequence can have no effect on the activity of the epitope. In preferred embodiments, the amino acid residues between the last upstream proteasomal cleavage site and the N-terminus of the MHC epitope do not include a proline residue. Serwold, T. et al., *Nature Immunol.* 2:644-651, 2001. Accordingly, effective epitopes can be generated from precursors larger than the preferred 9-mer class I motif.

Generally, peptides are useful to the extent that they correspond to epitopes actually displayed by MHC I on the surface of a target cell or a pACP. A single peptide can have varying affinities for different MHC molecules, binding some well, others adequately, and still others not appreciably (Table 2). MHC alleles have traditionally been grouped according to serologic reactivity which does not reflect the structure of the peptide-binding groove, which can differ among different alleles of the same type. Similarly, binding properties can be shared across types;

groups based on shared binding properties have been termed supertypes. There are numerous alleles of MHC I in the human population; epitopes specific to certain alleles can be selected based on the genotype of the patient.

Table 2.

5 **Predicted Binding of Tyrosinase₂₀₇₋₂₁₆ (SEQ ID NO. 1) to Various MHC types**

MHC I type	*Half time of dissociation (min)
A1	0.05
A*0201	1311.
A*0205	50.4
A3	2.7
A*1101 (part of the A3 supertype)	0.012
A24	6.0
B7	4.0
B8	8.0
B14 (part of the B27 supertype)	60.0
B*2702	0.9
B*2705	30.0
B*3501 (part of the B7 supertype)	2.0
B*4403	.0.1
B*5101 (part of the B7 supertype)	26.0
B*5102	55.0
B*5801	0.20
B60	0.40
B62	2.0

*HLA Peptide Binding Predictions (world wide web hypertext transfer protocol "access at bimas.dcrt.nih.gov/molbio/hla_bin").

In further embodiments of the invention, the epitope, as peptide or encoding polynucleotide, can be administered as a pharmaceutical composition, such as, for example, a vaccine or an immunogenic composition, alone or in combination with various adjuvants, carriers, or excipients. It should be noted that although the term vaccine may be used throughout the discussion herein, the concepts can be applied and used with any other pharmaceutical composition, including those mentioned herein. Particularly advantageous adjuvants include various cytokines and oligonucleotides containing immunostimulatory sequences (as set forth in greater detail in the co-pending applications referenced herein). Additionally the polynucleotide encoded epitope can be contained in a virus (e.g. *vaccinia* or adenovirus) or in a microbial host cell (e.g. *Salmonella* or *Listeria monocytogenes*) which is then used as a vector for the polynucleotide (Dietrich, G. et al. Nat. Biotech. 16:181-185, 1998). Alternatively a pAPC can be transformed, *ex vivo*, to express the epitope, or pulsed with peptide epitope, to be itself administered as a vaccine. To increase efficiency of these processes, the encoded epitope can be carried by a viral or bacterial vector, or complexed with a ligand of a receptor found on pAPC. Similarly the peptide epitope can

be complexed with or conjugated to a pAPC ligand. A vaccine can be composed of more than a single epitope.

5 Particularly advantageous strategies for incorporating epitopes and/or epitope clusters, into a vaccine or pharmaceutical composition are disclosed in U.S. Patent Application No. 09/560,465 entitled "EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS," filed on April 28, 2000. Epitope clusters for use in connection with this invention are disclosed in U.S. Patent Application No. 09/561,571 entitled "EPITOPE CLUSTERS," filed on April 28, 2000.

10 Preferred embodiments of the present invention are directed to vaccines and methods for causing a pAPC or population of pAPCs to present housekeeping epitopes that correspond to the epitopes displayed on a particular target cell. Any of the epitopes or antigens in Table 1, can be used for example. In one embodiment, the housekeeping epitope is a TuAA epitope processed by the housekeeping proteasome of a particular tumor type. In another embodiment, the housekeeping epitope is a virus-associated epitope processed by the housekeeping proteasome of a cell infected with a virus. This facilitates a specific T cell response to the target cells. Concurrent
15 expression by the pAPCs of multiple epitopes, corresponding to different induction states (pre- and post-attack), can drive a CTL response effective against target cells as they display either housekeeping epitopes or immune epitopes.

By having both housekeeping and immune epitopes present on the pAPC, this embodiment can optimize the cytotoxic T cell response to a target cell. With dual epitope expression, the
20 pAPCs can continue to sustain a CTL response to the immune-type epitope when the tumor cell switches from the housekeeping proteasome to the immune proteasome with induction by IFN, which, for example, may be produced by tumor-infiltrating CTLs.

In a preferred embodiment, immunization of a patient is with a vaccine that includes a housekeeping epitope. Many preferred TAAs are associated exclusively with a target cell,
25 particularly in the case of infected cells. In another embodiment, many preferred TAAs are the result of deregulated gene expression in transformed cells, but are found also in tissues of the testis, ovaries and fetus. In another embodiment, useful TAAs are expressed at higher levels in the target cell than in other cells. In still other embodiments, TAAs are not differentially expressed in the target cell compare to other cells, but are still useful since they are involved in a particular
30 function of the cell and differentiate the target cell from most other peripheral cells; in such embodiments, healthy cells also displaying the TAA may be collaterally attacked by the induced T cell response, but such collateral damage is considered to be far preferable to the condition caused by the target cell.

35 The vaccine contains a housekeeping epitope in a concentration effective to cause a pAPC or populations of pAPCs to display housekeeping epitopes. Advantageously, the vaccine can

include a plurality of housekeeping epitopes or one or more housekeeping epitopes optionally in combination with one or more immune epitopes. Formulations of the vaccine contain peptides and/or nucleic acids in a concentration sufficient to cause pAPCs to present the epitopes. The formulations preferably contain epitopes in a total concentration of about 1 μ g-1mg/100 μ l of vaccine preparation. Conventional dosages and dosing for peptide vaccines and/or nucleic acid vaccines can be used with the present invention, and such dosing regimens are well understood in the art. In one embodiment, a single dosage for an adult human may advantageously be from about 1 to about 5000 μ l of such a composition, administered one time or multiple times, e.g., in 2, 3, 4 or more dosages separated by 1 week, 2 weeks, 1 month, or more. insulin pump delivers 1 ul per hour (lowest frequency) ref intranodal method patent.

The compositions and methods of the invention disclosed herein further contemplate incorporating adjuvants into the formulations in order to enhance the performance of the vaccines. Specifically, the addition of adjuvants to the formulations is designed to enhance the delivery or uptake of the epitopes by the pAPCs. The adjuvants contemplated by the present invention are known by those of skill in the art and include, for example, GMCSF, GCSF, IL-2, IL-12, BCG, tetanus toxoid, osteopontin, and ETA-1.

In some embodiments of the invention, the vaccines can include a recombinant organism, such as a virus, bacterium or parasite, genetically engineered to express an epitope in a host. For example, *Listeria monocytogenes*, a gram-positive, facultative intracellular bacterium, is a potent vector for targeting TuAAs to the immune system. In a preferred embodiment, this vector can be engineered to express a housekeeping epitope to induce therapeutic responses. The normal route of infection of this organism is through the gut and can be delivered orally. In another embodiment, an adenovirus (Ad) vector encoding a housekeeping epitope for a TuAA can be used to induce anti-virus or anti-tumor responses. Bone marrow-derived dendritic cells can be transduced with the virus construct and then injected, or the virus can be delivered directly via subcutaneous injection into an animal to induce potent T-cell responses. Another embodiment employs a recombinant vaccinia virus engineered to encode amino acid sequences corresponding to a housekeeping epitope for a TAA. Vaccinia viruses carrying constructs with the appropriate nucleotide substitutions in the form of a minigene construct can direct the expression of a housekeeping epitope, leading to a therapeutic T cell response against the epitope.

The immunization with DNA requires that APCs take up the DNA and express the encoded proteins or peptides. It is possible to encode a discrete class I peptide on the DNA. By immunizing with this construct, APCs can be caused to express a housekeeping epitope, which is then displayed on class I MHC on the surface of the cell for stimulating an appropriate CTL response. Constructs generally relying on termination of translation or non-proteasomal proteases

for generation of proper termini of housekeeping epitopes have been described in U.S. Patent application No. 09/561,572 entitled EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS, filed on April 28, 2000.

As mentioned, it can be desirable to express housekeeping peptides in the context of a larger protein. Processing can be detected even when a small number of amino acids are present beyond the terminus of an epitope. Small peptide hormones are usually proteolytically processed from longer translation products, often in the size range of approximately 60-120 amino acids. This fact has led some to assume that this is the minimum size that can be efficiently translated. In some embodiments, the housekeeping peptide can be embedded in a translation product of at least about 60 amino acids. In other embodiments the housekeeping peptide can be embedded in a translation product of at least about 50, 30, or 15 amino acids.

Due to differential proteasomal processing, the immune proteasome of the pAPC produces peptides that are different from those produced by the housekeeping proteasome in peripheral body cells. Thus, in expressing a housekeeping peptide in the context of a larger protein, it is preferably expressed in the APC in a context other than its full length native sequence, because, as a housekeeping epitope, it is generally only efficiently processed from the native protein by the housekeeping proteasome, which is not active in the APC. In order to encode the housekeeping epitope in a DNA sequence encoding a larger protein, it is useful to find flanking areas on either side of the sequence encoding the epitope that permit appropriate cleavage by the immune proteasome in order to liberate that housekeeping epitope. Altering flanking amino acid residues at the N-terminus and C-terminus of the desired housekeeping epitope can facilitate appropriate cleavage and generation of the housekeeping epitope in the APC. Sequences embedding housekeeping epitopes can be designed *de novo* and screened to determine which can be successfully processed by immune proteasomes to liberate housekeeping epitopes.

Alternatively, another strategy is very effective for identifying sequences allowing production of housekeeping epitopes in APC. A contiguous sequence of amino acids can be generated from head to tail arrangement of one or more housekeeping epitopes. A construct expressing this sequence is used to immunize an animal, and the resulting T cell response is evaluated to determine its specificity to one or more of the epitopes in the array. By definition, these immune responses indicate housekeeping epitopes that are processed in the pAPC effectively. The necessary flanking areas around this epitope are thereby defined. The use of flanking regions of about 4-6 amino acids on either side of the desired peptide can provide the necessary information to facilitate proteasome processing of the housekeeping epitope by the immune proteasome. Therefore, a sequence ensuring epitope synchronization of approximately 16-22 amino acids can be inserted into, or fused to, any protein sequence effectively to result in

that housekeeping epitope being produced in an APC. In alternate embodiments the whole head-to-tail array of epitopes, or just the epitopes immediately adjacent to the correctly processed housekeeping epitope can be similarly transferred from a test construct to a vaccine vector.

5 In a preferred embodiment, the housekeeping epitopes can be embedded between known immune epitopes, or segments of such, thereby providing an appropriate context for processing. The abutment of housekeeping and immune epitopes can generate the necessary context to enable the immune proteasome to liberate the housekeeping epitope, or a larger fragment, preferably including a correct C-terminus. It can be useful to screen constructs to verify that the desired epitope is produced. The abutment of housekeeping epitopes can generate a site cleavable by the
10 immune proteasome. Some embodiments of the invention employ known epitopes to flank housekeeping epitopes in test substrates; in others, screening as described below are used whether the flanking regions are arbitrary sequences or mutants of the natural flanking sequence, and whether or not knowledge of proteasomal cleavage preferences are used in designing the substrates.

15 Cleavage at the mature N-terminus of the epitope, while advantageous, is not required, since a variety of N-terminal trimming activities exist in the cell that can generate the mature N-terminus of the epitope subsequent to proteasomal processing. It is preferred that such N-terminal extension be less than about 25 amino acids in length and it is further preferred that the extension have few or no proline residues. Preferably, in screening, consideration is given not only to
20 cleavage at the ends of the epitope (or at least at its C-terminus), but consideration also can be given to ensure limited cleavage within the epitope.

Shotgun approaches can be used in designing test substrates and can increase the efficiency of screening. In one embodiment multiple epitopes can be assembled one after the other, with individual epitopes possibly appearing more than once. The substrate can be screened to determine
25 which epitopes can be produced. In the case where a particular epitope is of concern a substrate can be designed in which it appears in multiple different contexts. When a single epitope appearing in more than one context is liberated from the substrate additional secondary test substrates, in which individual instances of the epitope are removed, disabled, or are unique, can be used to determine which are being liberated and truly constitute sequences ensuring epitope synchronization.

30 Several readily practicable screens exist. A preferred *in vitro* screen utilizes proteasomal digestion analysis, using purified immune proteasomes, to determine if the desired housekeeping epitope can be liberated from a synthetic peptide embodying the sequence in question. The position of the cleavages obtained can be determined by techniques such as mass spectrometry, HPLC, and N-terminal pool sequencing; as described in greater detail in U. S. Patent Applications entitled
35 METHOD OF EPIOTOPE DISCOVERY, EPIOTOPE SYNCHRONIZATION IN ANTIGEN

PRESENTING CELLS, two Provisional U. S. Patent Applications entitled EPITOPE SEQUENCES.

Alternatively, *in vivo* screens such as immunization or target sensitization can be employed. For immunization a nucleic acid construct capable of expressing the sequence in question is used. Harvested CTL can be tested for their ability to recognize target cells presenting the housekeeping epitope in question. Such targets cells are most readily obtained by pulsing cells expressing the appropriate MHC molecule with synthetic peptide embodying the mature housekeeping epitope. Alternatively, cells known to express housekeeping proteasome and the antigen from which the housekeeping epitope is derived, either endogenously or through genetic engineering, can be used. To use target sensitization as a screen, CTL, or preferably a CTL clone, that recognizes the housekeeping epitope can be used. In this case it is the target cell that expresses the embedded housekeeping epitope (instead of the pAPC during immunization) and it must express immune proteasome. Generally, the target cell can be transformed with an appropriate nucleic acid construct to confer expression of the embedded housekeeping epitope. Loading with a synthetic peptide embodying the embedded epitope using peptide loaded liposomes or a protein transfer reagent such as BIOPORTER™ (Gene Therapy Systems, San Diego, CA) represents an alternative.

Additional guidance on nucleic acid constructs useful as vaccines in accordance with the present invention are disclosed in U.S. Patent Application No. 09/561,572 entitled "EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS," filed on April 28, 2000. Further, expression vectors and methods for their design, which are useful in accordance with the present invention are disclosed in U.S. Patent Application No. 60/336,968 (attorney docket number CTLIMM.022PR) entitled "EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS AND METHODS FOR THEIR DESIGN," filed on 11/7/2001.

A preferred embodiment of the present invention includes a method of administering a vaccine including an epitope (or epitopes) to induce a therapeutic immune response. The vaccine is administered to a patient in a manner consistent with the standard vaccine delivery protocols that are known in the art. Methods of administering epitopes of TAAs including, without limitation, transdermal, intranodal, perinodal, oral, intravenous, intradermal, intramuscular, intraperitoneal, and mucosal administration, including delivery by injection, instillation or inhalation. A particularly useful method of vaccine delivery to elicit a CTL response is disclosed in Australian Patent No. 739189 issued January 17, 2002; U.S. Patent Application No. 09/380,534, filed on September 1, 1999; and a Continuation-in-Part thereof U.S. Patent Application No. 09/776,232 both entitled "A METHOD OF INDUCING A CTL RESPONSE," filed on February 2, 2001.

Reagents Recognizing Epitopes

In another aspect of the invention, proteins with binding specificity for the epitope and/or the epitope-MHC molecule complex are contemplated, as well as the isolated cells by which they can be expressed. In one set of embodiments these reagents take the form of immunoglobulins: polyclonal sera or monoclonal antibodies (mAb), methods for the generation of which are well known in the art. Generation of mAb with specificity for peptide-MHC molecule complexes is known in the art. See, for example, Aharoni et al. *Nature* 351:147-150, 1991; Andersen et al. *Proc. Natl. Acad. Sci. USA* 93:1820-1824, 1996; Dadaglio et al. *Immunity* 6:727-738, 1997; Duc et al. *Int. Immunol.* 5:427-431, 1993; Eastman et al. *Eur. J. Immunol.* 26:385-393, 1996; Engberg et al. *Immunotechnology* 4:273-278, 1999; Porgdor et al. *Immunity* 6:715-726, 1997; Puri et al. *J. Immunol.* 158:2471-2476, 1997; and Polakova, K., et al. *J. Immunol.* 165 342-348, 2000.

In other embodiments the compositions can be used to induce and generate, *in vivo* and *in vitro*, T-cells specific for the any of the epitopes and/or epitope-MHC complexes. In preferred embodiments the epitope can be any one or more of those listed in TABLE 1, for example. Thus, embodiments also relate to and include isolated T cells, T cell clones, T cell hybridomas, or a protein containing the T cell receptor (TCR) binding domain derived from the cloned gene, as well as a recombinant cell expressing such a protein. Such TCR derived proteins can be simply the extra-cellular domains of the TCR, or a fusion with portions of another protein to confer a desired property or function. One example of such a fusion is the attachment of TCR binding domains to the constant regions of an antibody molecule so as to create a divalent molecule. The construction and activity of molecules following this general pattern have been reported, for example, Plaksin, D. et al. *J. Immunol.* 158:2218-2227, 1997 and Lebowitz, M.S. et al. *Cell Immunol.* 192:175-184, 1999. The more general construction and use of such molecules is also treated in U.S. patent 5,830,755 entitled T CELL RECEPTORS AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC METHODS.

The generation of such T cells can be readily accomplished by standard immunization of laboratory animals, and reactivity to human target cells can be obtained by immunizing with human target cells or by immunizing HLA-transgenic animals with the antigen/epitope. For some therapeutic approaches T cells derived from the same species are desirable. While such a cell can be created by cloning, for example, a murine TCR into a human T cell as contemplated above, *in vitro* immunization of human cells offers a potentially faster option. Techniques for *in vitro* immunization, even using naive donors, are known in the field, for example, Stauss et al., *Proc. Natl. Acad. Sci. USA* 89:7871-7875, 1992; Salgaller et al. *Cancer Res.* 55:4972-4979, 1995; Tsai et al., *J. Immunol.* 158:1796-1802, 1997; and Chung et al., *J. Immunother.* 22:279-287, 1999.

Any of these molecules can be conjugated to enzymes, radiochemicals, fluorescent tags, and toxins, so as to be used in the diagnosis (imaging or other detection), monitoring, and treatment of the pathogenic condition associated with the epitope. Thus a toxin conjugate can be administered to kill tumor cells, radiolabeling can facilitate imaging of epitope positive tumor, an enzyme conjugate can be used in an ELISA-like assay to diagnose cancer and confirm epitope expression in biopsied tissue. In a further embodiment, such T cells as set forth above, following expansion accomplished through stimulation with the epitope and/or cytokines, can be administered to a patient as an adoptive immunotherapy.

Reagents Comprising Epitopes

A further aspect of the invention provides isolated epitope-MHC complexes. In a particularly advantageous embodiment of this aspect of the invention, the complexes can be soluble, multimeric proteins such as those described in U. S. Patent No. 5,635,363 (tetramers) or U. S. Patent No. 6,015,884 (Ig-dimers). Such reagents are useful in detecting and monitoring specific T cell responses, and in purifying such T cells.

Isolated MHC molecules complexed with epitopic peptides can also be incorporated into planar lipid bilayers or liposomes. Such compositions can be used to stimulate T cells *in vitro* or, in the case of liposomes, *in vivo*. Co-stimulatory molecules (e.g. B7, CD40, LFA-3) can be incorporated into the same compositions or, especially for *in vitro* work, co-stimulation can be provided by anti-co-receptor antibodies (e.g. anti-CD28, anti-CD154, anti-CD2) or cytokines (e.g. IL-2, IL-12). Such stimulation of T cells can constitute vaccination, drive expansion of T cells *in vitro* for subsequent infusion in an immunotherapy, or constitute a step in an assay of T cell function.

The epitope, or more directly its complex with an MHC molecule, can be an important constituent of functional assays of antigen-specific T cells at either an activation or readout step or both. Of the many assays of T cell function current in the art (detailed procedures can be found in standard immunological references such as *Current Protocols in Immunology* 1999 John Wiley & Sons Inc., N.Y. two broad classes can be defined, those that measure the response of a pool of cells and those that measure the response of individual cells. Whereas the former conveys a global measure of the strength of a response, the latter allows determination of the relative frequency of responding cells. Examples of assays measuring global response are cytotoxicity assays, ELISA, and proliferation assays detecting cytokine secretion. Assays measuring the responses of individual cells (or small clones derived from them) include limiting dilution analysis (LDA), ELISPOT, flow cytometric detection of unsecreted cytokine (described in U.S. Patent No. 5,445,939, entitled "METHOD FOR ASSESSMENT OF THE MONONUCLEAR LEUKOCYTE IMMUNE SYSTEM" and U.S. Patent Nos 5,656,446; and 5,843,689, both entitled "METHOD

FOR THE ASSESSMENT OF THE MONONUCLEAR LEUKOCYTE IMMUNE SYSTEM," reagents for which are sold by Becton, Dickinson & Company under the tradename 'FASTIMMUNE' and detection of specific TCR with tetramers or Ig-dimers as stated and referenced above. The comparative virtues of these techniques have been reviewed in Yee, C. et al. *Current Opinion in Immunology*, 13:141-146, 2001. Additionally detection of a specific TCR rearrangement or expression can be accomplished through a variety of established nucleic acid based techniques, particularly in situ and single-cell PCR techniques, as will be apparent to one of skill in the art.

These functional assays are used to assess endogenous levels of immunity, response to an immunologic stimulus (e.g. a vaccine), and to monitor immune status through the course of a disease and treatment. Except when measuring endogenous levels of immunity, any of these assays presume a preliminary step of immunization, whether *in vivo* or *in vitro* depending on the nature of the issue being addressed. Such immunization can be carried out with the various embodiments of the invention described above or with other forms of immunogen (e.g., pAPC-tumor cell fusions) that can provoke similar immunity. With the exception of PCR and tetramer/Ig-dimer type analyses which can detect expression of the cognate TCR, these assays generally benefit from a step of *in vitro* antigenic stimulation which can advantageously use various embodiments of the invention as described above in order to detect the particular functional activity (highly cytolytic responses can sometimes be detected directly). Finally, detection of cytolytic activity requires epitope-displaying target cells, which can be generated using various embodiments of the invention. The particular embodiment chosen for any particular step depends on the question to be addressed, ease of use, cost, and the like, but the advantages of one embodiment over another for any particular set of circumstances will be apparent to one of skill in the art.

The peptide MHC complexes described in this section have traditionally been understood to be non-covalent associations. However it is possible, and can be advantageous, to create a covalent linkages, for example by encoding the epitope and MHC heavy chain or the epitope, β 2-microglobulin, and MHC heavy chain as a single protein (Yu, Y.L.Y., et al., *J. Immunol.* 168:3145-3149, 2002; Mottez, E., et al., *J. Exp. Med.* 181:493,1995; Dela Cruz, C. S., et al., *Int. Immunol.* 12:1293, 2000; Mage, M. G., et al., *Proc. Natl. Acad. Sci. USA* 89:10658,1992; Toshitani, K., et al., *Proc. Natl. Acad. Sci. USA* 93:236,1996; Lee, L., et al., *Eur. J. Immunol.* 24:2633,1994; Chung, D. H., et al., *J. Immunol.* 163:3699,1999; Uger, R. A. and B. H. Barber, *J. Immunol.* 160:1598, 1998; Uger, R. A., et al., *J. Immunol.* 162:6024,1999; and White, J., et al., *J. Immunol.* 162:2671, 1999. Such constructs can have superior stability and overcome roadblocks in

the processing- presentation pathway. They can be used in the already described vaccines, reagents, and assays in similar fashion.

Tumor Associated Antigens

Epitopes of the present invention are derived from the TuAAs tyrosinase (SEQ ID NO. 2),
5 SSX-2, (SEQ ID NO. 3), PSMA (prostate-specific membrane antigen) (SEQ ID NO. 4), GP100,
(SEQ ID NO. 70), MAGE-1, (SEQ ID NO. 71), MAGE-2, (SEQ ID NO. 72), MAGE-3, (SEQ ID
NO. 73), NY-ESO-1, (SEQ ID NO. 74), PRAME, (SEQ ID NO. 77), PSA, (SEQ ID NO. 78),
PSCA, (SEQ ID NO. 79), the ED-B domain of fibronectin (SEQ ID NOS 589 and 590), CEA
10 (carcinoembryonic antigen) (SEQ ID NO. 592), Her2/Neu (SEQ ID NO. 594), SCP-1 (SEQ ID NO.
596) and SSX-4 (SEQ ID NO. 598). The natural coding sequences for these eleven proteins, or
any segments within them, can be determined from their cDNA or complete coding (cds)
sequences, SEQ ID NOS. 5-7, 80-87, 591, 593, 595, 597, and 599, respectively.

Tyrosinase is a melanin biosynthetic enzyme that is considered one of the most specific
markers of melanocytic differentiation. Tyrosinase is expressed in few cell types, primarily in
15 melanocytes, and high levels are often found in melanomas. The usefulness of tyrosinase as a
TuAA is taught in U.S. Patent 5,747,271 entitled "METHOD FOR IDENTIFYING
INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE
ABNORMAL CELLS PRESENT COMPLEXES OF HLA-A2/TYROSINASE DERIVED
PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS".

20 GP100, also known as PMel17, also is a melanin biosynthetic protein expressed at high
levels in melanomas. GP100 as a TuAA is disclosed in U.S. Patent 5,844,075 entitled
"MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC
METHODS,".

SSX-2, also know as Hom-Mel-40, is a member of a family of highly conserved cancer-
25 testis antigens (Gure, A.O. et al. *Int. J. Cancer* 72:965-971, 1997. Its identification as a TuAA is
taught in U.S. Patent 6,025,191 entitled "ISOLATED NUCLEIC ACID MOLECULES WHICH
ENCODE A MELANOMA SPECIFIC ANTIGEN AND USES THEREOF,". Cancer-testis
antigens are found in a variety of tumors, but are generally absent from normal adult tissues except
testis. Expression of different members of the SSX family have been found variously in tumor cell
30 lines. Due to the high degree of sequence identity among SSX family members, similar epitopes
from more than one member of the family will be generated and able to bind to an MHC molecule,
so that some vaccines directed against one member of this family can cross-react and be effective
against other members of this family (see example 3 below).

MAGE-1, MAGE-2, and MAGE-3 are members of another family of cancer-testis antigens
35 originally discovered in melanoma (MAGE is a contraction of melanoma-associated antigen) but

found in a variety of tumors. The identification of MAGE proteins as TuAAs is taught in U.S. Patent 5,342,774 entitled NUCLEOTIDE SEQUENCE ENCODING THE TUMOR REJECTION ANTIGEN PRECURSOR, MAGE-1, and in numerous subsequent patents. Currently there are 17 entries for (human) MAGE in the SWISS Protein database. There is extensive similarity among these proteins so in many cases, an epitope from one can induce a cross-reactive response to other members of the family. A few of these have not been observed in tumors, most notably MAGE-H1 and MAGE-D1, which are expressed in testes and brain, and bone marrow stromal cells, respectively. The possibility of cross-reactivity on normal tissue is ameliorated by the fact that they are among the least similar to the other MAGE proteins.

NY-ESO-1, is a cancer-testis antigen found in a wide variety of tumors, also known as CTAG-1 (Cancer-Testis Antigen-1) and CAG-3 (Cancer Antigen-3). NY-ESO-1 as a TuAA is disclosed in U.S. Patent 5,804,381 entitled ISOLATED NUCLEIC ACID MOLECULE ENCODING AN ESOPHAGEAL CANCER ASSOCIATED ANTIGEN, THE ANTIGEN ITSELF, AND USES THEREOF. A paralogous locus encoding antigens with extensive sequence identity, LAGE-1a/s (SEQ ID NO. 75) and LAGE-1b/L (SEQ ID NO. 76), have been disclosed in publicly available assemblies of the human genome, and have been concluded to arise through alternate splicing. Additionally, CT-2 (or CTAG-2, Cancer-Testis Antigen-2) appears to be either an allele, a mutant, or a sequencing discrepancy of LAGE-1b/L. Due to the extensive sequence identity, many epitopes from NY-ESO-1 can also induce immunity to tumors expressing these other antigens. See figure 1. The proteins are virtually identical through amino acid 70. From 71-134 the longest run of identities between NY-ESO-1 and LAGE is 6 residues, but potentially cross-reactive sequences are present. And from 135-180 NY-ESO and LAGE-1a/s are identical except for a single residue, but LAGE-1b/L is unrelated due to the alternate splice. The CAMEL and LAGE-2 antigens appear to derive from the LAGE-1 mRNA, but from alternate reading frames, thus giving rise to unrelated protein sequences. More recently, GenBank Accession AF277315.5, Homo sapiens chromosome X clone RP5-865E18, RP5-1087L19, complete sequence, reports three independent loci in this region which are labeled as LAGE1 (corresponding to CTAG-2 in the genome assemblies), plus LAGE2-A and LAGE2-B (both corresponding to CTAG-1 in the genome assemblies).

PSMA (prostate-specific membranes antigen), a TuAA described in U.S. Patent 5,538,866 entitled "PROSTATE-SPECIFIC MEMBRANES ANTIGEN", is expressed by normal prostate epithelium and, at a higher level, in prostatic cancer. It has also been found in the neovasculature of non-prostatic tumors. PSMA can thus form the basis for vaccines directed to both prostate cancer and to the neovasculature of other tumors. This later concept is more fully described in a provisional U.S. Patent application No. 60/274,063 entitled ANTI-NEOVASCULAR VACCINES

FOR CANCER, filed March 7, 2001, and U.S. Application No. 10/094,699, attorney docket number CTLIMM.015A, filed on March 7, 2002, entitled "ANTI-NEOVASCULAR PREPARATIONS FOR CANCER,". Briefly, as tumors grow they recruit ingrowth of new blood vessels. This is understood to be necessary to sustain growth as the centers of unvascularized tumors are generally necrotic and angiogenesis inhibitors have been reported to cause tumor regression. Such new blood vessels, or neovasculature, express antigens not found in established vessels, and thus can be specifically targeted. By inducing CTL against neovascular antigens the vessels can be disrupted, interrupting the flow of nutrients to (and removal of wastes from) tumors, leading to regression.

Alternate splicing of the PSMA mRNA also leads to a protein with an apparent start at Met₅₈, thereby deleting the putative membrane anchor region of PSMA as described in U.S. Patent 5,935,818 entitled "ISOLATED NUCLEIC ACID MOLECULE ENCODING ALTERNATIVELY SPLICED PROSTATE-SPECIFIC MEMBRANES ANTIGEN AND USES THEREOF". A protein termed PSMA-like protein, Genbank accession number AF261715, is nearly identical to amino acids 309-750 of PSMA and has a different expression profile. Thus the most preferred epitopes are those with an N-terminus located from amino acid 58 to 308.

PRAME, also know as MAPE, DAGE, and OIP4, was originally observed as a melanoma antigen. Subsequently, it has been recognized as a CT antigen, but unlike many CT antigens (e.g., MAGE, GAGE, and BAGE) it is expressed in acute myeloid leukemias. PRAME is a member of the MAPE family which consists largely of hypothetical proteins with which it shares limited sequence similarity. The usefulness of PRAME as a TuAA is taught in U.S. Patent 5,830,753 entitled "ISOLATED NUCLEIC ACID MOLECULES CODING FOR TUMOR REJECTION ANTIGEN PRECURSOR DAGE AND USES THEREOF".

PSA, prostate specific antigen, is a peptidase of the kallikrein family and a differentiation antigen of the prostate. Expression in breast tissue has also been reported. Alternate names include gamma-seminoprotein, kallikrein 3, seminogelase, seminin, and P-30 antigen. PSA has a high degree of sequence identity with the various alternate splicing products prostatic/glandular kallikrein-1 and -2, as well as kalikrein 4, which is also expressed in prostate and breast tissue. Other kallikreins generally share less sequence identity and have different expression profiles. Nonetheless, cross-reactivity that might be provoked by any particular epitope, along with the likelihood that that epitope would be liberated by processing in non-target tissues (most generally by the housekeeping proteasome), should be considered in designing a vaccine.

PSCA, prostate stem cell antigen, and also known as SCAH-2, is a differentiation antigen preferentially expressed in prostate epithelial cells, and overexpressed in prostate cancers. Lower level expression is seen in some normal tissues including neuroendocrine cells of the digestive

tract and collecting ducts of the kidney. PSCA is described in U.S. Patent 5,856,136 entitled "HUMAN STEM CELL ANTIGENS".

5 Synaptonemal complex protein 1 (SCP-1), also known as HOM-TES-14, is a meiosis-associated protein and also a cancer-testis antigen (Tureci, O., et al. *Proc. Natl. Acad. Sci. USA* 95:5211-5216, 1998). As a cancer antigen its expression is not cell-cycle regulated and it is found frequently in gliomas, breast, renal cell, and ovarian carcinomas. It has some similarity to myosins, but with few enough identities that cross-reactive epitopes are not an immediate prospect.

10 The ED-B domain of fibronectin is also a potential target. Fibronectin is subject to developmentally regulated alternative splicing, with the ED-B domain being encoded by a single exon that is used primarily in oncofetal tissues (Matsuura, H. and S. Hakomori *Proc. Natl. Acad. Sci. USA* 82:6517-6521, 1985; Carnemolla, B. et al. *J. Cell Biol.* 108:1139-1148, 1989; Loridon-Rosa, B. et al. *Cancer Res.* 50:1608-1612, 1990; Nicolo, G. et al. *Cell Differ. Dev.* 32:401-408, 1990; Borsi, L. et al. *Exp. Cell Res.* 199:98-105, 1992; Oyama, F. et al. *Cancer Res.* 53:2005-2011, 1993; Mandel, U. et al. *APMIS* 102:695-702, 1994; Farnoud, M.R. et al. *Int. J. Cancer* 61:27-34, 15 1995; Pujuguet, P. et al. *Am. J. Pathol.* 148:579-592, 1996; Gabler, U. et al. *Heart* 75:358-362, 1996; Chevalier, X. *Br. J. Rheumatol.* 35:407-415, 1996; Midulla, M. *Cancer Res.* 60:164-169, 2000).

20 The ED-B domain is also expressed in fibronectin of the neovasculature (Kaczmarek, J. et al. *Int. J. Cancer* 59:11-16, 1994; Castellani, P. et al. *Int. J. Cancer* 59:612-618, 1994; Neri, D. et al. *Nat. Biotech.* 15:1271-1275, 1997; Karelina, T.V. and A.Z. Eisen *Cancer Detect. Prev.* 22:438-444, 1998; Tarli, L. et al. *Blood* 94:192-198, 1999; Castellani, P. et al. *Acta Neurochir. (Wien)* 142:277-282, 2000). As an oncofetal domain, the ED-B domain is commonly found in the fibronectin expressed by neoplastic cells in addition to being expressed by the neovasculature. Thus, CTL-inducing vaccines targeting the ED-B domain can exhibit two mechanisms of action: 25 direct lysis of tumor cells, and disruption of the tumor's blood supply through destruction of the tumor-associated neovasculature. As CTL activity can decay rapidly after withdrawal of vaccine, interference with normal angiogenesis can be minimal. The design and testing of vaccines targeted to neovasculature is described in Provisional U.S. Patent Application No. 60/274,063 entitled "ANTI-NEOVASCULATURE VACCINES FOR CANCER" and in U.S. Patent Application No. 30 10/094,699, attorney docket number CTLIMM.015A, entitled "ANTI-NEOVASCULATURE PREPARATIONS FOR CANCER, filed on date even with this application (March 7, 2002). A tumor cell line is disclosed in Provisional U.S. Application No. 60/363,131, filed on March 7, 2002, attorney docket number CTLIMM.028PR, entitled "HLA-TRANSGENIC MURINE TUMOR CELL LINE,".

Carcinoembryonic antigen (CEA) is a paradigmatic oncofetal protein first described in 1965 (Gold and Freedman, *J. Exp. Med.* 121: 439-462, 1965. Fuller references can be found in the Online Medelian Inheritance in Man; record *114890). It has officially been renamed carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Its expression is most strongly associated with adenocarcinomas of the epithelial lining of the digestive tract and in fetal colon. CEA is a member of the immunoglobulin supergene family and the defining member of the CEA subfamily.

HER2/NEU is an oncogene related to the epidermal growth factor receptor (van de Vijver, et al., *New Eng. J. Med.* 319:1239-1245, 1988), and apparently identical to the c-ERBB2 oncogene (Di Fiore, et al., *Science* 237: 178-182, 1987). The over-expression of ERBB2 has been implicated in the neoplastic transformation of prostate cancer. As HER2 it is amplified and over-expressed in 25-30% of breast cancers among other tumors where expression level is correlated with the aggressiveness of the tumor (Slamon, et al., *New Eng. J. Med.* 344:783-792, 2001). A more detailed description is available in the Online Medelian Inheritance in Man; record *164870.

Additional disclosure related to embodiments of the present invention is found in U.S. Patent Application No. 10/005,905 (attorney docket number CTLIMM.021CP1) entitled "EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS," filed on November 7, 2001 and a continuation thereof, U.S. Application No. __/____, filed on December 7, 2000, attorney docket number CTLIMM.21CP1C, also entitled "EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS."

Useful epitopes were identified and tested as described in the following examples. However, these examples are intended for illustration purposes only, and should not be construed as limiting the scope of the invention in any way.

EXAMPLES

Sequences of Specific Preferred Epitopes

Example 1

Manufacture of epitopes.

A. Synthetic production of epitopes

Peptides having an amino acid sequence of any of SEQ ID NO: 1, 8, 9, 11-23, 26-29, 32-44, 47-54, 56-63, 66-68 88-253, or 256-588 are synthesized using either FMOC or tBOC solid phase synthesis methodologies. After synthesis, the peptides are cleaved from their supports with either trifluoroacetic acid or hydrogen fluoride, respectively, in the presence of appropriate protective scavengers. After removing the acid by evaporation, the peptides are extracted with ether to remove the scavengers and the crude, precipitated peptide is then lyophilized. Purity of

the crude peptides is determined by HPLC, sequence analysis, amino acid analysis, counterion content analysis and other suitable means. If the crude peptides are pure enough (greater than or equal to about 90% pure), they can be used as is. If purification is required to meet drug substance specifications, the peptides are purified using one or a combination of the following: re-precipitation; reverse-phase, ion exchange, size exclusion or hydrophobic interaction chromatography; or counter-current distribution.

Drug product formulation

GMP-grade peptides are formulated in a parenterally acceptable aqueous, organic, or aqueous-organic buffer or solvent system in which they remain both physically and chemically stable and biologically potent. Generally, buffers or combinations of buffers or combinations of buffers and organic solvents are appropriate. The pH range is typically between 6 and 9. Organic modifiers or other excipients can be added to help solubilize and stabilize the peptides. These include detergents, lipids, co-solvents, antioxidants, chelators and reducing agents. In the case of a lyophilized product, sucrose or mannitol or other lyophilization aids can be added. Peptide solutions are sterilized by membrane filtration into their final container-closure system and either lyophilized for dissolution in the clinic, or stored until use.

B. Construction of expression vectors for use as nucleic acid vaccines

The construction of three generic epitope expression vectors is presented below. The particular advantages of these designs are set forth in U.S. Patent Application No. 09/561,572 entitled "EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS,".

A suitable *E. coli* strain was then transfected with the plasmid and plated out onto a selective medium. Several colonies were grown up in suspension culture and positive clones were identified by restriction mapping. The positive clone was then grown up and aliquotted into storage vials and stored at -70°C.

A mini-prep (QIAprep Spin Mini-prep: Qiagen, Valencia, CA) of the plasmid was then made from a sample of these cells and automated fluorescent dideoxy sequence analysis was used to confirm that the construct had the desired sequence.

B.1 Construction of pVAX-EP1-IRES-EP2

Overview:

The starting plasmid for this construct is pVAX1 purchased from Invitrogen (Carlsbad, CA). Epitopes EP1 and EP2 were synthesized by GIBCO BRL (Rockville, MD). The IRES was excised from pIRES purchased from Clontech (Palo Alto, CA).

Procedure:

- 1 pIRES was digested with EcoRI and NotI. The digested fragments were separated by
agarose gel electrophoresis, and the IRES fragment was purified from the excised band.
- 2 pVAX1 was digested with EcoRI and NotI, and the pVAX1 fragment was gel-purified.
- 3 The purified pVAX1 and IRES fragments were then ligated together.
- 5 4 Competent E. coli of strain DH5 α were transformed with the ligation mixture.
- 5 5 Minipreps were made from 4 of the resultant colonies.
- 6 6 Restriction enzyme digestion analysis was performed on the miniprep DNA. One
recombinant colony having the IRES insert was used for further insertion of EP1 and EP2.
This intermediate construct was called pVAX-IRES.
- 10 7 Oligonucleotides encoding EP1 and EP2 were synthesized.
- 8 8 EP1 was subcloned into pVAX-IRES between AflII and EcoRI sites, to make pVAX-
EP1-IRES;
- 9 9 EP2 was subcloned into pVAX-EP1-IRES between SalI and NotI sites, to make the
final construct pVAX-EP1-IRES-EP2.
- 15 10 The sequence of the EP1-IRES-EP2 insert was confirmed by DNA sequencing.

B 2. Construction of pVAX-EP1-IRES-EP2-ISS-NIS

Overview:

- The starting plasmid for this construct was pVAX-EP1-IRES-EP2 (Example 1). The ISS (immunostimulatory sequence) introduced into this construct is AACGTT, and the NIS (standing for nuclear import sequence) used is the SV40 72bp repeat sequence. ISS-NIS was synthesized by GIBCO BRL. See Figure 2.

Procedure:

- 1 pVAX-EP1-IRES-EP2 was digested with NruI; the linearized plasmid was gel-
purified.
- 25 2 ISS-NIS oligonucleotide was synthesized.
- 3 The purified linearized pVAX-EP1-IRES-EP2 and synthesized ISS-NIS were ligated
together.
- 4 Competent E. coli of strain DH5 α were transformed with the ligation product.
- 5 Minipreps were made from resultant colonies.
- 30 6 Restriction enzyme digestions of the minipreps were carried out.
- 7 The plasmid with the insert was sequenced.

B3. Construction of pVAX-EP2-UB-EP1

Overview:

The starting plasmid for this construct was pVAX1 (Invitrogen). EP2 and EP1 were synthesized by GIBCO BRL. Wild type Ubiquitin cDNA encoding the 76 amino acids in the construct was cloned from yeast.

Procedure:

- 1 RT-PCR was performed using yeast mRNA. Primers were designed to amplify the complete coding sequence of yeast Ubiquitin.
- 2 The RT-PCR products were analyzed using agarose gel electrophoresis. A band with the predicted size was gel-purified.
- 3 The purified DNA band was subcloned into pZERO1 at EcoRV site. The resulting clone was named pZERO-UB.
- 4 Several clones of pZERO-UB were sequenced to confirm the Ubiquitin sequence before further manipulations.
- 5 EP1 and EP2 were synthesized.
- 6 EP2, Ubiquitin and EP1 were ligated and the insert cloned into pVAX1 between BamHI and EcoRI, putting it under control of the CMV promoter.
- 7 The sequence of the insert EP2-UB-EP1 was confirmed by DNA sequencing.

Example 2

Identification of useful epitope variants.

The 10-mer FLPWHRLFL (SEQ ID NO. 1) is identified as a useful epitope. Based on this sequence, numerous variants are made. Variants exhibiting activity in HLA binding assays (see Example 3, section 6) are identified as useful, and are subsequently incorporated into vaccines.

The HLA-A2 binding of length variants of FLPWHRLFL have been evaluated. Proteasomal digestion analysis indicates that the C-terminus of the 9-mer FLPWHRLFL (SEQ ID NO. 8) is also produced. Additionally the 9-mer LPWHRLFL (SEQ ID NO. 9) can result from N-terminal trimming of the 10-mer. Both are predicted to bind to the HLA-A*0201 molecule, however of these two 9-mers, FLPWHRLFL displayed more significant binding and is preferred (see Figs. 3A and B).

In vitro proteasome digestion and N-terminal pool sequencing indicates that tyrosinase₂₀₇₋₂₁₆ (SEQ ID NO. 1) is produced more commonly than tyrosinase₂₀₇₋₂₁₅ (SEQ ID NO. 8), however the latter peptide displays superior immunogenicity, a potential concern in arriving at an optimal vaccine design. FLPWHRLFL, tyrosinase₂₀₇₋₂₁₅ (SEQ ID NO. 8) was used in an in vitro immunization of HLA-A2⁺ blood to generate CTL (see CTL Induction Cultures below). Using

peptide pulsed T2 cells as targets in a standard chromium release assay it was found that the CTL induced by tyrosinase₂₀₇₋₂₁₅ (SEQ ID NO. 8) recognize tyrosinase₂₀₇₋₂₁₆ (SEQ ID NO. 1) targets equally well (see fig. 3C). These CTL also recognize the HLA-A2⁺, tyrosinase⁺ tumor cell lines 624.38 and HTB64, but not 624.28 an HLA-A2⁻ derivative of 624.38 (fig. 3C). Thus the relative amounts of these two epitopes produced in vivo, does not become a concern in vaccine design.

CTL induction cultures

PBMCs from normal donors were purified by centrifugation in Ficoll-Hypaque from buffy coats. All cultures were carried out using the autologous plasma (AP) to avoid exposure to potential xenogeneic pathogens and recognition of FBS peptides. To favor the in vitro generation of peptide-specific CTL, we employed autologous dendritic cells (DC) as APCs. DC were generated and CTL were induced with DC and peptide from PBMCs as described (Keogh et al., 2001). Briefly, monocyte-enriched cell fractions were cultured for 5 days with GM-CSF and IL-4 and were cultured for 2 additional days in culture media with 2 µg/ml CD40 ligand to induce maturation. 2 x10⁶ CD8⁺-enriched T lymphocytes/well and 2 x10⁵ peptide-pulsed DC/well were co-cultured in 24-well plates in 2 ml RPMI supplemented with 10% AP, 10 ng/ml IL-7 and 20 IU/ml IL-2. Cultures were restimulated on days 7 and 14 with autologous irradiated peptide-pulsed DC.

Sequence variants of FLPWHRLFL are constructed as follow. Consistent with the binding coefficient table (see Table 3) from the NIH/BIMAS MHC binding prediction program (see reference in example 3 below), binding can be improved by changing the L at position 9, an anchor position, to V. Binding can also be altered, though generally to a lesser extent, by changes at non-anchor positions. Referring generally to Table 3, binding can be increased by employing residues with relatively larger coefficients. Changes in sequence can also alter immunogenicity independently of their effect on binding to MHC. Thus binding and/or immunogenicity can be improved as follows:

By substituting F,L,M,W, or Y for P at position 3; these are all bulkier residues that can also improve immunogenicity independent of the effect on binding. The amine and hydroxyl-bearing residues, Q and N; and S and T; respectively, can also provoke a stronger, cross-reactive response.

By substituting D or E for W at position 4 to improve binding; this addition of a negative charge can also make the epitope more immunogenic, while in some cases reducing cross-reactivity with the natural epitope. Alternatively the conservative substitutions of F or Y can provoke a cross-reactive response.

By substituting F for H at position 5 to improve binding. H can be viewed as partially charged, thus in some cases the loss of charge can hinder cross-reactivity. Substitution of the fully

charged residues R or K at this position can enhance immunogenicity without disrupting charge-dependent cross-reactivity.

By substituting I, L, M, V, F, W, or Y for R at position 6. The same caveats and alternatives apply here as at position 5.

5 By substituting W or F for L at position 7 to improve binding. Substitution of V, I, S, T, Q, or N at this position are not generally predicted to reduce binding affinity by this model (the NIH algorithm), yet can be advantageous as discussed above.

10 Y and W, which are equally preferred as the Fs at positions 1 and 8, can provoke a useful cross-reactivity. Finally, while substitutions in the direction of bulkiness are generally favored to improve immunogenicity, the substitution of smaller residues such as A, S, and C, at positions 3-7 can be useful according to the theory that contrast in size, rather than bulkiness per se, is an important factor in immunogenicity. The reactivity of the thiol group in C can introduce other properties as discussed in Chen, J.-L., et al. *J. Immunol.* 165:948-955, 2000.

Table 3. 9-mer Coefficient Table for HLA-A*0201*

HLA Coefficient table for file "A_0201_standard"									
Amino Acid Type	1 st	2 nd	3 rd	4 th	5 th	6 th	7 th	8 th	9 th
A	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000
C	1.000	0.470	1.000	1.000	1.000	1.000	1.000	1.000	1.000
D	0.075	0.100	0.400	4.100	1.000	1.000	0.490	1.000	0.003
E	0.075	1.400	0.064	4.100	1.000	1.000	0.490	1.000	0.003
F	4.600	0.050	3.700	1.000	3.800	1.900	5.800	5.500	0.015
G	1.000	0.470	1.000	1.000	1.000	1.000	0.130	1.000	0.015
H	0.034	0.050	1.000	1.000	1.000	1.000	1.000	1.000	0.015
I	1.700	9.900	1.000	1.000	1.000	2.300	1.000	0.410	2.100
K	3.500	0.100	0.035	1.000	1.000	1.000	1.000	1.000	0.003
L	1.700	72.000	3.700	1.000	1.000	2.300	1.000	1.000	4.300
M	1.700	52.000	3.700	1.000	1.000	2.300	1.000	1.000	1.000
N	1.000	0.470	1.000	1.000	1.000	1.000	1.000	1.000	0.015
P	0.022	0.470	1.000	1.000	1.000	1.000	1.000	1.000	0.003
Q	1.000	7.300	1.000	1.000	1.000	1.000	1.000	1.000	0.003
R	1.000	0.010	0.076	1.000	1.000	1.000	0.200	1.000	0.003
S	1.000	0.470	1.000	1.000	1.000	1.000	1.000	1.000	0.015
T	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.500
V	1.700	6.300	1.000	1.000	1.000	2.300	1.000	0.410	14.000
W	4.600	0.010	8.300	1.000	1.000	1.700	7.500	5.500	0.015
Y	4.600	0.010	3.200	1.000	1.000	1.500	1.000	5.500	0.015

*This table and other comparable data that are publicly available are useful in designing epitope variants and in determining whether a particular variant is substantially similar, or is functionally similar.

5

Example 3

Cluster Analysis (SSX-2₃₁₋₆₈).

1. Epitope cluster region prediction:

The computer algorithms: SYFPEITHI (internet [http:// access at syfpeithi.bmi-heidelberg.com/Scripts/MHCServer.dll/EpPredict.htm](http://access.at.syfpeithi.bmi-heidelberg.com/Scripts/MHCServer.dll/EpPredict.htm)), based on the book "MHC Ligands and Peptide Motifs" by H.G.Rammensee, J.Bachmann and S.Stevanovic; and HLA Peptide Binding Predictions (NIH) (internet [http:// access at bimas.dcrf.nih.gov/molbio/hla_bin](http://access.at.bimas.dcrf.nih.gov/molbio/hla_bin)), described in Parker, K. C., et al., *J. Immunol.* 152:163, 1994; were used to analyze the protein sequence of SSX-2 (GI:10337583). Epitope clusters (regions with higher than average density of peptide fragments with high predicted MHC affinity) were defined as described fully in U.S. Patent Application No. 09/561,571 entitled "EPITOPE CLUSTERS," filed on April 28, 2000. Using a epitope density ratio cutoff of 2, five and two clusters were defined using the SYFPEITHI and NIH algorithms, respectively, and peptides score cutoffs of 16 (SYFPEITHI) and 5 (NIH). The highest

15

scoring peptide with the NIH algorithm, SSX-2₄₁₋₄₉, with an estimated halftime of dissociation of >1000 min., does not overlap any other predicted epitope but does cluster with SSX-2₅₇₋₆₅ in the NIH analysis.

2. Peptide synthesis and characterization:

5 SSX-2₃₁₋₆₈, YFSKEEWEKMKASEKIFYVYMKRKYEAMTKLGFKATLP (SEQ ID NO. 10) was synthesized by MPS (Multiple Peptide Systems, San Diego, CA 92121) using standard solid phase chemistry. According to the provided 'Certificate of Analysis', the purity of this peptide was 95%.

3. Proteasome digestion:

10 Proteasome was isolated from human red blood cells using the proteasome isolation protocol described in U.S. Patent Application No. 09/561,074 entitled "METHOD OF EPITOPE DISCOVERY," filed on April 28, 2000. SDS-PAGE, western-blotting, and ELISA were used as quality control assays. The final concentration of proteasome was 4 mg/ml, which was determined by non-interfering protein assay (Geno Technologies Inc.). Proteasomes were stored at -70°C in
15 25 µl aliquots.

 SSX-2₃₁₋₆₈ was dissolved in Milli-Q water, and a 2 mM stock solution prepared and 20µL aliquots stored at -20°C.

 1 tube of proteasome (25 µL) was removed from storage at -70°C and thawed on ice. It was then mixed thoroughly with 12.5µL of 2mM peptide by repipetting (samples were kept on
20 ice). A 5µL sample was immediately removed after mixing and transferred to a tube containing 1.25µL 10%TFA (final concentration of TFA was 2%); the T=0 min sample. The proteasome digestion reaction was then started and carried out at 37°C in a programmable thermal controller. Additional 5µL samples were taken out at 15, 30, 60, 120, 180 and 240 min respectively, the
25 reaction was stopped by adding the sample to 1.25µL 10% TFA as before. Samples were kept on ice or frozen until being analyzed by MALDI-MS. All samples were saved and stored at -20°C for HPLC analysis and N-terminal sequencing. Peptide alone (without proteasome) was used as a blank control: 2 µL peptide + 4µL Tris buffer (20 mM, pH 7.6) + 1.5µL TFA.

4. MALDI-TOF MS measurements:

30 For each time point 0.3 µL of matrix solution (10mg/ml α-cyano-4-hydroxycinnamic acid in AcCN/H₂O (70:30)) was first applied on a sample slide, and then an equal volume of digested sample was mixed gently with matrix solution on the slide. The slide was allowed to dry at ambient air for 3-5 min. before acquiring the mass spectra. MS was performed on a Lasermat 2000 MALDI-TOF mass spectrometer that was calibrated with peptide/protein standards. To improve the accuracy of measurement, the molecular ion weight (MH⁺) of the peptide substrate was used as

an internal calibration standard. The mass spectrum of the T=120 min. digested sample is shown in figure 4.

5. MS data analysis and epitope identification:

To assign the measured mass peaks, the computer program MS-Product, a tool from the UCSF Mass Spectrometry Facility (<http://prospector.ucsf.edu/ucsfhtml3.4/msprod.htm>), was used to generate all possible fragments (N- and C-terminal ions, and internal fragments) and their corresponding molecular weights. Due to the sensitivity of the mass spectrometer, average molecular weight was used. The mass peaks observed over the course of the digestion were identified as summarized in Table 4.

Fragments co-C-terminal with 8-10 amino acid long sequences predicted to bind HLA by the SYFPEITHI or NIH algorithms were chosen for further study. The digestion and prediction steps of the procedure can be usefully practiced in any order. Although the substrate peptide used in proteasomal digest described here was specifically designed to include predicted HLA-A2.1 binding sequences, the actual products of digestion can be checked after the fact for actual or predicted binding to other MHC molecules. Selected results are shown in Table 5.

Table 4. SSX-2₃₁₋₆₈ Mass Peak Identification.

MS PEAK (measured)	PEPTIDE	SEQUENCE	CALCULATED MASS (MH ⁺)
988.23	31-37	YFSKEEW	989.08
1377.68±2.3 8	31-40	YFSKEEWEKM	1377.68
1662.45±1.3 0	31-43	YFSKEEWEKMKAS	1663.90
2181.72±0.8 5	31-47	YFSKEEWEKMKASEKIF	2181.52
2346.6	31-48	YFSKEEWEKMKASEKIFY	2344.71
1472.16±1.5 4	38-49	EKMKASEKIFYV	1473.77
2445.78±1.1 8	31-49*	YFSKEEWEKMKASEKIFYV	2443.84
2607.	31-50	YFSKEEWEKMKASEKIFYVY	2607.02
1563.3	50-61	YMKRKYEAMTKL	1562.93
3989.9	31-61	YFSKEEWEKMKASEKIFYVYMKRKYEAMTKL	3987.77
1603.74±1.5	51-63		1603.98

3		MKRKYEAMTKLGF	
1766.45±1.5	50-63	YMKRKYEAMTKLGF	1767.16
1866.32±1.2			
2	49-63	VYMKRKYEAMTKLGF	1866.29
4192.6	31-63	YFSKEEWEKMKASEKIFYVYMKRKYEAMTKLG F	4192.00
4392.1	31-65**	YFSKEEWEKMKASEKIFYVYMKRKYEAMTKLG FKA	4391.25

Boldface sequence correspond to peptides predicted to bind to MHC.

* On the basis of mass alone this peak could also have been assigned to the peptide 32-50, however proteasomal removal of just the N-terminal amino acid is unlikely. N-terminal sequencing (below) verifies the assignment to 31-49.

5 ** On the basis of mass this fragment might also represent 33-68. N-terminal sequencing below is consistent with the assignment to 31-65.

Table 5. Predicted HLA binding by proteasomally generated fragments

SEQ ID NO.	PEPTIDE	HLA	SYFPEITHI	NIH
11	FSKEEWEKM	B*3501	NP†	90
12	KMKASEKIF	B*08	17	<5
13 & (14)	(K) MKASEKIFY	A1	19 (19)	<5
15 & (16)	(M) KASEKIFYV	A*0201	22 (16)	1017
		B*08	17	<5
		B*5101	22 (13)	60
		B*5102	NP	133
		B*5103	NP	121
17 & (18)	(K) ASEKIFYVY	A1	34 (19)	14
19 & (20)	(K) RKYEAMTKL	A*0201	15	<5
		A26	15	NP
		B14	NP	45 (60)
		B*2705	21	15
		B*2709	16	NP
		B*5101	15	<5
21	KYEAMTKLGF	A1	16	<5
		A24	NP	300
22	YEAMTKLGF	B*4403	NP	80
23	EAMTKLGF	B*08	22	<5

10

†No prediction

As seen in Table 5, N-terminal addition of authentic sequence to epitopes can generate epitopes for the same or different MHC restriction elements. Note in particular the pairing of (K)RKYEAMTKL (SEQ ID NOS 19 and (20)) with HLA-B14, where the 10-mer has a longer predicted halftime of dissociation than the co-C-terminal 9-mer. Also note the case of the 10-mer KYEAMTKLGF (SEQ ID NO. 21) which can be used as a vaccine useful with several MHC types by relying on N-terminal trimming to create the epitopes for HLA-B*4403 and -B*08.

6. HLA-A0201 binding assay:

Binding of the candidate epitope KASEKIFYV, SSX-2₄₁₋₄₉, (SEQ ID NO. 15) to HLA-A2.1 was assayed using a modification of the method of Stauss et al., (Proc Natl Acad Sci USA 89(17):7871-5 (1992)). Specifically, T2 cells, which express empty or unstable MHC molecules on their surface, were washed twice with Iscove's modified Dulbecco's medium (IMDM) and cultured overnight in serum-free AIM-V medium (Life Technologies, Inc., Rockville, MD) supplemented with human β 2-microglobulin at 3 μ g/ml (Sigma, St. Louis, MO) and added peptide, at 800, 400, 200, 100, 50, 25, 12.5, and 6.25 μ g/ml in a 96-well flat-bottom plate at 3x10⁵ cells/200 μ l/well. Peptide was mixed with the cells by repipeting before distributing to the plate (alternatively peptide can be added to individual wells), and the plate was rocked gently for 2 minutes. Incubation was in a 5% CO₂ incubator at 37°C. The next day the unbound peptide was removed by washing twice with serum free RPMI medium and a saturating amount of anti-class I HLA monoclonal antibody, fluorescein isothiocyanate (FITC)-conjugated anti-HLA A2, A28 (One Lambda, Canoga Park, CA) was added. After incubation for 30 minutes at 4°C, cells were washed 3 times with PBS supplemented with 0.5% BSA, 0.05%(w/v) sodium azide, pH 7.4-7.6 (staining buffer). (Alternatively W6/32 (Sigma) can be used as the anti-class I HLA monoclonal antibody the cells washed with staining buffer and then incubated with fluorescein isothiocyanate (FITC)-conjugated goat F(ab') antimouse-IgG (Sigma) for 30 min at 4°C and washed 3 times as before.) The cells were resuspended in 0.5 ml staining buffer. The analysis of surface HLA-A2.1 molecules stabilized by peptide binding was performed by flow cytometry using a FACScan (Becton Dickinson, San Jose, CA). If flow cytometry is not to be performed immediately the cells can be fixed by adding a quarter volume of 2% paraformaldehyde and storing in the dark at 4 C.

The results of the experiment are shown in Figure 5. SSX-2₄₁₋₄₉ (SEQ ID NO. 15) was found to bind HLA-A2.1 to a similar extent as the known A2.1 binder FLPSDYFPSV (HBV₁₈₋₂₇; SEQ ID NO: 24) used as a positive control. An HLA-B44 binding peptide, AEMGKYSFY (SEQ ID NO: 25), was used as a negative control. The fluorescence obtained from the negative control was similar to the signal obtained when no peptide was used in the assay. Positive and negative

control peptides were chosen from Table 18.3.1 in *Current Protocols in Immunology* p. 18.3.2, John Wiley and Sons, New York, 1998.

7. Immunogenicity:

A. In vivo immunization of mice.

5 HHD1 transgenic A*0201 mice (Pascolo, S., et al. *J. Exp. Med.* 185:2043-2051, 1997) were anesthetized and injected subcutaneously at the base of the tail, avoiding lateral tail veins, using 100 μ l containing 100 nmol of SSX-2₄₁₋₄₉ (SEQ ID NO. 15) and 20 μ g of HTL epitope peptide in PBS emulsified with 50 μ l of IFA (incomplete Freund's adjuvant).

B. Preparation of stimulating cells (LPS blasts).

10 Using spleens from 2 naive mice for each group of immunized mice, un-immunized mice were sacrificed and the carcasses were placed in alcohol. Using sterile instruments, the top dermal layer of skin on the mouse's left side (lower mid-section) was cut through, exposing the peritoneum. The peritoneum was saturated with alcohol, and the spleen was aseptically extracted. The spleen was placed in a petri dish with serum-free media. Splenocytes were isolated by using
15 sterile plungers from 3 ml syringes to mash the spleens. Cells were collected in a 50 ml conical tubes in serum-free media, rinsing dish well. Cells were centrifuged (12000 rpm, 7 min) and washed one time with RPMI. Fresh spleen cells were resuspended to a concentration of 1×10^6 cells per ml in RPMI-10%FCS (fetal calf serum). 25g/ml lipopolysaccharide and 7 μ g/ml Dextran Sulfate were added. Cell were incubated for 3 days in T-75 flasks at 37°C, with 5% CO₂. Splenic
20 blasts were collected in 50 ml tubes pelleted (12000 rpm, 7 min) and resuspended to 3×10^7 /ml in RPMI. The blasts were pulsed with the priming peptide at 50 μ g/ml, RT 4hr. mitomycin C-treated at 25 μ g/ml, 37°C, 20 min and washed three times with DMEM.

C. In vitro stimulation.

3 days after LPS stimulation of the blast cells and the same day as peptide loading, the
25 primed mice were sacrificed (at 14 days post immunization) to remove spleens as above. 3×10^6 splenocytes were co-cultured with 1×10^6 LPS blasts/well in 24-well plates at 37°C, with 5% CO₂ in DMEM media supplemented with 10% FCS, 5×10^{-5} M β -mercaptoethanol, 100 μ g/ml streptomycin and 100 IU/ml penicillin. Cultures were fed 5% (vol/vol) ConA supernatant on day 3 and assayed for cytolytic activity on day 7 in a ⁵¹Cr-release assay.

30 D. Chromium-release assay measuring CTL activity.

To assess peptide specific lysis, 2×10^6 T2 cells were incubated with 100 μ Ci sodium chromate together with 50 μ g/ml peptide at 37 C for 1 hour. During incubation they were gently shaken every 15 minutes. After labeling and loading, cells were washed three times with 10 ml of DMEM-10% FCS, wiping each tube with a fresh Kimwipe after pouring off the supernatant.
35 Target cells were resuspended in DMEM-10% FBS 1×10^5 /ml. Effector cells were adjusted to

1x10⁷/ml in DMEM-10% FCS and 100 µl serial 3-fold dilutions of effectors were prepared in U-bottom 96-well plates. 100 µl of target cells were added per well. In order to determine spontaneous release and maximum release, six additional wells containing 100 µl of target cells were prepared for each target. Spontaneous release was revealed by incubating the target cells with 100 µl medium; maximum release was revealed by incubating the target cells with 100µl of 2% SDS. Plates were then centrifuged for 5 min at 600 rpm and incubated for 4 hours at 37°C in 5% CO₂ and 80% humidity. After the incubation, plates were then centrifuged for 5 min at 1200 rpm. Supernatants were harvested and counted using a gamma counter. Specific lysis was determined as follows: % specific release = [(experimental release - spontaneous release)/(maximum release - spontaneous release)] x 100.

Results of the chromium release assay demonstrating specific lysis of peptide pulsed target cells are shown in figure 6.

8. Cross-reactivity with other SSX proteins:

SSX-2₄₁₋₄₉ (SEQ ID NO. 15) shares a high degree of sequence identity with the same region of the other SSX proteins. The surrounding regions have also been generally well conserved. Thus the housekeeping proteasome can cleave following V₄₉ in all five sequences. Moreover, SSX₄₁₋₄₉ is predicted to bind HLA-A*0201 (see Table 6). CTL generated by immunization with SSX-2₄₁₋₄₉ cross-react with tumor cells expressing other SSX proteins.

Table 6. SSX₄₁₋₄₉ – A*0201 Predicted Binding

SEQ ID NO.	Family Member	Sequence	SYFPEITHI Score	NIH Score
15	SSX-2	KASEKIFYV	22	1017
26	SSX-1	KYSEKISYV	18	1.7
27	SSX-3	KVSEKIVYV	24	1105
28	SSX-4	KSSEKIVYV	20	82
29	SSX-5	KASEKIYV	22	175

Example 4

Cluster Analysis (PSMA₁₆₃₋₁₉₂).

A peptide, AFSPQGMPEGDLVYVNYARTEDFFKLERDM, PSMA₁₆₃₋₁₉₂, (SEQ ID NO. 30), containing an A1 epitope cluster from prostate specific membrane antigen, PSMA₁₆₈₋₁₉₀ (SEQ ID NO. 31) was synthesized using standard solid-phase F-moc chemistry on a 433A ABI Peptide synthesizer. After side chain deprotection and cleavage from the resin, peptide first dissolved in formic acid and then diluted into 30% Acetic acid, was run on a reverse-phase preparative HPLC C4 column at following conditions: linear AB gradient (5% B/min) at a flow rate of 4 ml/min,

where eluent A is 0.1% aqueous TFA and eluent B is 0.1% TFA in acetonitrile. A fraction at time 16.642 min containing the expected peptide, as judged by mass spectrometry, was pooled and lyophilized. The peptide was then subjected to proteasome digestion and mass spectrum analysis essentially as described above. Prominent peaks from the mass spectra are summarized in Table 7.

Table 7. PSMA₁₆₃₋₁₉₂ Mass Peak Identification.

PEPTIDE	SEQUENCE	CALCULATE D MASS (MH ⁺)
163-177	AFSPQGMPEGDLVYV	1610.0
178-189	NYARTEDFFKLE	1533.68
170-189	PEGDLVYVNYARTEDFFKLE	2406.66
178-191	NYARTEDFFKLERD	1804.95
170-191	PEGDLVYVNYARTEDFFKLERD	2677.93
178-192	NYARTEDFFKLERDM	1936.17
163-176	AFSPQGMPEGDLVY	1511.70
177-192	VNYARTEDFFKLERDM	2035.30
163-179	AFSPQGMPEGDLVYVNY	1888.12
180-192	ARTEDFFKLERDM	1658.89
163-183	AFSPQGMPEGDLVYVNYARTE	2345.61
184-192	DDFKLERDM	1201.40
176-192	YVNYARTEDFFKLERDM	2198.48
167-185	QGMPEGDLVYVNYARTEDF	2205.41
178-186	NYARTEDFF	1163.22

Boldface sequences correspond to peptides predicted to bind to MHC, see Table 8.

N-terminal Pool Sequence Analysis

5 One aliquot at one hour of the proteasomal digestion (see Example 3 part 3 above) was subjected to N-terminal amino acid sequence analysis by an ABI 473A Protein Sequencer (Applied Biosystems, Foster City, CA). Determination of the sites and efficiencies of cleavage was based on consideration of the sequence cycle, the repetitive yield of the protein sequencer, and the relative yields of amino acids unique in the analyzed sequence. That is if the unique (in the

10 analyzed sequence) residue X appears only in the nth cycle a cleavage site exists n-1 residues before it in the N-terminal direction. In addition to helping resolve any ambiguity in the assignment of mass to sequences, these data also provide a more reliable indication of the relative yield of the various fragments than does mass spectrometry.

15 For PSMA₁₆₃₋₁₉₂ (SEQ ID NO. 30) this pool sequencing supports a single major cleavage site after V₁₇₇ and several minor cleavage sites, particularly one after Y₁₇₉. Reviewing the results presented in figures 7A-C reveals the following:

S at the 3rd cycle indicating presence of the N-terminus of the substrate.

Q at the 5th cycle indicating presence of the N-terminus of the substrate.

N at the 1st cycle indicating cleavage after V₁₇₇.

N at the 3rd cycle indicating cleavage after V₁₇₅. Note the fragment 176-192 in Table 7.

T at the 5th cycle indicating cleavage after V₁₇₇.

T at the 1st–3rd cycles, indicating increasingly common cleavages after R₁₈₁, A₁₈₀ and Y₁₇₉.

5 Only the last of these correspond to peaks detected by mass spectrometry; 163-179 and 180-192, see Table 7. The absence of the others can indicate that they are on fragments smaller than were examined in the mass spectrum.

K at the 4th, 8th, and 10th cycles indicating cleavages after E₁₈₃, Y₁₇₉, and V₁₇₇, respectively, all of which correspond to fragments observed by mass spectroscopy. See Table 7.

10 A at the 1st and 3rd cycles indicating presence of the N-terminus of the substrate and cleavage after V₁₇₇, respectively.

P at the 4th and 8th cycles indicating presence of the N-terminus of the substrate.

G at the 6th and 10th cycles indicating presence of the N-terminus of the substrate.

M at the 7th cycle indicating presence of the N-terminus of the substrate and/or cleavage after F₁₈₅.

15 M at the 15th cycle indicating cleavage after V₁₇₇.

The 1st cycle can indicate cleavage after D₁₉₁, see Table 7.

R at the 4th and 13th cycle indicating cleavage after V₁₇₇.

R at the 2nd and 11th cycle indicating cleavage after Y₁₇₉.

20 V at the 2nd, 6th, and 13th cycle indicating cleavage after V₁₇₅, M₁₆₉ and presence of the N-terminus of the substrate, respectively. Note fragments beginning at 176 and 170 in Table 7.

Y at the 1st, 2nd, and 14th cycles indicating cleavage after V₁₇₅, V₁₇₇, and presence of the N-terminus of the substrate, respectively.

25 L at the 11th and 12th cycles indicating cleavage after V₁₇₇, and presence of the N-terminus of the substrate, respectively, is the interpretation most consistent with the other data. Comparing to the mass spectrometry results we see that L at the 2nd, 5th, and 9th cycles is consistent with cleavage after F₁₈₆, E₁₈₃ or M₁₆₉, and Y₁₇₉, respectively. See Table 7.

Epitope Identification

30 Fragments co-C-terminal with 8-10 amino acid long sequences predicted to bind HLA by the SYFPEITHI or NIH algorithms were chosen for further analysis. The digestion and prediction steps of the procedure can be usefully practiced in any order. Although the substrate peptide used in proteasomal digest described here was specifically designed to include a predicted HLA-A1 binding sequence, the actual products of digestion can be checked after the fact for actual or
35 predicted binding to other MHC molecules. Selected results are shown in Table 8.

Table 8. Predicted HLA binding by proteasomally generated fragments

SEQ ID NO	PEPTIDE	HLA	SYFPEITHI	NIH
32 & (33)	(G)MPEGDLVY V	A*0201	17 (27)	(2605)
		B*0702	20	<5
		B*5101	22	314
34 & (35)	(Q)GMPEGDLV Y	A1	24 (26)	<5
		A3	16 (18)	36
		B*2705	17	25
		B*5101	15	NP†
36	MPEGDLVY			
37 & (38)	(P)EGDLVYVN Y	A1	27 (15)	12
		A26	23 (17)	NP
39	LVYVNYARTE	A3	21	<5
40 & (41)	(Y)VNYARTED F	A26	(20)	NP
		B*08	15	<5
		B*2705	12	50
42	NYARTEDFF	A24	NP†	100
		Cw*0401	NP	120
43	YARTEDFF	B*08	16	<5
44	RTEDFFKLE	A1	21	<5
		A26	15	NP

†No prediction

5 HLA-A*0201 binding assay:

HLA-A*0201 binding studies were performed with PSMA₁₆₈₋₁₇₇, GMPEGDLVYV, (SEQ ID NO. 33) essentially as described in Example 3 above. As seen in figure 8, this epitope exhibits significant binding at even lower concentrations than the positive control peptides. The Melan-A peptide used as a control in this assay (and throughout this disclosure), ELAGIGILTV, is actually a variant of the natural sequence (EAAGIGILTV) and exhibits a high affinity in this assay.

Example 5**Cluster Analysis (PSMA₂₈₁₋₃₁₀).**

Another peptide, RGIAEAVGLPSIPVHPIGYDAQKLLEKMG, PSMA₂₈₁₋₃₁₀ (SEQ ID NO. 45), containing an A1 epitope cluster from prostate specific membrane antigen, PSMA₂₈₃₋₃₀₇ (SEQ ID NO. 46), was synthesized using standard solid-phase F-moc chemistry on a 433A ABI Peptide synthesizer. After side chain deprotection and cleavage from the resin, peptide in ddH₂O

was run on a reverse-phase preparative HPLC C18 column at following conditions: linear AB gradient (5% B/min) at a flow rate of 4 ml/min, where eluent A is 0.1% aqueous TFA and eluent B is 0.1% TFA in acetonitrile. A fraction at time 17.061 min containing the expected peptide as judged by mass spectrometry, was pooled and lyophilized. The peptide was then subjected to proteasome digestion and mass spectrum analysis essentially as described above. Prominent peaks from the mass spectra are summarized in Table 9.

Table 9. PSMA₂₈₁₋₃₁₀ Mass Peak Identification.

PEPTIDE	SEQUENCE	CALCULATE D MASS (MH ⁺)
281-297	RGIAEAVGLPSIPVHPI*	1727.07
286-297	AVGLPSIPVHPI**	1200.46
287-297	VGLPSIPVHPI	1129.38
288-297	GLPSIPVHPI [†]	1030.25
298-310	GYDDAQKLEKMG [‡]	1516.5
298-305	GYDDAQKLS	958.05
281-305	RGIAEAVGLPSIPVHPIGYDDAQKL	2666.12
281-307	RGIAEAVGLPSIPVHPIGYDDAQKLE	2908.39
286-307	AVGLPSIPVHPIGYDDAQKLE [§]	2381.78
287-307	VGLPSIPVHPIGYDDAQKLE	2310.70
288-307	GLPSIPVHPIGYDDAQKLE [#]	2211.57
281-299	RGIAEAVGLPSIPVHPIGY	1947
286-299	AVGLPSIPVHPIGY	1420.69
287-299	VGLPSIPVHPIGY	1349.61
288-299	GLPSIPVHPIGY	1250.48
287-310	VGLPSIPVHPIGYDDAQKLEKMG	2627.14
288-310	GLPSIPVHPIGYDDAQKLEKMG	2528.01

Boldface sequences correspond to peptides predicted to bind to MHC, see Table 10.

*By mass alone this peak could also have been 296-310 or 288-303.

10 **By mass alone this peak could also have been 298-307. Combination of HPLC and mass spectrometry show that at some later time points this peak is a mixture of both species.

[†] By mass alone this peak could also have been 289-298.

By mass alone this peak could also have been 281-295 or 294-306.

§ By mass alone this peak could also have been 297-303.

15 ¶ By mass alone this peak could also have been 285-306.

By mass alone this peak could also have been 288-303.

None of these alternate assignments are supported N-terminal pool sequence analysis.

N-terminal Pool Sequence Analysis

One aliquot at one hour of the proteasomal digestion (see Example 3 part 3 above) was subjected to N-terminal amino acid sequence analysis by an ABI 473A Protein Sequencer (Applied Biosystems, Foster City, CA). Determination of the sites and efficiencies of cleavage was based on consideration of the sequence cycle, the repetitive yield of the protein sequencer, and the relative yields of amino acids unique in the analyzed sequence. That is if the unique (in the analyzed sequence) residue X appears only in the nth cycle a cleavage site exists n-1 residues before it in the N-terminal direction. In addition to helping resolve any ambiguity in the assignment of mass to sequences, these data also provide a more reliable indication of the relative yield of the various fragments than does mass spectrometry.

For PSMA₂₈₁₋₃₁₀ (SEQ ID NO. 45) this pool sequencing supports two major cleavage sites after V₂₈₇ and I₂₉₇ among other minor cleavage sites. Reviewing the results presented in Fig. 9 reveals the following:

S at the 4th and 11th cycles indicating cleavage after V₂₈₇ and presence of the N-terminus of the substrate, respectively.

H at the 8th cycle indicating cleavage after V₂₈₇. The lack of decay in peak height at positions 9 and 10 versus the drop in height present going from 10 to 11 can suggest cleavage after A₂₈₆ and E₂₈₅ as well, rather than the peaks representing latency in the sequencing reaction.

D at the 2nd, 4th, and 7th cycles indicating cleavages after Y₂₉₉, I₂₉₇, and V₂₉₄, respectively. This last cleavage is not observed in any of the fragments in Table 10 or in the alternate assignments in the notes below.

Q at the 6th cycle indicating cleavage after I₂₉₇.

M at the 10th and 12th cycle indicating cleavages after Y₂₉₉ and I₂₉₇, respectively.

Epitope Identification

Fragments co-C-terminal with 8-10 amino acid long sequences predicted to bind HLA by the SYFPEITHI or NIH algorithms were chosen for further study. The digestion and prediction steps of the procedure can be usefully practiced in any order. Although the substrate peptide used in proteasomal digest described here was specifically designed to include a predicted HLA-A1 binding sequence, the actual products of digestion can be checked after the fact for actual or predicted binding to other MHC molecules. Selected results are shown in Table 10.

Table 10.

Predicted HLA binding by proteasomally generated fragments: PSMA₂₈₁₋₃₁₀

SEQ ID NO.	PEPTIDE	HLA	SYFPEITHI	NIH
47 & (48)	(G) LPSIPVH	A*0201	16 (24)	(24)

	PI	B*0702/B7	23	12
		B*5101	24	572
		Cw*0401	NP†	20
		A*0201	(16)	<5
49 & (50)	(P) IGYDDAQ KL	A26	(20)	NP
		B*2705	16	25
		B*2709	15	NP
		B*5101	21	57
		Cw*0301	NP	24
51 & (52)	(P) SIPVHPI GY	A1	21 (27)	<5
		A26	22	NP
		A3	16	<5
		B*5101	16	NP
53	IPVHPIGY			
54	YYDAQKLE	A1	22	<5

†No prediction

As seen in Table 10, N-terminal addition of authentic sequence to epitopes can often generate still useful, even better epitopes, for the same or different MHC restriction elements. Note for example the pairing of (G)LPSIPVHPI with HLA-A*0201, where the 10-mer can be used as a vaccine useful with several MHC types by relying on N-terminal trimming to create the epitopes for HLA-B7, -B*5101, and Cw*0401.

HLA-A*0201 binding assay:

HLA-A*0201 binding studies were performed with PSMA₂₈₈₋₂₉₇, GLPSIPVHPI, (SEQ ID NO. 48) essentially as described in Examples 3 and 4 above. As seen in figure 8, this epitope exhibits significant binding at even lower concentrations than the positive control peptides.

Example 6

Cluster Analysis (PSMA₄₅₄₋₄₈₁).

Another peptide, SSIEGNYTLRVDCITPLMYSLVHLTKEL, PSMA₄₅₄₋₄₈₁, (SEQ ID NO. 55) containing an epitope cluster from prostate specific membrane antigen, was synthesized by MPS (purity >95%) and subjected to proteasome digestion and mass spectrum analysis as described above. Prominent peaks from the mass spectra are summarized in Table 11.

Table 11. PSMA₄₅₄₋₄₈₁ Mass Peak Identification.

MS PEAK (measured)	PEPTIDE	SEQUENCE	CALCULATED MASS (MH ⁺)
1238.5	454-464	SSIEGNYTLRV	1239.78
1768.38±0.60	454-469	SSIEGNYTLRVDCTPL	1768.99
1899.8	454-470	SSIEGNYTLRVDCTPLM	1900.19
1097.63±0.91	463-471	RVDCTPLMY	1098.32
2062.87±0.68	454-471*	SSIEGNYTLRVDCTPLMY	2063.36
1153	472-481**	SLVHNLTKEK	1154.36
1449.93±1.79	470-481	MYSLVHNLTKEK	1448.73

Boldface sequence correspond to peptides predicted to bind to MHC, see Table 12.

* On the basis of mass alone this peak could equally well be assigned to the peptide 455-472 however proteasomal removal of just the N-terminal amino acid is considered unlikely. If the issue were important it could be resolved by N-terminal sequencing.

**On the basis of mass this fragment might also represent 455-464.

Epitope Identification

Fragments co-C-terminal with 8-10 amino acid long sequences predicted to bind HLA by the SYFPEITHI or NIH algorithms were chosen for further study. The digestion and prediction steps of the procedure can be usefully practiced in any order. Although the substrate peptide used in proteasomal digest described here was specifically designed to include predicted HLA-A2.1 binding sequences, the actual products of digestion can be checked after the fact for actual or predicted binding to other MHC molecules. Selected results are shown in Table 12.

Table 12. Predicted HLA binding by proteasomally generated fragments

SEQ ID NO	PEPTIDE	HLA	SYFPEITHI	NIH
56 & (57)	(S) IEGNYTLRV	A1	(19)	<5
58	EGNYTLRV	A*0201	16 (22)	<5
		B*5101	15	NP†
59 & (60)	(Y) TLRVDCTPL	A*0201	20 (18)	(5)
		A26	16 (18)	NP
		B7	14	40
		B8	23	<5
		B*2705	12	30
		Cw*0301	NP	(30)
61	LRVDCTPLM	B*2705	20	600
		B*2709	20	NP
62 & (63)	(L) RVDCTPLMY	A1	32 (22)	125 (13.5)
		A3	25	<5

		A26	22	NP
		B*2702	NP	(200)
		B*2705	13 (NP)	(1000)

†No prediction

As seen in Table 12, N-terminal addition of authentic sequence to epitopes can often generate still useful, even better epitopes, for the same or different MHC restriction elements. Note for example the pairing of (L)RVDCITPLMY (SEQ ID NOS 62 and (63)) with HLA-B*2702/5, where the 10-mer has substantial predicted halftimes of dissociation and the co-C-terminal 9-mer does not. Also note the case of SIEGNYTLRV (SEQ ID NO 57) a predicted HLA-A*0201 epitope which can be used as a vaccine useful with HLA-B*5101 by relying on N-terminal trimming to create the epitope.

HLA-A*0201 binding assay

HLA-A*0201 binding studies were performed, essentially as described in Example 3 above, with PSMA₄₆₀₋₄₆₉, TLRVDCITPL, (SEQ ID NO. 60). As seen in figure 10, this epitope was found to bind HLA-A2.1 to a similar extent as the known A2.1 binder FLPSDYFPSV (HBV₁₈₋₂₇; SEQ ID NO: 24) used as a positive control. Additionally, PSMA₄₆₁₋₄₆₉, (SEQ ID NO. 59) binds nearly as well.

ELISPOT analysis: PSMA₄₆₃₋₄₇₁ (SEQ ID NO. 62)

The wells of a nitrocellulose-backed microtiter plate were coated with capture antibody by incubating overnight at 4°C using 50 µl/well of 4µg/ml murine anti-human γ-IFN monoclonal antibody in coating buffer (35 mM sodium bicarbonate, 15 mM sodium carbonate, pH 9.5). Unbound antibody was removed by washing 4 times 5 min. with PBS. Unbound sites on the membrane then were blocked by adding 200µl/well of RPMI medium with 10% serum and incubating 1 hr. at room temperature. Antigen stimulated CD8⁺ T cells, in 1:3 serial dilutions, were seeded into the wells of the microtiter plate using 100µl/well, starting at 2x10⁵ cells/well. (Prior antigen stimulation was essentially as described in Scheibenbogen, C. et al. *Int. J. Cancer* 71:932-936, 1997. PSMA₄₆₂₋₄₇₁ (SEQ ID NO. 62) was added to a final concentration of 10µg/ml and IL-2 to 100 U/ml and the cells cultured at 37°C in a 5% CO₂, water-saturated atmosphere for 40 hrs. Following this incubation the plates were washed with 6 times 200 µl/well of PBS containing 0.05% Tween-20 (PBS-Tween). Detection antibody, 50µl/well of 2g/ml biotinylated murine anti-human γ-IFN monoclonal antibody in PBS+10% fetal calf serum, was added and the plate incubated at room temperature for 2 hrs. Unbound detection antibody was removed by washing with 4 times 200 µl of PBS-Tween. 100µl of avidin-conjugated horseradish peroxidase (Pharmingen, San Diego, CA) was added to each well and incubated at room temperature for 1 hr.

Unbound enzyme was removed by washing with 6 times 200 μ l of PBS-Tween. Substrate was prepared by dissolving a 20 mg tablet of 3-amino 9-ethylcarbazole in 2.5 ml of N, N-dimethylformamide and adding that solution to 47,5 ml of 0.05 M phosphate-citrate buffer (pH 5.0). 25 μ l of 30% H_2O_2 was added to the substrate solution immediately before distributing substrate at 100 μ l/well and incubating the plate at room temperature. After color development (generally 15-30 min.), the reaction was stopped by washing the plate with water. The plate was air dried and the spots counted using a stereomicroscope.

Figure 11 shows the detection of PSMA₄₆₃₋₄₇₁ (SEQ ID NO. 62)-reactive HLA-A1⁺ CD8⁺ T cells previously generated in cultures of HLA-A1⁺ CD8⁺ T cells with autologous dendritic cells plus the peptide. No reactivity is detected from cultures without peptide (data not shown). In this case it can be seen that the peptide reactive T cells are present in the culture at a frequency between 1 in 2.2×10^4 and 1 in 6.7×10^4 . That this is truly an HLA-A1-restricted response is demonstrated by the ability of anti-HLA-A1 monoclonal antibody to block γ -IFN production; see figure 12.

Example 7

Cluster Analysis (PSMA₆₅₃₋₆₈₇).

Another peptide, FDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFY PSMA₆₅₃₋₆₈₇, (SEQ ID NO. 64) containing an A2 epitope cluster from prostate specific membrane antigen, PSMA₆₆₀₋₆₈₁ (SEQ ID NO 65), was synthesized by MPS (purity >95%) and subjected to proteasome digestion and mass spectrum analysis as described above. Prominent peaks from the mass spectra are summarized in Table 13.

Table 13. PSMA₆₅₃₋₆₈₇ Mass Peak Identification.

MS PEAK (measured)	PEPTIDE	SEQUENCE	CALCULATED MASS (MH ⁺)
906.17 \pm 0.65	681-687**	LPDRPFY	908.05
1287.73 \pm 0.76	677-687**	DPLGLPDRPFY	1290.47
1400.3 \pm 1.79	676-687	IDPLGLPDRPFY	1403.63
1548.0 \pm 1.37	675-687	FIDPLGLPDRPFY	1550.80
1619.5 \pm 1.51	674-687**	AFIDPLGLPDRPFY	1621.88
1775.48 \pm 1.32	673-687*	RAFIDPLGLPDRPFY	1778.07
2440.2 \pm 1.3	653-672	FDKSNPIVLRMMNDQLMFLE	2442.93

1904.63±1.56	672-687*	ERAFIDPLGLPDRPFY	1907.19
2310.6±2.5	653-671	FDKSNPIVLRMMNDQLMFL	2313.82
2017.4±1.94	671-687	LERAFIDPLGLPDRPFY	2020.35
2197.43±1.78	653-670	FDKSNPIVLRMMNDQLMF	2200.66

Boldface sequence correspond to peptides predicted to bind to MHC, see Table 13.

* On the basis of mass alone this peak could equally well be assigned to a peptide beginning at 654, however proteasomal removal of just the N-terminal amino acid is considered unlikely. If the issue were important it could be resolved by N-terminal sequencing.

5 ** On the basis of mass alone these peaks could have been assigned to internal fragments, but given the overall pattern of digestion it was considered unlikely.

Epitope Identification

10 Fragments co-C-terminal with 8-10 amino acid long sequences predicted to bind HLA by the SYFPEITHI or NIH algorithms were chosen for further study. The digestion and prediction steps of the procedure can be usefully practiced in any order. Although the substrate peptide used in proteasomal digest described here was specifically designed to include predicted HLA-A2.1 binding sequences, the actual products of digestion can be checked after the fact for actual or predicted binding to other MHC molecules. Selected results are shown in Table 14.

15 **Table 14. Predicted HLA binding by proteasomally generated fragments**

SEQ ID NO	PEPTIDE	HLA	SYFPEITHI	NIH
66 & (67)	(R)MMNDQLMF L	A*0201	24 (23)	1360 (722)
		A*0205	NP†	71 (42)
		A26	15	NP
		B*2705	12	50
68	RMMNDQLMF	B*2705	17	75

†No prediction

20 As seen in Table 14, N-terminal addition of authentic sequence to epitopes can generate still useful, even better epitopes, for the same or different MHC restriction elements. Note for example the pairing of (R)MMNDQLMFL (SEQ ID NOS. 66 and (67)) with HLA-A*02, where the 10-mer retains substantial predicted binding potential.

HLA-A*0201 binding assay

25 HLA-A*0201 binding studies were performed, essentially as described in Example 3 above, with PSMA₆₆₃₋₆₇₁ (SEQ ID NO. 66) and PSMA₆₆₂₋₆₇₁, RMMNDQLMFL (SEQ NO. 67). As

seen in figures 10, 13 and 14, this epitope exhibits significant binding at even lower concentrations than the positive control peptide (FLPSDYFPSV (HBV₁₈₋₂₇); SEQ ID NO: 24). Though not run in parallel, comparison to the controls suggests that PSMA₆₆₂₋₆₇₁ (which approaches the Melan A peptide in affinity) has the superior binding activity of these two PSMA peptides.

5 **Example 8**

Vaccinating with epitope vaccines.

1. Vaccination with peptide vaccines:

A. Intranodal delivery

10 A formulation containing peptide in aqueous buffer with an antimicrobial agent, an antioxidant, and an immunomodulating cytokine, was injected continuously over several days into the inguinal lymph node using a miniature pumping system developed for insulin delivery (MiniMed; Northridge, CA). This infusion cycle was selected in order to mimic the kinetics of antigen presentation during a natural infection.

B. Controlled release

15 A peptide formulation is delivered using controlled PLGA microspheres as is known in the art, which alter the pharmacokinetics of the peptide and improve immunogenicity. This formulation is injected or taken orally.

C. Gene gun delivery

20 A peptide formulation is prepared wherein the peptide is adhered to gold microparticles as is known in the art. The particles are delivered in a gene gun, being accelerated at high speed so as to penetrate the skin, carrying the particles into dermal tissues that contain pAPCs.

D. Aerosol delivery

A peptide formulation is inhaled as an aerosol as is known in the art, for uptake into appropriate vascular or lymphatic tissue in the lungs.

25 2. Vaccination with nucleic acid vaccines:

30 A nucleic acid vaccine is injected into a lymph node using a miniature pumping system, such as the MiniMed insulin pump. A nucleic acid construct formulated in an aqueous buffered solution containing an antimicrobial agent, an antioxidant, and an immunomodulating cytokine, is delivered over a several day infusion cycle in order to mimic the kinetics of antigen presentation during a natural infection.

Optionally, the nucleic acid construct is delivered using controlled release substances, such as PLGA microspheres or other biodegradable substances. These substances are injected or taken orally. Nucleic acid vaccines are given using oral delivery, priming the immune response through uptake into GALT tissues. Alternatively, the nucleic acid vaccines are delivered using a gene gun,

wherein the nucleic acid vaccine is adhered to minute gold particles. Nucleic acid constructs can also be inhaled as an aerosol, for uptake into appropriate vascular or lymphatic tissue in the lungs.

Example 9

Assays for the effectiveness of epitope vaccines.

5 1. Tetramer analysis:

Class I tetramer analysis is used to determine T cell frequency in an animal before and after administration of a housekeeping epitope. Clonal expansion of T cells in response to an epitope indicates that the epitope is presented to T cells by pAPCs. The specific T cell frequency is measured against the housekeeping epitope before and after administration of the epitope to an animal, to determine if the epitope is present on pAPCs. An increase in frequency of T cells specific to the epitope after administration indicates that the epitope was presented on pAPC.

2. Proliferation assay:

Approximately 24 hours after vaccination of an animal with housekeeping epitope, pAPCs are harvested from PBMCs, splenocytes, or lymph node cells, using monoclonal antibodies against specific markers present on pAPCs, fixed to magnetic beads for affinity purification. Crude blood or splenocyte preparation is enriched for pAPCs using this technique. The enriched pAPCs are then used in a proliferation assay against a T cell clone that has been generated and is specific for the housekeeping epitope of interest. The pAPCs are coincubated with the T cell clone and the T cells are monitored for proliferation activity by measuring the incorporation of radiolabeled thymidine by T cells. Proliferation indicates that T cells specific for the housekeeping epitope are being stimulated by that epitope on the pAPCs.

3. Chromium release assay:

A human patient, or non-human animal genetically engineered to express human class I MHC, is immunized using a housekeeping epitope. T cells from the immunized subject are used in a standard chromium release assay using human tumor targets or targets engineered to express the same class I MHC. T cell killing of the targets indicates that stimulation of T cells in a patient would be effective at killing a tumor expressing a similar TuAA.

Example 10

30 **Induction of CTL response with naked DNA is efficient by Intra-lymph node immunization.**

In order to quantitatively compare the CD8⁺ CTL responses induced by different routes of immunization a plasmid DNA vaccine (pEGFP33A) containing a well-characterized immunodominant CTL epitope from the LCMV-glycoprotein (G) (gp33; amino acids 33-41) (Oehen, S., et al., *Immunology* 99, 163-169 2000) was used, as this system allows a comprehensive assessment of antiviral CTL responses. Groups of 2 C57BL/6 mice were immunized once with

titrated doses (200-0.02 μ g) of pEGFPL33A DNA or of control plasmid pEGFP-N3, administered i.m. (intramuscular), i.d. (intradermal), i.spl. (intraspinal), or i.ln. (intra-lymph node). Positive control mice received 500 pfu LCMV i.v. (intravenous). Ten days after immunization spleen cells were isolated and gp33-specific CTL activity was determined after secondary *in vitro* restimulation. As shown in Fig. 15, i.m. or i.d. immunization induced weakly detectable CTL responses when high doses of pEGFPL33A DNA (200 μ g) were administered. In contrast, potent gp33-specific CTL responses were elicited by immunization with only 2 μ g pEGFPL33A DNA i.spl. and with as little as 0.2 μ g pEGFPL33A DNA given i.ln. (figure 15; symbols represent individual mice and one of three similar experiments is shown). Immunization with the control pEGFP-N3 DNA did not elicit any detectable gp33-specific CTL responses (data not shown).

Example 11

Intra-lymph node DNA immunization elicits anti-tumor immunity.

To examine whether the potent CTL responses elicited following i.ln. immunization were able to confer protection against peripheral tumors, groups of 6 C57BL/6 mice were immunized three times at 6-day intervals with 10 μ g of pEGFPL33A DNA or control pEGFP-N3 DNA. Five days after the last immunization small pieces of solid tumors expressing the gp33 epitope (EL4-33) were transplanted s.c. into both flanks and tumor growth was measured every 3-4d. Although the EL4-33 tumors grew well in mice that had been repetitively immunized with control pEGFP-N3 DNA (figure 16), mice which were immunized with pEGFPL33A DNA i.ln. rapidly eradicated the peripheral EL4-33 tumors (figure 16).

Example 12

Differences in lymph node DNA content mirrors differences in CTL response following intra-lymph node and intramuscular injection.

pEGFPL33A DNA was injected i.ln. or i.m. and plasmid content of the injected or draining lymph node was assessed by real time PCR after 6, 12, 24, 48 hours, and 4 and 30 days. At 6, 12, and 24 hours the plasmid DNA content of the injected lymph nodes was approximately three orders of magnitude greater than that of the draining lymph nodes following i.m. injection. No plasmid DNA was detectable in the draining lymph node at subsequent time points (Fig. 17). This is consonant with the three orders of magnitude greater dose needed using i.m. as compared to i.ln. injections to achieve a similar levels of CTL activity. CD8^{-/-} knockout mice, which do not develop a CTL response to this epitope, were also injected i.ln. showing clearance of DNA from the lymph node is not due to CD8⁺ CTL killing of cells in the lymph node. This observation also supports the conclusion that i.ln. administration will not provoke immunopathological damage to the lymph node.

Example 13

Administration of a DNA plasmid formulation of a therapeutic vaccine for melanoma to humans.

SYNCHROTOPE TA2M, a melanoma vaccine, encoding the HLA-A2-restricted tyrosinase epitope SEQ ID NO. 1 and epitope cluster SEQ ID NO. 69, was formulated in 1% Benzyl alcohol, 1% ethyl alcohol, 0.5mM EDTA, citrate-phosphate, pH 7.6. Aliquots of 80, 160, and 320 µg DNA/ml were prepared for loading into MINIMED 407C infusion pumps. The catheter of a SILHOUETTE infusion set was placed into an inguinal lymph node visualized by ultrasound imaging. The assembly of pump and infusion set was originally designed for the delivery of insulin to diabetics and the usual 17mm catheter was substituted with a 31mm catheter for this application. The infusion set was kept patent for 4 days (approximately 96 hours) with an infusion rate of about 25 µl/hour resulting in a total infused volume of approximately 2.4 ml. Thus the total administered dose per infusion was approximately 200, and 400 µg; and can be 800 µg, respectively, for the three concentrations described above. Following an infusion subjects were given a 10 day rest period before starting a subsequent infusion. Given the continued residency of plasmid DNA in the lymph node after administration (as in example 12) and the usual kinetics of CTL response following disappearance of antigen, this schedule will be sufficient to maintain the immunologic CTL response.

Example 14**Additional Epitopes.**

The methodologies described above, and in particular in examples 3-7, have been applied to additional synthetic peptide substrates, leading to the identification of further epitopes as set for the in tables 15-36 below. The substrates used here were designed to identify products of housekeeping proteasomal processing that give rise to HLA-A*0201 binding epitopes, but additional MHC-binding reactivities can be predicted, as discussed above. Many such reactivities are disclosed, however, these listings are meant to be exemplary, not exhaustive or limiting. As also discussed above, individual components of the analyses can be used in varying combinations and orders. The digests of the NY-ESO-1 substrates 136-163 and 150-177 (SEQ ID NOS. 254 and 255, respectively) yielded fragments that did not fly well in MALDI-TOF mass spectrometry. However, they were quite amenable to N-terminal peptide pool sequencing, thereby allowing identification of cleavage sites. Not all of the substrates necessarily meet the formal definition of an epitope cluster as referenced in example 3. Some clusters are so large, e.g. NY-ESO-1₈₆₋₁₇₁, that it was more convenient to use substrates spanning only a portion of this cluster. In other cases, substrates were extended beyond clusters meeting the formal definition to include neighboring

predicted epitopes. In some instances, actual binding activity may have dictated what substrate was made, as with for example the MAGE epitopes reported here, where HLA binding activity was determined for a selection of peptides with predicted affinity, before synthetic substrates were designed.

Table 15
 GPI00: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion
 †Scores are given from the two binding prediction programs referenced above (see example 3).

Substrate	Epitope	Sequence	SEQ ID NO	HLA Binding Predictions (SYFPEITHI/NIH)†					Comments
				A*0201	A1	A3	B7	B8	
609-644	630-638*	LPHSSSHWL	88				20/80	16/<5	*The digestion of 609-644 and 622-650 have generated the same epitopes.
	629-638*	QLPHSSSHWL	89	21/117					
	614-622	LIYRRRLMK	90			32/20			
	613-622	SLIYRRRLMK	91	14/<5		29/60		15/<5	
	615-622	IYRRRLMK	92				20/80	16/<5	
622-650	630-638*	LPHSSSHWL	93						
	629-638*	QLPHSSSHWL	94	21/117					

Table 16A

MAGE-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	SEQ ID NO	HLA Binding Predictions (SYRPE[THI]/NIH) [†]						
				A*0201	A1	A3	B7	B8	Other	
86-109	95-102	ESLFRAVI	95					16/<5		
	93-102	ILESFRVI	96	21/<5		20/<5				
	93-101	ILESFRV	97	23/<5						
	92-101	CILESFRV	98	23/55						
	92-100	CILESFR	99	20/138						
263-292	263-271	EFLWGPRAL	100						A26 (R 21), A24 (NIH 30)	
	264-271	FLWGPRAL	101					17/<5		
	264-273	FLWGPRALAE	102	16/<5		19/<5				
	265-274	LWGPRALAE	103	16/<5						
	268-276	PRALAE	104	15/<5						
	267-276	GPRALAE	105	15/<5			<15/<5		B4403 (NIH 7); B3501 (NIH 120)	
	269-277	RALAE	106	18/20						
	271-279	LAETSYVKV	107	19/<5						
	270-279	ALAETSYVKV	108	30/427		19/<5				
	272-280	AETSYVKVL	109	15/<5					B4403 (NIH 36)	
	271-280	LAETSYVKVL	110	18/<5			<15/<5			
	274-282	TSYVKVLEY	111		26/<5				B4403 (NIH 14)	
	273-282	ETSYVKVLEY	112		28/6				A26 (R 31), B4403 (NIH 14)	
	278-286	KVLEYVKV	113	26/743		16/<5				

Table 16B
MAGE-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	SEQ ID NO	HLA Binding Predictions (SYFPEITHI/NIH) [†]					
				A*0201	A1	A3	B7	B8	Other
168-193	168-177	SYVLVTCLGL	114						A24 (NIH 300)
	169-177	YVLVTCLGL	115	20/32		15/<5	<15/20		
	170-177	VLVTCLGL	116					17/<5	
	240-248	TQDLVQEKY	117		29/<5				
229-258	239-248	LTQDLVQEKY	118		23/<5				A26 (R 22)
	232-240	YGEPRKLLT	119		24/11				
	243-251	LVQEKYLEY	120		21/<5	21/<5			A26 (R 28)
	242-251	DLVQEKYLEY	121		22/<5	19/<5			A26 (R 30)
	230-238	SAYGEPRKL	122	21/<5					B5101 (25/121)
	278-286	KVLEYVIKV	123	26/743		16/<5			
	277-286	VKLEYVIKV	124	17/<5					
	276-284	YVKVLEYVI	125	15/<5		15/<5		17/<5	
272-297	274-282	TSYVKVLEY	126		26/<5				
	273-282	ETSYVKVLEY	127		28/6				
	283-291	VIKVSARVR	128			20/<5			
	282-291	YVIKVSARVR	129			24/<5			

[†]Scores are given from the two binding prediction programs referenced above (see example 3). R indicates a SYFPEITHI score.

Table 17A

MAGE-2: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	SEQ ID NO	HLA Binding Predictions (SYFPEITHI /NIB)†						
				A*0201	A1	A3	B7	B8	Other	
107-126	115-122	ELVHFLLL	130					18/<5		
	113-122	MVELVHFLLL	131		21/<5				A26 (R 22)	
	109-116	ISRKMVEL	132					17/<5		
	108-116	AISRKMVEL	133	25/7				26/<5		
	107-116	AAISRKMVEL	134	22/<5		19/<5	16/12	n.p./16		
	112-120	KMVELVHFL	135	27/2800			14/36			
	109-117	ISRKMVELV	136	16/<5						
	108-117	AISRKMVELV	137	24/11						
	116-124	LVHFLLLKY	138		23/<5	19/<5			A26 (R 26)	
	115-124	ELVHFLLLKY	139		24/<5	19/5			A26 (R 29)	
	111-119	RKMVELVHF	140							
145-175	158-166	LQLVFGIEV	141	17/168						
	157-166	YQLVFGIEV	142	24/1215						
	159-167	QLVFGIEVV	143	25/32		18/<5				
	158-167	LQLVFGIEVV	144	18/20						
	164-172	IEVVEVVPI	145	16/<5						
	163-172	GIEVVEVVPI	146	22/<5						
	162-170	FGIEVVEVV	147	19/<5					B5101(24/69.212)	
	154-162	ASEYLQLVF	148		22/68					
	153-162	KASEYLQLVF	149			15/<5				

†Scores are given from the two binding prediction programs referenced above (see example 3). R indicates a SYFPEITHI score.

Table 17B
MAGE-2: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	HLA Binding Predictions (SYFPEITHI /NIH)†						
			A*0201	A1	A3	B7	B8	Other	
213-233	218-225	EEKIWEEL	150				22/<5		
	216-225	APEEKIWEEL	151			22/72			
	216-223	APEEKIWE	152				18/<5		
	220-228	KIWEELSML	153		16/<5		16/<5	A26 (R 26)	
	219-228	EKIWEELSML	154					A26 (R 22)	
271-291	271-278	FLWGPRAL	155				17/<5		
	271-279	FLWGPRALI	156		16/7				
	278-286	LIETSYVKV	157						
	277-286	ALIETSYVKV	158		21/<5				
	276-284	RALIETSYV	159					B5101 (20/55)	
	279-287	IETSYVKVL	160						
	278-287	LIETSYVKVL	161					A26 (R 22)	

[†]Scores are given from the two binding prediction programs referenced above (see example 3). R indicates a SYFPEITHI score.

Table 18

MAGE-3: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	SEQ ID NO	HLA Binding Predictions (SYFPEITHI /NIH) [†]					
				A*0201	A1	A3	B7	B8	Other
267-286	271-278	FLWGPRAL	162					17/<5	
	270-278	EFLWGPRAL	163						A26 (R 21); A24 (NIH 30)
	271-279	FLWGPRALV	164	27/2655		16/<5			
	276-284	RALVETSYV	165	18/19					B5101 (20/55)
	272-280	LWGPRALVE	166			15/<5			
	271-280	FLWGPRALVE	167	15/<5		22/<5			
	272-281	LWGPRALVET	168	16/<5					

[†]Scores are given from the two binding prediction programs referenced above (see example 3). R indicates a SYFPEITHI score.

Table 19A
NY-ESO-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	SEQ ID NO	HLA Binding Predictions (SYFPEITHI/NIH) [†]					Other
				A*0201	A1	A3	B7	B8	
81-113	82-90	GPESRLLEF	169		16/11		18/<5	22/<5	
	83-91	PESRLLEFY	170		15/<5				B4403 (NIH 18)
	82-91	GPESRLLEFY	171		25/11				
	84-92	ESRLLEFY	172					19/8	
	86-94	RLLEFYLAM	173	21/430		21/<5			
	88-96	LEFYLAMPF	174						B4403 (NIH 60)
	87-96	LLEFYLAMPF	175		<15/45	18/<5			
	93-102	AMPFATPMEA	176	15/<5					
101-133	94-102	MPFATPMEA	177				17/<5		
	115-123	PLPVPGVLL	178	20/<5		17/<5	16/<5	18/<5	
	114-123	PPLPVPGVLL	179				23/12		
	116-123*	LPVPGVLL	180					16/<5	*Evidence of the same epitope obtained from two digests.
	103-112	ELARRSLAQD	181	15/<5		20/<5			
	118-126*	VPGVLLKEF	182				17/<5	16/<5	
	117-126*	PVPGVLLKEF	183			16/<5			
	116-123*	LPVPGVLL	184					16/<5	
116-145	127-135	TVSGNLTIT	185	21/<5		19/<5			
	126-135	FTVSGNLTIT	186	20/<5					
	120-128	GVLLEKFTV	187	20/130		18/<5			
	121-130	VLLKEFTVSG	188	17/<5		18/<5			
	122-130	LLKEFTVSG	189	20/<5		18/<5			
	118-126*	VPGVLLKEF	190				17/<5	16/<5	
	117-126*	PVPGVLLKEF	191			16/<5			

[†]Scores are given from the two binding prediction programs referenced above (see example 3).

Table 19B
NY-ESO-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	HLA Binding Predictions (SYFPEITHI /NIH) [†]				
			SEQ ID NO	A*0201	A1	A3	Other
136-163 (SEQ ID NO 254)	139-147	AADHRQLQL	192	17/<5	17/<5		
	148-156	SISSCLQQL	193	24/7			A26 (R 25)
	147-156	LSISSCLQQL	194	18/<5			
	138-147	TAADHRQLQL	195	18/<5			
	161-169	WITQCFLPV	196	18/84			
150-177 (SEQ ID NO 255)	157-165	SLLMWITQC	197	18/42		17/<5	
	150-158	SSCLQQLSL	198	15/<5			
	154-162	QQLSLLMWI	199	15/50			
	151-159	SCLQQLSLL	200	18/<5			
	150-159	SSCLQQLSLL	201	16/<5			
	163-171	TQCFLPVFL	202	<15/12			
	162-171	ITQCFLPVFL	203	18/<5			A26 (R 19)

[†]Scores are given from the two binding prediction programs referenced above (see example 3). R indicates a SYFPEITHI score

Table 20
PRAME: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	HLA Binding Predictions (SYFPEITHI /NIH) [†]				
			SEQ ID NO	A*0201	A1	A3	Other
211-245	219-227	PMQDIKMIL	204	16/<5			A26 (R 20)
	218-227	MPMQDIKMIL	205			<15/240	
411-446	428-436	QHLIGLSNL	206	18/<5			
	427-436	LQHLIGLSNL	207	16/8			
	429-436	HLIGLSNL	208				B15 (R 21)
	431-439	IGLSNLTHV	209	18/7			B*5101 (R 22)
	430-439	LIGLSNLTHV	210	24/37			

[†]Scores are given from the two binding prediction programs referenced above (see example 3). R indicates a SYFPEITHI score.

Table 21
PSA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	SEQ ID NO	HLA Binding Predictions (SYFPEITHI /NIH) [†]					
				A*0201	A1	A3	B7	B8	Other
42-77	53-61	VLVHPQWVL	211	22/112			<15/6	17/<5	
	52-61	GVLVHPQWVL	212	17/21		16/<5	<15/30		A26 (R 18)
	52-60	GVLVHPQWV	213	17/124					
	59-67	WVLTAACHCI	214	15/16					
	54-63	LVHPQWVLTA	215	19/<5		20/<5			A26 (R 16)
	53-62	VLVHPQWVLT	216	17/22					
	54-62	LVHPQWVLT	217			17/n.d.			
55-95	66-73	CIRNKSVI	218					26/20	
	65-73	HCIRNKSVI	219					<15/16	
	56-64	HPQWVLTAA	220				18/<5		
	63-72	AAHCIRNKSV	221	17/<5					

[†]Scores are given from the two binding prediction programs referenced above (see example 3). R indicates a SYFPEITHI score.

Table 22
PSCA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	SEQ ID NO	HLA Binding Predictions (SYFPEITHI /NIH) [†]					
				A*0201	A1	A3	B7	B8	Other
93-123*	116-123	LLWGPQQL	222					16/<5	
	115-123	LLLWGPQQL	223	<15/18					
	114-123	GLLLWGPQQL	224	<15/10					
	99-107	ALQPAAAIL	225	26/9		22/<5	<15/12	16/<5	A26 (R 19)
	98-107	HALQPAAIL	226	18/<5			<15/12		

*L123 is the C-terminus of the natural protein.

[†]Scores are given from the two binding prediction programs referenced above (see example 3).

Table 23
Tyrosinase: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	SEQ ID		HLA Binding Predictions (SYFPEITHI/NIH) [†]							
			NO	A*0201	A1	A3	B7	B8	Other			
128-157	128-137	APEKDKFFAY	227		29/6		15/<5		B4403 (NIH 14)			
	129-137	PEKDKFFAY	228		18/<5			21/<5				
	130-138	EKDKFFAYL	229				15/<5					
	131-138	KDKFFAYL	230					20/<5				
197-228	205-213	PAFLPWHL	231					15/<5				
	204-213	APAFLPWHL	232				23/360					
	207-216	FLPWHLFL	1	25/1310				<15/8				
	208-216	LPWHLFL	9	17/26			20/80	24/16				
	214-223	FLRWEQEIQ	233			15/<5						
	212-220	RLFLLRWEQ	234			16/<5						
191-211	191-200	GSEIWRDIDF	235		18/68							
	192-200	SEIWRDIDF	236					16/<5	B4403 (NIH 400)			
207-230	207-215	FLWHLFL	8	22/540			<15/6	17/<5				
466-484	473-481	RIWSWLLGA	237	19/13		15/<5						
476-497	476-484	SWLLGAAMV	238	18/<5								
	477-486	WLLGAAMVGA	239	21/194		18/<5						
	478-486	LLGAAMVGA	240	19/19		16/<5						

[†]Scores are given from the two binding prediction programs referenced above (see example 3).

Table 24
PSMA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	SEQ ID NO	HLA Binding Predictions (SYFPEITHI /NIH) [†]					
				A*0201	A1	A3	B7	B8	Other
1-30	4-12	LLHETDSAV	241	25/485		15/<5			
	13-21	ATARRPRWL	242	18/<5				18/<5	A26 (R 19)
	53-61	TPKHNMKAF	243					24/<5	
53-80	64-73	ELKAENIKKF	244			17/<5			A26 (R 30)
	69-77	NIKKFLH'NF	245						A26 (R 27)
	68-77	ENIKKFLH'NF	246						A26 (R 24)
	220-228	AGAKGVILY	247		25/<5				
457-489	468-477	PLMYSLVHNL	248	22/<5					
	469-477	LMYSLVHNL	249	27/193		<15/9			
	463-471	RVDCTPLMY	250		32/125	25/<5			A26 (R 22)
	465-473	DCTPLMYSL	251						A26 (R 22)
503-533	507-515	SGMPRISKL	252	21/<5				21<5	
	506-515	FSGMPRISKL	253	17/<5					

[†] This H was reported as Y in the SWISSPROT database.

[†] Scores are given from the two binding prediction programs referenced above (see example 3).

Table 25A
MAGE-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
Mage-1 119-146	125-132	KAEMLESV	256	B5101	19	n.a.
	124-132	TKAEMLESV	257	A0201	20	<5
	123-132	VTKAEMLESV	258	A0201	20	<5
	128-136	MLESVIKNY	259	A1	28	45
				A26	24	n.a.
				A3	17	5
				A1	15	<1.0
Mage-1 143-170	127-136	EMLESVIKNY	260	A26	23	<1.0
	125-133	KAEMLESVI	261	B5101	23	100
				A24	N.A.	4
	146-153	KASESLQL	262	B08	16	<1.0
				B5101	17	N.A.
	145-153	GKASESLQL	263	B2705	17	1
				B2709	16	N.A.
Mage-1 143-170	147-155	ASESLQLVF	264	A1	22	68
	153-161	LVFGIDVKE	265	A26	16	N.A.
				A3	16	<1.0

Table 25B
MAGE-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
Mage-1 99-125	114-121	LLKYRARE	266	B8	25	<1.0
	106-113	VADLVGFL	267	B8	16	<1.0
				B5101	21	N.A.
				A0201	23	44
	105-113	KVADLVGFL	268	A26	25	N.A.
				A3	16	<5
				B0702	14	20
				B2705	14	30
				A0201	17	<5
	107-115	ADLVGFLL	269	B0702	15	<5
				B2705	16	1
				A0201	16	<5
	106-115	VADLVGFLL	270	A1	22	3
	114-123	LLKYRAREPV	271	A0201	20	2

Table 26
MAGE-3: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYRPEITHI	NIH
Mage-3 267-295	271-278	FLWGPRAL	162	B08	17	<5
	270-278	EFLWGPRAL	163	A26	21	N.A.
				A24	N.A.	30
				B1510	16	N.A.
				A0201	27	2655
	271-279	FLWGPRALV	164	A3	16	2
				A0201	19	<1.0
	278-286	LVETSYVKV	272	A26	17	N.A.
				A0201	28	428
	277-286	ALVETSYVKV	273	A26	16	<5
				A3	18	<5
				A0201	19	27
	285-293	KVLHHMVKI	274	A3	19	<5
				A0201	18	20
	276-284	RALVETSYV	165	A0201	17	<1.0
	283-291	YVKVLHMHV	275	A0201	17	<1.0
	275-283	PRALVETSY	276	A1	15	<1.0
	274-283	GPRALVETSY	277	A1	15	<1.0
	278-287	LVETSYVKVL	278	A0201	18	<1.0
	272-281	LWGPRALVET	168	A0201	16	<1.0
	271-280	FLWGPRALVE	167	A3	22	<5

Table 27A
Fibronectin ED-B: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
ED-B 14'-21*	4'-5**	<i>TTIPEVPQL</i> [†]	279	A0201	27	7
				A26	28	N.A.
				A3	17	<5
				B8	15	<5
				B1510	15	N.A.
				B2705	17	10
				B2709	15	N.A.
	5'-5**	<i>DTIPEVPQL</i> [†]	280	A0201	20	<5
	1-10	<i>EVPQLTDLSE</i>	281	A26	32	N.A.
				A26	29	N.A.

*This substrate contains the 14 amino acids from fibronectin flanking ED-B to the N-terminal side.

**These peptides span the junction between the N-terminus of the ED-B domain and the rest of fibronectin.

[†] The italicized lettering indicates sequence outside the ED-B domain.

Table 27B
Fibronectin ED-B: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
ED-B 8-35	23-30	TPLNSSTI	282	B5101	22	N.A.
	18-25	IGLRWTPL	283	B5101	18	N.A.
	17-25	SIGLRWTPL	284	A0201	20	5
				A26	18	N.A.
				B08	25	<5
				A1	19	<5
	25-33	LNSSTIIGY	285	A26	16	<5
	24-33	PLNSSTIIGY	286	A1	20	<5
				A26	24	N.A.
				A3	16	<5
	23-31	TPLNSSTII	287	B0702	17	8
				B5101	25	440

Table 27C
Fibronectin ED-B: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NTH
ED-B 20-49	31-38	IGYRITVV	288	B5101	25	N.A.
	30-38	IIGYRITVV	289	A0201	23	15
				A3	17	<1.0
				B08	15	<1.0
				B5101	15	3
	29-38	TIIGYRITVV	290	A0201	26	9
				A26	18	N.A.
				A3	18	<5
				B5101	22	N.A.
	23-30	TPLNSSTI	282	A1	19	<5
	25-33	LNSSTIGY	285	A26	16	N.A.
				A26	24	N.A.
	24-33	PLNSSTIGY	286	A3	16	<5
	31-39	IGYRITVVA	291	A3	17	<5
				A0201	15	<5
	30-39	IIGYRITVVA	292	A3	18	<5
				B0702	17	8
23-31	TPLNSSTII		287	B5101	25	440

Table 28A
CEA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
CEA 176-202	184-191	SLPVSRL	293	B08	19	<5
	183-191	QSLPVSPRL	294	A0201	15	<5
				B1510	15	
				B2705	18	10
				B2709	15	
	186-193	PVSPRLQL	295	B08	18	<5
	185-193	LPVSPRLQL	296	B0702	26	180
				B08	16	<5
				B5101	19	130
	184-193	SLPVSPRLQL	297	A0201	23	21
				A26	18	N.A.
				A3	18	<5
	185-192	LPVSPRLQ	298	B5101	17	N.A.
	192-200	QLSNGNRTL	299	A0201	21	4
				A26	16	N.A.
				A3	19	<5
				B08	17	<5
				B1510	15	
	191-200	LQLSNGNRTL	300	A0201	16	3
	179-187	WVNNQSLPV	301	A0201	16	28
	186-194	PVSPRLQLS	302	A26	17	N.A.
				A3	15	<5

Table 28B
CEA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
CEA 354-380	362-369	SLPVSPRL	303	B08	19	<1.0
	361-369	QSLPVSPRL	304	A0201	15	<1.0
				B2705	18	10
				B2709	15	
	364-371	PVSPRLQL	305	B08	18	<1.0
	363-371	LPVSPRLQL	306	B0702	26	180
				B08	16	<1.0
				B5101	19	130
	362-371	SLPVSPRLQL	307	A0201	23	21
				A26	18	N.A.
				A24	N.A.	6
				A3	18	<5
	363-370	LPVSPRLQ	308	B5101	17	N.A.
	370-378	QLSNDNRTL	309	A0201	22	4
				A26	16	N.A.
				A3	17	<1.0
	369-378	LQLSNDNRTL	310	B08	17	<1.0
				A0201	16	3
	357-365	WVNNQSLPV	311	A0201	16	28
	360-368	NQSLPVSPR	312	B2705	14	100

Table 28C
CEA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
CEA 532-558	540-547	SLPVSPRL	313	B08	19	<5
	539-547	QSLPVSPRL	314	A0201	15	<5
				B1510	15	<5
				B2705	18	10
				B2709	15	
	542-549	PVSPRLQL	315	B08	18	<5
	541-549	LPVSPRLQL	316	B0702	26	180
				B08	16	<1.0
				B5101	19	130
	540-549	SLPVSPRLQL	317	A0201	23	21
				A26	18	N.A.
				A3	18	<5
	541-548	LPVSPRLQ	318	B5101	17	N.A.
	548-556	QLSNGNRTL	319	A0201	24	4
				A26	16	N.A.
				A3	19	<1.0
				B08	17	<1.0
	547-556	LQLSNGNRTL	320	B1510	15	
				A0201	16	3
	535-543	WVNGQSLPV	321	A0201	18	28
				A3	15	<1.0
	533-541	LWWVNGQSL	322	A0201	15	<5

Table 28D
CEA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
CEA 532-558 (continued)	532-541	YLWWVNGQSL	323	A0201	25	816
				A26	18	N.A.
	538-546	GQSLPVSPR	324	B2705	17	100

Table 29A
HER2/NEU: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
Her-2 25-52	30-37	DMKLRIPA	325	B08	19	8
	28-37	GTDMLRIPA	326	A1	23	6
	42-49	HLDMLRHL	327	B08	17	<5
	41-49	THLDMLRHL	328	A0201	17	<5
				B1510	24	N.A.
	40-49	ETHLDMLRHL	329	A26	29	N.A.
	36-43	PASPETHL	330	B5101	17	N.A.
				A0201	15	<5
	35-43	LPASPETHL	331	B5101	20	130
				B5102	N.A.	100
	34-43	RLPASPETHL	332	A0201	20	21
				A0201	15	<5
	38-46	SPETHLDML	333	B0702	20	24
				B08	18	<5
				B5101	18	110
	37-46	ASPETHLDML	334	A0201	18	<5
	42-50	HLDMLRHLY	335	A1	29	25
				A26	20	N.A.
				A3	17	4
	41-50	THLDMLRHLY	336	A1	18	<1.0

Table 29B
HER2/NEU: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
Her-2 705-732	719-726	ELRKVKVL	337	B08	24	16
				A0201	16	1
	718-726	TELKVKVL	338	B08	22	<5
				B5101	16	<5
	717-726	ETELRKVKVL	339	A1	18	2
				A26	28	6
	715-723	LKETELRKV	340	A0201	17	<5
				B5101	15	<5
	714-723	ILKETELRKV	341	A0201	29	8
				A0201	15	<5
	712-720	MRILKETEL	342	B08	22	<5
				B2705	27	2000
				B2709	21	N.A.
	711-720	QMRILKETEL	343	A0201	20	2
				B0702	13	40
	717-725	ETELRKVKV	344	A1	18	5
				A26	18	N.A.
	716-725	KETELRKVKV	345	A0201	16	19
	706-714	MPNQAQMRI	346	B0702	16	8
				B5101	22	629
	705-714	AMPNQAQMRI	347	A0201	18	8
	706-715	MPNQAQMRI	348	B0702	20	80

Table 29C
HER2/NEU: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
Her-2 954-982	966-973	RPRFREL V	349	B08	20	24
				B5101	18	N.A.
	965-973	CRPRFREL V	350	B2709	18	
				A26	25	N.A.
				A24	N.A.	32
	968-976	RFREL VSEF	351	A3	15	<5
				B08	16	<5
				B2705	19	
	967-976	PRFREL VSEF	352	A26	18	N.A.
				A26	21	N.A.
	964-972	ECRPRFREL	353	A24	N.A.	6
				B0702	15	40
				B8	27	640
				B1510	16	<5

Table 30
NY-ESO-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
NY-ESO-1 51-77	67-75	GAASGLNGC	354	A0201	15	<5
	52-60	RASGPGGGA	355	B0702	15	<5
	64-72	PHGGAASGL	356	B1510	21	N.A.
	63-72	GPHGGAASGL	357	B0702	22	80
	60-69	APRGPHGGA	358	B0702	23	60

Table 31A
PRAME: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
PRAME 103-135	112-119	VRPRRWKL	359	B08	19	
				A26	27	N.A.
				A24	N.A.	5
	111-119	EVRPRRWKL	360	A3	19	N.A.
				B0702	15	(B7) 300.00
				B08	26	160
	113-121	RPRRWKLQV	361	B0702	21	(B7) 40.00
				B5101	19	110
	114-122	PRRWKLQVL	362	B08	26	<5
				B2705	23	200
				B0702	24	(B7) 800.00
	113-122	RPRRWKLQVL	363	B8	N.A.	160
				B5101	N.A.	61
PRAME 161-187				B5102	N.A.	61
				A24	N.A.	10
	116-124	RWKLQVLDL	364	B08	22	<5
				B2705	17	3
	115-124	RRWKLQVLDL	365	A0201	16	<5
	174-182	PVEVLVDLF	366	A26	25	N.A.

Table 31B
PRAME: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
PRAME 185-215	199-206	VKRKKNVL	367	B08	27	8
	198-206	KVKRKKKNVL	368	A0201	16	<1.0
				A26	20	N.A.
				A3	22	<1.0
				B08	30	40
				B2705	16	
	197-206	EKVKRKKKNVL	369	A26	15	N.A.
	198-205	KVKRKKKNV	370	B08	20	6
	201-208	RKKNVLRL	371	B08	20	<5
	200-208	KRKKNVLRL	372	A0201	15	<1.0
				A26	15	N.A.
				B0702	15	<1.0
				B08	21	<1.0
				B2705	28	
	199-208	VKRKKKNVLRL	373	B2709	25	
				A0201	16	<1.0
				B0702	16	4
	189-196	DELFSYLI	374	B5101	15	N.A.
	205-213	VLRLCCKKL	375	A0201	22	3
				A26	17	N.A.
				B08	25	8
	204-213	NVLRICCKKL	376	A0201	17	7
				A26	19	N.A.

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
PRAME 185-215 (continued)	194-202	YLIEKVKRK	377	A0201	20	<1.0
				A26	18	N.A.
				A3	25	68
				B08	20	<1.0
				B2705	17	
PRAME 71-98	74-81	QAWPFTCL	378	B5101	17	n.a.
	73-81	VQAWPFTCL	379	A0201	14	7
				A24	n.a.	5
				B0702	16	6
	72-81	MVQAWPFTCL	380	A26	22	n.a.
				A24	n.a.	7
				B0702	13	30
	81-88	LPLGVLMK	381	B5101	18	n.a.
	80-88	CLPLGVLMK	382	A0201	17	<1.0
				A3	27	120
	79-88	TCLPLGVLMK	383	A1	12	10
				A3	19	3
	84-92	GVLMKGQHL	384	A0201	18	7
				A26	21	n.a.
				B08	21	4
	81-89	LPLGVLMKG	385	B5101	20	2
	80-89	CLPLGVLMKG	386	A0201	16	<1.0
	76-85	WFTCLPLGV	387	B0702	18	4

Table 31D
PRAME: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
PRAME 39-65	51-59	ELFPPLFMA	388	A0201	19	18
				A26	23	N.A.
	49-57	PRELFPPLF	389	B2705	22	
				B2709	19	
	48-57	LPRELFPPLF	390	B0702	19	4
	50-58	RELFPPLFM	391	B2705	16	
				B2705	15	
	49-58	PRELFPPLFM	392	A1	16	<1.0

Table 32
PSA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
PSA 232-258	239-246	RPSLYTKV	393	B5101	21	N.A.
	238-246	ERPSLYTKV	394	B2705	15	60
	236-243	LPERPSLY	395	B5101	18	N.A.
	235-243	ALPERPSLY	396	A1	19	<1.0
				A26	22	N.A.
				A3	26	6
				B08	16	<1.0
				B2705	11	15
				B2709	19	N.A.
	241-249	SLYTKVVHY	397	A0201	20	<1.0
				A1	19	<1.0
				A26	25	N.A.
				A3	26	60
				B08	20	<1.0
	240-249	PSLYTKVVHY	398	B2705	13	75
				A1	20	<1.0
	239-247	RPSLYTKVV	399	A26	16	N.A.
				B0702	21	4
				B5101	23	110

Table 33A
PSMA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
PSMA 202-228	211-218	GNKVKNAQ	400	B08	22	<5
	202-209	IARYGKVF	401	B08	18	<5
	217-225	AQLAGAKGV	402	A0201	16	26
	207-215	KVFRGNKVK	403	A3	32	15
	211-219	GNKVKNAQL	404	B8	33	80
PSMA 255-282				B2705	17	20
	269-277	TPGYPANEY	405	A1	16	<5
	268-277	LTPGYPANEY	406	A1	21	1
				A26	24	N.A.
	271-279	GYPANEYAY	407	A1	15	<5
	270-279	PGYPANEYAY	408	A1	19	<5
PSMA 483-509	266-274	DPLTPGYPA	409	B0702	21	3
				B5101	17	20
				A0201	17	<5
	492-500	SLYESWTKK	410	A3	27	150
				B2705	18	150
	491-500	KSLYESWTKK	411	A3	16	<5
				A1	19	<5
	486-494	EGFEGKSLY	412	A26	21	N.A.
PSMA 485-494				B2705	16	<5
	485-494	DEGFEGKSLY	413	A1	17	<5
				A26	17	N.A.
	498-506	TKKSPSPEF	414	B08	17	<5

Table 33B
PSMA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
PSMA 483-509 (continued)	497-506	WTKKSPSEF	415	A26	24	N.A.
	492-501	SLYESWTKKS	416	A0201	16	<5
				A3	16	<5
	725-732	WGEVKRQI	417	B08	17	<5
PSMA 721-749	724-732	AWGEVKRQI	418	B5101	17	N.A.
				B5101	15	6
	723-732	KAWGEVKRQI	419	A0201	16	<1.0
	723-730	KAWGEVKR	420	B5101	15	N.A.
	722-730	SKAWGEVKR	421	B2705	15	<5
	731-739	QIYVAAFIV	422	A0201	21	177
				A3	21	<1.0
				B5101	15	5
	733-741	YVAAFIVQA	423	A0201	17	6
	725-733	WGEVKRQIY	424	A3	20	<1.0
				A1	26	11
	727-735	EVKRQIYVA	425	A26	22	N.A.
				A3	18	<1.0
	738-746	TVQAAAETL	426	A26	18	N.A.
				A3	19	<1.0
	737-746	FTVQAAAETL	427	A0201	17	<1.0
				A26	19	N.A.

Table 33C
PSMA: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
PSMA 721-749 (continued)	729-737	KRQIYVAAF	428	A26	16	N.A.
				B2705	24	3000
				B2709	21	N.A.
	721-729	PSKAWGEVK	429	A3	20	<1.0
PSMA 95-122	723-731	KAWGEVKRQ	430	B5101	16	<1.0
	100-108	WKEFGLDV	431	A0201	16	<5
	99-108	QWKEFGLDV	432	A0201	17	<5
	102-111	EFGLDSVELA	433	A26	16	N.A.

Table 34A
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 117-143	126-134	ELRQKESKL	434	A0201	20	<5
				A26	26	N.A.
				A3	17	<5
				B0702	13	(B7) 40.00
				B8	34	320
SCP-1 281-308	125-134	AELRQKESKL	435	A0201	16	<5
	133-141	KLQENRKII	436	A0201	20	61
	298-305	QLEEKTKL	437	B08	28	2
	297-305	NQLEEKTKL	438	A0201	16	33
				B2705	19	200
	288-296	LLEESRDKV	439	A0201	25	15
				B5101	15	3
	287-296	FLLEESRDKV	440	A0201	27	2378
	291-299	ESRDKNVQL	441	A26	21	N.A.
				B08	29	240
SCP-1 471-498	290-299	EESRDKNVQL	442	A26	19	N.A.
	475-483	EKEVHDLEY	443	A1	31	11
				A26	17	N.A.
	474-483	REKEVHDLEY	444	A1	21	<1.0
	480-488	DLEYSYCHY	445	A1	26	45
				A26	30	N.A.
				A3	16	<5
	477-485	EVHDLEYSY	446	A1	15	1

Table 34B
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 471-498 (continued)	477-485	EVHDL EYSY		A26	29	N.A.
	477-486	EVHDL EYSY		A3	19	<1.0
	502-509	KLSSKREL	447	A26	22	N.A.
	508-515	ELKNT EYF	448	B08	26	4
	507-515	RELKNT EYF	449	B08	24	<1.0
SCP-1 493-520	496-503	KRGQRPKL	450	B2705	18	45
	494-503	LPKRGQRPKL	451	B4403	N.A.	120
	509-517	LKNT EYFTL	452	B08	18	<1.0
	508-517	ELKNT EYFTL	453	B0702	22	120
	506-514	KRELKNT EY	454	B8	N.A.	16
	502-510	KLSSKRELK	455	B5101	N.A.	130
	498-506	GQRPKLSSK	456	B3501	N.A.	60
	497-506	RGQRPKLSSK	457	A0201	15	<5
	500-508	RPKLSSKRE	458	A0201	18	<1.0
				A26	27	N.A.
				A3	16	<1.0
				A1	26	2
				B2705	26	3000
				A3	25	60
				A3	22	4
				B2705	18	200
				A3	22	<1.0
				B08	18	<1.0

Table 34C
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 570-596	573-580	LEYVREEL	460	B08	19	<5
	572-580	ELEYVREEL	461	A0201	17	<1.0
				A26	23	N.A.
				A24	N.A.	9
				B08	20	N.A.
	571-580	NELEYVREEL	462	A0201	16	4
	579-587	ELKQKRDEV	463	A0201	19	<1.0
				A26	18	N.A.
				B08	29	48
				A26	17	N.A.
SCP-1 618-645	575-583	YVREELKQK	464	A3	27	2
	632-640	QLNVYEIKV	465	A0201	24	70
	630-638	SKQLNVYEI	466	A0201	17	<5
	628-636	AESKQLNVY	467	A1	19	<5
				A26	16	N.A.
	627-636	TAESKQLNVY	468	A1	26	45
				A26	15	N.A.

Table 34E
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYRPEITHI	NIH
SCP-1 768-796	771-778	KEKLKREA	478	B08	21	<5
				A0201	18	<5
				A26	18	N.A.
				A24	N.A.	5
	777-785	EAKENTATL	479	B0702	13	12
				B08	28	48
				B5101	20	121
	776-785	REAKENTATL	480	A0201	16	<5
	773-782	KLKREKENT	481	A3	17	<5
	112-119	EAEKIKKW	482	B5101	17	N.A.
SCP-1 92-125				A0201	23	32
				A26	22	N.A.
	101-109	GLSRVYSKL	483	A24	N.A.	6
				A3	17	3
				B08	17	<1.0
				A26	21	N.A.
	100-109	EGLSRVYSKL	484	A24	N.A.	9
				A0201	22	57
	108-116	KLYKEAEKI	485	A3	20	9
				B5101	18	5
	98-106	NSEGLSRVY	486	A1	31	68
	97-106	ENSEGLSRVY	487	A26	18	N.A.
	102-110	LSRVYSKLY	488	A1	22	<1.0

Table 34F
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 92-125 (continued)	101-110	GLSRVYSKLY	489	A1	18	<1.0
				A26	18	N.A.
				A3	19	18
	96-105	LENSEGLSRV	490	A0201	17	5
SCP-1 931-958	108-117	KLYKEAEKIK	491	A3	27	150
	949-956	REDRWAVI	492	B5101	15	N.A.
				B2705	18	600
	948-956	MREDRWAVI	493	B2709	18	N.A.
				B5101	15	1
	947-956	KMREDRWAVI	494	A0201	21	6
				B08	N.A.	15
	947-955	KMREDRWAV	495	A0201	22	411
	934-942	TTPGSTLKF	496	A26	25	N.A.
	933-942	LTPGSTLKF	497	A26	23	N.A.
SCP-1 232-259	937-945	GSTLKFGAI	498	B08	19	1
	945-953	IRKMREDRW	499	B08	19	<5
	236-243	RLEMHFKL	500	B08	16	<5
	235-243	SRLEMHFKL	501	A0201	18	<5
				B2705	25	2000
	242-250	KLKEDYEKI	502	B2709	22	
				A0201	22	4

Table 34G
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 232-259 (continued)				A26	16	N.A.
				A3	15	3
				B08	24	<5
				B5101	14	2
				A1	15	<5
	249-257	KIQHLEQY	503	A26	23	N.A.
				A3	17	<5
	248-257	EKIQHLEQY	504	A1	15	<5
				A26	21	N.A.
	233-242	ENSRLEMHF	505	A26	19	N.A.
SCP-1 310-340	236-245	RLEMHFKLKE	506	A1	19	<5
				A3	17	<5
	324-331	LEDIKVSL	507	B08	20	<1.0
				A0201	21	<1.0
	323-331	ELEDIKVSL	508	A26	25	N.A.
				A24	N.A.	10
				A3	17	<1.0
				B08	19	<1.0
				B1510	16	N.A.
	322-331	KELEDIKVSL	509	A0201	19	22
	320-327	LTKLEDI	500	B08	18	<5
	319-327	HLTKLEDI	511	A0201	21	<1.0
	330-338	SLQRSVSTQ	512	A0201	18	<1.0

Table 34H
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 310-340 (continued)	321-329	TKELEDIKV	513	A1	16	<1.0
	320-329	LTKLEDIKV	514	A0201	19	<1.0
	326-335	DIKVSQRSV	515	A26	18	N.A.
	281-288	KMKDLTFL	516	B08	20	3
SCP-1 272-305	280-288	NKMKDLTFL	517	A0201	15	1
	279-288	ENKMKDLTFL	518	A26	19	N.A.
	288-296	LLEESRDKV	519	A0201	25	15
				B5101	15	3
	287-296	FLLEESRDKV	520	A0201	27	2378
	291-299	ESRDKVNQL	521	A26	21	N.A.
				B08	29	240
	290-299	ESRDKVNQL	522	A26	19	N.A.
	277-285	EKENKMKDL	523	A26	19	N.A.
				B08	23	<1.0
SCP-1 211-239	276-285	TEKENKMKDL	524	A26	15	N.A.
	279-287	ENKMKDLTF	525	A26	18	N.A.
				B08	28	4
	218-225	IEKMITAF	526	B08	17	<5
	217-225	NIEKMITAF	527	A26	26	N.A.
	216-225	SNIEKMITAF	528	A26	19	N.A.
	223-230	TAFEELRV	529	B5101	23	N.A.
	222-230	ITAFEELRV	530	A0201	18	2
	221-230	MITAFEELRV	531	A0201	18	16

Table 34I
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 211-239 (continued)	220-228	KMITAFEEL	532	A0201	23	50
				A26	15	N.A.
				A24	N.A.	16
	219-228	EKMITAFEEL	533	A26	19	N.A.
				A3	16	<1.0
	227-235	ELRVQAENS	534	B08	15	<1.0
				A0201	17	<1.0
	213-222	DLNSNIEKMI	535	A26	16	N.A.
	837-844	WTSAKNTL	536	B08	20	4
				A0201	18	2
SCP-1 836-863	846-854	TPLPKAYTV	537	B0702	17	4
				B08	16	2
				B5101	25	220
	845-854	STPLPKAYTV	538	A0201	19	<5
	844-852	LSTPLPKAY	539	A1	23	8
				A1	16	<1.0
	843-852	TLSTPLPKAY	540	A26	19	N.A.
				A3	18	2
	842-850	NTLSTPLPK	541	A3	16	3
	841-850	KNTLSTPLPK	542	A3	18	<1.0

Table 34J
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 819-845	828-835	ISKDKRDY	543	B08	21	3
				A26	21	N.A.
	826-835	HGSKDKRDY	544	A1	15	<5
	832-840	KRDYLWTS	545	B2705	16	600
	829-838	SKDKRDYLT	546	A1	18	<5
SCP-1 260-288	279-286	ENKMKDLT	547	B08	22	8
				A0201	17	3
	260-268	EINDKEKQV	548	A26	19	N.A.
				B08	17	<5
				A0201	17	3
	274-282	QITEKENKM	549	A26	22	N.A.
				B08	16	<5
				A0201	16	<1.0
	269-277	SLLLIQITE	550	A3	18	<1.0
				B08	21	<1.0
SCP-1 437-464	453-460	FEKIAEEL	551	B2705	15	
	452-460	QFEKIAEEL	552	A0201	16	56
	451-460	KQFEKIAEEL	553	B08	16	2
	449-456	DNKQFEKI	554	B5101	16	N.A.
	448-456	YDNKQFEKI	555	B5101	16	1
	447-456	LYDNKQFEKI	556	A1	15	<1.0

Table 34K
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 437-464 (continued)	440-447	LGEKETLL	557	B5101	16	N.A.
	439-447	VLGEKETLL	558	A0201	24	149
				A26	19	N.A.
				B08	29	12
	438-447	KVLGEKETLL	559	A0201	19	24
				A26	20	N.A.
				A24	N.A.	12
				A3	18	<1.0
				B0702	14	20
				A0201	22	3
SCP-1 383-412	390-398	LLRTEQQRL	560	A26	18	N.A.
				B08	22	1.6
				B2705	15	30
				A0201	19	6
	389-398	ELLRTEQQRL	561	A26	24	N.A.
				A3	15	<1.0
				A1	15	<5
	393-401	TEQQRLNLY	562	A26	16	N.A.
	392-401	RTEQQRLNLY	563	A1	31	113
				A26	26	N.A.
	402-410	EDQLILTM	564	A26	18	N.A.
	397-406	RLNLYEDQLI	565	A0201	17	<1.0
				A3	15	<1.0

Table 34L
SCP-1: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SCP-1 366-394	368-375	KARAAHSF	566	B08	16	<1.0
	376-384	VVTEFETTV	567	A0201	19	161
				A3	16	<1.0
	375-384	FVVTEFETTV	568	A0201	17	106
	377-385	VTEFETTV	569	A1	18	2
SCP-1 331-357	376-385	VVTEFETTV	570	A3	16	<5
	344-352	DLQIATNTI	571	A0201	22	<5
				A3	15	<1.0
				B5101	17	11
	347-355	IATNTICQL	572	A0201	19	1
				B08	16	<1.0
				B5101	20	79
SCP-1 346-355	346-355	QIATNTICQL	573	A0201	24	7
				A26	24	N.A.

Table 35
 SSX-4: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
SSX4 45-76	57-65	VMTKLGFKV	574	A0201	21	495
	53-61	LNVEVMTKL	575	A0201	17	7
	52-61	KLNVEVMTKL	576	A0201	23	172
				A26	21	N.A.
				A24	N.A.	18
				A3	14	4
				B7	N.A.	4
	66-74	TLPPFMRSK	577	A26	16	N.A.
				A3	25	14
SSX4 98-124	110-118	KMPKKPAE	578	A0201	15	<5
				A26	15	N.A.
				A3	16	<5
	103-112	SLQRIFPKIM	579	A0201	15	8
				A26	16	N.A.
				A3	15	<5

Table 36
Tyrosinase: Preferred Epitopes Revealed by Housekeeping Proteasome Digestion

Substrate	Epitope	Sequence	Seq. ID No.	Binding Prediction		
				HLA type	SYFPEITHI	NIH
Tyr 445-474	463-471	YKSYLEQA	580	A0201	18	<5
				A26	17	N.A.
	459-467	SFQDYKSY	581	A1	18	<5
				A26	22	N.A.
Tyr 490-518	458-467	DSFQDYKSY	582	A1	19	<5
				A26	24	N.A.
	507-514	LPEEKQPL	583	B08	28	5
				B5101	18	N.A.
				A0201	22	88
	506-514	QLPEEKQPL	584	A26	20	N.A.
				A24	N.A.	9
				B08	18	<5
	505-514	KQLPEEKQPL	585	A0201	15	28
				A24	N.A.	17
Tyr 506-515				A0201	15	<5
	507-515	LPEEKQPLL	586	B0702	21	24
				B08	28	5
				B5101	21	157
	506-515	QLPEEKQPLL	587	A0201	23	88
				A26	20	N.A.
497-505	SLLCRHKRK		588	A24	N.A.	7
				A3	25	15

Example 15**Evaluating Likelihood of Epitope Cross-reactivity on Non-target Tissues.**

As noted above PSA is a member of the kallikrein family of proteases, which is itself a subset of the serine protease family. While the members of this family sharing the greatest degree of sequence identity with PSA also share similar expression profiles, it remains possible that individual epitope sequences might be shared with proteins having distinctly different expression profiles. A first step in evaluating the likelihood of undesirable cross-reactivity is the identification of shared sequences. One way to accomplish this is to conduct a BLAST search of an epitope sequence against the SWISSPROT or Entrez non-redundant peptide sequence databases using the "Search for short nearly exact matches" option; hypertext transfer protocol accessible on the world wide web (<http://www.ncbi.nlm.nih.gov/blast/index.html>) at "ncbi.nlm.nih.gov/blast/index.html". Thus searching SEQ ID NO. 214, WVLTAHCI, against SWISSPROT (limited to entries for homo sapiens) one finds four exact matches, including PSA. The other three are from kallikrein 1 (tissue kallikrein), and elastase 2A and 2B. While these nine amino acid segments are identical, the flanking sequences are quite distinct, particularly on the C-terminal side, suggesting that processing may proceed differently and that thus the same epitope may not be liberated from these other proteins. (Please note that kallikrein naming is confused. Thus the kallikrein 1 [accession number P06870] is a different protein than the one [accession number AAD13817] mentioned in the paragraph on PSA above in the section on tumor-associated antigens).

It is possible to test this possibility in several ways. Synthetic peptides containing the epitope sequence embedded in the context of each of these proteins can be subjected to *in vitro* proteasomal digestion and analysis as described above. Alternatively, cells expressing these other proteins, whether by natural or recombinant expression, can be used as targets in a cytotoxicity (or similar) assay using CD8⁺ T cells that recognize the epitope, in order to determine if the epitope is processed and presented.

Example 16**Epitope Clusters.**

Known and predicted epitopes are generally not evenly distributed across the sequences of protein antigens. As referred to above, we have defined segments of sequence containing a higher than average density of (known or predicted) epitopes as epitope clusters. Among the uses of epitope clusters is the incorporation of their sequence into substrate peptides used in proteasomal digestion analysis as described herein. Epitope clusters can also be useful as vaccine components. A fuller discussion of the definition and uses of epitope clusters is found in U.S. Patent Application No. 09/561,571 entitled EPITOPE CLUSTERS.

The following tables (37-60) present 9-mer epitopes predicted for HLA-A2 binding using both the SYFPEITHI and NIH algorithms and the epitope density of regions of overlapping epitopes, and of epitopes in the whole protein, and the ratio of these two densities. (The ratio must exceed one for there to be a cluster by the above definition; requiring higher values of this ratio reflect preferred embodiments). Individual 9-mers are ranked by score and identified by the position of their first amino in the complete protein sequence. Each potential cluster from a protein is numbered. The range of amino acid positions within the complete sequence that the cluster covers is indicated as are the rankings of the individual predicted epitopes it is made up of.

10

Table 37
BIMAS-NIH/Parker algorithm Results for gp100

Rank	Start	Score	Rank	Start	Score
1	619	1493	21	416	19
2	602	413	22	25	18
3	162	226	23	566	17
4	18	118	24	603	15
5	178	118	25	384	14
6	273	117	26	13	14
7	601	81	27	290	12
8	243	63	28	637	10
9	606	60	29	639	9
10	373	50	30	485	9
11	544	36	31	453	8
12	291	29	32	102	8
13	592	29	33	399	8
14	268	29	34	456	7
15	47	27	35	113	7
16	585	26	36	622	7
17	576	21	37	69	7
18	465	21	38	604	6
19	570	20	39	350	6
20	9	19	40	583	5

Table 38
SYFPEITHI (Rammensee algorithm) Results for gp100

Rank	Start	Score	Rank	Start	Score	Rank	Start	Score
1	606	30	37	291	20	73	60	18
2	162	29	38	269	20	74	17	18
3	456	28	39	2	20	75	613	17
4	18	28	40	610	19	76	599	17
5	602	27	41	594	19	77	572	17
6	598	27	42	591	19	78	557	17
7	601	26	43	583	19	79	556	17
8	597	26	44	570	19	80	512	17
9	13	26	45	488	19	81	406	17
10	585	25	46	446	19	82	324	17
11	449	25	47	322	19	83	290	17
12	4	25	48	267	19	84	101	17
13	603	24	49	250	19	85	95	17
14	576	24	50	205	19	86	635	16
15	453	24	51	180	19	87	588	16
16	178	24	52	169	19	88	584	16
17	171	24	53	88	19	89	577	16
18	11	24	54	47	19	90	559	16
19	619	23	55	10	19	91	539	16
20	280	23	56	648	18	92	494	16
21	268	23	57	605	18	93	482	16
22	592	22	58	604	18	94	468	16
23	544	22	59	595	18	95	442	16
24	465	22	60	571	18	96	413	16
25	399	22	61	569	18	97	408	16
26	373	22	62	450	18	98	402	16
27	273	22	63	409	18	99	286	16
28	243	22	64	400	18	100	234	16
29	566	21	65	371	18	101	217	16
30	563	21	66	343	18	102	211	16
31	485	21	67	298	18	103	176	16
32	384	21	68	209	18	104	107	16
33	350	21	69	102	18	105	96	16
34	9	21	70	97	18	106	80	16
35	463	20	71	76	18	107	16	16
36	397	20	72	69	18	108	14	16
						109	7	16

Table 39

Prediction of clusters for gp100

Total AAs: 661

Total 9-mers: 653

SYFPEITHI 16: 109 9-mers

NIH 5: 40 9-mers

	Cluster #	AAs	Epitopes (by Rank)	Epitopes/AA		
				Cluster	Whole Pr	Ratio
SYFPEITHI	1	2 to 26	39, 12, 109, 34, 55, 11, 9, 108, 107, 74, 4	0.440	0.165	2.668
	2	69-115	72, 71, 106, 53, 85, 105, 70, 84, 69, 104	0.213	0.165	1.290
	3	95-115	85, 105, 70, 84, 69	0.238	0.165	1.444
	4	162-188	2, 52, 17, 103, 16, 51	0.222	0.165	1.348
	5	205-225	50, 68, 102, 101	0.190	0.165	1.155
	6	243-258	28, 49	0.125	0.165	0.758
	7	267-306	48, 21, 38, 27, 20, 99, 83, 37, 67	0.225	0.165	1.364
	8	322-332	47, 82	0.182	0.165	1.103
	9	343-358	66, 33	0.125	0.165	0.758
	10	371-381	65, 26	0.182	0.165	1.103
	11	397-421	36, 25, 64, 98, 81, 97, 63, 96	0.320	0.165	1.941
	12	442-476	95, 46, 11, 62, 15, 3, 35, 24, 94	0.257	0.165	1.559
	13	482-502	93, 31, 45, 93	0.190	0.165	1.155
	14	539-552	91, 23	0.143	0.165	0.866
	15	556-627	79, 78, 90, 30, 29, 61, 44, 60, 77, 14, 89, 43, 88, 10, 87, 42, 22, 41, 59, 8, 6, 76, 7, 5, 13, 58, 57, 1, 40, 75, 19	0.431	0.165	2.611
NIH	1	9 to 33	20, 26, 4, 22	0.160	0.061	2.644
	2	268-281	14, 6	0.143	0.061	2.361
	3	290-299	27, 12	0.200	0.061	3.305
	4*	102-121	32, 35	0.100	0.061	1.653
	5*	373-392	10, 25	0.100	0.061	1.653
	6	453-473	31, 34, 18	0.143	0.061	2.361
	7	566-600	23, 19, 17, 40, 16, 13	0.171	0.061	2.833
	8	601-614	7, 2, 24, 38, 9	0.357	0.061	5.902
	9	619-630	1, 36	0.17	0.061	2.754
	10	637-647	28, 29	0.18	0.061	3.005

*Nearby but not overlapping epitopes

Table 40

BIMAS-NIH/Parker algorithm Results for PSMA

Rank	Start	Score
1	663	1360
2	711	1055
3	4	485
4	27	400
5	26	375
6	668	261
7	707	251
8	469	193
9	731	177
10	35	67
11	33	64
12	554	59
13	427	50
14	115	47
15	20	40
16	217	26
17	583	24
18	415	19
19	193	14
20	240	12
21	627	11
22	260	10
23	130	10
24	741	9
25	3	9
26	733	8
27	726	7
28	286	6
29	174	5
30	700	5

Table 41
SYFPEITHI (Rammensee algorithm) Results for PSMA

Rank	Start	Score	Rank	Start	Score	Rank	Start	Score
1	469	27	31	26	20	61	305	17
2	27	27	32	3	20	62	304	17
3	741	26	33	583	19	63	286	17
4	711	26	34	579	19	64	282	17
5	354	25	35	554	19	65	169	17
6	4	25	36	550	19	66	142	17
7	663	24	37	547	19	67	122	17
8	130	24	38	390	19	68	738	16
9	57	24	39	219	19	69	634	16
10	707	23	40	193	19	70	631	16
11	260	23	41	700	18	71	515	16
12	20	23	42	472	18	72	456	16
13	603	22	43	364	18	73	440	16
14	218	22	44	317	18	74	385	16
15	109	22	45	253	18	75	373	16
16	731	21	46	91	18	76	365	16
17	668	21	47	61	18	77	361	16
18	660	21	48	13	18	78	289	16
19	507	21	49	733	17	79	278	16
20	454	21	50	673	17	80	258	16
21	427	21	51	671	17	81	247	16
22	358	21	52	642	17	82	217	16
23	284	21	53	571	17	83	107	16
24	115	21	54	492	17	84	100	16
25	33	21	55	442	17	85	75	16
26	606	20	56	441	17	86	37	16
27	568	20	57	397	17	87	30	16
28	473	20	58	391	17	88	21	16
29	461	20	59	357	17			
30	200	20	60	344	17			

Table 42

Prediction of clusters for prostate-specific membrane antigen (PSMA)

Total AAs: 750

Total 9-mers: 742

SYFPEITHI 16: 88 9-mers

NIH 5: 30 9-mers

	Cluster #	Aas	Epitopes (by rank)	Epitopes/AA		
				Cluster	Whole Pr	Ratio
SYFPEITHI	1	3 to 12	32, 6	0.200	0.117	1.705
	2	13-45	13, 12, 88, 31, 2, 87, 25, 86	0.242	0.117	2.066
	3	57-69	9, 47	0.154	0.117	1.311
	4	100-138	84, 83, 15, 24, 67, 8	0.154	0.117	1.311
	5	193-208	40, 30	0.111	0.117	0.947
	6	217-227	82, 14, 39	0.273	0.117	2.324
	7	247-268	81, 45, 80, 11	0.182	0.117	1.550
	8	278-297	79, 64, 23, 63, 78	0.250	0.117	2.131
	9	354-381	5, 59, 22, 77, 43, 76, 75	0.250	0.117	2.131
	10	385-405	74, 38, 58, 57	0.190	0.117	1.623
	11	440-450	73, 56, 55	0.273	0.117	2.324
	12	454-481	20, 72, 29, 1, 42, 28	0.214	0.117	1.826
	13	507-523	17, 71	0.118	0.117	1.003
	14	547-562	37, 36, 35	0.188	0.117	1.598
	15	568-591	27, 53, 34, 33	0.167	0.117	1.420
	16	603-614	13, 26	0.167	0.117	1.420
	17	631-650	70, 69, 52	0.150	0.117	1.278
	18	660-681	18, 7, 17, 51, 50	0.227	0.117	1.937
	19	700-719	41, 10, 4	0.150	0.117	1.278
	20	731-749	16, 49, 68, 3	0.211	0.117	1.794
NIH	1	3 to 12	25, 3	0.200	0.040	5.000
	2	20-43	15, 5, 4, 11, 10	0.208	0.040	5.208
	3*	415-435	18, 13	0.095	0.040	2.381
	4	663-676	1, 6	0.143	0.040	3.571
	5	700-715	30, 7, 3	0.188	0.040	4.688
	6	726-749	27, 9, 26, 24	0.167	0.040	4.167

*Nearby but not overlapping epitopes

Table 43
BIMAS-NIH/Parker algorithm Results for PSA

Rank	Start	Score
1	7	607
2	170	243
3	52	124
4	53	112
5	195	101
6	165	23
7	72	18
8	245	18
9	2	16
10	59	16
11	122	15
12	125	15
13	191	13
14	9	8
15	14	6
16	175	5
17	130	5

Table 44
SYFPEITHI (Rammensee algorithm) Results for PSA

Rank	Start	Score
1	72	26
2	170	22
3	53	22
4	7	22
5	234	21
6	166	21
7	140	21
8	66	21
9	241	20
10	175	20
11	12	20
12	41	19
13	20	19
14	14	19
15	130	18
16	124	18
17	121	18
18	47	18
19	17	18
20	218	17
21	133	17
22	125	17
23	122	17
24	118	17
25	110	17
26	67	17
27	52	17
28	21	17
29	16	17
30	2	17
31	184	16
32	179	16
33	158	16
34	79	16
35	73	16
36	4	16

Table 45

Prediction of clusters for prostate specific antigen (PSA)

Total AAs: 261

Total 9-mers: 253

SYFPEITHI 16: 36 9-mers

NIH 5: 17 9-mers

	Cluster #	AAs	Epitopes (by rank)	Epitopes/AA		
				Cluster	Whole Pr	Ratio
SYFPEITHI	1	2 to 29	30, 36, 4, 11, 14, 29, 19, 13, 28	0.321	0.138	2.330
	2	41-61	12, 18, 27, 3	0.190	0.138	1.381
	3	66-87	8, 26, 1, 35, 34	0.227	0.138	1.648
	4	110-148	25, 24, 17, 23, 16, 22, 15, 21, 7	0.184	0.138	1.332
	5	158-192	33, 6, 2, 10, 32, 31	0.171	0.138	1.243
	6	234-249	5, 9	0.125	0.138	0.906
	7*	118-133	24, 17, 23, 16, 22	0.313	0.138	2.266
	8*	118-138	24, 17, 23, 16, 22, 15	0.286	0.138	2.071
NIH	1	2-22	9, 1, 14, 15	0.190	0.065	2.924
	2	52-67	3, 4, 10	0.188	0.065	2.879
	3	122-138	11, 12, 17	0.176	0.065	2.709
	4	165-183	6, 2, 16	0.158	0.065	2.424
	5	191-203	13, 5	0.154	0.065	2.362
	6**	52-80	3, 4, 10, 7	0.138	0.065	2.118

*These clusters are internal to the less preferred cluster #4.

**Includes a nearby but not overlapping epitope.

Table 46
BIMAS-NIH/Parker algorithm Results for PSCA

Rank	Start	Score
1	43	53
2	5	84
3	7	79
4	109	36
5	105	105
6	108	24
7	14	21
8	20	18
9	115	17
10	42	15
11	36	15
12	99	9
13	58	8

20

Table 47
SYFPEITHI (Rammensee algorithm) Results for PSCA

25

Rank	Start	Score	Rank	Start	Score
1	108	30	17	54	19
2	14	30	18	12	19
3	105	29	19	4	19
4	5	28	20	1	19
5	115	26	21	112	18
6	99	26	22	101	18
7	7	26	23	98	18
8	109	24	24	51	18
9	53	23	25	43	18
10	107	21	26	106	17
11	20	21	27	104	17
12	8	21	28	83	17
13	13	20	29	63	17
14	102	19	30	50	17
15	60	19	31	3	17
16	57	19	32	9	16
			33	92	16

Table 48

Prediction of clusters for prostate stem cell antigen (PSCA)

Total AAs: 123

Total 9-mers: 115

SYFPEITHI 16: 33;

SYFPEITHI 20: 13

NIH 5: 13

	Cluster #	AAs	Epitopes (by rank)	Epitopes/AA		
				Cluster	Whole Pr.	Ratio
SYFPEITHI >16	1	1 to 28	20, 31, 19, 4, 7, 12, 33, 18, 13, 2, 11	0.393	0.268	1.464
	2	43-71	25, 30, 24, 9, 17, 16, 15, 29	0.276	0.268	1.028
	3	92-123	32, 23, 6, 27, 14, 22, 3, 26, 10, 1, 8, 21, 5	0.406	0.268	1.514
SYFPEITHI >20	1	5 to 28	4, 7, 12, 13, 2, 11	0.250	0.106	2.365
	2	99-123	6, 3, 10, 1, 8, 5	0.240	0.106	2.271
NIH	1	5 to 28	2, 3, 7, 8	0.167	0.106	1.577
	2	36-51	11, 10, 1	0.188	0.106	1.774
	3	99-123	12, 5, 6, 4, 9	0.200	0.106	1.892
	4*	105-116	5, 6, 4	0.250	0.106	2.365

* This cluster is internal to the less preferred cluster no.

In tables 49-60 epitope prediction and cluster analysis data for each algorithm are presented together in a single table.

5

Table 49

Prediction of clusters for MAGE-1 (NIH algorithm)

Total AAs: 309

Total 9-mers: 301

NIH 5:19 9-mers

Cluster #	AAs	Epitope Rank	Start Position	NIH Score	Epitopes/AA		
					Cluster	Whole Pr.	Ratio
1	18-32	16	18	9	0.133	0.063	2.112
		19	24	7			
2	101-113	14	101	11	0.154	0.063	2.442
		7	105	44			
3	146-159	9	146	32	0.143	0.063	2.263
		3	151	169			
4	169-202	10	169	32	0.176	0.063	2.796
		13	174	16			
		18	181	8			
		17	187	8			
		6	188	74			
		5	194	110			
5	264-277	2	264	190	0.143	0.063	2.263
		12	269	20			
6	278-290	1	278	743	0.154	0.063	2.437

11 282 28

Table 50

Prediction of clusters for MAGE-1 (SYFPEITHI algorithm)

Total AAs: 309

Total 9-mers: 301

SYFPEITHI 16: 46 9-mers

Cluster #	Aas	Epitope Rank	Start Position	SYFPEITHI Score	Epitopes/AA		
					Cluster	Whole	Ratio
1	7-49	22	7	19	0.233	0.153	1.522
		9	15	22			
		27	18	18			
		16	20	20			
		28	22	18			
		29	24	18			
		33	31	17			
		30	35	18			
		2	38	26			
		17	41	20			
2	89-132	10	89	22	0.273	0.153	1.783
		18	92	20			
		7	93	23			
		23	96	19			
		43	98	16			
		4	101	25			
		8	105	23			
		34	107	17			
		35	108	17			
		36	113	17			
3	167-203	37	118	17	0.270	0.153	1.766
		19	124	20			
		44	167	16			
		20	169	20			
		12	174	21			
		24	181	19			
		6	187	24			
		31	188	18			
		25	191	19			
		38	192	17			
4	230-246	1	194	27	0.118	0.153	0.769
		13	195	21			
		14	230	21			
5	264-297	39	238	17	0.235	0.153	1.538
		15	264	21			
		32	269	18			
		40	270	17			
		26	271	19			
		46	275	16			
		3	278	26			
		21	282	20			
		41	289	17			

Table 51

Prediction of clusters for MAGE-2 (NIH algorithm)

Total AAs: 314

Total 9-mers: 308

NIH ≥ 5 : 20 9-mers

Cluster #	AAs	Epitope Rank	Start Position	NIH Score	Cluster	Epitope/AA Whole Pr.	Ratio
1	101-120	18	101	5.373	0.150	0.065	2.310
		16	108	6.756			
		1	112	2800.697			
2	153-167	8	153	31.883	0.200	0.065	3.080
		4	158	168.552			
		7	159	32.138			
3	169-211	14	169	8.535	0.209	0.065	3.223
		19	174	5.346			
		6	176	49.993			
		11	181	15.701			
		15	188	7.536			
		12	195	12.809			
		5	200	88.783			
		10	201	16.725			
4	271-284	3	271	398.324	0.143	0.065	2.200
		9	276	19.658			

Table 52

Prediction of clusters for MAGE-2 (SYFPEITHI algorithm)

Total AAs: 314

Total 9-mers: 308

SYFPEITHI 16: 52 9-mers

Cluster #	AAs	Epitope Rank	Start Position	SYFPEITHI Score	Cluster	Epitopes/AA Whole Pr.	Ratio
1	15-32	13	15	21	0.278	0.169	1.645
		29	18	18			
		43	20	16			
		30	22	18			
		21	24	19			
2	37-56	31	37	18	0.250	0.169	1.481
		16	40	20			
		44	44	16			
		14	45	21			
		22	48	19			
3	96-133	36	96	17	0.211	0.169	1.247
		46	101	16			
		6	108	25			
		47	109	16			
		2	112	27			
		37	120	17			
		38	125	17			
		17	131	20			
4	153-216	12	153	22	0.344	0.169	2.036
		39	158	17			
		7	159	25			
		23	161	19			
		24	162	19			
		48	164	16			
		49	167	16			
		32	170	18			
		50	171	16			
		4	174	26			
		9	176	24			
		51	177	16			
		15	181	21			
		25	188	19			
		18	194	20			
		33	195	18			
		19	198	20			
		3	200	27			
		1	201	28			
		40	202	17			
		10	203	23			
		52	208	16			
5	237-254	26	237	19	0.167	0.169	0.987
		27	245	19			
		34	246	18			
6	271-299	8	271	25	0.241	0.169	1.430
		35	276	18			
		41	277	17			
		11	278	23			
		28	283	19			
		20	285	20			
		42	291	17			

Table 53**Prediction of clusters for MAGE-3 (NIH algorithm)**

Total AAs: 314

Total 9-mers: 308

NIH 5: 22 9-mers

Cluster #	AAs	Epitope Rank	Start Position	NIH Score	Cluster	Epitopes/AA Whole Pr.	Ratio
1	101-120	15	101	11.002	0.200	0.071	2.800
		21	105	6.488			
		8	108	49.134			
		2	112	339.313			
2	153-167	18	153	7.776	0.200	0.071	2.800
		6	158	51.77			
		22	159	5.599			
3	174-209	17	174	8.832	0.194	0.071	2.722
		7	176	49.993			
		13	181	15.701			
		19	188	7.536			
		14	195	12.809			
		5	200	88.783			
		12	201	16.725			
4	237-251	16	237	10.868	0.200	0.071	2.800
		4	238	148.896			
		20	243	6.88			
5	271-284	1	271	2655.495	0.143	0.071	2.000
		11	276	19.658			

Table 54

Prediction of clusters for MAGE-3 (SYFPEITHI algorithm)

Total AAs: 314

Total 9-mers: 308

SYFPEITHI 16: 47 9-mers

Cluster #	AAs	Epitope Rank	Start Position	SYFPEITHI Score	Cluster	Epitopes/AA Whole Pr.	Ratio
1	15-32	12	15	21	0.278	0.153	1.820
		26	18	18			
		37	20	16			
		27	22	18			
		18	24	19			
2	38-56	38	38	16	0.263	0.153	1.725
		15	40	20			
		39	44	16			
		13	45	21			
		19	48	19			
3	101-142	28	101	18	0.190	0.153	1.248
		40	105	16			
		1	108	31			
		6	112	25			
		31	120	17			
		32	125	17			
		16	131	20			
4	153-216	41	134	16	0.313	0.153	2.048
		20	153	19			
		29	156	18			
		33	158	17			
		21	159	19			
		34	161	17			
		42	164	16			
		43	167	16			
		10	174	22			
		8	176	23			
		14	181	21			
		22	188	19			
		44	193	16			
		11	194	22			
		23	195	19			
		45	197	16			
		17	198	20			
		3	200	27			
5	220-230	2	201	28	0.182	0.153	1.191
		35	202	17			
		46	208	16			
6	237-246	5	220	26	0.200	0.153	1.311
		47	222	16			
7	271-293	7	237	25	0.217	0.153	1.425
		9	238	23			
		4	271	27			
		30	276	18			
		24	278	19			
		36	283	17			
		25	285	19			

Table 55

Prediction of clusters for PRAME (NIH algorithm)

Total AAs: 509

Total 9-mers: 501

NIH 5: 40 9-mers

Cluster #	AAs	Epitope Rank	Start Position	NIH Score	Cluster.	Epitopes/AA Whole Pr.	Ratio
1	33-47	20	33	18	0.133	0.080	1.670
		17	39	21			
2	71-81	9	71	50	0.2	0.07984	2.505
		32	73	7			
3	99-108	23	100	15	0.2	0.07984	2.505
		24	99	13			
4	126-135	38	126	5	0.2	0.07984	2.505
		35	127	6			
5	224-246	5	224	124	0.130	0.080	1.634
		8	230	63			
		39	238	5			
6	290-303	18	290	18	0.214	0.080	2.684
		14	292	23			
		7	295	66			
7	305-324	28	305	10	0.200	0.080	2.505
		30	308	8			
		25	312	13			
		36	316	6			
8	394-409	2	394	182	0.188	0.080	2.348
		12	397	42			
		31	401	7			
9	422-443	10	422	49	0.227	0.080	2.847
		3	425	182			
		34	431	7			
		29	432	9			
		4	435	160			
10	459-487	15	459	21	0.172	0.080	2.159
		11	462	45			
		22	466	15			
		40	472	5			
		37	479	6			

Table 56

Prediction of clusters for PRAME (SYFPEITHI algorithm)

Total AAs: 509

Total 9-mers: 501

SYFPEITHI 17: 80 9-mers

Cluster #	AAs	Epitope Rank	Start Position	SYFPEITHI Score	Cluster	Epitopes/AA Whole Pr.	Ratio
1	18-59	65	18	17	0.238	0.160	1.491
		50	21	18			
		66	26	17			
		35	33	20			
		22	34	22			
		51	37	18			
		5	39	27			
		23	40	22			
		13	44	24			
		46	51	19			
2	78-115	36	78	20	0.263	0.160	1.648
		67	80	17			
		52	84	18			
		24	86	22			
		53	91	18			
		25	93	22			
		9	99	25			
		8	100	26			
		54	103	18			
		55	107	18			
3	191-202	56	191	18	0.167	0.160	1.044
		38	194	20			
4	205-215	26	205	22	0.182	0.160	1.139
		27	207	22			
5	222-238	47	222	19	0.235	0.160	1.474
		14	224	24			
		69	227	17			
		57	230	18			
6	241-273	70	241	17	0.212	0.160	1.328
		15	248	24			
		71	255	17			
		30	258	21			
		39	259	20			
		58	261	18			
7	290-342	40	265	20	0.208	0.160	1.300
		72	290	17			
		48	293	19			
		31	298	21			
		73	301	17			
		18	305	23			
		6	308	27			
		10	312	25			
		19	316	23			
		28	319	22			

Prediction of clusters for PRAME (SYFPEITHI algorithm)

Total AAs: 509

Total 9-mers: 501

SYFPEITHI 17: 80 9-mers

Cluster #	AAs	Epitope Rank	Start Position	SYFPEITHI Score	Cluster	Epitopes/AA Whole Pr.	Ratio
8	343-363	41	326	20	0.238	0.160	1.491
		74	334	17			
		59	343	18			
		60	348	18			
		75	351	17			
		20	353	23			
9	364-447	76	355	17	0.250	0.160	1.566
		49	364	19			
		32	371	21			
		11	372	25			
		61	375	18			
		77	382	17			
		21	390	23			
		78	391	17			
		1	394	30			
		42	397	20			
		62	403	18			
		33	410	21			
		43	418	20			
		34	419	21			
		7	422	27			
		2	425	29			
		79	426	17			
		63	428	18			
		64	431	18			
		12	432	25			
10	455-474	16	435	24	0.200	0.160	1.253
		80	439	17			
		29	455	22			
		17	459	24			
		4	462	28			
		3	466	29			

Table 57
Predication of clusters for CEA (NIH algorithm)

Total AAs:702

Total 9-mers: 694

NIH 5: 30 9-mers

Cluster #	AA	Peptides Rank	Start Position	Score	Cluster	Peptides/AAs Whole Pr.	Ratio
1	17-32	5	17	79.041	0.188	0.043	4.388
		7	18	46.873			
		20	24	12.668			
2	113-129	2	113	167.991	0.118	0.043	2.753
		15	121	21.362			
3	172-187	25	172	9.165	0.125	0.043	2.925
		14	179	27.995			
4	278-291	30	278	5.818	0.143	0.043	3.343
		17	283	19.301			
5	350-365	9	350	43.075	0.125	0.043	2.925
		12	357	27.995			
6	528-543	8	528	43.075	0.125	0.043	2.925
		13	535	27.995			
7	631-645	23	631	9.563	0.200	0.043	4.680
		19	634	13.381			
		24	637	9.245			
8	691-702	1	691	196.407	0.167	0.043	3.900
		27	694	7.769			

Table 58
Predication of clusters for CEA (SYFPEITHI algorithm)

Total AAs:702

Total 9-mers: 694

SYFPEITHI 16: 81 9-mers

Cluster #	AA	Peptides Rank	Start Position	Score	Cluster	Peptides/AAs Whole Pr.	Ratio
1	5-36	67	5	16	0.250	0.117	2.140
		23	12	19			
		24	16	19			
		9	17	22			
		25	18	19			
		32	19	18			
		68	23	16			
		33	28	18			
2	37-62	41	37	17	0.269	0.117	2.305
		20	44	20			
		26	45	19			
		42	46	17			
		27	50	19			
		43	53	17			
		44	54	17			
3	99-115	14	99	21	0.235	0.117	2.014
		5	100	23			
		45	104	17			
		34	107	18			
4	116-129	69	116	16	0.143	0.117	1.223
		21	121	20			
5	172-187	46	172	17	0.125	0.117	1.070
		70	179	16			
6	192-202	3	192	24	0.182	0.117	1.557
		47	194	17			
7	226-241	48	226	17	0.188	0.117	1.605
		49	229	17			
		15	233	21			
8	307-318	11	307	22	0.250	0.117	2.140
		71	308	16			
		51	310	17			
9	319-349	52	319	17	0.129	0.117	1.105
		53	327	17			
		72	335	16			
		35	341	18			
10	370-388	12	370	22	0.211	0.117	1.802
		54	372	17			
		74	375	16			
		6	380	23			
11	403-419	56	403	17	0.235	0.117	2.014
		57	404	17			

		58	407	17			
		28	411	19			
12	427-442	59	427	17	0.188	0.117	1.605
		75	432	16			
		76	434	16			
13	450-462	77	450	16	0.154	0.117	1.317
		13	454	22			
14	488-505	36	488	18	0.167	0.117	1.427
		18	492	21			
		60	497	17			
15	548-558	4	548	24	0.182	0.117	1.557
		61	550	17			
16	565-577	62	565	17	0.154	0.117	1.317
		19	569	21			
17	579-597	78	579	16	0.143	0.117	1.223
		79	582	16			
		7	589	23			
18	605-618	2	605	25	0.143	0.117	1.223
		38	610	18			
19	631-669	29	631	19	0.154	0.117	1.317
		63	637	17			
		80	644	16			
		64	652	17			
		39	660	18			
		81	661	16			
20	675-702	22	675	20	0.286	0.117	2.446
		30	683	19			
		31	687	19			
		40	688	18			
		65	690	17			
		1	691	31			
		66	692	17			
		8	694	23			

Table 59

Predication of clusters for SCP-1 (NIH algorithm)

Total AAs: 976

Total 9-mers: 968

NIH 5: 37 9-mers

Cluster #	AA	Peptides Rank	Start Position	Score	Cluster	Peptides/AAs Whole Pr.	Ratio
1	101-116	15	101	40.589	0.125	0.038	3.270
		13	108	57.255			
2*	281-305	14	281	44.944	0.12	0.038	3.139
		24	288	15.203			
		17	297	32.857			
3	431-447	8	431	80.217	0.073	0.038	1.914
		26	438	11.861			
		4	439	148.896			
4	557-579	11	557	64.335	0.174	0.038	4.550
		19	560	24.937			
		6	564	87.586			
		18	571	32.765			
5	635-650	10	635	69.552	0.125	0.038	3.270
		34	642	6.542			
6	755-767	36	755	5.599	0.154	0.038	4.025
		35	759	5.928			
7	838-854	2	838	284.517	0.118	0.038	3.078
		28	846	11.426			

Table 60

Predication of clusters for SCP-1

Total AAs: 976

Total 9-mers: 968

Rammensee 16: 118 9-mers

Cluster #	AA	Peptides Rank	Start Position	Score	Cluster	Peptides/AAs Whole Pr.	Ratio
1	8-28	99	8	16	0.143	0.121	1.182
		77	15	17			
		100	20	16			
2	63-80	78	63	17	0.222	0.121	1.838
		50	66	19			
		102	69	16			
		60	72	18			
3	94-123	79	94	17	0.133	0.121	1.103
		12	101	23			
		17	108	22			
		103	115	16			
4	126-158	35	126	20	0.182	0.121	1.504
		36	133	20			
		51	139	19			

		80	140	17			
		61	143	18			
		37	150	20			
5	161-189	38	161	20	0.207	0.121	1.711
		52	165	19			
		81	171	17			
		82	177	17			
		62	178	18			
		39	181	20			
6	213-230	40	213	20	0.167	0.121	1.379
		13	220	23			
		28	222	21			
7	235-250	63	235	18	0.125	0.121	1.034
		18	242	22			
8	260-296	83	260	17	0.243	0.121	2.012
		105	262	16			
		84	267	17			
		106	269	16			
		41	270	20			
		64	271	18			
		85	274	17			
		19	281	22			
		3	288	25			
9	312-338	108	312	16	0.148	0.121	1.225
		29	319	21			
		30	323	21			
		65	330	18			
10	339-355	66	339	18	0.235	0.121	1.946
		31	340	21			
		42	344	20			
		53	347	19			
11	376-447	54	376	19	0.194	0.121	1.608
		43	382	20			
		44	386	20			
		20	390	22			
		55	397	19			
		6	404	24			
		86	407	17			
		45	411	20			
		67	417	18			
		21	425	22			
		46	431	20			
		68	432	18			
		32	438	21			
		7	439	24			
12	455-488	33	455	21	0.235	0.121	1.946
		47	459	20			
		56	462	19			
		87	463	17			
		88	466	17			
		14	470	23			
		109	473	16			

		34	480	21			
13	515-530	57	515	19	0.125	0.121	1.034
		22	522	22			
14	557-590	8	557	24	0.147	0.121	1.216
		23	564	22			
		9	571	24			
		90	575	17			
		58	582	19			
15	610-625	69	610	18	0.125	0.121	1.034
		91	617	17			
16	633-668	92	633	17	0.222		
		10	635	24			
		70	638	18			
		93	640	17			
		48	642	20			
		49	645	20			
		111	652	16			
		112	660	16			
17	674-685	71	674	18	0.167	0.121	1.379
		11	677	24			
18	687-702	1	687	26	0.125	0.121	1.034
		94	694	17			
19	744-767	113	744	16	0.250	0.121	2.068
		95	745	17			
		4	745	25			
		24	752	22			
		2	755	26			
		72	759	18			
20	812-827	97	812	17	0.125	0.121	1.034
		115	819	16			
21	838-857	116	838	16	0.150	0.121	1.241
		25	846	22			
		74	849	18			
22	896-913	117	896	16	0.222	0.121	1.838
		98	899	17			
		26	902	22			
		76	905	18			

5 The embodiments of the invention are applicable to and contemplate variations in the sequences of the target antigens provided herein, including those disclosed in the various databases that are accessible by the world wide web. Specifically for the specific sequences disclosed herein, variation in sequences can be found by using the provided accession numbers to access information for each antigen.

TYROSINASE PROTEIN; SEQ ID NO 2

1 MLLAVLYCLL WSFQTSAGHF PRACVSSKNL MEKECCPPWS GDRSPCGQLS
GRGSCQNILL
61 SNAPLGPQFP FTGVDDRESW PSVFYNRTCQ CSGNFMGFNC GNCKFGFWGP
NCTERRLLVR
5 121 RNIFDLSAPE KDKFFAYLTL AKHTISSDYV IPIGTYGQMK NGSTPMFNDI
NIYDLFVWMH
181 YYVSMDALLG GSEIWRDIDF AHEAPAFLPW HRLFLLRWEQ EIQKLTGDEN
FTIPYWDWRD
241 AEKCDICTDE YMGQHPPTNP NLLSPASFFS SWQIVCSRLE EYNHQSLCN
10 GTPEGPLRRN
301 PGNHDKSRTP RLPSSADVEF CLSLTQYESG SMDKAANFSF RNTLEGFASP
LTGIADASQS
361 SMHNALHIYM NGTMSQVQGS ANDPIFLLHH AFVDSIFEQW LRRHRPLQEV
YPEANAPIGH
15 421 NRESYMPFI PLYRNGDFFI SSKDLGYDYS YLQSDPDPSF QDYIKSYLEQ
ASRIWSWLLG
481 AAMVGAVLTA LLAGLVSLLC RHKRKQLPEE KQPLLMEKED YHSLYQSHL

20 SSX-2 PROTEIN; SEQ ID NO 3

1 MNGDDAFARR PTVGAQIPEK IQKAFDDIAK YFSKEEWEKM KASEKIFYVY
MKRKYEAMTK
61 LGFKATLPPF MCNKRAEDFQ GNDLDNDPNR GNQVERPQMT FGRLQGISPK
25 IMPKKPAEEG
121 NDSEEVPEAS GPQNDGKELC PPGKPTTSEK IHERSGPKRG EHAWTHRLRE
RKQLVIYEEI
181 SDPEEDDE

30 PSMA PROTEIN; SEQ ID NO 4

1 MWNLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLEF WFIKSSNEAT
NITPKHNMKA
35 61 FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW KEFGLDSVEL
AHYDVLLSYP
121 NKTHPNYISI INEDGNEIFN TSLFEPPPPG YENVSDIVPP FSAFSPQGMP
EGDLVYVNYA
181 RTEDFFKLER DMKINCSGKI VIARYGKVFR GNKVKNQAQLA GAKGVILYSD
40 PADYFAPGVK
241 SYPDGWNLP GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP
SIPVHPIGYY
301 DAQKLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
EVTRIYNVIG
45 361 TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR SFGTLKKEGW
RPRRTILFAS
421 WDAEEFGLLG STEWAEENSR LLQERGVAYI NADSSIEGNY TLRVDCTPLM
YSLVHNLTKE
481 LKSPDEGFEG KSLYESWTKK SPSPEFSGMP RISKLGSGND FEVFFQRLGI
50 ASGRARYTKN
541 WETNKFSGYP LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVPELANS
IVLPFDCRDY

601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSAVKNFT EIASKFSERL
 QDFDKSNPIV
 661 LMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNKY AGESFPGIYD
 ALFDIESKVD
 721 PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA

5

10 Homo sapiens tyrosinase (oculocutaneous albinism IA) (TYR), mRNA.;
 ACCESSION NM_000372
 VERSION NM_000372.1 GI:4507752
 SEQ ID NO 2
 /translation="MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRS
 15 PCGQLSGRGSCQNILLSNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGN
 CKFGFWGPNCTERRLLVRRNIFDLSAFEKDKFFAYLTLAKHTISSDYVIPIGTYGQMK
 20 NGSTPMFNDINIYDLFVWMHYVSMALLGGSEIWRDIDFAHEAPAFPLPWHRLFLLRW
 EQEIQKLTGDENFTIPYWDWRDAEKCDICTDEYMGQHPNPNLLSPASFFSSWQIVC
 SRLEEYNHQSLCNGTPEGPLRRNPGNHDKSRTPLRPSSADVEFCLSLTQYESGSMDK
 25 AANFSFRNTLEGFASPLTGIADASQSSMHNALHIYMNGTMSQVQGSANDPIFLLHHA
 VDSIFEQWLRRHRPLQEVYPEANAPIGHNRESYMPFIPLYRNGDFFISSKDLGYDYS
 30 YLQDSDPDSFQDIKSYLEQASRIWSWLLGAAMVGAVLTALLAGLVSLLCRHKRKQLP
 EEKQPLLMEKEDYHSQSHL"

SEQ ID NO 5

ORIGIN

35 1 atcactgtag tagtagctgg aaagagaaat ctgtgactcc aattagccag
 ttctctgcaga
 61 ccttgtagagg actagaggaa gaatgctcct ggctgttttg tactgcctgc
 tgtggagttt
 121 ccagacctcc gctggccatt tccctagagc ctgtgtctcc tctaagaacc
 40 tgatggagaa
 181 ggaatgctgt ccaccgtgga gcggggacag gagtccctgt ggccagcttt
 caggcagagg
 241 ttctgtcag aatatacttc tgtccaatgc accacttggg cctcaatttc
 ccttcacagg
 45 301 ggtggatgac cgggagtcgt ggccttccgt cttttataat aggacctgcc
 agtgctctgg
 361 caacttcacg ggattcaact gtggaaactg caagtttggc ttttggggac
 caaactgcac
 421 agagagacga ctcttggtga gaagaaacat cttcgatttg agtgccccag
 50 agaaggacaa
 481 attttttgcc tacctcactt tagcaaagca taccatcagc tcagactatg
 tcatcccat

541 agggacctat ggccaaatga aaaatggatc aacacccatg ttttaacgaca
tcaatatatta
601 tgacctcttt gtctggatgc attattatgt gtcaatggat gcactgcttg
ggggatctga
5 661 aatctggaga gacattgatt ttgcccataga agcaccagct tttctgcctt
ggcatagact
721 cttcttggtg cgggtgggaac aagaaatcca gaagctgaca ggagatgaaa
acttcactat
781 tccatattgg gactggcggg atgcagaaaa gtgtgacatt tgcacagatg
10 agtacatggg
841 aggtcagcac cccacaaatc ctaacttact cagcccagca tcattcttct
cctcttgcca
901 gattgtctgt agccgattgg aggagtacaa cagccatcag tctttatgca
atggaacgcc
15 961 cgagggaact ttacggcgta atcctggaaa ccatgacaaa tccagaaccc
caaggctccc
1021 ctcttcagct gatgtagaat tttgcctgag tttgacccaa tatgaatctg
gttccatgga
1081 taaagctgcc aatttcagct ttagaaatac actggaagga tttgctagtc
20 cacttactgg
1141 gatagcggat gcctctcaaa gcagcatgca caatgccttg cacatctata
tgaatggaac
1201 aatgtcccag gtacagggat ctgccaacga tcctatcttc cttcttcacc
atgcatttgt
25 1261 tgacagtatt tttgagcagt ggctccgaag gcaccgtcct cttcaagaag
tttatccaga
1321 agccaatgca cccattggac ataaccggga atcctacatg gttcctttta
taccactgta
1381 cagaaatggg gatttcttta tttcatccaa agatctgggc tatgactata
30 gctatctaca
1441 agattcagac ccagactctt ttcaagacta cattaagtcc tatttggaac
aagcgagtcg
1501 gatctggtca tggctccttg gggcggcgat ggtagggggc gtcctcactg
ccctgctggc
35 1561 agggcttggt agcttgctgt gtcgtcacia gagaaagcag cttcctgaag
aaaagcagcc
1621 actcctcatg gagaaagagg attaccacag cttgtatcag agccatttat
aaaaggctta
1681 ggcaatagag tagggccaaa aagcctgacc tcaactaac tcaaagtaat
40 gtccagggtc
1741 ccagagaata tctgctggta tttttctgta aagaccattt gcaaaattgt
aacctaatac
1801 aaagtgtagc cttcttccaa ctcaggtaga acacacctgt ctttgtcttg
ctgttttcac
45 1861 tcagcccttt taacattttc ccctaagccc atatgtctaa ggaaaggatg
ctatttggtg
1921 atgaggaact gttatttgta tgtgaattaa agtgccttta tttt

50

Homo sapiens synovial sarcoma, X breakpoint 2 (SSX2), mRNA.
ACCESSION NM_003147

VERSION NM_003147.1 GI:10337582
SEQ ID NO 3

/translation="MNGDDAFARRPTVGAQIPEKIQKAFDDIAKYFSKEEWEKMKASE
KIFYVYMKRKYEAMTKLGFKATLPPFMCNKRAEDFQGNLDNDPNRGNQVERPQMTFG
RLQGISPKIMPKKPAEEGNDSEEVPEASGPQNDGKELCPPGKPTTSEKIHERSGPKRG
EHAWTHRLRERKQLVIYEEISDPEEDE"

SEQ ID NO 6
ORIGIN

1 ctctctttcg attcttccat actcagagta cgcacggtct gattttctct
ttggattctt
61 ccaaaatcag agtcagactg ctcccggtgc catgaacgga gacgacgcct
ttgcaaggag
121 acccacggtt ggtgctcaaa taccagagaa gatccaaaag gccttcgatg
atattgcaa
181 atacttctct aaggaagagt gggaaaagat gaaagcctcg gagaaaatct
tctatgtgta
241 tatgaagaga aagtatgagg ctatgactaa actaggtttc aaggccaccc
tcccaccttt
301 catgtgtaat aaacgggccg aagacttcca ggggaatgat ttggataatg
accctaaccg
361 tgggaatcag gttgaacgtc ctcatgatgac tttcggcagg ctccagggaa
tctccccgaa
421 gatcatgcc aagaagccag cagaggaagg aaatgattcg gaggaagtgc
cagaagcatc
481 tggcccacaa aatgatggga aagagctgtg cccccggga aaaccaacta
cctctgagaa
541 gattcacgag agatctggac caaaagggg ggaacatgcc tggaccacaca
gactgcgtga
601 gagaaaacag ctggtgattt atgaagagat cagcgaccct gaggaagatg
acgagtaact
661 cccctcaggg atacgacaca tgcccatgat gagaagcaga acgtggtgac
ctttcacgaa
721 catgggcatg gctgcggacc cctcgtcac aggtgcatag caagtg

Homo sapiens folate hydrolase (prostate-specific membrane antigen)
1 (FOLH1), mRNA.
ACCESSION NM_004476
VERSION NM_004476.1 GI:4758397

/translation="MWNLLHETDSAVATARRPRWLCAGALVLAGGFLLGFLFGWFIK
SSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKE
FGLDSVELAHYDVLLSYPNKTHPNYISIIINEDGNEIFNTSLFEPPIPGYENVSDIVPP
FSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVARIYGVFRGNKVKNAQ

LAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNI LNNGAGDPLTPGYPANE
YAYRRGIAEAVGLPSIPVHPIGYYDAQKLEKMGG SAPPDSSWRGSLKVPYNVGP GFT
5 GNFSTQKV KMHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGA
AVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRL LQERG VAYI
10 NADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSG
MPRISKLGSCNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFY
DPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKT
15 YSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLP
DRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQ
AAAETLSEVA"
20
SEQ ID NO 7
ORIGIN
1 ctcaaaaggg gccggatttc cttctcctgg aggcagatgt tgcctctctc
tctcgctcgg
25 61 attggttcag tgcactctag aaacactgct gtggtggaga aactggaccc
caggtctgga
121 gcgaattcca gcctgcaggg ctgataagcg aggcattagt gagattgaga
gagactttac
181 cccgccgtgg tgggtggagg gcgcgcagta gagcagcagc acaggcgcgg
30 gtcccgggag
241 gccggctctg ctgcgcgccg gatgtggaat ctccctcacg aaaccgactc
ggctgtggcc
301 accgcgcgcc gccgcgcgtg gctgtgcgct ggggcgctgg tgctggcggg
tggtctcttt
35 361 ctccctcggt tccctcttcgg gtggtttata aaatcctcca atgaagctac
taacattact
421 ccaaagcata atatgaaagc atttttggat gaattgaaag ctgagaacat
caagaagttc
481 ttatataatt ttacacagat accacattta gcaggaacag aacaaaactt
40 tcagcttgca
541 aagcaaattc aatcccagtg gaaagaattt ggcctggatt ctgttgagct
agcacattat
601 gatgtcctgt tgtcctaccc aaataagact catoccaact acatctcaat
aattaatgaa
45 661 gatggaaatg agattttcaa cacatcatta tttgaaccac ctccctcagg
atatgaaaat
721 gtttcggata ttgtaccacc tttcagtgtt ttctctctctc aaggaatgcc
agagggcgat
781 ctagtgtatg ttaactatgc acgaactgaa gacttcttta aattggaacg
50 ggacatgaaa
841 atcaattgct ctgggaaaat tgtaattgcc agatatggga aagttttcag
aggaaataag

901 gttaaaaatg cccagctggc aggggccaaa ggagtcattc tctactccga
ccctgctgac
961 tactttgctc ctggggtgaa gtcctatcca gatggttgga atcttctcgg
aggtggtgct
5 1021 cagcgtggaa atatcctaaa tctgaatggg gcaggagacc ctctcacacc
aggttaccca
1081 gcaaatgaat atgcttatag gcgtggaatt gcagaggctg ttggtcttcc
aagtattcct
1141 gttcatccaa ttggatacta tgatgcacag aagctcctag aaaaaatggg
10 ttggtcagca
1201 ccaccagata gcagctggag aggaagtctc aaagtgcctt acaatgttgg
acctggcttt
1261 actggaaact tttctacaca aaaagtcaag atgcacatcc actctacca
tgaagtgaca
15 1321 agaatttaca atgtgatagg tactctcaga ggagcagtgg aaccagacag
atatgtcatt
1381 ctgggaggct accgggactc atgggtggtt ggtggtattg acctcagag
tggagcagct
1441 gttgttcatt aaattgtgag gagctttgga acactgaaaa aggaagggtg
20 gagacctaga
1501 agaacaattt tgtttgcaag ctgggatgca gaagaatttg gtcttcttgg
ttctactgag
1561 tgggcagagg agaattcaag actccttcaa gagcgtggcg tggcttatat
taatgctgac
25 1621 tcatctatag aaggaaacta cactctgaga gttgattgta caccgctgat
gtacagcttg
1681 gtacacaacc taacaaaaga gctgaaaagc cctgatgaag gctttgaagg
caaatctctt
1741 tatgaaagtt ggactaaaaa aagtccttcc ccagagttca gtggcatgcc
30 caggataagc
1801 aaattgggat ctggaaatga ttttgagggtg ttcttccaac gacttggaat
tgcttcaggc
1861 agagcacggg atactaaaaa ttgggaaaca aacaaattca gcggctatcc
actgtatcac
35 1921 agtgtctatg aaacatatga gttggtggaa aagttttatg atccaatgtt
taaataatcac
1981 ctactgtgg cccagggtcg aggaggatg gtgtttgagc tagccaattc
catagtgtc
2041 ccttttgatt gtogagatta tgctgtagtt ttaagaaagt atgtgacaa
40 aatctacagt
2101 atttctatga aacatccaca ggaaatgaag acatacagtg tatcatttga
ttcacttttt
2161 tctgcagtaa agaattttac agaaattgct tccaagttca gtgagagact
ccaggacttt
45 2221 gacaaaagca acccaatagt attaagaatg atgaatgatc aactcatgtt
tctggaaaga
2281 gcatttattg atccattagg gttaccagac aggccttttt ataggcatgt
catctatgct
2341 ccaagcagcc acaacaagta tgcaggggag tcattcccag gaatttatga
50 tgctctgttt
2401 gatattgaaa gcaaagtgga cccttccaag gcctggggag aagtgaagag
acagatttat

2461 gttgcagcct tcacagtgcg gccagctgca gagactttga gtgaagtagc
ctaagaggat
2521 tcttttagaga atccgtattg aatttgtgtg gtatgtcact cagaaagaat
cgtaatgggt
5 2581 atattgataa attttaaaat tggatatattt gaaataaaagt tgaatattat
atataaaaaa
2641 aaaaaaaaaa aaa

10 Human melanocyte-specific (pmel 17) gene, exons 2-5, and complete
cds.
ACCESSION U20093
VERSION U20093.1 GI:1142634
15 SEQ ID NO 70

/translation="MDLVLRCLLHLAVIGALLAVGATKVPNRQDWLGVSRLTKAWNRLYPEW
TEAQRLLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPQSQKVLDPGQVIWVNNNTIINGSQVWGG
QPVYPQETDDACIFPDGGPCPSGWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAMLGHTM
20 EVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQPLTFALQLHDPGYSY
LAEADLSYTWDFGDSSGTLISRAPVVHTHTYLEPGPVTAQVVLQAAIPLTSCGSSPVPGTDDGHRPT
AEAPNTTAGQVPTTEVVGTTGQAPTAEPSGTTSVQVPTTEVISTAPVQMPTAESTGMTPEKVPVS
EVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMSTE
SITGSLGPLLDGTATLRLVKRQVPLDCVLYRYGSFSVTLDIVQIESAEILQAVPSGEGDAFELTV
25 SCQGGLPKEACMEISSPGCQPPAQRQCQVLPSPACQLVLHQILKGGSGTYCLNVSLADTNSLAVV
STQLIMPQGEAGLGQVPLIVGILLVMAVVLASLIYRRRLMKQDFSVPLPHSSSHWLRLPRIFCS
CPIGENSPLLSGQQV"

SEQ ID NO 80
30 ORIGIN

1 gtgctaaaaa gatgccttct tcatttggct gtgataggct ctttgtggct
gtggggggcta
61 caaaagtacc cagaaaccag gactggcctt gtgtctcaag gcaactcaga
accaaagcct
35 121 ggaacaggca gctgtatcca gagtggacag aagcccagag acttgactgc
tggagagggtg
181 gtcaagtgtc cctcaaggct agtaatgatg ggcctacact gattgggtgca
aatgcctcct
40 241 tctctattgc cttgaacttc cctggaagcc aaaagggtatt gccagatggg
cagggttatct
301 gggtaacaa taccatcatc aatgggagcc aggtgtgggg aggacagcca
gtgtatcccc
361 aggaactga cgatgcctgc atcttccttg atggtggacc ttgcccattc
ggctcttggt
45 421 ctcaagaagag aagctttggt tatgtctgga agacctgggg tgagggactc
ccttctcagc
481 ctatcatcca cacttgtgtt tacttctttc tactgatca ctttctttt
ggccgcccct
541 tccaccttaa cttctgtgat tttctctaata cttcattttc ctcttagatc
50 ttttctcttt
601 cttagcacct agcccccttc aagctctatc ataattcttt ctggcaactc
ttggcctcaa

	661	ttgtagtcct	accccatgga	atgcctcatt	aggacccctt	ccctgtcccc
		ccatatcaca				
	721	gccttccaaa	caccctcaga	agtaatcata	cttcctgacc	tcccatctcc
		agtgccgttt				
5	781	cgaagcctgt	ccctcagtc	cctttgacca	gtaatctctt	cttccttgct
		tttcattcca				
	841	aaaatgcttc	aggccaatac	tggcaagttc	tagggggccc	agtgtctggg
		ctgagcattg				
	901	ggacaggcag	ggcaatgctg	ggcacacaca	ccatggaagt	gactgtctac
10		catcgccggg				
	961	gatcccggag	ctatgtgcct	cttgctcatt	ccagctcagc	cttcaccatt
		actggtaagg				
	1021	gttcaggaag	ggcaaggcca	gttgtagggc	aaagagaagg	cagggaggct
		tggatggact				
15	1081	gcaaaggaga	aaggtgaaat	gctgtgcaaa	cttaaagtag	aagggccagg
		aagacctagg				
	1141	cagagaaatg	tgaggcttag	tgccagtga	gggccagcca	gtcagcttgg
		agttggaggg				
	1201	tgtggctgtg	aaaggagaag	ctgtggctca	ggcctgggtc	tcaccttttc
20		tggctccaat				
	1261	cccagaccag	gtgcctttct	ccgtgagcgt	gtcccagttg	cgggccttgg
		atggagggaa				
	1321	caagcacttc	ctgagaaatc	agcctctgac	ctttgccctc	cagctccatg
		accccgtagg				
25	1381	ctatctggct	gaagctgacc	tctcctacac	ctgggacttt	ggagacagta
		gtggaaccct				
	1441	gatctctcgg	gcacctgtgg	tactcatac	ttacctggag	cctggcccag
		tcactgccc				
	1501	ggtggctcctg	caggctgcca	ttcctctcac	ctcctgtggc	tcctccccag
30		ttccaggcac				
	1561	cacagatggg	cacaggccaa	ctgcagaggc	ccctaacc	acagctggcc
		aagtgcctac				
	1621	tacagaagtt	gtgggtacta	cacctgggtc	ggcgccaact	gcagagccct
		ctggaaccac				
35	1681	atctgtgcag	gtgccaaacca	ctgaagtc	aagcactgca	cctgtgcaga
		tgccaactgc				
	1741	agagagcaca	ggtatgacac	ctgagaaggt	gccagtttca	gaggtcatgg
		gtaccacact				
	1801	ggcagagatg	tcaactccag	aggctacagg	tatgacacct	gcagaggtat
40		caattgtgg				
	1861	gctttctgga	accacagctg	cacaggtaac	aactacagag	tgggtggaga
		ccacagctag				
	1921	agagctacct	atccctgagc	ctgaagggtc	agatgccagc	tcaatcatgt
		ctacggaaaag				
45	1981	tattacaggt	tcctggggcc	ccctgctgga	tggtagagcc	accttaaggc
		tggtagagag				
	2041	acaagtcccc	ctggattgtg	ttctgtatcg	atatgggtcc	ttttccgtca
		ccctggacat				
	2101	tgtccaggg	attgaaagt	ccgagatcct	gcaggtgtg	ccgtccgggtg
50		agggggatgc				
	2161	atgtgagctg	actgtgtcct	gccaaaggcg	gctgccaag	gaagcctgca
		tggagatctc				

```

    2221 atcgccaggg tgcagcccc ctgccagcgc gctgtgccag cctgtgctac
ccagcccagc
    2281 ctgccagctg gttctgcacc agatactgaa gggtaggctcg gggacatact
gcctcaatgt
5    2341 gtctctggct gataccaaca gcctggcagt ggtcagcacc cagcttatca
tgcctggtag
    2401 gtccttggac agagactaag tgaggaggga agtggataga ggggacagct
ggcaagcagc
    2461 agacatgagt gaagcagtgc ctgggattct tctcacaggt caagaagcag
10   gccttgggca
    2521 gggtccgctg atcgtgggca tcttgctggg gttgatggct gtggctcctg
catctctgat
    2581 atataggcgc agacttatga agcaagactt ctccgtacct cagttgccac
atagcagcag
15   2641 tcaactggctg cgtctacccc gcatcttctg ctcttgctcc attggtgaga
atagccccct
    2701 cctcagtggg cagcagggtct gagtactctc atatgatgct gtgattttcc
tggagttgac
    2761 agaaacacct atattttcccc cagtcttccc tgggagacta ctattaactg
20   aaataaa
    //

Homo sapiens kallikrein 3, (prostate specific antigen) (KLK3),
25   mRNA.
    ACCESSION   NM_001648
    VERSION     NM_001648.1   GI:4502172
    SEQ ID NO 78

30   /translation="MWVPVVFLLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVAS
RGRAVCGGVLVHPQWVLTAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRF
LRPGDDSSHDLMLRLSEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIPEEFLLTPKKLQCVDL
HVISNDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSL
YTKVVHYRKWIKDTIVANP"

35   SEQ ID NO 86
    ORIGIN
        1 agccccaagc ttaccacctg caccgggaga gctgtgtgtc accatgtggg
tcccggttgt
40   61 cttectcacc ctgtccgtga cgtggattgg tgctgcaccc ctcatcctgt
ctcggattgt
        121 gggaggctgg gagtgcgaga agcattccca accctggcag gtgcttggg
cctctcgtgg
45   181 cagggcagtc tgcggcggtg ttctggtgca ccccgagtgg gtccctcacag
ctgcccactg
        241 catcaggaac aaaagcgtga tcttgctggg tcggcacagc ctgtttcctc
ctgaagacac
        301 aggccaggta tttcaggta gccacagctt cccacacccg ctctacgata
tgagcctcct
50   361 gaagaatcga ttctcaggc caggtgatga ctccagccac gacctcatgc
tgctccgct
```

```

      421 gtcagagcct gccgagctca cggatgctgt gaaggtcatg gacctgcccc
cccaggagcc
      481 agcactgggg accacctgct acgcctcagg ctggggcagc attgaaccag
aggagttctt
5      541 gaccccaaag aaacttcagt gtgtggacct ccatgttatt tccaatgacg
tgtgtgcgca
      601 agttcacctc cagaagggtga ccaagttcat gctgtgtgct ggacgctgga
cagggggcaa
      661 aagcacctgc tcgggtgatt ctggggggccc acttgtctgt aatggtgtgc
10     ttcaagggtat
      721 cacgtcatgg ggcagtgaac catgtgccct gcccgaaagg ccttcctgt
acaccaaggt
      781 ggtgcattac cggaagtgga tcaaggacac catcgtggcc aaccctgag
caccctatc
15     841 aacccctat tgtagtaaac ttggaacctt ggaaatgacc aggccaagac
tcaagcctcc
      901 ccagttctac tgacctttgt ccttaggtgt gaggtccagg gttgctagga
aaagaaatca
      961 gcagacacag gtgtagacca gagtgtttct taaatggtgt aattttgtcc
20     tctctgtgtc
     1021 ctggggaata ctggccatgc ctggagacat atcactcaat ttctctgagg
acacagatag
     1081 gatggggtgt ctgtgttatt tgtggggtac agagatgaaa gaggggtggg
atccacactg
25     1141 agagagtgga gagtgcacat tgctggacac tgtccatgaa gactgagca
gaagctggag
     1201 gcacaacgca ccagacactc acagcaagga tggagctgaa aacataaccc
actctgtcct
     1261 ggaggcactg ggaagcctag agaaggctgt gagccaagga gggagggctc
30     tcctttggca
     1321 tgggatgggg atgaagtaag gagagggact ggacccctg gaagctgatt
cactatgggg
     1381 ggaggtgtat tgaagtctc cagacaaccc tcagatttga tgatttcta
gtagaactca
35     1441 cagaaataaa gagctgttat actgtg
//

```

```

40     Human autoimmunogenic cancer/testis antigen NY-ESO-1 mRNA,
complete cds.
      ACCESSION   U87459
      VERSION     U87459.1  GI:1890098
      SEQ ID NO 74

```

```

45     /translation="MQAEGRGTTGGSTGDADGPGGPGIPDGPGGNAGGPGEAG
ATGGRGPRGAGAARASGPGGAPRGPHGGAASGLNGCCRCGARGPESRLLEF
YLAMPFATPMEAELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAADH
RQLQLSISSCLQQLSLLMWITQCFLPVFLAQPPSGQRR"

```

```

50     SEQ ID NO 84
      ORIGIN

```



```
      1 atcctcgtgg gccctgacct tctctctgag agccggggcag aggctccgga
gccatgcagg
      61 ccgaaggccg gggcacaggg gggtcgacgg gcgatgctga tggcccagga
ggccctggca
5      121 ttctgatgg cccagggggc aatgctggcg gccaggaga ggcgggtgcc
acgggcggca
      181 gaggtccccg gggcgcaggg gcagcaaggg cctcggggcc gggaggaggc
gccccgcggg
      241 gtccgcatgg cggcgcggct tcagggctga atggatgctg cagatgcggg
10 gccagggggc
      301 cggagagccg cctgcttgag ttctacctcg ccatgccttt cgcgacaccc
atggaagcag
      361 agctggcccc caggagcctg gccaggatg cccaccgct tcccgtgcca
ggggtgcttc
15      421 tgaaggagtt cactgtgtcc ggcaacatac tgactatccg actgactgct
gcagaccacc
      481 gccaaactgca gctctccatc agctcctgtc tccagcagct ttccctgttg
atgtggatca
      541 cgcagtgctt tctgcccggtg tttttggctc agcctccctc agggcagagg
20 cgctaagccc
      601 agcctggcgc cccttcctag gtcatgcctc ctcccctagg gaatgggtccc
agcacgagtg
      661 gccagttcat tgtggggggc tgattgtttg tcgctggagg aggacggctt
acatgtttgt
25      721 ttctgtagaa aataaaaactg agctacgaaa aa
//
```

LAGE-1a protein [Homo sapiens].

```
30  ACCESSION  CAA11116
    PID      g3255959
    VERSION   CAA11116.1  GI:3255959
```

SEQ ID NO 75

ORIGIN

```
35      1 mqaegrvtgg stgdadgpgg pgipdgpggn aggpgeagat ggrgprgaga
arasgprgga
      61 prgphggaas aqdgrcpcga rrpdsrllel hitmpfsspm eaelvrrils
rdaaplprpg
      121 avlkdfvtvg nllfirltaa dhrqlqlsis sclqqlslm witqcflpvf
40 laqapsgqrr
      181
//
```

45 LAGE-1b protein [Homo sapiens].

```
    ACCESSION  CAA11117
    PID      g3255960
    VERSION   CAA11117.1  GI:3255960
```

50 SEQ ID NO 76

ORIGIN

1 mqaegrgtgg stgdadgpgg pgipdgpggn aggpgeagat ggrgprgaga
arasgprgga
61 prgphggaas aqdgrcpcga rrpdsrlllel hitmpfsspm eaelvrrils
rdaaplprpg
5 121 avlkdfvtvg nllfmsvwdq dregagrmrv vgwglgsasp egqkardlrt
pkhkvsegrp
181 gtpgpppppeg aggdgcrava fnvmfsaphi
//
10
Human antigen (MAGE-1) gene, complete cds.
ACCESSION M77481
VERSION M77481.1 GI:416114
SEQ ID NO 71
15
/translation="MSLEQ RSLHCKPEEAL EAQQEALGLVCVQAATSSSSPL
VLGTLEEVP TAGSTDPPQSPQGASAFPTTINFTRQRPSEGSSSREEEGPST
SCILESLFRAVITKKVADLVGFLLK YRAREPVTKAEMLESVIKNYKHC FPE
IFGKASESLQLVFGIDVKEADPTGHSYVLVTCLGLSYDGLLDNQIMPKTGF
20 LIIVLVMIAMEGGHAPEEEIWEELSVM EVYDGREHSAYGEPRKLLTQDLVQE
KLEYRQVPDSDPARYEFLWGPRLAETSXVKVLEYVIKVSARV RFFFPSLR
EAALREEEEGV"
SEQ ID NO 81
25 ORIGIN
1 ggatccaggc cctgccagga aaaatataag ggccctgcgt gagaacagag
ggggtcaccc
61 actgcatgag agtggggatg tcacagagtc cagcccaccc tcctggtagc
actgagaagc
30 121 cagggctgtg cttgcggtct gcaccctgag ggcccgtaga ttctctctcc
tgagactcca
181 ggaaccaggc agtgaggcct tggctctgaga cagtatcctc aggtcacaga
gcagaggatg
241 cacagggtgt gccagcagtg aatgtttgcc ctgaatgcac accaagggcc
35 ccacctgcca
301 caggacacat aggactccac agagtctggc ctcacctccc tactgtcagt
cctgtagaat
361 cgacctctgc tggccggctg taccctgagt accctctcac ttctctcttc
aggttttcag
40 421 gggacaggcc aaccagagg acaggattcc ctggaggcca cagaggagca
ccaaggagaa
481 gatctgtaag taggcctttg ttagagtctc caaggttcag ttctcagctg
aggcctctca
541 cacactccct ctctccccag gcctgtgggt cttcattgcc cagctcctgc
45 ccacactcct
601 gcctgctgcc ctgacgagag tcatcatgtc tcttgagcag aggagtctgc
actgcaagcc
661 tgaggaagcc cttgaggccc aacaagaggc cctgggcctg gtgtgtgtgc
aggctgccac
50 721 ctctctctcc ttctctctgg ttctgggcac cctggaggag gtgccactgc
ctgggtcaac

	781	agatcctccc	cagagtcctc	agggagcctc	cgcctttccc	actaccatca
		acttcactcg				
	841	acagaggcaa	cccagtgagg	gttccagcag	ccgtgaagag	gagggggccaa
		gcacctcttg				
5	901	tatcctggag	tccttggtcc	gagcagtaat	cactaagaag	gtggctgatt
		tggttggttt				
	961	tctgctcctc	aaatatcgag	ccagggagcc	agtcacaaag	gcagaaatgc
		tggagagtgt				
10	1021	catcaaaaat	tacaagcact	gttttcctga	gatcttcggc	aaagcctctg
		agtccttgca				
	1081	gctggtcttt	ggcattgaag	tgaaggaagc	agaccccacc	ggccactcct
		atgtccttgt				
	1141	cacctgccta	ggtctctcct	atgatggcct	gctgggtgat	aatcagatca
		tgcccaagac				
15	1201	aggcttcctg	ataattgtcc	tggtcatgat	tgcaatggag	ggcggccatg
		ctcctgagga				
	1261	ggaaatctgg	gaggagctga	gtgtgatgga	ggtgtatgat	gggagggagc
		acagtgccta				
20	1321	tggggagccc	aggaagctgc	tcaccaaga	tttgggtgcag	gaaaagtacc
		tggagtaccg				
	1381	gcagggtgccg	gacagtgatc	cgcacgccta	tgagttcctg	tgggggtccaa
		gggccctcgc				
	1441	tgaaaccagc	tatgtgaaag	tccttgagta	tgtgatcaag	gtcagtgcaa
		gagttcgctt				
25	1501	tttcttccca	tccttgctg	aagcagcttt	gagagaggag	gaagagggag
		tctgagcatg				
	1561	agttgcagcc	aaggccagtg	ggagggggac	tgggccagtg	caccttccag
		ggccgcgtcc				
30	1621	agcagcttcc	cctgcctcgt	gtgacatgag	gcccattcct	cactctgaag
		agagcgggtca				
	1681	gtgttctcag	tagtaggttt	ctgttctatt	gggtgaactg	gagattttatc
		tttggttctct				
	1741	tttggaattg	ttcaaagtgt	tttttttaag	ggatgggtga	atgaacttca
		gcatccaagt				
35	1801	ttatgaatga	cagcagtcac	acagttctgt	gtatatagtt	taagggtgaag
		agtcttgtgt				
	1861	tttattcaga	ttgggaaatc	cattctatct	tgtgaattgg	gataataaca
		gcagtgggaat				
40	1921	aagtacttag	aaatgtgaaa	aatgagcagt	aaaatagatg	agataaagaa
		ctaaagaaat				
	1981	taagagatag	tcaattcttg	ccttatacct	cagtctattc	tgtaaaattt
		ttaaagatat				
	2041	atgcatacct	ggatttcctt	ggcttctttg	agaatgtaag	agaaattaaa
		tctgaataaaa				
45	2101	gaattcttcc	tgttcactgg	ctcttttctt	ctccatgcac	tgagcatctg
		cttttttgaa				
	2161	ggccctgggt	tagtagtgga	gatgctaagg	taagccagac	tcatacccac
		ccatagggtc				
50	2221	gtagagtcta	ggagctgcag	tcacgtaatc	gaggtggcaa	gatgtcctct
		aaagatgtag				
	2281	ggaaaagtga	gagaggggtg	aggggtgtggg	gctccgggtg	agagtgggtg
		agtggtcaatg				

2341 ccctgagctg gggcattttg ggctttggga aactgcagtt ccttctgggg
gagctgattg
2401 taatgatctt gggatggatcc
//

5

Human MAGE-2 gene exons 1-4, complete cds.

ACCESSION L18920

VERSION L18920.1 GI:436180

SEQ ID NO 72

10

/translation="MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQQTASSSSSTLVEVT
LGEVPAADSPSPPHSPQGASSFSTTINYTLWRQSDGSSNQEEGPRMFPDLE
SEFQAAISRKMVELVHFLLKYRAREPVTKAEMLESVLRNCQDFPVIKASEYLQLVFGIE
VVEVVPISHLYILVTCLGLSYDGLLDGNQVMPKTGLLIIVLAIIEGDCAPEEKIWEELSML
15 EVFEGREDSVFAHPRKLLMQDLVQENYLEYRQVPGSDPACYEFLWGPRLIETSYVKVLHHTL
KIGGEPHISYPPLHERALREGEE"

SEQ ID NO 82

ORIGIN

20

1 attccttcat caaacagcca ggagtgagga agaggaccct cctgagttag
gactgaggat

61 ccaccctcac cacatagtgg gaccacagaa tccagctcag cccctcttgt
cagccctggg

25

121 acacactggc aatgatctca ccccgagcac accctcccc ccaatgccac
ttcgggccga

181 ctgagagtca gagacttggg ctgaggggag cagacacaat cggcagagga
tggcggtcca

241 ggctcagtct ggcatccaag tcaggacctt gagggatgac caaaggcccc
tcccaccccc

30

301 aactcccccg accccaccag gatctacagc ctgaggatcc ccgccccaat
ccctaccctt

361 acaccaacac catcttcatg cttaccccca ccccccatc cagatcccca
tccggggcaga

35

421 atccggttcc acccttgccg tgaaccagg gaagtcacgg gcccggtatgt
gacgccactg

481 acttgacat tggaggtcag aggacagcga gattctcgcc ctgagcaacg
gcctgacgtc

541 ggcggaggga agcaggcgca ggctccgtga ggaggcaagg taagacgccg
agggaggact

40

601 gaggcgggcc tcaccccaga cagagggcc ccaataatcc agcgctgcct
ctgctgccgg

661 gcctggacca ccctgcaggg gaagacttct caggctcagt cgccaccacc
tcaccccgcc

45

721 accccccgcc gctttaaccg cagggaactc tggcgtaaga gctttgtgtg
accagggcag

781 ggctggtag aagtgtcag ggcccagact cagccaggaa tcaaggtag
gacccaaga

841 ggggactgag ggcaaccac ccctaccct cactaccaat cccatcccc
aacaccaacc

50

901 ccacccccat ccctcaaaca ccaacccac ccccaaaccc cattcccatc
tcctcccca

	961	ccaccatcct	ggcagaatcc	ggctttgccc	ctgcaatcaa	cccacggaag
		ctccgggaat				
	1021	ggcggccaag	cacgcggatc	ctgacgttca	catgtacggc	taagggaggg
		aaggggttgg				
5	1081	gtctcgtgag	tatggccttt	gggatgcaga	ggaagggccc	aggcctcctg
		gaagacagtg				
	1141	gagtccttag	gggacccagc	atgccaggac	agggggccca	ctgtaccctt
		gtctcaaact				
	1201	gagccacctt	ttcattcagc	cgagggaaatc	ctagggatgc	agaccactt
10		cagcaggggg				
	1261	ttggggccca	gcctgcgagg	agtcaagggg	aggaagaaga	gggaggactg
		aggggacctt				
	1321	ggagtccaga	tcagtggcaa	ccttgggctg	ggggatcctg	ggcacagtgg
		cgaatgtgc				
15	1381	cccgtgctca	ttgcaccttc	agggtgacag	agagttgagg	gctgtggtct
		gagggctggg				
	1441	acttcaggtc	agcagaggga	ggaatcccag	gatctgccgg	acccaagggtg
		tgcccccttc				
	1501	atgaggactg	gggatacccc	cggcccagaa	agaagggatg	ccacagagtc
20		tggaaagtc				
	1561	ttgttcttag	ctctggggga	acctgatcag	ggatggccct	aagtgacaat
		ctcatttcta				
	1621	ccacaggcag	gaggttgggg	aacctcagg	gagataaggt	gttgggtgtaa
		agaggagctg				
25	1681	tctgctcatt	tcaggggggt	gggggttgag	aaagggcagt	ccctggcagg
		agtaaagatg				
	1741	agtaaccac	aggaggccat	cataacgttc	accctagaac	caaaggggtc
		agccctggac				
	1801	aacgcacgtg	ggggtaacag	gatgtggccc	ctcctcactt	gtctttccag
30		atctcaggg				
	1861	gttgatgacc	ttgttttcag	aagggtgactc	aggtcaacac	aggggcccc
		tctggtcgac				
	1921	agatgcagtg	gttctaggat	ctgccaagca	tccagggtga	gagcctgagg
		taggattgag				
35	1981	ggtaccctg	ggccagaatg	cagcaagggg	gccccataga	aatctgccct
		gcccctgcgg				
	2041	ttacttcaga	gaccctgggc	agggctgtca	gctgaagtcc	ctccattatc
		ctgggatctt				
	2101	tgatgtcagg	gaaggggagg	ccttgggtctg	aaggggctgg	agtcagggtca
40		gtagagggag				
	2161	ggtctcaggc	cctgccagga	gtggacgtga	ggaccaagcg	gactcgtcac
		ccaggacacc				
	2221	tggactccaa	tgaatttgga	catctctcgt	tgtccttcgc	gggaggacct
		ggtcacgtat				
45	2281	ggccagatgt	gggtcccctc	atatacttct	gtaccatatc	agggatgtga
		gttcttgaca				
	2341	tgagagattc	tcaagccagc	aaaaggggtg	gattaggccc	tacaaggaga
		aaggtgaggg				
	2401	ccctgagtga	gcacagaggg	gaccctccac	ccaagtagag	tggggacctc
50		acggagtctg				
	2461	gccaaccctg	ctgagacttc	tgggaatccg	tggctgtgct	tgagtcctgc
		acactgaagg				

	2521	cccgtgcatt	cctctcccag	gaatcaggag	ctccaggaac	caggcagtga
		ggccttggtc				
	2581	tgagtcagtg	tcctcaggtc	acagagcaga	ggggacgcag	acagtgccaa
		caactgaaggt				
5	2641	ttgcctggaa	tgcacaccaa	gggccccacc	cgcccagaac	aaatgggact
		ccagagggcc				
	2701	tggcctcacc	ctccctattc	tcagtcctgc	agcctgagca	tgtgctggcc
		ggctgtaccc				
	2761	tgaggtgccc	tcccacttcc	tccttcaggt	tctgaggggg	acaggctgac
10		aagtaggacc				
	2821	cgaggcactg	gaggagcatt	gaaggagaag	atctgtaagt	aagcctttgt
		cagagcctcc				
	2881	aaggttcagt	tcagttctca	cctaaggcct	cacacacgct	ccttctctcc
		ccaggcctgt				
15	2941	gggtcttcat	tgcccagctc	ctgcccgcac	tcctgcctgc	tgccctgacc
		agagtcatca				
	3001	tgccctctga	gcagaggagt	cagcactgca	agcctgaaga	aggccttgag
		gcccaggag				
	3061	aggccctggg	cctgggtggg	gcgcaggctc	ctgctactga	ggagcagcag
20		accgcttctt				
	3121	cctcttctac	tctagtggaa	gttaccctgg	gggaggtgcc	tgctgccgac
		tcaccgagtc				
	3181	ctccccacag	tcctcagggg	gcctccagct	tctcgactac	catcaactac
		actcttttga				
25	3241	gacaatccga	tgagggtcc	agcaaccaag	aagaggaggg	gccaagaatg
		tttcccagcc				
	3301	tggagtccga	gttccaagca	gcaatcagta	ggaagatggg	tgagttgggt
		cattttctgc				
	3361	tcctcaagta	tcgagccagg	gagccgggtca	caaaggcaga	aatgctggag
30		agtgtcctca				
	3421	gaaattgcc	ggacttcttt	cccgtgatct	tcagcaaagc	ctccgagtac
		ttgcagctgg				
	3481	tctttggcat	cgagggtggg	gaagtgggtc	ccatcagcca	cttgtagatc
		cttgtcacct				
35	3541	gcctgggcct	ctcctacgat	ggcctgctgg	gcgacaatca	ggcatgccc
		aagacaggcc				
	3601	tcctgataat	cgtcctggcc	ataatcgcaa	tagagggcga	ctgtgcccct
		gaggagaaaa				
	3661	tctgggagga	gctgagtatg	ttggaggtgt	ttgaggggag	ggaggacagt
40		gtcttcgcac				
	3721	atcccaggaa	gctgctcatg	caagatctgg	tgaggaaaa	ctacctggag
		taccggcagg				
	3781	tgcccggcag	tgatcctgca	tgctacaggt	tcctgtgggg	tccaagggcc
		ctcattgaaa				
45	3841	ccagctatgt	gaaagtcctg	caccatacac	taaagatcgg	tggagaacct
		cacatttcct				
	3901	accaccccct	gcatgaacgg	gctttgagag	agggagaaga	gtgagtctca
		gcacatgttg				
	3961	cagccagggc	cagtgggagg	gggtctgggc	cagtgcacct	tccagggccc
50		catccattag				
	4021	cttccactgc	ctcgtgtgat	atgaggccca	ttcctgcctc	tttgaagaga
		gcagtcagca				

4081 ttcttagcag tgagtttctg ttctgttgga tgactttgag atttatcttt
ctttcctggt
4141 ggaattgttc aaatgttctt tttacaaaat gggtggatga acttcagcat
ccaagtttat
5 4201 gaatgacagt agtcacacat agtgctgttt atatagttta ggggtaagag
tctgtgtttt
4261 tattcagatt gggaaatcca ttccattttg tgagttgtca cataataaca
gcagtggaaat
10 4321 atgtatttgc ctatattgtg aacgaattag cagtaaaata catgatacaa
ggaactcaaa
4381 agatagttaa ttcttgccctt atacctcagt ctattatgta aaattaaaaa
tatgtgtatg
4441 tttttgcttc tttgagaatg caaaagaaat taaatctgaa taaattcttc
ctgttcaactg
15 4501 gctcatttct ttaccattca ctcagcatct gctctgtgga aggccttggg
agtagtggg
//

20 Human MAGE-3 antigen (MAGE-3) gene, complete cds.
ACCESSION U03735
VERSION U03735.1 GI:468825
SEQ ID NO 73

25 /translation="MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGE
VPAESPDPQSPQGASSLPTTMNYPLWSQSYEDSSNQEEGPSTFPDLESEFQAALSRKVAELVH
FLLKRYRAREPVTKAEMLGSVVGNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLIYIFATCLGL
SYDGLLDGNQIMPKAGLLIIVLAI IAREGDCAPEEKIWEELSVLEVFEGREDSILGDPKLLTQHF
VQENYLEYRQVPGSDPACYEFLWGPRLVETSYVKVLHMHMVKISGGPHISYPPLHEWVLEEGEE"

30 SEQ ID NO 83
ORIGIN
1 acgcaggcag tgatgtcacc cagaccacac cccttcccc aatgccactt
caggggggtac
35 61 tcagagtcag agacttggtc tgagggggagc agaagcaatc tgcagaggat
ggcgggtccag
121 gctcagccag gcatcaactt caggaccctg agggatgacc gaaggccccg
cccaccacc
181 cccaactccc ccgacccac caggatctac agcctcagga cccccgtccc
40 aatccttacc
241 ccttgcccca tcaccatctt catgcttacc tccaccccca tccgatcccc
atccaggcag
301 aatccagttc caccctgccc cggaaaccag ggtagtaccg ttgccaggat
gtgacgccac
45 361 tgacttgccc attggaggtc agaagaccgc gagattctcg ccctgagcaa
cgagcgacgg
421 cctgacgtcg ggggagggaa gccggcccag gctcggtgag gaggcaaggt
aagacgctga
481 gggaggactg aggggggcct cacctcagac agagggcctc aaataatcca
50 gtgctgcctc
541 tgctgccggg cctggggccac cccgcagggg aagacttcca ggctgggtcg
ccactacctc

	601	accccgccga	cccccgccgc	tttagccacg	gggaactctg	gggacagagc
		ttaatgtggc				
	661	cagggcaggg	ctgggttagaa	gaggtcaggg	cccacgctgt	ggcaggaatc
		aaggtcagga				
5	721	ccccgagagg	gaactgaggg	cagcctaacc	accaccctca	ccaccattcc
		cgtcccccaa				
	781	cacccaaccc	cacccccatc	ccccattccc	atccccaccc	ccacccttat
		cctggcagaa				
	841	tccgggcttt	gccccctggta	tcaagtcacg	gaagctccgg	gaatggcggc
10		caggcacgtg				
	901	agtccctgagg	ttcacatcta	cggctaaggg	aggggaagggg	ttcgggtatcg
		cgagtatggc				
	961	cgttgggagg	cagcgaaagg	gcccaggcct	cctggaagac	agtggagtcc
		tgaggggacc				
15	1021	cagcatgcca	ggacaggggg	cccactgtac	ccctgtctca	aaccgaggca
		cctttttcatt				
	1081	cggctacggg	aatcctaggg	atgcagaccc	acttcagcag	gggggttgggg
		cccagccctg				
	1141	cgaggagtca	tggggaggaa	gaagagggag	gactgagggg	accttggagt
20		ccagatcagt				
	1201	ggcaaccctg	ggctggggga	tgctgggcac	agtggccaaa	tgtgctctgt
		gctcattgcg				
	1261	ccttcagggt	gaccagagag	ttgagggctg	tggtctgaag	agtgggactt
		caggtcagca				
25	1321	gagggaggaa	tcccaggatc	tgcagggccc	aaggtgtacc	cccaaggggc
		ccctatgtgg				
	1381	tggacagatg	cagtggctct	aggatctgcc	aagcatccag	gtgaagagac
		tgagggagga				
	1441	ttgagggtag	ccctgggaca	gaatgcggac	tgggggcccc	ataaaaatct
30		gcctgctcc				
	1501	tgctgttacc	tcagagagcc	tgggcagggc	tgtcagctga	ggtccctcca
		ttatcctagg				
	1561	atcactgatg	tcaggggaagg	ggaagccttg	gtctgagggg	gctgcactca
		gggcagtaga				
35	1621	gggaggctct	cagaccctac	taggagtggg	ggtgaggacc	aagcagtctc
		ctcaccacag				
	1681	gtacatggac	ttcaataaat	ttggacatct	ctcgttgtcc	tttccgggag
		gacctgggaa				
	1741	tgtatggcca	gatgtgggtc	ccctcatggt	tttctgtacc	atatcaggta
40		tgtgagttct				
	1801	tgacatgaga	gattctcagg	ccagcagaag	ggagggatta	ggccctataa
		ggagaaagggt				
	1861	gagggccctg	agtgagcaca	gaggggatcc	tccaccccag	tagagtgggg
		acctcacaga				
45	1921	gtctggccaa	ccctcctgac	agttctggga	atccgtggct	gcgtttgctg
		tctgcacatt				
	1981	gggggcccgt	ggattcctct	cccaggaatc	aggagctcca	ggaacaaggc
		agtgaggact				
	2041	tggtctgagg	cagtgtcctc	aggtcacaga	gtagaggggg	ctcagatagt
50		gccaacggtg				
	2101	aaggtttgcc	ttggattcaa	accaagggcc	ccacctgccc	cagaacacat
		ggactccaga				

	2161	gcgcctggcc	tcacctcaa	tactttcagt	cctgcagcct	cagcatgcgc
		tgcccgatg				
	2221	tacctgagg	tgccctotca	cttcctcctt	caggttctga	ggggacagggc
		tgacctggag				
5	2281	gaccagaggc	ccccggagga	gcactgaagg	agaagatctg	taagtaagcc
		tttgtttagag				
	2341	cctccaaggt	tccattcagt	actcagctga	ggtctctcac	atgctccctc
		tctccccagg				
	2401	ccagtgggtc	tccattgccc	agctcctgcc	cacactcccc	cctggtgccc
10		tgaccagagt				
	2461	catcatgcct	cttgagcaga	ggagtcagca	ctgcaagcct	gaagaaggcc
		ttgaggccccg				
	2521	aggagaggcc	ctgggcctgg	tgggtgcgca	ggctcctgct	actgaggagc
		aggaggctgc				
15	2581	ctcctcctct	tctactctag	ttgaagtcac	cctgggggag	gtgcctgctg
		ccgagtcacc				
	2641	agatcctccc	cagagtcctc	agggagcctc	cagcctcccc	actaccatga
		actaccctct				
	2701	ctggagccaa	tcctatgagg	actccagcaa	ccaagaagag	gaggggccaa
20		gcaccttccc				
	2761	tgacctggag	tccgagttcc	aagcagcact	cagtaggaag	gtggccgagt
		tggttcattt				
	2821	tctgctcctc	aagtatcgag	ccagggagcc	ggtcacaaag	gcagaaatgc
		tggggagtgt				
25	2881	cgtcggaaat	tggcagtatt	tctttcctgt	gatcttcagc	aaagcttcca
		gttccttgca				
	2941	gctgggtcttt	ggcatcgagc	tgatggaagt	ggaccccatc	ggccacttgt
		acatctttgc				
	3001	cacctgcctg	ggcctctcct	acgatggcct	gctgggtgac	aatcagatca
30		tgcccaaggc				
	3061	aggcctcctg	ataatcgcc	tggccataat	cgcaagagag	ggcgactgtg
		cccctgagga				
	3121	gaaaatctgg	gaggagctga	gtgtgttaga	ggtgtttgag	gggagggaaag
		acagtatctt				
35	3181	gggggatccc	aagaagctgc	tcacccaaca	tttcgtgcag	gaaaactacc
		tggagtaccg				
	3241	gcagggtccc	ggcagtgatc	ctgcatgtta	tgaattcctg	tgggggtccaa
		gggcccctcgt				
	3301	tgaaaccagc	tatgtgaaag	tcctgcacca	tatggtaaag	atcagtggag
40		gacctcacat				
	3361	ttcctaccca	ccctgcatg	agtgggtttt	gagagagggg	gaagagttag
		tctgagcacg				
	3421	agttgcagcc	agggccagtg	ggaggggggc	tgggccagtg	caccttccgg
		ggccgcatcc				
45	3481	cttagtttcc	actgcctcct	gtgacgtgag	gcccattcct	cactctttga
		agcgagcagt				
	3541	cagcattcct	agtagtgggt	ttctgttctg	ttggatgact	ttgagattat
		tctttgtttc				
	3601	ctggtggagt	tgttcaaagt	ttccttttaa	cggatgggtg	aatgagcgct
50		agcatccagg				
	3661	tttatgaatg	acagtagtca	cacatagtgc	tgtttatata	gtttaggagt
		aagagtcttg				

```

      3721 ttttttactc aaattgggaa atccattcca ttttgtgaat tgtgacataa
taatagcagt
      3781 ggtaaaagta tttgcttaaa attgtgagcg aattagcaat aacatacatg
agataactca
5      3841 agaaatcaaa agatagttga ttcttgcctt gtacctcaat ctattctgta
aaattaaaca
      3901 aatatgcaaa ccaggatttc cttgacttct ttgagaatgc aagcgaaatt
aaatctgaat
      3961 aaataattct tcctcttcac tggctcgttt cttttccggt cactcagcat
10 ctgctctgtg
      4021 ggaggccctg ggtagtagt ggggatgcta aggtaagcca gactcacgcc
taccatagg
      4081 gctgtagagc ctaggacctg cagtcataata attaaggtag tgagaagtcc
tgtaagatgt
15      4141 agaggaaatg taagagaggg gtgaggggtg ggcgctccgg gtgagagtag
tggagtgtca
      4201 gtgc
//

20 Homo sapiens prostate stem cell antigen (PSCA) mRNA, complete
   cds.
   ACCESSION   AF043498
   VERSION     AF043498.1   GI:2909843
   SEQ ID NO 79

25 /translation="MKAVLLALLMAGLALQPGTALLCYSCKAQVSNECDLQVENCTQLGEQCW
   TARIRAVGLLTVISKGCSLNCVDDSDYYVGKKNITCCDLDLCNASGAHALQPAAILALLPA
   LGLLLWGPQL"

30 SEQ ID NO 87
   ORIGIN
      1 agggagaggc agtgaccatg aaggctgtgc tgcttgccct gttgatggca
ggcttgggcc
      61 tgcagccagg cactgccctg ctgtgctact cctgcaaagc ccaggtgagc
35 aacgaggact
      121 gcctgcaggt ggagaactgc acccagctgg gggagcagtg ctggaccgcg
cgcacccgcg
      181 cagttggcct cctgaccgtc atcagcaaag gctgcagctt gaactgctg
gatgactcac
40      241 aggactacta cgtgggcaag aagaacatca cgtgctgtga caccgacttg
tgcaacgcca
      301 gcggggccca tgccctgcag ccggtgcgcg ccacccctgc gctgctccct
gcactcggcc
      361 tgctgctctg gggacccggc cagctatagg ctctgggggg ccccgctgca
45 gccacactg
      421 ggtgtggtgc cccaggcctt tgtgccactc ctcacagaac ctggcccagt
gggagcctgt
      481 cctggttcct gaggcacatc ctaacgcaag ttgaccatg tatgtttgca
ccctttttcc
50      541 ccnaaccctg accttcccat gggccttttc caggattccn accnggcaga
tcagtttttag

```

601 tganacanat cgcgtgcag atggcccctc caacnttttn tgttgntgtt
tccatggccc
661 agcattttcc acccttaacc ctgtgttcag gcacttnttc ccccaggaag
ccttcctgc
5 721 ccacccatt tatgaattga gccaggtttg gtccgtggtg tccccgcac
ccagcagggg
781 acaggcaatc aggagggccc agtaaaggct gagatgaagt ggactgagta
gaactggagg
841 acaagagttg acgtgagttc ctgggagttt ccagagatgg ggcctggagg
10 cctggaggaa
901 ggggccaggc ctcacatttg tgggntccc gaatggcagc ctgagcacag
cgtaggccct
961 taataaacac ctgttgata agccaaaaa
//

15

GLANDULAR KALLIKREIN 1 PRECURSOR (TISSUE KALLIKREIN)
(KIDNEY/PANCREAS/SALIVARY GLAND KALLIKREIN).

ACCESSION P06870
20 PID g125170
VERSION P06870 GI:125170

SEQ ID NO 600

ORIGIN

25 1 mwflvlclal slggtgaapp iqsrivgwe ceqhsqpwa alyhfstfqc
ggilvhrqvw
61 ltaahcisdn yqlwlgrhnl fddentaqfv hvsesfphpg fnmsllenht
rqadedyshd
121 lmlrltepa dtitdavkvv elptqepevg stclasgws iepenfsfpd
30 dlqcvdlkil
181 pndecekahv qkvtdfmlcv ghleggkdtc vgdsggplmc dglvggvtsw
gyvpcgtpnk
241 psvavrvlsy vkwiedtiaa ns
//

35

ELASTASE 2A PRECURSOR.

ACCESSION P08217
PID g119255
40 VERSION P08217 GI:119255

SEQ ID NO 601

ORIGIN

45 1 mirtlllstl vagalscgdp typpvtrvv ggeearpns pwqvslyqys
ngkwyhtcgg
61 slianswvlt aahciassrt yrvglgrhnl yvaesglav svskivvhkd
wnsnqiskgn
121 diallklanp vsldkiqla clppagtilp nnypcyvtgw grlqtngavp
dvlqggrllv
50 181 vdyatcssa wwgssvktm icaggdgvis scngdsggpl ncqasdgrwq
vhgivsfgsr
241 lgcnyyhkps vftrvsnyid winsviann

//

pancreatic elastase IIB [Homo sapiens].

ACCESSION NP_056933

5 PID g7705648

VERSION NP_056933.1 GI:7705648

SEQ ID NO 602

ORIGIN

10 1 mirtlllstl vagalscgvs tyapdmsrml ggeearpns w pwqvslyqyss
ngqwyhtcgg
61 slianswvlt aahciyssri yrvmlgqhn1 yvaesgslav svskivvhkd
wnsnqvskgn
121 diallklanp vsltldkiqla clppagtilp nnypcyvtgw grlqtngalp
15 ddlkqgrllv
181 vdyatcsssg wwgstvktnm icaggdgvic tcngdsggpl ncqasdgrwe
vhgigsltsv
241 lgcnyyykps iftrvsnynd winsviann

//

20

PRAME Homo sapiens preferentially expressed antigen in melanoma
(PRAME), mRNA.

ACCESSION NM_006115

25 VERSION NM_006115.1 GI:5174640

SEQ ID NO 77

30 /translation="MERRRLWGSIQSRYISMSVWTSPPRLVELAGQSLLKDEALAIAALELLPREL
FPPLFMAAFDGRHSQTLKAMVQAWPFTCLPLGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWK
LQVLDLRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKRKVDGLSTEAEQFPFIPVEVLVDLFLK
EGACDELFSYLIKVKRKKNVLRCLCKKLIKIFAMPMDIKMILKMVQLDSIEDLEVTCTWKLP TLA
KFSPYLGQMINLRRLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQALYVDSLFFLRGRLDQL
LRHVMNPLETSLITNCR LSEGDVMHLSQSPSVS QLSVLSLSGVMLTDVSPEPLQALLERASATLQD
LVFDECGITDDQLLALLPSLSHCSQLTTL SFYGN SISISALQSL LQHLIGLSNLTHVLYPVPLESY
35 EDIHGTLHLERLAYLHARLRELLCELGRPSMVWLSANPCPHCGDRTFYDPEPILCPCFMPN"

SEQ ID NO 85

ORIGIN

40 1 gcttcagggt acagctcccc cgcagccaga agccgggcct gcagcccctc
agcaccgctc
61 cgggacaccc caccgccttc ccaggcgtga cctgtcaaca gcaacttcgc
ggtgtggtga
121 actctctgag gaaaaaccat tttgattatt actctcagac gtgcgtggca
acaagtgact
45 181 gagacctaga aatccaagcg ttggagggtcc tgaggccagc ctaagtcgct
tcaaaatgga
241 acgaaggcgt ttgtgggggt ccattcagag ccgatacatc agcatgagtg
tgtggacaag
301 cccacggaga cttgtggagc tggcagggca gagcctgctg aaggatgagg
50 ccctggccat
361 tgccgccctg gagttgctgc ccaggagct cttcccgcca ctcttcatgg
cagcctttga

421 cgggagacac agccagaccc tgaaggcaat ggtgcaggcc tggcccttca
cctgcctccc
481 tctgggagtg ctgatgaagg gacaacatct tcacctggag accttcaaag
ctgtgcttga
5 541 tggacttgat gtgctccttg cccaggaggt tgcgccagg aggtggaaac
ttcaagtgct
601 ggatttacgg aagaactctc atcaggactt ctggactgta tggctctggaa
acagggccag
661 tctgtactca tttccagagc cagaagcagc tcagcccatg acaaagaagc
10 gaaaagtaga
721 tggtttgagc acagaggcag agcagccctt cattccagta gaggtgctcg
tagacctgtt
781 cctcaaggaa ggtgcctgtg atgaattgtt ctctacctc attgagaaa
tgaagcgaaa
15 841 gaaaaatgta ctacgcctgt gctgtaagaa gctgaagatt tttgcaatgc
ccatgcagga
901 tatcaagatg atcctgaaaa tgggtgcagct ggactctatt gaagatttgg
aagtgacttg
961 tacctggaag ctaccacact tggcgaaatt ttctccttac ctgggccaga
20 tgattaatct
1021 gcgtagactc ctctctccc acatccatgc atcttcctac atttccccgg
agaaggaaga
1081 gcagtatata gccagttca cctctcagtt cctcagctcg cagtgcctgc
aggctctcta
25 1141 tgtggactct ttatTTTTTcc ttagaggccg cctggatcag ttgctcaggc
acgtgatgaa
1201 ccccttgga accctctcaa taactaactg ccggctttcg gaaggggatg
tgatgcatct
1261 gtcccagagt cccagcgtca gtcagctaag tgtcctgagt ctaagtgggg
30 tcatgctgac
1321 cgatgtaagt cccagagccc tccaagctct gctggagaga gcctctgcc
ccctccagga
1381 cctgggtcttt gatgagtgtg ggatcacgga tgatcagctc cttgccctcc
tgcttccct
35 1441 gagccactgc tcccagctta caaccttaag cttctacggg aattccatct
ccatatctgc
1501 cttgcagagt ctctgcagc acctcatcgg gctgagcaat ctgaccacg
tgctgtatcc
1561 tgtccccctg gagagttagt aggacatcca tggtagcctc cacctggaga
40 ggcttgcccta
1621 tctgcatgcc aggtcaggg agttgctgtg tgagttgggg cggcccagca
tggctctggct
1681 tagtgccaac ccctgtctc actgtgggga cagaacctc tatgaccgg
agcccatcct
45 1741 gtgcccctgt ttcatgccta actagctggg tgcacatata aaatgcttca
ttctgcatac
1801 ttggacacta aagccaggat gtgcatgcat cttgaagcaa caaagcagcc
acagtttcag
1861 acaaatgttc agtgtgagtg aggaaaacat gttcagtgag gaaaaaacat
50 tcagacaaat
1921 gttcagtgag gaaaaaaagg ggaagttggg gataggcaga tgttgacttg
aggagttaat

1981 gtgatctttg gggagataca tcttatagag ttagaaatag aatctgaatt
tctaaagggga
2041 gattctggct tgggaagtac atgtaggagt taatccctgt gtagactggt
gtaaagaaac
5 2101 tgttgaaaat aaagagaagc aatgtgaagc aaaaaaaaaa aaaaaaaaaa

ED-B domain of Fibronectin

Human fibronectin gene ED-B region.

10 ACCESSION X07717
VERSION X07717.1 GI:31406
SEQ ID NO 590

15 /translation="CTFDNLSPGLEYNVSVYTVKDDKESVPISDTIPEVPQLTDLFSF

'VDITDSSIGLRWTPLNSSTIIGYRITVVAAGEGIPIFEDFVDSSVGYYTVTGLEPGID

YDISVITLINGGESAPTTLTQQTAVPPPTDLRFTNIGPDTMRVTW"

20 SEQ ID NO 591

ORIGIN

1 ctgcactttt gataacctga gtcccgccct ggagtacaat gtcagtgttt
acactgtcaa
61 ggatgacaag gaaagtgtcc ctatctctga taccatcatc ccaggtaata
25 gaaaataagc
121 tgctatcctg agagtgcacat tccaataaga gtggggatta gcatcttaat
ccccagatgc
181 ttaagggtgt caactatatt tgggatttaa ttccgatctc ccagctgcac
tttccaaaac
30 241 caagaagtca aagcagcgat ttggacaaaa tgcttgctgt taactgtctg
ttactgtctg
301 tgcttcactg ggatgctgtg tgttgccagcg agtatgtaat ggagtggcag
ccatggcttt
361 aactctgtat tgtctgctca catggaagta tgactaaaac actgtcacgt
35 gtctgtactc
421 agtactgata ggctcaaagt aatatggtaa atgcatccca tcagtacatt
tctgccccgat

481 tttaacaatcc atatcaattt ccaacagctg cctatttcat cttgcagttt
caaatccttc
541 tttttgaaaa ttggatttta aaaaaaagtt aagtaaaagt cacaccttca
gggttggttct
5 601 ttcttggtgc cttgaaagac aacattgcaa aggcctgtcc taaggatagg
cttgtttgtc
661 cattgggtta taacataatg aaagcattgg acagatcgtg tccccctttg
gactcttcag
721 tagaatgctt ttactaacgc taattacatg ttttgattat gaatgaacct
10 aaaatagtagg
781 caatggcctt aacctaggcc tgtctttcct cagcctgaat gtgcttttga
atggcacatt
841 tcacaccata cattcataat gcattagcgt tatggccatg atgttgtcat
gagttttgta
15 901 tgggagaaaa aaaatcaatt tatcacccat ttattatttt ttccggttgt
tcatgcaagc
961 ttatttttcta ctaaaacagt tttggaatta ttaaaagcat tgctgatact
tacttcagat
1021 attatgtcta ggctctaaga atggtttcga catcctaaac agccatatga
20 tttttaggaa
1081 tctgaacagt tcaaattgta ccctttaagg atgttttcaa aatgtaaaaa
atatatatat
1141 atatatatat tccctaaaag aatattcctg tttattcttc tagggaagca
aactgttcat
25 1201 gatgcttagg aagtcttttc agagaattta aaacagattg catattacca
tcattgcttt
1261 aacattccac caattttact actagtaacc tgatatacac tgctttattt
tttctctttt
1321 ttttccctct attttccttt tgcctcccc tccctttgct ttgtaactca
30 atagaggtgc
1381 cccaactcac tgacctaaagc tttgttgata taaccgattc aagcatcggc
ctgaggtgga
1441 ccccgctaaa ctcttccacc attattgggt accgcatcac agtagttgcg
gcaggagaag

1501 gtatccctat ttttgaagat tttgtggact cctcagtagg atactacaca
gtcacagggc
1561 tggagccggg cattgactat gatatcagcg ttatcactct cattaatggc
ggcgagagtg
5 1621 cccctactac actgacacaa caaacgggtg aattttgaaa acttctgcgt
ttgagacata
1681 gatggtgttg catgctgcc aagttactc cggttaaata tggatgttcc
atgggggaag
1741 tcagcaattg gccaaagatt cagatagggtg gaattggggg gataaggaat
10 caaatgcac
1801 tgctaaactg attggagaaa aacacatgca atatcttcag tacactctca
tttaaaccac
1861 aagtagatat aaagcctaga gaaatacaga tgtctgctct gttaaata
aaatagcaaa
15 1921 tgttcattca atttgaagac ctagaatttt tcttcttaaa taccaaacac
gaatacaaaa
1981 ttgcgtaagt accaattgat aagaatatat caccaaatg taccatcatg
ctcttccttc
2041 taccctttga taaactctac catgctcctt cttttagct aaaaacccat
20 caaaatttag
2101 ggtagagtgg atgggcattg ttttgaggta ggagaaaagt aaacttggga
ccattctagg
2161 ttttgttgct gtcactagggt aaagaaacac ctctttaacc acagtctggg
gacaagcatg
25 2221 caacatttta aaggttctct gctgtgcatg ggaaaagaaa catgctgaga
accaatttgc
2281 atgaacatgt tcacttgtaa gtagaattca ctgaatggaa ctgtagctct
agatatctca
2341 catgggggga agtttaggac cctcttgtct ttttgtctgt gtgcatgtat
30 ttctttgtaa
2401 agtactgcta tgtttctctt tgctgtgtgg caacttaagc ctcttcggcc
tgggataaaa
2461 taatctgcag tggattaat aatgtacata aagtcaacat atttgaaggt
agattaaaat

2521 cttttttaaa tatatcaatg atggcaaaaa ggttaaaggg ggcctaacag
tactgtgtgt
2581 agtggtttat ttttaacagt agtacactat aacttaaaat agacttagat
tagactgttt
5 2641 gcatgattat gattctgttt cctttatgca tgaaatattg attttacctt
tccagctact
2701 tcgtagctt taattttaaa atacattaac tgagtcttcc ttcttgttog
aaaccagctg
2761 ttcctcctcc cactgacctg cgattcacca acattggtcc agacaccatg
10 cgtgtcacct
2821 ggg
//

CEA Homo sapiens carcinoembryonic antigen-related cell adhesion
15 molecule 5 (CEACAM5), mRNA.
ACCESSION NM_004363
VERSION NM_004363.1 GI:11386170
SEQ ID NO 592

20 /translation="MESPSAPPHRWCI PWQRLLLTASLLTFWNPPTAKLTIESTPFN
VAEGKEVLLL VHNLPQH LFGYSWYKGERVDGNRQIIGYVIGTQQATPGPAYSGREIIY
PNASLLIQNIIQNDTG FYTLHVIKSDLVNEEATGQFRVYPELPKPSISSNNSKPVEDK
DAVAFTCEPETQDATYLWWVNNQSLPVSPRLQLSNGNRTLTLFNVTRNDTASYKCETQ
NPVSARRSDSVILNVLYGPDAPTISPLNTSYRSGENLNL SCHAASNPPAQYSWFVNGT
25 FQOSTQELFIPNITVNNSGSYTCQAHNSDTGLNR'TVTITITVYAEPPKPFITSNNSNP
VEDEDAVALTCEPEIQNTTYLWWVNNQSLPVSPRLQLSNDNRTLTL LSVTRNDVGPYE
CGIQNELSVDHSDPVILNVLYGPDPTISPSYTYRPGVNLSLSCHAASNPPAQYSWL
IDGNIQQHTQELFISNITEKNSGLYTCQANNSASGHSRTTVKTITVSAELPKPSISSN
NSKPVEDKDAVAFTCEPEAQNTTYLWWVNGQSLPVSPRLQLSNGNRTLTLFNVTRNDA
30 RAYVCGIQNSVSANRSDPVTLDVLYGPDTPII SPDSYLSGANLNL SCHAASNPSPO
YSWRINGIPQQHTQVLFIAKITPNNNGTYACFVSNLATGRNNSIVKSITVSASGTSPG
LSAGATVGIMIGVLGVVALI"

SEQ ID NO 593
35 ORIGIN

1 ctcagggcag agggaggaag gacagcagac cagacagtca cagcagcctt
gacaaaacgt
61 tcttggaact caagctcttc tccacagagg aggacagagc agacagcaga
gaccatggag
5 121 tctccctcgg cccctcccca cagatgggtgc atcccctggc agaggctcct
gtcacagcc
181 tcacttctaa ccttctggaa cccgcccacc actgccaaagc tcactattga
atccacgccg
241 ttcaatgtcg cagaggggaa ggaggtgctt ctacttgctc acaatctgcc
10 ccagcatctt
301 tttggctaca gctggtacaa aggtgaaaga gtggatggca accgtcaa
tataggatat
361 gtaataggaa ctcaacaagc taccacaggc cccgcataca gtggtcgaga
gataatatac
15 421 cccaatgcat cctgtgtgat ccagaacatc atccagaatg acacaggatt
ctacacccta
481 cacgtcataa agtcagatct tgtgaatgaa gaagcaactg gccagttccg
ggtatacccg
541 gagctgcca agccctccat ctccagcaac aactccaaac ccgtggagga
20 caaggatgct
601 gtggccttca cctgtgaacc tgagactcag gacgcaacct acctgtggtg
ggtaaacaat
661 cagagcctcc cggtcagtcc caggctgcag ctgtccaatg gcaacaggac
cctcactcta
25 721 ttcaatgtca caagaaatga cacagcaagc tacaaatgtg aaaccagaa
cccagtgagt
781 gccaggcgca gtgattcagt catcctgaat gtcctctatg gcccggtgc
ccccaccatt
841 tccctcttaa acacatctta cagatcaggc gaaaatctga acctctctg
30 ccacgcagcc
901 tctaaccac ctgcacagta ctcttggtt gtcaatggga ctttcagca
atccacccaa
961 gagctcttta tccccaacat cactgtgaat aatagtggat cctatacgtg
ccaagcccat

1021 aactcagaca ctggcctcaa taggaccaca gtcacgacga tcacagtcta
tgcagagcca
1081 cccaaacct tcatcaccag caacaactcc aaccccgtgg aggatgagga
tgctgtagcc
5 1141 ttaacctgtg aacctgagat tcagaacaca acctacctgt ggtgggtaaa
taatcagagc
1201 ctcccggcca gtcccaggct gcagctgtcc aatgacaaca ggaccctcac
tctactcagt
1261 gtcacaagga atgatgtagg accctatgag tgtggaatcc agaacgaatt
10 aagtgttgac
1321 cacagcgacc cagtcacact gaatgtcctc tatggcccag acgacccccc
catttcccc
1381 tcatacacct attacccgtcc aggggtgaac ctcagcctct cctgccatgc
agcctctaac
15 1441 ccacctgcac agtattcttg gctgattgat gggacatcc agcaacacac
acaagagctc
1501 tttatctcca acatcactga gaagaacagc ggactctata cctgccaggc
caataactca
1561 gccagtggcc acagcaggac tacagtcaag acaatcacag tctctgcgga
20 gctgcccagg
1621 ccctccatct ccagcaacaa ctccaaacct gtggaggaca aggatgctgt
ggccttcacc
1681 tgtgaacctg aggctcagaa cacaacctac ctgtgggtggg taaatggcca
gagcctccca
25 1741 gtcagtccca ggctgcagct gtccaatggc aacaggaccc tcaactctatt
caatgtcaca
1801 agaaatgacg caagagccta tgtatgtgga atccagaact cagtgagtgc
aaaccgcagt
1861 gaccagtcac ccctggatgt cctctatggg ccggacaccc ccatcatttc
30 cccccagac
1921 tcgtcttacc tttcgggagc gaacctcaac ctctcctgcc actcggcctc
taacccatcc
1981 ccgcagtatt cttggcgat caatgggata ccgcagcaac acacacaagt
tctctttatc

2041 gccaaaatca cgccaaataa taacgggacc tatgcctgtt ttgtctctaa
cttggtact
2101 ggccgcaata attccatagt caagagcatc acagtctctg catctggaac
ttctcctggg
5 2161 ctctcagctg gggccactgt cggcatcatg attggagtgc tggttggggg
tgctctgata
2221 tagcagccct ggtgtagttt cttcatttca ggaagactga cagttgtttt
gcttcttcct
2281 taaagcattt gcaacagcta cagtctaaaa ttgcttcttt accaaggata
10 tttacagaaa
2341 agactctgac cagagatcga gaccatccta gccaacatcg tgaaacccca
tctctactaa
2401 aaatacaaaa atgagctggg cttgggtggcg cgcacctgta gtcccagtta
ctcgggaggc
15 2461 tgaggcagga gaatcgcttg aaccggggag gtggagattg cagtgaagccc
agatcgacc
2521 actgcactcc agtctggcaa cagagcaaga ctccatctca aaaagaaaag
aaaagaagac
2581 tctgacctgt actcttgaat acaagtttct gataccactg cactgtctga
20 gaatttccaa
2641 aactttaatg aactaactga cagcttcatg aaactgtcca ocaagatcaa
gcagagaaaa
2701 taattaattt catgggacta aatgaactaa tgaggattgc tgatttctta
aatgtcttgt
25 2761 ttcccagatt tcaggaaact ttttttcttt taagctatcc actcttacag
caatttgata
2821 aaatatactt ttgtgaacaa aaattgagac atttacattt tctccctatg
tggtcgctcc
2881 agacttggga aactattcat gaatatttat attgtatggg aatatagtta
30 ttgcacaagt
2941 tcaataaaaa tctgctcttt gtataacaga aaaa

//

35 Her2/Neu Human tyrosine kinase-type receptor (HER2) mRNA, complete
cds.

ACCESSION M11730
VERSION M11730.1 GI:183986
SEQ ID NO 594

5 /translation="MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLD
MLRHLYQGCQVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIV
RGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQ
LCYQDTILWKDIFHKNNQLALTIDTNRSRACHPCSPMCKGSRGWGESSEDCQSLTRT
VCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLFHNSGICELHCPALVTYNT
10 DTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSTLVCPHNQEVTAEDGTQRCEKC
SKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPL
QPEQLQVFETLEEITGYLYISAWPDSLPLDSVFNQLQVIRGRILHNGAYSLTLQGLGI
SWLGLRSLRELGSGLALIHNTLHCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEG
LACHQLCARGHCWGPPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPE
15 CQPQNGSVTCFGPEADQCACAHYKDPFVCVARCPSGVKPDLSPYMPIWKFPDEEGACQ
PCPINCTHSCVDLDDKGCPAEQRASPLTSIVSAVVGILLVVVLGVVFGILIKRRQQKI
RKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWI
PDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVT
QLMPYGCLLDHVRENRRGLGSQDLLNWCMIKAGMSYLEDVRLVHRDLAARNVLVKSP
20 NHVKITDFGLARLLDIDETEFHADGGKVPIKWMALLESILRRRFTHQSDVWSYGVTVWE
LMTFGAKPYDGIPIREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFREL
VSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGF
FCPDPAPGAGGMVHHRHRSSTRSGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDG
DLGMAAKGLQSLPTHDPSPLOQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVR
25 PQPPSPREGPLPAARPAGATLERAKTILSPGKNGVVKDVFAFGGAVENPEYLTPOGGAA
PQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV"

SEQ ID NO 595

ORIGIN Chromosome 17q21-q22.

30 1 aattctcgag ctcgtcgacc ggtcgacgag ctcgagggtc gacgagctcg
agggcgcgcg
61 cccggccccc acccctcgca gcaccccgcg ccccgcgccc tcccagccgg
gtccagccgg
121 agccatgggg ccggagccgc agtgagcacc atggagctgg cggccttggtg
35 ccgctggggg

181 ctctctctcg cctctctgcc ccccgagacc gcgagcacc aagtgtgcac
 cggcacagac
 241 atgaagctgc ggtccctgc cagtcccgag acccacctgg acatgtctccg
 ccacctctac
 5 301 cagggctgcc aggtggtgca gggaaacctg gaactcacct acctgcccac
 caatgccagc
 361 ctgtccttcc tgcaggatat ccaggagggtg cagggctacg tgctcatcgc
 tcacaaccaa
 421 gtgaggcagg tcccactgca gaggtgcgg attgtgcgag gcaccagct
 10 ctttgaggac
 481 aactatgccc tggcgtgct agacaatgga gaccgctga acaataccac
 ccctgtcaca
 541 ggggcctccc caggaggcct gcgggagctg cagcttcgaa gcctcacaga
 gatcttgaaa
 15 601 ggaggggtct tgatccagcg gaacccccag ctctgctacc aggacacgat
 tttgtggaag
 661 gacatottcc acaagaacaa ccagctggct ctcacactga tagacaccaa
 ccgctctcgg
 721 gcctgccacc cctgtttctcc gatgtgtaag ggctcccgt gctggggaga
 20 gagttctgag
 781 gattgtcaga gcctgacgcg cactgtctgt gccggtggct gtgcccgtg
 caaggggcca
 841 ctgcccactg actgtgcca tgagcagtgt gctgccggt gcacgggccc
 caagcactct
 25 901 gactgcctgg cctgcctcca cttcaaccac agtggcatct gtgagctgca
 ctgcccagcc
 961 ctggtcacct acaacacaga cacgtttgag tccatgccc atcccagggg
 ccggtataca
 1021 ttggcgcca gctgtgtgac tgctgtccc tacaactacc tttctacgga
 30 cgtgggatcc
 1081 tgcaccctcg tctgccccct gcacaaccaa gaggtgacag cagaggatgg
 aacacagcgg
 1141 tgtgagaagt gcagcaagcc ctgtgcccga gtgtgctatg gtctgggcat
 ggagcacttg

	1201	cgagaggtga	gggcagttac	cagtgccaat	atccaggagt	ttgctggctg
		caagaagatc				
	1261	tttgggagcc	tggcatttct	gccggagagc	tttgatgggg	accagcctc
		caacactgcc				
5	1321	ccgctccagc	cagagcagct	ccaagtgttt	gagactctgg	aagagatcac
		aggttaccta				
	1381	tacatctcag	catggccgga	cagcctgcct	gacctcagcg	tcttccagaa
		cctgcaagta				
	1441	atccggggac	gaattctgca	caatggcgcc	tactcgctga	ccctgcaagg
10		gctgggcata				
	1501	agctggctgg	ggctgcgctc	actgaggga	ctgggcagtg	gactggcct
		catccaccat				
	1561	aacacccacc	tctgcttctg	gcacacggtg	ccctgggacc	agctctttcg
		gaacccgcac				
15	1621	caagctctgc	tccacactgc	caaccggcca	gaggacgagt	gtgtgggcga
		gggcctggcc				
	1681	tgccaccagc	tgtgcgccc	agggcactgc	tgggggccag	ggcccaccca
		gtgtgtcaac				
	1741	tgcagccagt	tccttcgggg	ccaggagtgc	gtggaggaat	gccgagtact
20		gcaggggctc				
	1801	cccaggaggt	atgtgaatgc	caggcactgt	ttgccgtgcc	accctgagtg
		tcagccccag				
	1861	aatggctcag	tgacctgttt	tggaccggag	gctgaccagt	gtgtggcctg
		tgcccactat				
25	1921	aaggaccctc	ccttctgogt	ggcccgtgc	cccagcgggtg	tgaaacctga
		cctctcctac				
	1981	atgcccata	ggaagtttcc	agatgaggag	ggcgcatgcc	agccttgccc
		catcaactgc				
	2041	accactcct	gtgtggacct	ggatgacaag	ggctgccccg	ccgagcagag
30		agccagccct				
	2101	ctgacgtcca	tcgtctctgc	ggtggttggc	attctgctgg	tcgtggtctt
		gggggtggtc				
	2161	tttgggatcc	tcatcaagcg	acggcagcag	aagatccgga	agtacacgat
		gcggagactg				

2221 ctgcaggaaa cggagctggt ggagccgctg acacctagcg gagcgatgcc
caaccaggcg

2281 cagatgcgga tcctgaaaga gacggagctg aggaaggtga aggtgcttgg
atctggcgct

5 2341 tttggcacag tctacaaggg catctggatc cctgatgggg agaattgtgaa
aattccagtg

2401 gccatcaaag tgttgaggga aaacacatcc cccaaagcca acaaagaaat
cttagacgaa

2461 gcatacgtga tggctggtgt gggctcccca tatgtctccc gccttctggg
10 catctgcctg

2521 acatccacgg tgcagctggt gacacagctt atgccctatg gctgcctctt
agaccatgtc

2581 cgggaaaacc gcggacgcct gggctcccag gacctgctga actgggtgat
gcagattgcc

15 2641 aaggggatga gctacctgga ggatgtgcgg ctctacaca gggacttggc
cgctcggaac

2701 gtgctggtca agagtcccaa ccatgtcaaa attacagact tcgggctggc
tcggctgctg

2761 gacattgacg agacagagta ccatgcagat gggggcaagg tgcccatcaa
20 gtggatggcg

2821 ctggagtcca ttctccgcgg gcggttcacc caccagagtg atgtgtggag
ttatgggtgtg

2881 actgtgtggg agctgatgac ttttggggcc aaaccttacg atgggatccc
agcccgggag

25 2941 atccctgacc tgctggaaaa gggggagcgg ctgccccagc ccccatctg
caccattgat

3001 gtctacatga tcatggtcaa atgttggatg attgactctg aatgtcggcc
aagattccgg

3061 gagttggtgt ctgaattctc ccgcatggcc agggaccccc agcgctttgt
30 ggtcatccag

3121 aatgaggact tgggcccagc cagtcccttg gacagcacct tctaccgctc
actgctggag

3181 gacgatgaca tgggggacct ggtggatgct gaggagtatc tggtagccca
gcagggttc

3241 ttctgtccag accctgcccc gggcgctggg ggcatgggtcc accacaggca
ccgcagctca
3301 tctaccagga gtggcggtgg ggacctgaca ctagggctgg agccctctga
agaggaggcc
5 3361 cccaggtctc cactggcacc ctccgaaggg gctggctccg atgtatttga
tggtgacctg
3421 ggaatggggg cagccaaggg gctgcaaagc ctccccacac atgaccccag
ccctctacag
3481 cggtacagtg aggaccccac agtaccctg ccctctgaga ctgatggcta
10 cgttgcccc
3541 ctgacctgca gccccagcc tgaatatgtg aaccagccag atgttcggcc
ccagccccct
3601 tcgccccgag agggccctct gcctgctgcc cgacctgctg gtgccactct
ggaaagggcc
15 3661 aagactctct ccccaggga gaatggggtc gtcaaagacg tttttgcctt
tgggggtgcc
3721 gtggagaacc ccgagtactt gacaccccag ggaggagctg cccctcagcc
ccaccctct
3781 cctgccttca gccagcctt cgacaacctc tattactggg accaggaccc
20 accagagcgg
3841 ggggctccac ccagcacctt caaagggaca cctacggcag agaaccaga
gtacctgggt
3901 ctggacgtgc cagtgtgaac cagaaggcca agtccgcaga agccctgatg
tgtcctcagg
25 3961 gagcagggaa ggccctgactt ctgctggcat caagagggtg gagggccctc
cgaccacttc
4021 caggggaacc tgccatgcca ggaacctgtc ctaagggaacc ttccttctg
cttgagttcc
4081 cagatggctg gaagggtcc agcctcgttg gaagaggaac agcactgggg
30 agtctttgtg
4141 gattctgagg ccctgccccaa tgagactcta ggggtccagt gatgccacag
cccagcttgg
4201 ccctttcctt ccagatcctg ggtactgaaa gccttaggga agctggcctg
agaggggaag

4261 cggccctaag ggagtgtcta agaacaaaag cgacccattc agagactgtc
cctgaaacct
4321 agtactgccc cccatgagga aggaacagca atggtgtcag tatccaggct
ttgtacagag
5 4381 tgcttttctg tttagttttt actttttttg ttttgttttt ttaaagacga
aataaagacc
4441 caggggagaa tgggtgttgt atggggaggc aagtgtgggg ggtccttctc
cacacccact
4501 ttgtccattt gcaaatatat tttggaaaac
10 //

H.sapiens mRNA for SCP1 protein.

ACCESSION X95654

15 VERSION X95654.1 GI:1212982

SEQ ID NO 596

/translation="MEKQKPFALFVPPRSSSSQVSAVKPQTLGGDSTFFKSFNKCTED
DLEFPFAKTNLSKNGENIDSDPALQKVNFLPVLEQVGNSDCHYQEGLKDSLENSEGL
20 SRVFSKLYKEAEKIKKWKVSTEAE LRQKESKLQENRKII EAQRKAIQELQFGNEKVS
KLEEGI QENKDLIKENNATRHL CNLLKETCARSAEKT KKYEYEREETRQVYMDLNNNI
EKMITAHGELRVQAENSRLMHFKLKEDYEKIQHLEQYKKEINDKEKQVSLLLIQIT
EKENMKD LTFLL EESRDKNQLEEKTKLQSEN LKQSIEKHHLTKELEDIKVSLQRS
VSTQKALEEDLQIATKTICQLTEEKETQMEESNKARAAHSFVVTEFETTVCSLEELLR
25 TEQQRLEKNEDQLKILTMELQKKSSELEEMTKLTNNKEVELEELKKVLGEKETLLYEN
KQFEKIAEELKGTEQELIGLLQAREKEVHDLEIQLTAITTSEQYYSKEVKDLKTELEN
EKLKNT ELTSHCNKLSLENKELTQETSDMTLELKNQOEDINNNKKQEERMLKQIENLQ
ETETQLRNELEYVREELKQKRDEVKCKLDKSEENCNNLRKQVENKNKYIEELQQENKA
LKKKGTAESKQLNVYEIKVNKLELELES AKQKFGEITDTYQKEIEDKKISEENLLEEV
30 EKAKVIAD EAVKLQKEIDKRCQH KIAEMVALMEKHKHQYDKII EERDSELGLYKSKEQ
EQSSLRASLEIELSNLKAELLSVKKQLEIEREEKEKLKREAKENTATLKEKKDKKTQT
FLLETPEIYWKLDSKAVPSQTVSRNFTSVDHGISKDKRDYLWTSAKNTLSTPLPKAYT
VKTPTKPKLQQRENLNPIEESKKKRKMAFEFDINSDSSETTDLLSMVSEETLKTLY
RNNNPPASHLCVKTPKKAPSSLTPGP TLKFGAIRKMREDRWAVIAKMDRKKKLKEAE
35 KLFV"

SEQ ID NO 597

ORIGIN

```

      1 gccctcatag accgtttggt gtagttcgcg tgggaacagc aaccacgggt
5  ttcccgatag
      61 ttcttcaaag atatttaca ccgtaacaga gaaaatggaa aagcaaaagc
      cctttgcatt
      121 gtctgtacca ccgagatcaa gcagcagtca ggtgtctgcg gtgaaacctc
      agaccctggg
10      181 aggcgattcc actttcttca agagtttcaa caaatgtact gaagatgatt
      tggagtttcc
      241 atttgcaaag actaatctct ccaaaaatgg ggaaaacatt gattcagatc
      ctgctttaca
      301 aaaagttaat ttcttgcccg tgcttgagca ggttggaat tctgactgtc
15  actatcagga
      361 aggactaaaa gactctgatt tggagaattc agagggattg agcagagtgt
      tttcaaaact
      421 gtataaggag gctgaaaaga taaaaaatg gaaagtaagt acagaagctg
      aactgagaca
20      481 gaaagaaagt aagttgcaag aaaacagaaa gataattgaa gcacagcgaa
      aagccattca
      541 ggaactgcaa tttggaaatg aaaaagtaag tttgaaatta gaagaaggaa
      tacaagaaaa
      601 taaagattta ataaaagaga ataatgccac aaggcattta tgtaatctac
25  tcaaagaaac
      661 ctgtgctaga tctgcagaaa agacaaagaa atatgaatat gaacgggaag
      aaaccaggca
      721 agttttatatg gatctaaata ataacattga gaaaatgata acagctcatg
      gggaacttcg
30      781 tgtgcaagct gagaattcca gactggaaat gcattttaag ttaaaggaag
      attatgaaaa
      841 aatccaacac cttgaacaag aatacaagaa ggaaataaat gacaaggaaa
      agcaggatc
      901 actactattg atccaaatca ctgagaaaga aaataaaatg aaagatttaa
35  catttctgct

```

961 agaggaatcc agagataaag ttaatcaatt agaggaaaag aaaaaattac
agagtgaaaa
1021 cttaaaacaa tcaattgaga aacagcatca ttgactaaa gaactagaag
atattaaagt
5 1081 gtcattacaa agaagtgtga gtactcaaaa ggctttagag gaagatttac
agatagcaac
1141 aaaaacaatt tgtcagctaa ctgaagaaaa agaaactcaa atggaagaat
ctaataaagc
1201 tagagctgct cattcgtttg tggttactga atttgaaact actgtctgca
10 gcttggaaga
1261 attattgaga acagaacagc aaagattgga aaaaaatgaa gatcaattga
aaatacttac
1321 catggagctt caaaagaaat caagtgaagct ggaagagatg actaagctta
caaataacaa
15 1381 agaagtagaa cttgaagaat tgaaaaaagt cttgggagaa aaggaaacac
ttttatatga
1441 aaataaacaa ttgagaaga ttgctgaaga attaaaagga acagaacaag
aactaattgg
1501 tcttctccaa gccagagaga aagaagtaca tgatttgga atacagttaa
20 ctgccattac
1561 cacaagtga cagtattatt caaaagaggt taaagatcta aaaactgagc
ttgaaaacga
1621 gaagcttaag aatactgaat taacttcaca ctgcaacaag ctttcactag
aaaacaaaga
25 1681 gctcacacag gaaacaagt atatgaccct agaactcaag aatcagcaag
aagatattaa
1741 taataacaaa aagcaagaag aaaggatggt gaaacaaata gaaaatcttc
aagaaacaga
1801 aaccaatta agaaatgaac tagaatatgt gagagaagag ctaaacaga
30 aaagagatga
1861 agttaaatgt aaattggaca agagtgaaga aaattgtaac aatttaagga
aacaagttga
1921 aaataaaaac aagtatattg aagaacttca gcaggagaat aaggccttga
aaaaaaaagg

1981 tacagcagaa agcaagcaac tgaatgttta tgagataaag gtcaataaat
tagagttaga

2041 actagaaagt gccaaacaga aatttgagaga aatcacagac acctatcaga
aagaaattga

5 2101 ggacaaaaag atatcagaag aaaatctttt ggaagagggt gagaaagcaa
aagtaatagc

2161 tgatgaagca gtaaaattac agaaagaaat tgataagcga tgtcaacata
aaatagctga

2221 aatggtagca cttatggaaa aacataagca ccaatatgat aagatcattg
10 aagaaagaga

2281 ctccagaatta ggactttata agagcaaaga acaagaacag tcatcactga
gagcatcttt

2341 ggagattgaa ctatccaatc tcaaagctga acttttgtct gttagaagc
aacttgaaat

15 2401 agaaagagaa gagaaggaaa aactcaaaag agaggcaaaa gaaaacacag
ctactcttaa

2461 agaaaaaaaa gacaagaaaa cacaaacatt tttattggaa acacctgaaa
tttattggaa

2521 attggattct aaagcagttc cttcaciaaac tgtatctcga aatttcacat
20 cagttgatca

2581 tggcatatcc aaagataaaa gagactatct gtggacatct gccaaaaata
ctttatctac

2641 accattgcca aaggcatata cagtgaagac accaacaaaa ccaaaactac
agcaaagaga

25 2701 aaacttgaat ataccattg aagaaagtaa aaaaaagaga aaaatggcct
ttgaatttga

2761 tattaattca gatagttcag aaactactga tcttttgagc atggtttcag
aagaagagac

2821 attgaaaaca ctgtatagga acaataatcc accagcttct catctttgtg
30 tcaaaacacc

2881 aaaaaaggcc ccttcatctc taacaacccc tggacctaca ctgaagtttg
gagctataag

2941 aaaaatgcgg gaggaccgtt gggctgtaat tgctaaaatg gatagaaaaa
aaaaactaaa

3001 agaagctgaa aagttatttg ttttaatttca gagaatcagt gtagttaagg
agcctaataa
3061 cgtgaaactt atagttaata ttttgttcct atttgccaga gccacatttt
atctggaagt
5 3121 tgagacttaa aaaatacttg catgaatgat ttgtgtttct ttatatattt
agcctaaatg
3181 ttaactacat attgtctgga aacctgtcat tgtattcaga taattagatg
attatatatt
3241 gttgttactt tttcttgat tcatgaaaac tgtttttact aagttttcaa
10 atttgtaaag
3301 ttagcctttg aatgctagga atgcattatt gagggtcatt ctttattctt
tactattaaa
3361 atattttgga tgcaaaaaaa aaaaaaaaaa aaa
//

15

Homo sapiens synovial sarcoma, X breakpoint 4 (SSX4), mRNA.

ACCESSION NM_005636

VERSION NM_005636.1 GI:5032122

20

SEQ ID NO 598

/translation="MNGDDAFARRPRDDAQISEKLRKAFDDIAKYFSKKEWEKMSSEKIVY
VYMKLNYEVMTKLGFKVTLPPFMRSKRAADFHGNDFGNDRNHRNQVERPQMTFG
SLQRIFPKIMPKPAEEENGLKEVPEASGPQNDGKQLCPPGNPSTLEKINKTSGPKRG
25 KHAWTHRLRERKQLVVYEEISDPEEDE"

SEQ ID NO 599

ORIGIN

1 atgaacggag acgacgcctt tgcaaggaga cccagggatg atgctcaaat
30 atcagagaag
61 ttacgaaagg ccttcgatga tattgccaaa tacttctcta agaaagagtg
ggaaaagatg
121 aaatcctcgg agaaaatcgt ctatgtgtat atgaagctaa actatgaggt
catgactaaa

181 ctaggtttca aggtcacct cccaccttc atgcgtagta aacgggctgc
agacttcac
241 gggaatgatt ttggtaacga tcgaaaccac aggaatcagg ttgaacgtcc
tcagatgact
5 301 ttggcagcc tccagagaat cttcccgaag atcatgccc agaagccagc
agaggaagaa
361 aatggtttga aggaagtgcc agaggcatct ggcccacaaa atgatgggaa
acagctgtgc
421 cccccgggaa atccaagtac cttggagaag attaacaaga catctggacc
10 caaaaggggg
481 aaacatgcct ggaccacag actgcgtgag agaaagcagc tggtggttta
tgaagagatc
541 agcgaccctg aggaagatga cgagtaactc ccctcg

15 All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of
20 limitation, and there is no intention that in the use of such terms and expressions indicates the exclusion of equivalents of the features shown and described or portions thereof. It is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed
25 may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

WHAT IS CLAIMED IS:

1. An isolated epitope, comprising a component selected from the group consisting of:
 - (i) a polypeptide having the sequence as disclosed in TABLE 1;
 - (ii) an epitope cluster comprising the polypeptide of (i);
 - (iii) a polypeptide having substantial similarity to (i) or (ii);
 - (iv) a polypeptide having functional similarity to any of (i) through (iii); and
 - (v) a nucleic acid encoding the polypeptide of any of (i) through (iv).
2. The epitope of claim 1, wherein the epitope is immunologically active.
3. The epitope of claim 1, wherein the polypeptide is less than about 30 amino acids in length.
4. The epitope of claim 1, wherein the polypeptide is 8 to 10 amino acids in length.
5. The epitope of claim 1, wherein the substantial or functional similarity comprises addition of at least one amino acid.
6. The epitope of claim 5, wherein the at least one additional amino acid is at an N-terminus of the polypeptide.
7. The epitope of claim 1, wherein the substantial or functional similarity comprises a substitution of at least one amino acid.
8. The epitope of claim 1, the polypeptide having affinity to an HLA-A2 molecule.
9. The epitope of claim 8, wherein the affinity is determined by an assay of binding.
10. The epitope of claim 8, wherein the affinity is determined by an assay of restriction of epitope recognition.
11. The epitope of claim 8, wherein the affinity is determined by a prediction algorithm.
12. The epitope of claim 1, the polypeptide having affinity to an HLA-B7 or HLA-B51 molecule.
13. The epitope of claim 1, wherein the polypeptide is a housekeeping epitope.
14. The epitope of claim 1, wherein the polypeptide corresponds to an epitope displayed on a tumor cell.
15. The epitope of claim 1, wherein the polypeptide corresponds to an epitope displayed on a neovasculature cell.
16. The epitope of claim 1, wherein the polypeptide is an immune epitope.
17. The epitope of claim 1 wherein the epitope is a nucleic acid.
18. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable adjuvant, carrier, diluent, or excipient.

19. The composition of claim 18, where the adjuvant is a polynucleotide.
20. The composition of claim 19 wherein the polynucleotide comprises a dinucleotide.
21. The composition of claim 20 wherein the dinucleotide is CpG.
22. The composition of claim 18, wherein the adjuvant is encoded by a polynucleotide.
- 5 23. The composition of claim 18 wherein the adjuvant is a cytokine.
24. The composition of claim 23 wherein the cytokine is GM-CSF.
25. The composition of claim 18 further comprising a professional antigen-presenting cell (pAPC).
26. The composition of claim 25, wherein the pAPC is a dendritic cell.
- 10 27. The composition of claim 18, further comprising a second epitope.
28. The composition of claim 27, wherein the second epitope is a polypeptide.
29. The composition of claim 27, wherein the second epitope is a nucleic acid.
30. The composition of claim 27, wherein the second epitope is a housekeeping epitope.
- 15 31. The composition of claim 27, wherein the second epitope is an immune epitope.
32. A pharmaceutical composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable adjuvant, carrier, diluent, or excipient.
33. A recombinant construct comprising the nucleic acid of Claim 1.
34. The construct of claim 33, further comprising a plasmid, a viral vector, or an artificial chromosome.
- 20 35. The construct of claim 33, further comprising a sequence encoding at least one feature selected from the group consisting of a second epitope, an IRES, an ISS, an NIS, and ubiquitin.
36. A purified antibody that specifically binds to the epitope of claim 1.
- 25 37. A purified antibody that specifically binds to a peptide-MHC protein complex comprising the epitope of claim 1.
38. The antibody of claim 36 or claim 37, wherein the antibody is a monoclonal antibody.
39. A multimeric MHC-peptide complex comprising the epitope of claim 1.
- 30 40. An isolated T cell expressing a T cell receptor specific for an MHC-peptide complex, the complex comprising the epitope of claim 1.
41. The T cell of claim 40, produced by an *in vitro* immunization.
42. The T cell of claim 40, isolated from an immunized animal.
43. A T cell clone comprising the T cell of claim 40.
- 35 44. A polyclonal population of T cells comprising the T cell of claim 40.

45. A pharmaceutical composition comprising the T cell of claim 40 and a pharmaceutically acceptable adjuvant, carrier, diluent, or excipient.
46. An isolated protein molecule comprising the binding domain of a T cell receptor specific for an MHC-peptide complex, the complex comprising the epitope of claim 1.
- 5 47. The protein of claim 46, wherein the protein is multivalent.
48. An isolated nucleic acid encoding the protein of claim 46.
49. A recombinant construct comprising the nucleic acid of claim 48.
50. A host cell expressing the recombinant construct, the construct comprising the nucleic acid of claim 1, or the construct encoding a protein molecule comprising the binding domain of a T cell receptor specific for an MHC-peptide complex.
- 10 51. The host cell of claim 50, wherein the host cell is a dendritic cell, macrophage, tumor cell, or tumor-derived cell.
52. The host cell of claim 50, wherein the host cell is a bacterium, fungus, or protozoan.
- 15 53. A pharmaceutical composition comprising the host cell of claim 50 and a pharmaceutically acceptable adjuvant, carrier, diluent, or excipient.
54. A vaccine or immunotherapeutic composition comprising at least one component selected from the group consisting of the epitope of claim 1; the composition of claim 18, 32, or 45, the construct of claim 33; the T cell of claim 40, a host cell expressing a recombinant construct comprising a nucleic acid encoding a T cell receptor binding domain specific for an MHC-peptide complex and a composition comprising the same, and a host cell expressing a recombinant construct comprising the nucleic acid of claim 1 and a composition comprising the same.
- 20 55. A method of treating an animal, comprising:
administering to an animal the vaccine or immunotherapeutic composition of claim 54.
- 25 56. The method of claim 55, wherein the administering step comprises a mode of delivery selected from the group consisting of transdermal, intranodal, perinodal, oral, intravenous, intradermal, intramuscular, intraperitoneal, mucosal, aerosol inhalation, and instillation.
57. The method of claim 55, further comprising a step of assaying to determine a characteristic indicative of a state of a target cell or target cells.
- 30 58. The method of claim 57, comprising a first assaying step and a second assaying step, wherein the first assaying step precedes the administering step, and wherein the second assaying step follows the administering step.

59. The method of claim 58, further comprising a step of comparing the characteristic determined in the first assaying step with the characteristic determined in the second assaying step to obtain a result.

60. The method of claim 59, wherein the result is selected from the group consisting of: evidence of an immune response, a diminution in number of target cells, a loss of mass or size of a tumor comprising target cells, a decrease in number or concentration of an intracellular parasite infecting target cells.

61. A method of evaluating immunogenicity of a vaccine or immunotherapeutic composition, comprising:
10 administering to an animal the vaccine or immunotherapeutic composition of claim 54; and

evaluating immunogenicity based on a characteristic of the animal.

62. The method of claim 61, wherein the animal is HLA-transgenic.

63. A method of evaluating immunogenicity, comprising:
15 *in vitro* stimulation of a T cell with the vaccine or immunotherapeutic composition of claim 54; and

evaluating immunogenicity based on a characteristic of the T cell.

64. The method of claim 63, wherein the stimulation is a primary stimulation.

65. A method of making a passive/adoptive immunotherapeutic, comprising:
20 combining the T cell of claim 40, or a host cell expressing a recombinant construct comprising a nucleic acid encoding a T cell receptor binding domain specific for an MHC-peptide complex, or a host cell expressing a recombinant construct comprising the nucleic acid of claim 1 with a pharmaceutically acceptable adjuvant, carrier, diluent, or excipient.

66. A method of determining specific T cell frequency comprising the step of
25 contacting T cells with a MHC-peptide complex comprising the epitope of claim 1.

67. The method of claim 66, wherein the contacting step comprises at least one feature selected from the group consisting of immunization, restimulation, detection, and enumeration.

68. The method of Claim 66, further comprising ELISPOT analysis, limiting dilution
30 analysis, flow cytometry, in situ hybridization, the polymerase chain reaction or any combination thereof.

69. A method of evaluating immunologic response, comprising the method of claim 66 carried out prior to and subsequent to an immunization step.

70. A method of evaluating immunologic response, comprising:

determining frequency, cytokine production, or cytolytic activity of T cells, prior to and subsequent to a step of stimulation with MHC-peptide complexes comprising the epitope of claim 1.

71. A method of diagnosing a disease comprising:

5 contacting a subject tissue with at least one component selected from the group consisting of the T cell of claim 40, the host cell of claim 50, the antibody of claim 36, and the protein of claim 46; and

 diagnosing the disease based on a characteristic of the tissue or of the component.

72. The method of claim 71, wherein the contacting step takes place *in vivo*.

10 73. The method of claim 71, wherein the contacting step takes place *in vitro*.

74. A method of making a vaccine, comprising:

 combining at least one component selected from the group consisting of the epitope of claim 1; the composition of claim 18, 32, 45, or 53; the construct of claim 33; the T cell of claim 40, and the host cell of claim 50, with a pharmaceutically acceptable
15 adjuvant, carrier, diluent, or excipient.

75. A computer readable medium having recorded thereon the sequence of any one of SEQ ID NOS: 1-602, in a machine having a hardware or software that calculates the physical, biochemical, immunologic, or molecular genetic properties of a molecule embodying said sequence.

20 76. A method of treating an animal comprising combining the method of claim 55 combined with at least one mode of treatment selected from the group of radiation therapy, chemotherapy, biochemotherapy, and surgery.

77. An isolated polypeptide comprising an epitope cluster from a target-associated antigen having the sequence as disclosed in Tables 25-44, wherein the amino acid sequence
25 consists of not more than about 80% of the amino acid sequence of the antigen.

78. A vaccine or immunotherapeutic product comprising the polypeptide of claim 78.

79. An isolated polynucleotide encoding the polypeptide of claim 78.

80. A vaccine or immunotherapeutic product comprising the polynucleotide of claim
80.

30 81. The polynucleotide of claim 79 or 80, wherein the polynucleotide is DNA.

82. The polynucleotide of claim 79 or 80, wherein the polynucleotide is RNA.

FIG. 1B

CTAG_HUMAN	NY-ESO	(101)	101	150
AAD05202 - CAG-3		(101)		
CAA11044 -LAGE-1a		(101)		
CAA10194 - LAGE-1s		(101)		
CAA11043 - LAGE-1b		(101)		
CAA10196 - LAGE-1L		(101)		
AAH02833 CT-2		(101)		
Consensus		(101)		
CTAG_HUMAN	NY-ESO	(151)	151	200
AAD05202 - CAG-3		(151)		
CAA11044 -LAGE-1a		(151)		
CAA10194 - LAGE-1s		(151)		
CAA11043 - LAGE-1b		(151)		
CAA10196 - LAGE-1L		(151)		
AAH02833 CT-2		(151)		
Consensus		(151)		

3/23

FIG. 1C

CTAG_HUMAN	NY-ESO	(181)	-----	201
AAD05202	- CAG-3	(181)	-----	
CAA11044	-LAGE-1a	(181)	-----	
CAA10194	- LAGE-1s	(181)	-----	
CAA11043	- LAGE-1b	(201)	FNVMFSAPHI	
CAA10196	- LAGE-1L	(201)	FNVMFSAPHI	
AAH02833	CT-2	(201)	FNVMFSAPHI	
	Consensus	(201)		

4/23





FIG. 2

5/23

FIG. 3A

FACscan Analysis of Binding Assay to Determine the Binding Ability of Tyrosinase 208-216 Peptide to MHC Class 1




F1 (HLA A2 Peptide) = 3.13

F1 (TYR 208-216 Peptide) = 0.01

6/23

FIG. 3B

FACscan Analysis of Binding Assay to Determine the Binding Ability of Tyrosinase 207-215 Peptide to MHC Class 1




F1 (HLA A2 Peptide) = 3.13

F1 (TYR 207-215 Peptide) = 2.00

7/23


FIG. 3C
HLA A2 restricted and tyrosinase specific lysis by
CTL from Tyr207-215 IVS blood




CTL from Tyr 207-215 IVS blood

8/23

FIG. 4




9/23




10/23

FIG. 6
**SSX2₄₁₋₄₉ specific lysis by CTL from peptide
injected HHD1 mice**




12/23

FIG. 7B



Pool sequencing of PSMA_163-192 Digested for 60 min by proteasome


13/23



Pool sequencing of PSMA₁₆₃₋₁₉₂ Digested for 60 min by proteasome

FIG. 7C


15/23



Pool sequencing of PSMA_281_310 Digested for 60 min by Proteasome


16/23

FIG. 10
Comparison of Peptides Binding
Affinity to HLA A2
by Binding Assay



17/23

Autologous DC Present A1 Peptide to CD8 T cell

*FIG. 11*

18/23

Secretion of IFN γ Was Blocked by Anti-A1 Antibody


*FIG. 12*

FIG. 13
Comparison of Peptides Binding Affinity
to HLA A2 by Binding Assay






FIG. 14
Comparison of Peptides Binding Affinity
to HLA A2 by Binding Assay




21/23



Graphs show lysis of unpulsed EL4 cells (open circles) and EL4 cells pulsed with gp33 peptide (solid triangles). Symbols represent individual mice and one of three similar experiments is shown.

FIG. 15

22/23



Mean tumor volumes \pm 1SD are shown for mice immunized with pEFGPL33A DNA (solid circles) or control pEGFP-N3 DNA (open triangles). Numbers in brackets indicate number of mice with tumors/total number of mice in group. One of two similar experiments is shown.

FIG. 16




FIG. 17

SEQUENCE LISTING

<110> CTL IMMUNO THERAPIES CORP.

SIMARD, John, J.L.

DIAMOND, David, C.

LIU, Liping

XIE, Zhidong

<120> EPITOPE SEQUENCES

<130> CTLIMM.027QPC

<150> US 60/282,211

<151> 2001-04-06

<150> US 60/337,017

<151> 2001-11-07

<150> US 60/363,210

<151> 2002-07-03

<160> 602

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 10

<212> PRT

<213> Homo sapiens

<400> 1

Phe Leu Pro Trp His Arg Leu Phe Leu Leu

1 5 10

<210> 2

<211> 529

<212> PRT

<213> Homo sapiens

<400> 2

Met Leu Leu Ala Val Leu Tyr Cys Leu Leu Trp Ser Phe Gln Thr Ser

1 5 10 15

Ala Gly His Phe Pro Arg Ala Cys Val Ser Ser Lys Asn Leu Met Glu

20 25 30

Lys Glu Cys Cys Pro Pro Trp Ser Gly Asp Arg Ser Pro Cys Gly Gln

35 40 45

Leu Ser Gly Arg Gly Ser Cys Gln Asn Ile Leu Leu Ser Asn Ala Pro

50 55 60

Leu Gly Pro Gln Phe Pro Phe Thr Gly Val Asp Asp Arg Glu Ser Trp

65 70 75 80

Pro Ser Val Phe Tyr Asn Arg Thr Cys Gln Cys Ser Gly Asn Phe Met

85 90 95

Gly Phe Asn Cys Gly Asn Cys Lys Phe Gly Phe Trp Gly Pro Asn Cys

100 105 110

Thr Glu Arg Arg Leu Leu Val Arg Arg Asn Ile Phe Asp Leu Ser Ala
 115 120 125
 Pro Glu Lys Asp Lys Phe Phe Ala Tyr Leu Thr Leu Ala Lys His Thr
 130 135 140
 Ile Ser Ser Asp Tyr Val Ile Pro Ile Gly Thr Tyr Gly Gln Met Lys
 145 150 155 160
 Asn Gly Ser Thr Pro Met Phe Asn Asp Ile Asn Ile Tyr Asp Leu Phe
 165 170 175
 Val Trp Met His Tyr Tyr Val Ser Met Asp Ala Leu Leu Gly Gly Ser
 180 185 190
 Glu Ile Trp Arg Asp Ile Asp Phe Ala His Glu Ala Pro Ala Phe Leu
 195 200 205
 Pro Trp His Arg Leu Phe Leu Leu Arg Trp Glu Gln Glu Ile Gln Lys
 210 215 220
 Leu Thr Gly Asp Glu Asn Phe Thr Ile Pro Tyr Trp Asp Trp Arg Asp
 225 230 235 240
 Ala Glu Lys Cys Asp Ile Cys Thr Asp Glu Tyr Met Gly Gly Gln His
 245 250 255
 Pro Thr Asn Pro Asn Leu Leu Ser Pro Ala Ser Phe Phe Ser Ser Trp
 260 265 270
 Gln Ile Val Cys Ser Arg Leu Glu Tyr Asn Ser His Gln Ser Leu
 275 280 285
 Cys Asn Gly Thr Pro Glu Gly Pro Leu Arg Arg Asn Pro Gly Asn His
 290 295 300
 Asp Lys Ser Arg Thr Pro Arg Leu Pro Ser Ser Ala Asp Val Glu Phe
 305 310 315 320
 Cys Leu Ser Leu Thr Gln Tyr Glu Ser Gly Ser Met Asp Lys Ala Ala
 325 330 335
 Asn Phe Ser Phe Arg Asn Thr Leu Glu Gly Phe Ala Ser Pro Leu Thr
 340 345 350
 Gly Ile Ala Asp Ala Ser Gln Ser Ser Met His Asn Ala Leu His Ile
 355 360 365
 Tyr Met Asn Gly Thr Met Ser Gln Val Gln Gly Ser Ala Asn Asp Pro
 370 375 380
 Ile Phe Leu Leu His His Ala Phe Val Asp Ser Ile Phe Glu Gln Trp
 385 390 395 400
 Leu Arg Arg His Arg Pro Leu Gln Glu Val Tyr Pro Glu Ala Asn Ala
 405 410 415
 Pro Ile Gly His Asn Arg Glu Ser Tyr Met Val Pro Phe Ile Pro Leu
 420 425 430
 Tyr Arg Asn Gly Asp Phe Phe Ile Ser Ser Lys Asp Leu Gly Tyr Asp
 435 440 445
 Tyr Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln Asp Tyr Ile
 450 455 460
 Lys Ser Tyr Leu Glu Gln Ala Ser Arg Ile Trp Ser Trp Leu Leu Gly
 465 470 475 480
 Ala Ala Met Val Gly Ala Val Leu Thr Ala Leu Leu Ala Gly Leu Val
 485 490 495
 Ser Leu Leu Cys Arg His Lys Arg Lys Gln Leu Pro Glu Glu Lys Gln
 500 505 510
 Pro Leu Leu Met Glu Lys Glu Asp Tyr His Ser Leu Tyr Gln Ser His
 515 520 525
 Leu

<210> 3

<211> 188
 <212> PRT
 <213> Homo sapiens

<400> 3

```

Met Asn Gly Asp Asp Ala Phe Ala Arg Arg Pro Thr Val Gly Ala Gln
 1           5           10           15
Ile Pro Glu Lys Ile Gln Lys Ala Phe Asp Asp Ile Ala Lys Tyr Phe
           20           25           30
Ser Lys Glu Glu Trp Glu Lys Met Lys Ala Ser Glu Lys Ile Phe Tyr
           35           40           45
Val Tyr Met Lys Arg Lys Tyr Glu Ala Met Thr Lys Leu Gly Phe Lys
           50           55           60
Ala Thr Leu Pro Pro Phe Met Cys Asn Lys Arg Ala Glu Asp Phe Gln
65           70           75           80
Gly Asn Asp Leu Asp Asn Asp Pro Asn Arg Gly Asn Gln Val Glu Arg
           85           90           95
Pro Gln Met Thr Phe Gly Arg Leu Gln Gly Ile Ser Pro Lys Ile Met
           100          105          110
Pro Lys Lys Pro Ala Glu Glu Gly Asn Asp Ser Glu Glu Val Pro Glu
           115          120          125
Ala Ser Gly Pro Gln Asn Asp Gly Lys Glu Leu Cys Pro Pro Gly Lys
130          135          140
Pro Thr Thr Ser Glu Lys Ile His Glu Arg Ser Gly Pro Lys Arg Gly
145          150          155          160
Glu His Ala Trp Thr His Arg Leu Arg Glu Arg Lys Gln Leu Val Ile
           165          170          175
Tyr Glu Glu Ile Ser Asp Pro Glu Glu Asp Asp Glu
           180          185

```

<210> 4
 <211> 750
 <212> PRT
 <213> Homo sapiens

<400> 4

```

Met Trp Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg
 1           5           10           15
Arg Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe
           20           25           30
Phe Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Asn Glu
           35           40           45
Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu
           50           55           60
Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Gln Ile
65           70           75           80
Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile
           85           90           95
Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His
           100          105          110
Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile
           115          120          125
Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe
130          135          140
Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro
145          150          155          160

```

Phe	Ser	Ala	Phe	Ser	Pro	Gln	Gly	Met	Pro	Glu	Gly	Asp	Leu	Val	Tyr
			165						170					175	
Val	Asn	Tyr	Ala	Arg	Thr	Glu	Asp	Phe	Phe	Lys	Leu	Glu	Arg	Asp	Met
			180					185						190	
Lys	Ile	Asn	Cys	Ser	Gly	Lys	Ile	Val	Ile	Ala	Arg	Tyr	Gly	Lys	Val
		195					200					205			
Phe	Arg	Gly	Asn	Lys	Val	Lys	Asn	Ala	Gln	Leu	Ala	Gly	Ala	Lys	Gly
	210				215						220				
Val	Ile	Leu	Tyr	Ser	Asp	Pro	Ala	Asp	Tyr	Phe	Ala	Pro	Gly	Val	Lys
225					230					235					240
Ser	Tyr	Pro	Asp	Gly	Trp	Asn	Leu	Pro	Gly	Gly	Gly	Val	Gln	Arg	Gly
			245						250					255	
Asn	Ile	Leu	Asn	Leu	Asn	Gly	Ala	Gly	Asp	Pro	Leu	Thr	Pro	Gly	Tyr
		260					265						270		
Pro	Ala	Asn	Glu	Tyr	Ala	Tyr	Arg	Arg	Gly	Ile	Ala	Glu	Ala	Val	Gly
		275					280						285		
Leu	Pro	Ser	Ile	Pro	Val	His	Pro	Ile	Gly	Tyr	Tyr	Asp	Ala	Gln	Lys
	290				295						300				
Leu	Leu	Glu	Lys	Met	Gly	Gly	Ser	Ala	Pro	Pro	Asp	Ser	Ser	Trp	Arg
305				310					315						320
Gly	Ser	Leu	Lys	Val	Pro	Tyr	Asn	Val	Gly	Pro	Gly	Phe	Thr	Gly	Asn
			325						330					335	
Phe	Ser	Thr	Gln	Lys	Val	Lys	Met	His	Ile	His	Ser	Thr	Asn	Glu	Val
		340					345						350		
Thr	Arg	Ile	Tyr	Asn	Val	Ile	Gly	Thr	Leu	Arg	Gly	Ala	Val	Glu	Pro
	355						360					365			
Asp	Arg	Tyr	Val	Ile	Leu	Gly	Gly	His	Arg	Asp	Ser	Trp	Val	Phe	Gly
	370				375					380					
Gly	Ile	Asp	Pro	Gln	Ser	Gly	Ala	Ala	Val	Val	His	Glu	Ile	Val	Arg
385				390					395						400
Ser	Phe	Gly	Thr	Leu	Lys	Lys	Glu	Gly	Trp	Arg	Pro	Arg	Arg	Thr	Ile
			405						410					415	
Leu	Phe	Ala	Ser	Trp	Asp	Ala	Glu	Glu	Phe	Gly	Leu	Leu	Gly	Ser	Thr
		420					425						430		
Glu	Trp	Ala	Glu	Glu	Asn	Ser	Arg	Leu	Leu	Gln	Glu	Arg	Gly	Val	Ala
	435						440					445			
Tyr	Ile	Asn	Ala	Asp	Ser	Ser	Ile	Glu	Gly	Asn	Tyr	Thr	Leu	Arg	Val
	450				455						460				
Asp	Cys	Thr	Pro	Leu	Met	Tyr	Ser	Leu	Val	His	Asn	Leu	Thr	Lys	Glu
465				470					475						480
Leu	Lys	Ser	Pro	Asp	Glu	Gly	Phe	Glu	Gly	Lys	Ser	Leu	Tyr	Glu	Ser
			485						490					495	
Trp	Thr	Lys	Lys	Ser	Pro	Ser	Pro	Glu	Phe	Ser	Gly	Met	Pro	Arg	Ile
			500					505					510		
Ser	Lys	Leu	Gly	Ser	Gly	Asn	Asp	Phe	Glu	Val	Phe	Phe	Gln	Arg	Leu
		515					520					525			
Gly	Ile	Ala	Ser	Gly	Arg	Ala	Arg	Tyr	Thr	Lys	Asn	Trp	Glu	Thr	Asn
	530					535						540			
Lys	Phe	Ser	Gly	Tyr	Pro	Leu	Tyr	His	Ser	Val	Tyr	Glu	Thr	Tyr	Glu
545					550					555					560
Leu	Val	Glu	Lys	Phe	Tyr	Asp	Pro	Met	Phe	Lys	Tyr	His	Leu	Thr	Val
			565						570					575	
Ala	Gln	Val	Arg	Gly	Gly	Met	Val	Phe	Glu	Leu	Ala	Asn	Ser	Ile	Val
		580						585					590		
Leu	Pro	Phe	Asp	Cys	Arg	Asp	Tyr	Ala	Val	Val	Leu	Arg	Lys	Tyr	Ala
	595						600					605			
Asp	Lys	Ile	Tyr	Ser	Ile	Ser	Met	Lys	His	Pro	Gln	Glu	Met	Lys	Thr

610		615		620
Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr				
625		630		635
Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser				
	645		650	655
Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu				
	660		665	670
Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg				
	675		680	685
His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser				
	690		695	700
Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp				
705		710		715
Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala				
	725		730	735
Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala				
	740		745	750

<210> 5

<211> 1964

<212> DNA

<213> Homo sapiens

<400> 5

```

atcactgtag tagtagctgg aaagagaaat ctgtgactcc aattagccag ttcctgcaga 60
ccttgtgagg actagaggaa gaatgtcctt ggctgttttg tactgcctgc tgtggagttt 120
ccagacctcc gctggccatt tccctagagc ctgtgtctcc tctaagaacc tgaaggagaa 180
ggaatgctgt ccaccgtgga gcggggacag gagtccctgt ggccagcttt caggcagagg 240
ttcctgtcag aatatacttc tgtccaatgc accacttggg cctcaatttc ccttcacagg 300
ggatgatgac cgggagtcgt ggccttccgt cttttataat aggacctgcc agtgctctgg 360
caacttcatg ggattcaact gtggaaactg caagtttggc ttttggggac caaactgcac 420
agagagacga ctcttggtga gaagaaacat cttcgatttg agtgccccag agaaggacaa 480
attttttgcc taactcactt tagcaaaagca taccatcagc tcagactatg tcatcccat 540
agggacctat ggccaaatga aaaatggatc aacacccatg ttttaacgaca tcaatattta 600
tgacctcttt gtctggatgc attattatgt gtcaatggat gcaactgctg ggggatctga 660
aatctggaga gacattgatt ttgcccatag agcaccagct tttctgcctt ggcatagact 720
cttcttgttg cggtgggaaac aagaaatcca gaagctgaca ggagatgaaa acttcactat 780
tccatattgg gactggcggg atgcagaaaa gtgtgacatt tgcacagatg agtacatggg 840
aggtcagcac ccacaaaatc ctaacttact cagcccagca tcattcttct cctcttggca 900
gattgtctgt agccgatttg aggagtacaa cagccatcag tctttatgca atggaacgcc 960
cgagggacct ttacggcgta atcctggaaa ccatgacaaa tccagaacct caaggctccc 1020
ctcttcagct gatgtagaat tttgctgag tttgacccaa tatgaatctg gttccatgga 1080
taaagctgcc aatttcagct ttagaaatac actggaagga tttgctagtc cacttactgg 1140
gatagcggat gcctctcaaa gcagcatgca caatgccttg cacatctata tgaatggaac 1200
aatgtccagc gtacagggat ctgccaaagc tcctatcttc cttcttcacc atgcatttgt 1260
tgacagtatt tttgagcagt ggctccgaag gcaccgtcct cttcaagaag tttatccaga 1320
agccaatgca cccattggac ataaccggga atcctacatg gttcctttta taccactgta 1380
cagaaatggt gatttcttta tttcatccaa agatctgggc tatgactata gctatctaca 1440
agattcagac ccagactctt ttcaagacta cattaagtcc tatttggaa aagcgagtcg 1500
gatctgggtc tggctccttg gggcgcgat ggtagggggc gtccctcactg ccctgctggc 1560
agggcttgtg agcttgcctg gtgcgcacaa gagaaagcag cttcctgaag aaaagcagcc 1620
actcctcatg gagaaagagg attaccacag cttgtatcag agccatttat aaaaggctta 1680
ggcaatagag tagggccaaa aagcctgacc tcaactaac tcaaagtaat gtccagggtt 1740
ccagagaata tctgtctgga tttttctgta aagaccattt gcaaaattgt aacctaatac 1800
aaagtgtagc cttcttccaa ctcaggtaga acacacctgt ctttgtcttg ctgttttcac 1860
tcagcccttt taacattttc ccctaagccc atatgtctaa ggaaaggatg ctatttggtg 1920

```


atgaggaact gttatttgta tgtgaattaa agtgccttta tttt

1964

<210> 6

<211> 766

<212> DNA

<213> Homo sapiens

<400> 6

ctctcttttcg	attcttccat	actcagagta	cgacgggtct	gattttctct	ttggattctt	60
ccaaaatcag	agtcagactg	ctcccggtgc	catgaacgga	gacgacgct	ttgcaaggag	120
acccacgggt	gggtgctcaa	taccagagaa	gatccaaaag	gccttcgatg	atattgcaa	180
atacttctct	aaggaagagt	gggaaaagat	gaaagcctcg	gagaaaatct	tctatgtgta	240
tatgaagaga	aagtatgagg	ctatgactaa	actaggtttc	aaggccaccc	tcccaccttt	300
catgtgtaat	aaacgggccc	aagacttcca	ggggaatgat	ttggataatg	accctaaccg	360
tgggaatcag	gttgaaactg	ctcagatgac	tttcggcagg	ctccagggaa	tctccccgaa	420
gatcatgccc	aagaagccag	cagaggaagg	aaatgattcg	gaggaagtgc	cagaagcatc	480
tggccacaaa	aatgatggga	aagagctgtg	cccccgagg	aaaccaacta	cctctgagaa	540
gattcacgag	agatctggac	ccaaaagggg	ggaacatgcc	tggacccaca	gactgcgtga	600
gagaaaacag	ctggtgattt	atgaagagat	cagcgaccct	gaggaagatg	acgagtaact	660
cccctcaggg	atacagacac	tgcccatgat	gagaagcaga	acgtggtgac	ctttcacgaa	720
catgggcatg	gctgcggacc	cctcgtcatc	aggtgcatag	caagtg		766

<210> 7

<211> 2653

<212> DNA

<213> Homo sapiens

<400> 7

ctcaaaaggg	gccggatttc	cttctcctgg	aggcagatgt	tgcctctctc	tctcgctcgg	60
attgggttcag	tgcactctag	aaacactgct	gtgggtggaga	aactggaccc	caggtctgga	120
gcgaattcca	gcctgcaggg	ctgataagcg	aggcattagt	gagattgaga	gagactttac	180
cccgccgtgg	tgggtggagg	gcgcgcagta	gagcagcagc	acaggcgagg	gtcccgagg	240
gccggctctg	ctcgcgcgga	gatgtggaat	ctccttcacg	aaaccgactc	ggctgtggcc	300
accgcgcgcc	gcccgcgctg	gctgtgcgct	ggggcgctgg	tgctggcggg	tggcttcttt	360
ctcctcggct	tctcttcggg	gtggtttata	aaatcctcca	atgaagctac	taacattact	420
ccaaagcata	atatgaaagc	atttttggat	gaattgaaag	ctgagaacat	caagaagtgc	480
ttatataatt	ttacacagat	accacattta	gcaggaacag	aacaaaactt	tcagcttgca	540
aagcaaatcc	aatcccagtg	gaaagaattt	ggcctggatt	ctgttgagct	agcacattat	600
gatgtcctgt	tgtcctaccc	aaataagact	catcccaact	acatctcaat	aattaatgaa	660
gatggaaatg	agattttcaa	cacatcatta	tttgaaccac	ctcctccagg	atatgaaaat	720
gtttcgggata	ttgtaccacc	tttcagtgct	ttctctcctc	aaggaaatgcc	agaggggcag	780
ctagtgtatg	ttaactatgc	acgaactgaa	gacttcttta	aattggaacg	ggacatgaaa	840
atcaattgct	ctgggaaaat	tgttaattgcc	agatatggga	aagttttcag	aggaaataag	900
gttaaaaaatg	cccagctggc	aggggccaac	ggagtcattc	tctactccga	ccctgctgac	960
tactttgctc	ctggggtgaa	gtcctatcca	gatgggttga	atcttctcgg	aggtggtgtc	1020
cagcgtggaa	atatacctaaa	tctgaatggg	gcaggagacc	ctctcacacc	aggttaccca	1080
gcaaatgaat	atgcttatag	gcgtggaatt	gcagaggctg	ttggtcttcc	aagtattcct	1140
gttcattcaa	ttggatacta	tgatgcacag	aagctcctag	aaaaaatggg	tggctcagca	1200
ccaccagata	gcagctggag	aggaagtctc	aaagtgcctc	acaatgttgg	acctggcttt	1260
actggaaact	tttctacaca	aaaagtcaag	atgcacatcc	actctaccaa	tgaagtgaac	1320
agaatttaca	atgtgatagg	tactctcaga	ggagcagtgg	aaccagacag	atatgtcatt	1380
ctgggaggtc	accgggactc	atgggtgttt	ggtgggtattg	accctcagag	tggagcagct	1440
gttggttcag	aaattgtgag	gagctttgga	acactgaaaa	aggaaggggtg	gagacctaga	1500
agaacaattt	tgtttgcaag	ctgggatgca	gaagaatttg	gtcttcttgg	ttctactgag	1560
tgggcagagg	agaattcaag	actccttcaa	gagcgtggcg	tggcttatat	taatgctgac	1620
tcatctatag	aaggaaacta	cactctgaga	gttgattgta	caccgctgat	gtacagcttg	1680
gtacacaacc	taacaaaaga	gctgaaaagc	cctgatgaag	gctttgaagg	caaactctct	1740

```

tatgaaagtt ggactaaaaa aagtccttcc ccagagttca gtggcatgcc caggataagc 1800
aaattgggat ctggaaatga ttttgagggtg ttcttccaac gacttggaat tgcttcaggc 1860
agagcacggt atactaaaaa ttgggaaaca aacaaattca gcggctatcc actgtatcac 1920
agtgtctatg aaacatatga gttggtggaa aagttttatg atccaatgtt taaatatcac 1980
ctcactgtgg cccagggttcg aggaggggatg gtgtttgagc tagccaattc catagtgtc 2040
ccttttgatt gtcgagatta tgctgtagtt ttaagaaagt atgctgacaa aatctacagt 2100
atttctatga aacatccaca ggaaatgaag acatacagt tatcatttga ttcacttttt 2160
tctgcagtaa agaattttac agaaattgct tccaagttca gtgagagact ccaggacttt 2220
gacaaaagca acccaatagt attaagaatg atgaatgatc aactcatgtt tctggaaaga 2280
gcattttattg atccattagg gttaccagac aggccttttt ataggcatgt catctatgct 2340
ccaagcagcc acaacaagta tgcaggggag tcattcccag gaatttatga tgctctgttt 2400
gatattgaaa gcaaagtgga ccttccaag gcctggggag aagtgaagag acagatttat 2460
gttgcagcct tcacagtgca ggcagctgca gagactttga gtgaagtagc ctaagaggat 2520
tctttagaga atccgtattg aatttgtgtg gtatgtcact cagaaagaat cgtaatgggt 2580
atattgataa attttaaaat tggtatattt gaaataaagt tgaatattat atataaaaaa 2640
aaaaaaaaa aaa 2653

```

<210> 8
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 8
 Phe Leu Pro Trp His Arg Leu Phe Leu
 1 5

<210> 9
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 9
 Leu Pro Trp His Arg Leu Phe Leu Leu
 1 5

<210> 10
 <211> 38
 <212> PRT
 <213> Homo sapiens

<400> 10
 Tyr Phe Ser Lys Glu Glu Trp Glu Lys Met Lys Ala Ser Glu Lys Ile
 1 5 10 15
 Phe Tyr Val Tyr Met Lys Arg Lys Tyr Glu Ala Met Thr Lys Leu Gly
 20 25 30
 Phe Lys Ala Thr Leu Pro
 35

<210> 11
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 11

Phe Ser Lys Glu Glu Trp Glu Lys Met
1 5

<210> 12
<211> 9
<212> PRT
<213> Homo sapiens

<400> 12
Lys Met Lys Ala Ser Glu Lys Ile Phe
1 5

<210> 13
<211> 9
<212> PRT
<213> Homo sapiens

<400> 13
Met Lys Ala Ser Glu Lys Ile Phe Tyr
1 5

<210> 14
<211> 10
<212> PRT
<213> Homo sapiens

<400> 14
Lys Met Lys Ala Ser Glu Lys Ile Phe Tyr
1 5 10

<210> 15
<211> 9
<212> PRT
<213> Homo sapiens

<400> 15
Lys Ala Ser Glu Lys Ile Phe Tyr Val
1 5

<210> 16
<211> 10
<212> PRT
<213> Homo sapiens

<400> 16
Met Lys Ala Ser Glu Lys Ile Phe Tyr Val
1 5 10

<210> 17
<211> 10
<212> PRT

<213> Homo sapiens

<400> 17

Lys Ala Ser Glu Lys Ile Phe Tyr Val Tyr
1 5 10

<210> 18

<211> 9

<212> PRT

<213> Homo sapiens

<400> 18

Ala Ser Glu Lys Ile Phe Tyr Val Tyr
1 5

<210> 19

<211> 9

<212> PRT

<213> Homo sapiens

<400> 19

Arg Lys Tyr Glu Ala Met Thr Lys Leu
1 5

<210> 20

<211> 10

<212> PRT

<213> Homo sapiens

<400> 20

Lys Arg Lys Tyr Glu Ala Met Thr Lys Leu
1 5 10

<210> 21

<211> 10

<212> PRT

<213> Homo sapiens

<400> 21

Lys Tyr Glu Ala Met Thr Lys Leu Gly Phe
1 5 10

<210> 22

<211> 9

<212> PRT

<213> Homo sapiens

<400> 22

Tyr Glu Ala Met Thr Lys Leu Gly Phe
1 5

<210> 23
<211> 8
<212> PRT
<213> Homo sapiens

<400> 23
Glu Ala Met Thr Lys Leu Gly Phe
1 5

<210> 24
<211> 10
<212> PRT
<213> Homo sapiens

<400> 24
Phe Leu Pro Ser Asp Tyr Phe Pro Ser Val
1 5 10

<210> 25
<211> 9
<212> PRT
<213> Homo sapiens

<400> 25
Ala Glu Met Gly Lys Tyr Ser Phe Tyr
1 5

<210> 26
<211> 9
<212> PRT
<213> Homo sapiens

<400> 26
Lys Tyr Ser Glu Lys Ile Ser Tyr Val
1 5

<210> 27
<211> 9
<212> PRT
<213> Homo sapiens

<400> 27
Lys Val Ser Glu Lys Ile Val Tyr Val
1 5

<210> 28
<211> 9
<212> PRT
<213> Homo sapiens

<400> 28
Lys Ser Ser Glu Lys Ile Val Tyr Val

1 5

<210> 29
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 29
 Lys Ala Ser Glu Lys Ile Ile Tyr Val
 1 5

<210> 30
 <211> 30
 <212> PRT
 <213> Homo sapiens

<400> 30
 Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr Val Asn
 1 5 10 15
 Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met
 20 25 30

<210> 31
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 31
 Gly Met Pro Glu Gly Asp Leu Val Tyr Val Asn Tyr Ala Arg Thr Glu
 1 5 10 15
 Asp Phe Phe Lys Leu Glu Arg
 20

<210> 32
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 32
 Met Pro Glu Gly Asp Leu Val Tyr Val
 1 5

<210> 33
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 33
 Gly Met Pro Glu Gly Asp Leu Val Tyr Val
 1 5 10

<210> 34
<211> 9
<212> PRT
<213> Homo sapiens

<400> 34
Gly Met Pro Glu Gly Asp Leu Val Tyr
1 5

<210> 35
<211> 10
<212> PRT
<213> Homo sapiens

<400> 35
Gln Gly Met Pro Glu Gly Asp Leu Val Tyr
1 5 10

<210> 36
<211> 8
<212> PRT
<213> Homo sapiens

<400> 36
Met Pro Glu Gly Asp Leu Val Tyr
1 5

<210> 37
<211> 9
<212> PRT
<213> Homo sapiens

<400> 37
Glu Gly Asp Leu Val Tyr Val Asn Tyr
1 5

<210> 38
<211> 10
<212> PRT
<213> Homo sapiens

<400> 38
Pro Glu Gly Asp Leu Val Tyr Val Asn Tyr
1 5 10

<210> 39
<211> 10
<212> PRT
<213> Homo sapiens

<400> 39
Leu Val Tyr Val Asn Tyr Ala Arg Thr Glu

```

1                                5                                10

<210> 40
<211> 9
<212> PRT
<213> Homo sapiens

<400> 40
Val Asn Tyr Ala Arg Thr Glu Asp Phe
1                                5

<210> 41
<211> 10
<212> PRT
<213> Homo sapiens

<400> 41
Tyr Val Asn Tyr Ala Arg Thr Glu Asp Phe
1                                5                                10

<210> 42
<211> 9
<212> PRT
<213> Homo sapiens

<400> 42
Asn Tyr Ala Arg Thr Glu Asp Phe Phe
1                                5

<210> 43
<211> 8
<212> PRT
<213> Homo sapiens

<400> 43
Tyr Ala Arg Thr Glu Asp Phe Phe
1                                5

<210> 44
<211> 9
<212> PRT
<213> Homo sapiens

<400> 44
Arg Thr Glu Asp Phe Phe Lys Leu Glu
1                                5

<210> 45
<211> 30
<212> PRT
<213> Homo sapiens

```


<400> 45

```

Arg Gly Ile Ala Glu Ala Val Gly Leu Pro Ser Ile Pro Val His Pro
 1           5           10           15
Ile Gly Tyr Tyr Asp Ala Gln Lys Leu Leu Glu Lys Met Gly
          20           25           30

```

<210> 46

<211> 25

<212> PRT

<213> Homo sapiens

<400> 46

```

Ile Ala Glu Ala Val Gly Leu Pro Ser Ile Pro Val His Pro Ile Gly
 1           5           10           15
Tyr Tyr Asp Ala Gln Lys Leu Leu Glu
          20           25

```

<210> 47

<211> 9

<212> PRT

<213> Homo sapiens

<400> 47

```

Leu Pro Ser Ile Pro Val His Pro Ile
 1           5

```

<210> 48

<211> 10

<212> PRT

<213> Homo sapiens

<400> 48

```

Gly Leu Pro Ser Ile Pro Val His Pro Ile
 1           5           10

```

<210> 49

<211> 9

<212> PRT

<213> Homo sapiens

<400> 49

```

Ile Gly Tyr Tyr Asp Ala Gln Lys Leu
 1           5

```

<210> 50

<211> 10

<212> PRT

<213> Homo sapiens

<400> 50

```

Pro Ile Gly Tyr Tyr Asp Ala Gln Lys Leu

```

1 5 10

<210> 51
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 51
 Ser Ile Pro Val His Pro Ile Gly Tyr
 1 5

<210> 52
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 52
 Pro Ser Ile Pro Val His Pro Ile Gly Tyr
 1 5 10

<210> 53
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 53
 Ile Pro Val His Pro Ile Gly Tyr
 1 5

<210> 54
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 54
 Tyr Tyr Asp Ala Gln Lys Leu Leu Glu
 1 5

<210> 55
 <211> 27
 <212> PRT
 <213> Homo sapiens

<400> 55
 Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val Asp Cys Thr Pro Leu
 1 5 10 15
 Met Tyr Ser Leu Val His Leu Thr Lys Glu Leu
 20 25

<210> 56
 <211> 9

<212> PRT

<213> Homo sapiens

<400> 56

Ile Glu Gly Asn Tyr Thr Leu Arg Val
1 5

<210> 57

<211> 10

<212> PRT

<213> Homo sapiens

<400> 57

Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val
1 5 10

<210> 58

<211> 8

<212> PRT

<213> Homo sapiens

<400> 58

Glu Gly Asn Tyr Thr Leu Arg Val
1 5

<210> 59

<211> 9

<212> PRT

<213> Homo sapiens

<400> 59

Thr Leu Arg Val Asp Cys Thr Pro Leu
1 5

<210> 60

<211> 10

<212> PRT

<213> Homo sapiens

<400> 60

Tyr Thr Leu Arg Val Asp Cys Thr Pro Leu
1 5 10

<210> 61

<211> 9

<212> PRT

<213> Homo sapiens

<400> 61

Leu Arg Val Asp Cys Thr Pro Leu Met
1 5

<210> 62
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 62
 Arg Val Asp Cys Thr Pro Leu Met Tyr
 1 5

<210> 63
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 63
 Leu Arg Val Asp Cys Thr Pro Leu Met Tyr
 1 5 10

<210> 64
 <211> 35
 <212> PRT
 <213> Homo sapiens

<400> 64
 Phe Asp Lys Ser Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu
 1 5 10 15
 Met Phe Leu Glu Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg
 20 25 30
 Pro Phe Tyr
 35

<210> 65
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 65
 Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu Arg Ala Phe
 1 5 10 15
 Ile Asp Pro Leu Gly Leu
 20

<210> 66
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 66
 Met Met Asn Asp Gln Leu Met Phe Leu
 1 5

<210> 67
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 67
 Arg Met Met Asn Asp Gln Leu Met Phe Leu
 1 5 10

<210> 68
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 68
 Arg Met Met Asn Asp Gln Leu Met Phe
 1 5

<210> 69
 <211> 17
 <212> PRT
 <213> Homo sapiens

<400> 69
 Met Leu Leu Ala Val Leu Tyr Cys Leu Leu Trp Ser Phe Gln Thr Ser
 1 5 10 15
 Ala

<210> 70
 <211> 661
 <212> PRT
 <213> Homo sapiens

<400> 70
 Met Asp Leu Val Leu Lys Arg Cys Leu Leu His Leu Ala Val Ile Gly
 1 5 10 15
 Ala Leu Leu Ala Val Gly Ala Thr Lys Val Pro Arg Asn Gln Asp Trp
 20 25 30
 Leu Gly Val Ser Arg Gln Leu Arg Thr Lys Ala Trp Asn Arg Gln Leu
 35 40 45
 Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly
 50 55 60
 Gln Val Ser Leu Lys Val Ser Asn Asp Gly Pro Thr Leu Ile Gly Ala
 65 70 75 80
 Asn Ala Ser Phe Ser Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys Val
 85 90 95
 Leu Pro Asp Gly Gln Val Ile Trp Val Asn Asn Thr Ile Ile Asn Gly
 100 105 110
 Ser Gln Val Trp Gly Gly Gln Pro Val Tyr Pro Gln Glu Thr Asp Asp
 115 120 125
 Ala Cys Ile Phe Pro Asp Gly Gly Pro Cys Pro Ser Gly Ser Trp Ser
 130 135 140
 Gln Lys Arg Ser Phe Val Tyr Val Trp Lys Thr Trp Gly Gln Tyr Trp

19

Val Val Leu Ala Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys Gln Asp
 610 615 620
 Phe Ser Val Pro Gln Leu Pro His Ser Ser Ser His Trp Leu Arg Leu
 625 630 635 640
 Pro Arg Ile Phe Cys Ser Cys Pro Ile Gly Glu Asn Ser Pro Leu Leu
 645 650 655
 Ser Gly Gln Gln Val
 660

<210> 71
 <211> 309
 <212> PRT
 <213> Homo sapiens

<400> 71
 Met Ser Leu Glu Gln Arg Ser Leu His Cys Lys Pro Glu Glu Ala Leu
 1 5 10 15
 Glu Ala Gln Gln Glu Ala Leu Gly Leu Val Cys Val Gln Ala Ala Thr
 20 25 30
 Ser Ser Ser Ser Pro Leu Val Leu Gly Thr Leu Glu Glu Val Pro Thr
 35 40 45
 Ala Gly Ser Thr Asp Pro Pro Gln Ser Pro Gln Gly Ala Ser Ala Phe
 50 55 60
 Pro Thr Thr Ile Asn Phe Thr Arg Gln Arg Gln Pro Ser Glu Gly Ser
 65 70 75 80
 Ser Ser Arg Glu Glu Gly Pro Ser Thr Ser Cys Ile Leu Glu Ser
 85 90 95
 Leu Phe Arg Ala Val Ile Thr Lys Lys Val Ala Asp Leu Val Gly Phe
 100 105 110
 Leu Leu Leu Lys Tyr Arg Ala Arg Glu Pro Val Thr Lys Ala Glu Met
 115 120 125
 Leu Glu Ser Val Ile Lys Asn Tyr Lys His Cys Phe Pro Glu Ile Phe
 130 135 140
 Gly Lys Ala Ser Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys
 145 150 155 160
 Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly
 165 170 175
 Leu Ser Tyr Asp Gly Leu Leu Gly Asp Asn Gln Ile Met Pro Lys Thr
 180 185 190
 Gly Phe Leu Ile Ile Val Leu Val Met Ile Ala Met Glu Gly Gly His
 195 200 205
 Ala Pro Glu Glu Glu Ile Trp Glu Glu Leu Ser Val Met Glu Val Tyr
 210 215 220
 Asp Gly Arg Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu Thr
 225 230 235 240
 Gln Asp Leu Val Gln Glu Lys Tyr Leu Glu Tyr Arg Gln Val Pro Asp
 245 250 255
 Ser Asp Pro Ala Arg Tyr Glu Phe Leu Trp Gly Pro Arg Ala Leu Ala
 260 265 270
 Glu Thr Ser Tyr Val Lys Val Leu Glu Tyr Val Ile Lys Val Ser Ala
 275 280 285
 Arg Val Arg Phe Phe Phe Pro Ser Leu Arg Glu Ala Ala Leu Arg Glu
 290 295 300
 Glu Glu Glu Gly Val
 305

<210> 72
 <211> 314
 <212> PRT
 <213> Homo sapiens

<400> 72
 Met Pro Leu Glu Gln Arg Ser Gln His Cys Lys Pro Glu Glu Gly Leu
 1 5 10 15
 Glu Ala Arg Gly Glu Ala Leu Gly Leu Val Gly Ala Gln Ala Pro Ala
 20 25 30
 Thr Glu Glu Gln Gln Thr Ala Ser Ser Ser Ser Thr Leu Val Glu Val
 35 40 45
 Thr Leu Gly Glu Val Pro Ala Asp Ser Pro Ser Pro Pro His Ser
 50 55 60
 Pro Gln Gly Ala Ser Ser Phe Ser Thr Thr Ile Asn Tyr Thr Leu Trp
 65 70 75 80
 Arg Gln Ser Asp Glu Gly Ser Ser Asn Gln Glu Glu Glu Gly Pro Arg
 85 90 95
 Met Phe Pro Asp Leu Glu Ser Glu Phe Gln Ala Ala Ile Ser Arg Lys
 100 105 110
 Met Val Glu Leu Val His Phe Leu Leu Lys Tyr Arg Ala Arg Glu
 115 120 125
 Pro Val Thr Lys Ala Glu Met Leu Glu Ser Val Leu Arg Asn Cys Gln
 130 135 140
 Asp Phe Phe Pro Val Ile Phe Ser Lys Ala Ser Glu Tyr Leu Gln Leu
 145 150 155 160
 Val Phe Gly Ile Glu Val Val Glu Val Val Pro Ile Ser His Leu Tyr
 165 170 175
 Ile Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp
 180 185 190
 Asn Gln Val Met Pro Lys Thr Gly Leu Leu Ile Ile Val Leu Ala Ile
 195 200 205
 Ile Ala Ile Glu Gly Asp Cys Ala Pro Glu Glu Lys Ile Trp Glu Glu
 210 215 220
 Leu Ser Met Leu Glu Val Phe Glu Gly Arg Glu Asp Ser Val Phe Ala
 225 230 235 240
 His Pro Arg Lys Leu Leu Met Gln Asp Leu Val Gln Glu Asn Tyr Leu
 245 250 255
 Glu Tyr Arg Gln Val Pro Gly Ser Asp Pro Ala Cys Tyr Glu Phe Leu
 260 265 270
 Trp Gly Pro Arg Ala Leu Ile Glu Thr Ser Tyr Val Lys Val Leu His
 275 280 285
 His Thr Leu Lys Ile Gly Gly Glu Pro His Ile Ser Tyr Pro Pro Leu
 290 295 300
 His Glu Arg Ala Leu Arg Glu Gly Glu Glu
 305 310

<210> 73
 <211> 314
 <212> PRT
 <213> Homo sapiens

<400> 73
 Met Pro Leu Glu Gln Arg Ser Gln His Cys Lys Pro Glu Glu Gly Leu
 1 5 10 15

Glu Ala Arg Gly Glu Ala Leu Gly Leu Val Gly Ala Gln Ala Pro Ala
 20 25 30
 Thr Glu Glu Gln Glu Ala Ala Ser Ser Ser Ser Thr Leu Val Glu Val
 35 40 45
 Thr Leu Gly Glu Val Pro Ala Ala Glu Ser Pro Asp Pro Pro Gln Ser
 50 55 60
 Pro Gln Gly Ala Ser Ser Leu Pro Thr Thr Met Asn Tyr Pro Leu Trp
 65 70 75 80
 Ser Gln Ser Tyr Glu Asp Ser Ser Asn Gln Glu Glu Glu Gly Pro Ser
 85 90 95
 Thr Phe Pro Asp Leu Glu Ser Glu Phe Gln Ala Ala Leu Ser Arg Lys
 100 105 110
 Val Ala Glu Leu Val His Phe Leu Leu Leu Lys Tyr Arg Ala Arg Glu
 115 120 125
 Pro Val Thr Lys Ala Glu Met Leu Gly Ser Val Val Gly Asn Trp Gln
 130 135 140
 Tyr Phe Phe Pro Val Ile Phe Ser Lys Ala Ser Ser Ser Leu Gln Leu
 145 150 155 160
 Val Phe Gly Ile Glu Leu Met Glu Val Asp Pro Ile Gly His Leu Tyr
 165 170 175
 Ile Phe Ala Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp
 180 185 190
 Asn Gln Ile Met Pro Lys Ala Gly Leu Leu Ile Ile Val Leu Ala Ile
 195 200 205
 Ile Ala Arg Glu Gly Asp Cys Ala Pro Glu Glu Lys Ile Trp Glu Glu
 210 215 220
 Leu Ser Val Leu Glu Val Phe Glu Gly Arg Glu Asp Ser Ile Leu Gly
 225 230 235 240
 Asp Pro Lys Lys Leu Leu Thr Gln His Phe Val Gln Glu Asn Tyr Leu
 245 250 255
 Glu Tyr Arg Gln Val Pro Gly Ser Asp Pro Ala Cys Tyr Glu Phe Leu
 260 265 270
 Trp Gly Pro Arg Ala Leu Val Glu Thr Ser Tyr Val Lys Val Leu His
 275 280 285
 His Met Val Lys Ile Ser Gly Gly Pro His Ile Ser Tyr Pro Pro Leu
 290 295 300
 His Glu Trp Val Leu Arg Glu Gly Glu Glu
 305 310

<210> 74

<211> 180

<212> PRT

<213> Homo sapiens

<400> 74

Met Gln Ala Glu Gly Arg Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp
 1 5 10 15
 Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly
 20 25 30
 Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly Ala
 35 40 45
 Gly Ala Ala Arg Ala Ser Gly Pro Gly Gly Gly Ala Pro Arg Gly Pro
 50 55 60
 His Gly Gly Ala Ala Ser Gly Leu Asn Gly Cys Cys Arg Cys Gly Ala
 65 70 75 80
 Arg Gly Pro Glu Ser Arg Leu Leu Glu Phe Tyr Leu Ala Met Pro Phe

```

      85      90      95
Ala Thr Pro Met Glu Ala Glu Leu Ala Arg Arg Ser Leu Ala Gln Asp
      100      105      110
Ala Pro Pro Leu Pro Val Pro Gly Val Leu Leu Lys Glu Phe Thr Val
      115      120      125
Ser Gly Asn Ile Leu Thr Ile Arg Leu Thr Ala Ala Asp His Arg Gln
      130      135      140
Leu Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met
      145      150      155      160
Trp Ile Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser
      165      170      175
Gly Gln Arg Arg
      180

```

```

<210> 75
<211> 180
<212> PRT
<213> Homo sapiens

```

```

<400> 75
Met Gln Ala Glu Gly Arg Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp
  1      5      10      15
Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly
      20      25      30
Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly Ala
      35      40      45
Gly Ala Ala Arg Ala Ser Gly Pro Arg Gly Gly Ala Pro Arg Gly Pro
      50      55      60
His Gly Gly Ala Ala Ser Ala Gln Asp Gly Arg Cys Pro Cys Gly Ala
      65      70      75      80
Arg Arg Pro Asp Ser Arg Leu Leu Glu Leu His Ile Thr Met Pro Phe
      85      90      95
Ser Ser Pro Met Glu Ala Glu Leu Val Arg Arg Ile Leu Ser Arg Asp
      100      105      110
Ala Ala Pro Leu Pro Arg Pro Gly Ala Val Leu Lys Asp Phe Thr Val
      115      120      125
Ser Gly Asn Leu Leu Phe Ile Arg Leu Thr Ala Ala Asp His Arg Gln
      130      135      140
Leu Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met
      145      150      155      160
Trp Ile Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Ala Pro Ser
      165      170      175
Gly Gln Arg Arg
      180

```

```

<210> 76
<211> 210
<212> PRT
<213> Homo sapiens

```

```

<400> 76
Met Gln Ala Glu Gly Arg Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp
  1      5      10      15
Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly
      20      25      30

```

Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly Ala
 35 40 45
 Gly Ala Ala Arg Ala Ser Gly Pro Arg Gly Gly Ala Pro Arg Gly Pro
 50 55 60
 His Gly Gly Ala Ala Ser Ala Gln Asp Gly Arg Cys Pro Cys Gly Ala
 65 70 75 80
 Arg Arg Pro Asp Ser Arg Leu Leu Glu Leu His Ile Thr Met Pro Phe
 85 90 95
 Ser Ser Pro Met Glu Ala Glu Leu Val Arg Arg Ile Leu Ser Arg Asp
 100 105 110
 Ala Ala Pro Leu Pro Arg Pro Gly Ala Val Leu Lys Asp Phe Thr Val
 115 120 125
 Ser Gly Asn Leu Leu Phe Met Ser Val Trp Asp Gln Asp Arg Glu Gly
 130 135 140
 Ala Gly Arg Met Arg Val Val Gly Trp Gly Leu Gly Ser Ala Ser Pro
 145 150 155 160
 Glu Gly Gln Lys Ala Arg Asp Leu Arg Thr Pro Lys His Lys Val Ser
 165 170 175
 Glu Gln Arg Pro Gly Thr Pro Gly Pro Pro Pro Pro Glu Gly Ala Gln
 180 185 190
 Gly Asp Gly Cys Arg Gly Val Ala Phe Asn Val Met Phe Ser Ala Pro
 195 200 205
 His Ile
 210

<210> 77

<211> 509

<212> PRT

<213> Homo sapiens

<400> 77

Met Glu Arg Arg Arg Leu Trp Gly Ser Ile Gln Ser Arg Tyr Ile Ser
 1 5 10 15
 Met Ser Val Trp Thr Ser Pro Arg Arg Leu Val Glu Leu Ala Gly Gln
 20 25 30
 Ser Leu Leu Lys Asp Glu Ala Leu Ala Ile Ala Ala Leu Glu Leu Leu
 35 40 45
 Pro Arg Glu Leu Phe Pro Pro Leu Phe Met Ala Ala Phe Asp Gly Arg
 50 55 60
 His Ser Gln Thr Leu Lys Ala Met Val Gln Ala Trp Pro Phe Thr Cys
 65 70 75 80
 Leu Pro Leu Gly Val Leu Met Lys Gly Gln His Leu His Leu Glu Thr
 85 90 95
 Phe Lys Ala Val Leu Asp Gly Leu Asp Val Leu Leu Ala Gln Glu Val
 100 105 110
 Arg Pro Arg Arg Trp Lys Leu Gln Val Leu Asp Leu Arg Lys Asn Ser
 115 120 125
 His Gln Asp Phe Trp Thr Val Trp Ser Gly Asn Arg Ala Ser Leu Tyr
 130 135 140
 Ser Phe Pro Glu Pro Glu Ala Ala Gln Pro Met Thr Lys Lys Arg Lys
 145 150 155 160
 Val Asp Gly Leu Ser Thr Glu Ala Glu Gln Pro Phe Ile Pro Val Glu
 165 170 175
 Val Leu Val Asp Leu Phe Leu Lys Glu Gly Ala Cys Asp Glu Leu Phe
 180 185 190
 Ser Tyr Leu Ile Glu Lys Val Lys Arg Lys Lys Asn Val Leu Arg Leu

```

      195              200              205
Cys Cys Lys Lys Leu Lys Ile Phe Ala Met Pro Met Gln Asp Ile Lys
 210              215              220
Met Ile Leu Lys Met Val Gln Leu Asp Ser Ile Glu Asp Leu Glu Val
 225              230              235              240
Thr Cys Thr Trp Lys Leu Pro Thr Leu Ala Lys Phe Ser Pro Tyr Leu
      245              250              255
Gly Gln Met Ile Asn Leu Arg Arg Leu Leu Ser His Ile His Ala
      260              265              270
Ser Ser Tyr Ile Ser Pro Glu Lys Glu Gln Tyr Ile Ala Gln Phe
      275              280              285
Thr Ser Gln Phe Leu Ser Leu Gln Cys Leu Gln Ala Leu Tyr Val Asp
      290              295              300
Ser Leu Phe Phe Leu Arg Gly Arg Leu Asp Gln Leu Leu Arg His Val
 305              310              315              320
Met Asn Pro Leu Glu Thr Leu Ser Ile Thr Asn Cys Arg Leu Ser Glu
      325              330              335
Gly Asp Val Met His Leu Ser Gln Ser Pro Ser Val Ser Gln Leu Ser
      340              345              350
Val Leu Ser Leu Ser Gly Val Met Leu Thr Asp Val Ser Pro Glu Pro
      355              360              365
Leu Gln Ala Leu Leu Glu Arg Ala Ser Ala Thr Leu Gln Asp Leu Val
      370              375              380
Phe Asp Glu Cys Gly Ile Thr Asp Asp Gln Leu Leu Ala Leu Leu Pro
 385              390              395              400
Ser Leu Ser His Cys Ser Gln Leu Thr Thr Leu Ser Phe Tyr Gly Asn
      405              410              415
Ser Ile Ser Ile Ser Ala Leu Gln Ser Leu Leu Gln His Leu Ile Gly
      420              425              430
Leu Ser Asn Leu Thr His Val Leu Tyr Pro Val Pro Leu Glu Ser Tyr
      435              440              445
Glu Asp Ile His Gly Thr Leu His Leu Glu Arg Leu Ala Tyr Leu His
      450              455              460
Ala Arg Leu Arg Glu Leu Leu Cys Glu Leu Gly Arg Pro Ser Met Val
 465              470              475              480
Trp Leu Ser Ala Asn Pro Cys Pro His Cys Gly Asp Arg Thr Phe Tyr
      485              490              495
Asp Pro Glu Pro Ile Leu Cys Pro Cys Phe Met Pro Asn
      500              505

```

```

<210> 78
<211> 261
<212> PRT
<213> Homo sapiens

```

```

<400> 78
Met Trp Val Pro Val Val Phe Leu Thr Leu Ser Val Thr Trp Ile Gly
 1              5              10              15
Ala Ala Pro Leu Ile Leu Ser Arg Ile Val Gly Gly Trp Glu Cys Glu
      20              25              30
Lys His Ser Gln Pro Trp Gln Val Leu Val Ala Ser Arg Gly Arg Ala
      35              40              45
Val Cys Gly Gly Val Leu Val His Pro Gln Trp Val Leu Thr Ala Ala
      50              55              60
His Cys Ile Arg Asn Lys Ser Val Ile Leu Leu Gly Arg His Ser Leu
 65              70              75              80

```

```

Phe His Pro Glu Asp Thr Gly Gln Val Phe Gln Val Ser His Ser Phe
      85          90          95
Pro His Pro Leu Tyr Asp Met Ser Leu Leu Lys Asn Arg Phe Leu Arg
      100          105          110
Pro Gly Asp Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu
      115          120          125
Pro Ala Glu Leu Thr Asp Ala Val Lys Val Met Asp Leu Pro Thr Gln
      130          135          140
Glu Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser Ile
      145          150          155
Glu Pro Glu Glu Phe Leu Thr Pro Lys Lys Leu Gln Cys Val Asp Leu
      165          170          175
His Val Ile Ser Asn Asp Val Cys Ala Gln Val His Pro Gln Lys Val
      180          185          190
Thr Lys Phe Met Leu Cys Ala Gly Arg Trp Thr Gly Gly Lys Ser Thr
      195          200          205
Cys Ser Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gln
      210          215          220
Gly Ile Thr Ser Trp Gly Ser Glu Pro Cys Ala Leu Pro Glu Arg Pro
      225          230          235          240
Ser Leu Tyr Thr Lys Val Val His Tyr Arg Lys Trp Ile Lys Asp Thr
      245          250          255
Ile Val Ala Asn Pro
      260

```

```

<210> 79
<211> 123
<212> PRT
<213> Homo sapiens

```

```

<400> 79
Met Lys Ala Val Leu Leu Ala Leu Leu Met Ala Gly Leu Ala Leu Gln
  1          5          10          15
Pro Gly Thr Ala Leu Leu Cys Tyr Ser Cys Lys Ala Gln Val Ser Asn
      20          25          30
Glu Asp Cys Leu Gln Val Glu Asn Cys Thr Gln Leu Gly Glu Gln Cys
      35          40          45
Trp Thr Ala Arg Ile Arg Ala Val Gly Leu Leu Thr Val Ile Ser Lys
      50          55          60
Gly Cys Ser Leu Asn Cys Val Asp Asp Ser Gln Asp Tyr Tyr Val Gly
      65          70          75          80
Lys Lys Asn Ile Thr Cys Cys Asp Thr Asp Leu Cys Asn Ala Ser Gly
      85          90          95
Ala His Ala Leu Gln Pro Ala Ala Ala Ile Leu Ala Leu Leu Pro Ala
      100          105          110
Leu Gly Leu Leu Leu Trp Gly Pro Gly Gln Leu
      115          120

```

```

<210> 80
<211> 2817
<212> DNA
<213> Homo sapiens

```

```

<400> 80
gtgctaaaaa gatgccttct tcatttggct gtgatagggtg ctttgtggct gtgggggcta 60

```

```

caaaagtacc cagaaaccag gactggcttg gtgtctcaag gcaactcaga accaaagcct 120
ggaacaggca gctgtatcca gagtggacag aagcccagag acttgactgc tggagaggtg 180
gtcaagtgtc cctcaaggtc agtaatgatg ggcctacact gattggtgca aatgcctcct 240
tctctattgc cttgaacttc cctggaagcc aaaaggtatt gccagatggg caggttatct 300
gggtcaacaa taccatcatc aatgggagcc aggtgtgggg aggacagcca gtgtatcccc 360
aggaaactga cgatgcctgc atcttccctg atggtggacc ttgccatctt ggctcttggg 420
ctcagaagag aagctttgtt tatgtctgga agacctgggg tgagggactc ccttctcage 480
ctatcatcca cacttgtgtt tacttcttct tacctgatca ccttctcttt ggccgcccct 540
tccaccttaa cttctgtgat tttctcta atctattttc ctcttagatc ttttctcttt 600
cttagcacct agcccccttc aagctctatc ataattcttt ctggcaactc ttggcctcaa 660
ttgtagtctt accccatgga atgcctcatt aggacccctt cctgtcccc ccatatcaca 720
gccttccaaa caccctcaga agtaatcata cttcctgacc tcccatctcc agtgccgttt 780
cgaagcctgt ccctcagtc cctttgacca gtaatctctt ctctcttgct tttcattcca 840
aaaatgcttc aggccaatac tggcaagttc tagggggccc agtgtctggg ctgagcattg 900
ggacaggcag ggcaatgctg ggcacacaca ccatggaagt gactgtctac catcgccggg 960
gatcccgagg ctatgtgctt cttgctcatt ccagctcagc cttcaccatt actggttaagg 1020
gttcaggaag ggcaaggcca gttgtagggc aagagagaag cagggaggct tggatggact 1080
gcaaaggaga aaggtgaaat gctgtgcaaa cttaaagtag aaggggccagg aagacctagg 1140
cagagaaatg tgaggcttag tgccagtga gggccagcca gtcagcttgg agttggaggg 1200
tgtggctgtg aaaggagaag ctgtggctca ggcctgggtc tcaccttttc tggctccaat 1260
cccagaccag gtgcctttct ccgtgagcgt gtcccagttg cgggccttgg atggagggaa 1320
caagcacttc ctgagaaatc agcctctgac ctttgccctc cagctccatg accccagtgg 1380
ctatctggct gaagctgacc tctcctacac ctgggacttt ggagacagta gtggaacct 1440
gatctctcgg gcacctgtgg tcaactacac ttacctggag cctggcccag tcaactgcca 1500
ggtggtcctg caggctgcca ttctctcac ctctgtggc tctctcccag ttccaggcac 1560
cacagatggg cacaggccaa ctgcagaggg ccctaacacc acagctggcc aagtgcctac 1620
tacagaagtt gtgggtacta cacctggtca ggcgccaaact gcagagccct ctggaaccac 1680
atctgtgcag gtgccaacca ctgaagtcat aagcactgca cctgtgcaga tgccaactgc 1740
agagagcaca ggtatgacac ctgagaaggt gccagtttca gaggctatgg gtaccacact 1800
ggcagagatg tcaactccag aggctacagg tatgacacct gcagaggtat caattgtgg 1860
gcttctctgga accacagctg cacaggtaac aactacagag tgggtggaga ccacagctag 1920
agagctacct atccctgagc ctgaaggtcc agatgccagc tcaatcatgt ctacggaaag 1980
tattacaggt tccctgggcc cctgctgga tggtagagcc accttaaggc tggtagaag 2040
acaagtcccc ctggattgtg ttctgtatcg atatgggtcc ttttccgtca ccctggacat 2100
tgtccagggt attgaaagtg ccgagatcct gcaggtctgt ccgtccgttg agggggatgc 2160
atttgagctg actgtgtcct gccaaaggcg gctgcccagg gaagcctgca tggagatctc 2220
atcgccaggg tgccagcccc ctgcccagcg gctgtgccag cctgtgttac ccagcccagc 2280
ctgccagctg gttctgcacc agatactgaa ggggtggctc gggacatact gcctcaatgt 2340
gtctctggct gataccaaca gcctggcagt gctcagcacc cagcttatca tgcctggtag 2400
gtccttggac agagactaag tgaggaggga agtggataga ggggacagct ggcaagcagc 2460
agacatgagt gaagcagtg cctgggtatt tctcacaggt caagaagcag gccttgggca 2520
ggttccgctg atcgtgggca tcttctgggt gttgatggct gtggtccttg catctctgat 2580
atataggcgc agacttatga agcaagact ctccgtacct cagttgccac atagcagcag 2640
tcaactggctg cgtctacccc gcactctctg ctctgtccc attggtgaga atagccccct 2700
cctcagtggg cagcaggtct gactactctc atatgatgct gtgattttcc tggagtgtgac 2760
agaaacacct atatttcccc cagtcttccc tgggagacta ctattaactg aaataaaa 2817

```

<210> 81

<211> 2420

<212> DNA

<213> Homo sapiens

<400> 81

```

ggatccaggc cctgccagga aaaatataag ggccctgcgt gagaacagag ggggtcatcc 60
actgcatgag agtggggatg tcacagagtc cagcccaccc tcctggtagc actgagaagc 120
cagggtctgt cttcggtct gcacctgag ggcctggga ttctcttcc tggagctcca 180
ggaaccaggc agtgaggcct tggctctgaga cagtatcctc aggtcacaga gcagaggatg 240

```

```

cacaggggtgt gccagcagtg aatgttttgc ctgaatgcac accaagggcc ccacctgcca 300
caggacacat aggactccac agagtctggc ctcacctccc tactgtcagt cctgtagaat 360
cgacctctgc tggccggctg taccctgagt accctctcac ttctccttc aggttttcag 420
gggacaggcc aaccagagg acaggattcc ctggaggcca cagaggagca ccaaggagaa 480
gatctgtaag taggcctttg ttagagtctc caaggttcag ttctcagctg aggctctca 540
cacactccct ctctcccag gcctgtgggt cttcattgcc cagctcctgc ccacactcct 600
gcctgtctgc ctgacgagag tcatcatgtc tcttgagcag aggagtctgc actgcaagcc 660
tgaggaagcc cttgaggccc aacaagaggc cctgggctct gtgtgtgtgc aggtgcccac 720
ctcctcctcc tctcctctgg tcttggggcac cctggaggag gtgcccactg ctgggtcaac 780
agatcctccc cagagtcctc agggagcctc cgcctttccc actaccatca acttcaactg 840
acagaggcaa ccagtgagg gttccagcag ccgtgaagag gaggggcca gcacctcttg 900
tatcctggag tccttgttcc gagcagtaat cactaagaag gtggtctgatt tgggttggtt 960
tctgtcctc aaatatcgag ccagggagcc agtcacaaag gcagaaatgc tggagagtgt 1020
catcaaaaat tacaagcact gttttcctga gatcttcggc aaagcctctg agtctctgca 1080
gctggctctt ggcattgacg tgaaggaagc agacccacc ggccactcct atgtccttgt 1140
cacctgecta ggtctctcct atgatggcct gctgggtgat aatcagatca tgccaagac 1200
aggcttctctg ataattgtcc tggcatgat tgcaatggag ggcggccatg ctctgagga 1260
ggaaatctgg gaggaagctga gtgtgatgga ggtgatgat gggaggagc acagtgccta 1320
tggggagccc aggaagctgc taccccaaga tttggtgcag gaaaagtacc tggagtaccg 1380
gcaggtgccc gacagtgatc ccgcaagcta tgagttcctg tggggtccaa gggccctcgc 1440
tgaaaccagc tatgtgaaag tccttgagta tgtgatcaag gtcagtgcac gagttcgctt 1500
tttcttccca tcctgcctg aagcagcttt gagagaggag gaagaggag tctgagcatg 1560
agttgcagcc aaggccagtg ggagggggac tgggccagtg caccttccag ggcgcgctc 1620
agcagcttcc cctgcctcgt gtgacatgag gccattctt cactctgaag agagcggctc 1680
gtgttctcag tagtaggttt ctgttctatt gggtgacttg gagatttatc tttgttctct 1740
tttggaattg ttcaaatgtt tttttttaag ggatggttga atgaacttca gcatccaagt 1800
ttatgaatga cagcagtcac acagttctgt gtatatagtt taagggtgaa agtcttgtgt 1860
tttattcaga ttgggaaatc cattctattt tgtgaattgg gataataaca gcagtggaa 1920
aagtacttag aaatgtgaaa aatgagcagt aaaatagatg agataaagaa ctaagaaat 1980
taagagatag tcaattcttg ccttatacct cagtctattc tgtaaaattt ttaaagatat 2040
atgcatacct ggatttcctt ggcttctttg agaatgtaag agaaattaaa tctgaataaa 2100
gaattcttcc tgttcaactg ctcttttctt ctccatgcac tgagcatctg ctttttgga 2160
ggccctgggt tagtagtgga gatgctaagg taagccagac tcatacccac ccatagggtc 2220
gtagagtcta ggagctgcag tcacgtaatc gaggtggcaa gatgtcctc aaagatgtag 2280
ggaaaagtga gagaggggtg aggggtgtgg gctccgggtg agagtgggtg agtgtcaatg 2340
ccctgagctg gggcattttg ggctttggga aactgcagtt ccttctgggg gagctgattg 2400
taatgatctt ggggtgatcc
2420

```

<210> 82

<211> 4559

<212> DNA

<213> Homo sapiens

<400> 82

```

attccttcat caaacagcca ggagtgagga agaggaccct cctgagttag gactgaggat 60
ccacctcac cacatagtgg gaccacagaa tccagctcag cccctcttgt cagccctgg 120
acacactggc aatgatctca ccccgagcac accctcccc ccaatgccac ttcgggccga 180
ctcagagtca gagacttggg ctgaggggag cagacacaat cggcagagga tggcgggtcca 240
ggctcagctt ggcattccaag tcaggacett gagggatgac caaaggcccc tcccccccc 300
aactcccccg accccaccag gatctacagc ctcaggatcc ccgtcccaat cctaccctc 360
acaccaacac catcttcatg cttaccccca ccccccatc cagatcccca tccgggcaga 420
atccggttcc acccttgccg tgaaccagg gaagtcacgg gcccgatgt gacgccactg 480
acttgcacat tggaggtcag aggacagcga gattctcgcc ctgagcaacg gcctgacgtc 540
ggcggaggga agcagcgcca ggctccgtga ggaggcaagg taagacgcc agggaggact 600
gaggggggcc tcacccagga cagagggccc ccaataatcc agcgtgcct ctgtgcccg 660
gcctggacca cctgcaggg gaagacttct caggctcagt cggcaccac tcacccgcc 720
acccccgcc gctttaaccg cagggaactc tggcgtaaga gctttgtgtg accagggcag 780

```

```

ggctgggttag aagtgtctcag ggcccagact cagccaggaa tcaagggtcag gaccccaaga 840
ggggactgag ggcaaccac cccctaccct cactaccaat cccatcccc aacaccaacc 900
ccaccccat cctcaaaca ccaaccac ccccaaacc cattcccatc tccctcccca 960
ccaccatcct ggagaaatcc ggctttgccc ctgcaatcaa cccacggaag ctccgggaat 1020
ggcgcccaag cacgcggatc ctgacgttca catgtacggc taaggaggag aaggggttgg 1080
gtctcgtgag tatggccttt gggatgcaga ggaaggggccc aggcctcctg gaagacagt 1140
gagtcccttag gggaccacgc atgccaggac agggggccca ctgtaccctt gtctcaact 1200
gagccacctt ttcattcagc cgagggaatc ctagggatgc agaccactt cagcaggggg 1260
ttggggccca gcctgcgagg agtcaagggg aggaagaaga gggaggactg aggggacctt 1320
ggagtccaga tcagtggcaa ccttgggctg ggggatcctg ggcacagtgg ccgaatgtgc 1380
cccgtgtcga ttgcaccttc aggggtgacag agagttaggg gctgtggtct gagggctggg 1440
acttcagggtc agcagagggg ggaatcccag gatctgcccg acccaagggt tgcccccttc 1500
atgaggactg gggatacccc cggcccagaa agaagggatg ccacagagtc tggaaagtc 1560
ttgttcttag ctctggggga acctgatcag ggatggcctt aagtgacaat ctcatattgt 1620
ccacaggcag gaggttgggg aacctcagg gagataaggt gttggtgtaa agaggagctg 1680
tctgtcatt tcagggggtt gggggttag aaaggcgagt ccctggcagg agtaaagatg 1740
agtaaccac aggaggccat cataacgttc accctagaac caaagggttc agccctggac 1800
aacgcacgtg ggggtaacag gatgtggccc ctctcactt gtctttccag atctcaggga 1860
gttgatgacc ttgttttcag aagggtgactc aggtcaacac aggggccccca tctggtcgac 1920
agatgcagtg gttctaggat ctgccaagca tccagggtga gagcctgagg taggattgag 1980
ggtaccctg ggcagaatg cagcaagggg gcccataga aatctgcctt gccctgctg 2040
ttacttcaga gacctgggc agggctgtca gctgaagtc ctccattatc ctgggatctt 2100
tgatgtcagg gaaggggagg ccttggctg aagggtctg agtcagggtc gtagaggag 2160
ggtctcaggc cctgcccagg gtggacgtga ggaccaagcg gactcgtcac ccaggacacc 2220
tggactccaa tgaatttggg catctctcgt tgtccttcgc gggaggacct ggtcacgtat 2280
ggccagatgt ggggtcccctc atatccttct gtaccatata agggatgtga gttcttgaca 2340
tgagagattc tcaagccagc aaaagggttg gattaggccc tacaaggaga aagggtgagg 2400
ccctgagtga gcacagagg gacctccac ccaagtagag tggggacctc acggagtctg 2460
gccaaccctg ctgagacttc tgggaatccg tggctgtgct tgcagtctgc aactgaagg 2520
cccgtgcatt cctctcccag gaatcaggag ctccagggaac caggcagtga ggccttggtc 2580
tgagtacgtg tccctcaggtc acagagcaga ggggacgcag acagtgccaa cactgaagg 2640
ttgcctggaa tgcacacca gggcccacc cgcccagaac aaatgggact ccagagggcc 2700
tggcctcacc ctccctattc tcagtcctgc agcctgagca tgtgctggcc ggtgtgacct 2760
tgagggtccc tccacttcc tcttcagggt ctgaggggg acaggctgac aagtaggacc 2820
cgaggcactg gaggagcatt gaaggagaag atctgtaagt aagcctttgt cagagcctcc 2880
aagggtcagt tcagtctca cctaaggcct cacacacgct ccttctctcc ccaggcctgt 2940
gggtcttcat tgcccagctc ctgcccgcac tccctgctgc tgccctgacc agagtcatca 3000
tgctcttga gcagaggagt cagcactgca agcctgaaga aggccttgag gcccgaggag 3060
agggcctggg cctggtgggt cgcagggctc ctgctactga ggagcagcag accgcttctt 3120
cctctcttac tctagtggaa gttaccctgg gggagggtgc tgcctgcgac tcaccgagtc 3180
ctcccacag tccctcaggga gcctccagct tctcgactac catcaactac actctttgga 3240
gacaatccga tgagggtcc agcaaccaag aagaggagg gccaagaatg tttcccgacc 3300
tggagtccga gttccaagca gcaatcagta ggaagatggg tgagttggtt cattttctgc 3360
tcccaagta tcgagccagg gagccgtca caaaggcaga aatgctggag agtgtcctca 3420
gaaattgcca ggacttcttt cccgtgatct tcagcaaagc ctccgagtac ttgcagctgg 3480
tctttggcat cgagggtggtg gaagtgttcc ccatcagcca cttgtacatc cttgtcacct 3540
gcctgggcct ctctacgat ggcctgctgg gcgacaatca ggtcatgccc aagacaggcc 3600
tccgtataat cgtcctggcc ataatcgcaa tagagggcga ctgtgcccc gaggagaaaa 3660
tctgggagga gctgagtatg ttggaggtgt ttgaggggag ggaggacagt gtcttcgcac 3720
atcccaggaa gctgctcatg caagatctgg tgcaggaaaa ctacctggag taccggcagg 3780
tgccggcag tgatcctgca tgctacagat tccgtgggg tccaagggcc ctcatgaaa 3840
ccagctatgt gaaagtccct caccatacac taaagatcgg tggagaacct cacatttcc 3900
accacccct gcatgaacgg gctttgagag agggagaaga gtgagtctca gcacatgtt 3960
cagccagggc cagtgggagg ggtctgggc cagtgcacct tccagggcc catccattag 4020
cttcactgc ctggtgtgat atgaggccca ttccctgcctc tttgaagaga gcagtcagca 4080
ttcttagcag taagtctctg ttctgttggg tgcatttgag atttatcttt ctttccgtt 4140
ggaattgttc aaatgttcc ttttaacaat ggttggtgga acttcagcat ccaagtttat 4200

```



```

gaatgacagt agtcacacat agtgctgttt atatatgttta ggggtaagag tctgtttttt 4260
tattcagatt gggaaatcca ttccattttg tgagttgtca cataataaca gcagtggaaat 4320
atgtattttgc ctatatgttg aacgaattag cagtaaaata catgatacaa ggaactcaaa 4380
agatagttaa ttcttgcctt atacctcagt ctattatgta aaattaaaaa tatgtgtatg 4440
tttttgcttc tttgagaatg caaaagaaat taaatctgaa taaattcttc ctgttcactg 4500
gctcatttct ttaccattca ctcagcatct gctctgtgga aggcctcggg agtagtggg 4559

```

<210> 83

<211> 4204

<212> DNA

<213> Homo sapiens

<400> 83

```

acgcaggcag tgatgtcacc cagaccacac cccttccccc aatgccactt cagggggtag 60
tcagagtcag agacttggtc tgaggggagc agaagcaatc tgcagaggat ggcggtccag 120
gctcagccag gcatcaactt caggaccctg agggatgacc gaaggccccc cccaccacc 180
cccaactccc cggaccccac caggatctac agcctcagga ccccgtccc aatccttacc 240
ccttgcccca tcaccatctt catgcttacc tccaccccca tccgatcccc atccaggcag 300
aatccagttc caccctgcc cggaaacccag gtagtaccg ttgccaggat gtgacgccac 360
tgacttgccg attggaggtc agaagaccgc gagattctcg cctgagcaa cgagcgacgg 420
cctgacgtcg gcggagggaa gccggcccag gctcgggtgag gaggcaagggt aagacgtga 480
gggaggactg aggcgggcct caccctcagc agagggcctc aaataatcca gtgctgcctc 540
tgctgccggg cctggggccac ccgcagggg aagacttcca ggctgggtcg ccactacctc 600
acccgcgcga ccccgccgcg tttagccacg gggaaactctg gggacagagc ttaatgtggc 660
cagggcaggg ctggttagaa gaggtcaggg cccacgctgt ggcaggaatc aaggtcagga 720
ccccgagagg gaactgaggg cagcctaacc accaccctca ccaccattcc cgtcccccaa 780
caccacaacc caccctcacc cccattccc atccccacc ccacctat cctggcagaa 840
tccgggcttt gcccttggtc tcaagtcacg gaagctccgg gaatggcggc caggcacgtg 900
agtcctgagg ttcacatcta cggctaaggg aggaaggggg ttcgggtatcg cgagtatggc 960
cgttgggagg cagcgaaagg gcccaggcct cctggaagac agtggagtcc tgaggggacc 1020
cagcatgccg ggacaggggg ccactgtac cctgtctca aaccgaggca ccttttatt 1080
cggctacggg aatcctaggg atgcagacc acttcagcag ggggttgggg cccagccctg 1140
cgaggagtca tggggaggaa gaagaggag gactgagggg acctggagt ccagatcagt 1200
ggcaaccttg ggctggggga tgctgggcac agtggccaaa tgtgctctgt gctcattgcg 1260
ccttcagggg gaccagagag ttgagggctg tggctctgaag agtgggactt caggtcagca 1320
gagggaggaa tcccaggatc tgcagggccc aaggtgtacc cccaaggggc ccctatgtg 1380
tggaagatg cagtggctct aggatctgcc aagcatccag gtgaagagac tgagggagga 1440
ttgagggtag ccctgggaca gaatgcggac tgggggcccc ataaaaatct gccctgctcc 1500
tgctgttacc tcagagagcc tgggcagggc tgtcagctga ggtccctcca ttatcctagg 1560
atcactgatg tcaggggaagg ggaagccttg gtctgagggg gctgactca gggcagtaga 1620
gggaggctct cagaccctac taggagtggg ggtgaggacc aagcagtctc ctacccagg 1680
gtacatggac ttcaataaat ttggacatct ctggtgtcc tttccgggag gacctgggaa 1740
tgtatggcca gatgtgggtc cctcatgtt tttctgtacc atatcaggta tgtgagttct 1800
tgacatgaga gattctcagg ccagcagaag ggagggatta gccctataaa ggagaaagg 1860
gagggccctg agtgagcaca gaggggatcc tccacccag tagagtgggg acctcacaga 1920
gtctggccaa ccctcctgac agttctggga atccgtggct gcgtttgctg tctgcacatt 1980
gggggcccgt ggattcctct cccaggaaac aggagctcca ggaacaaggc agtgaggact 2040
tggtctgagg cagtgtcctc aggtcacaga gtagaggggg ctcatagat gccaacggtg 2100
aaggtttgct ttggattcaa accaagggcc ccacctgcc cagaacacat ggactccaga 2160
gcgcctggcc tcacctcaa tactttcagt cctgcagcct cagcatgcgc tggccggatg 2220
tacctgagg tgccctctca ctctctcctt caggttctga ggggacaggc tgacctggag 2280
gaccagaggc ccccgaggga gcaactgaag agaagatctg taagtaagcc tttgttagag 2340
cctccaagggt tcatttcagt actcagctga ggtctctcac atgctccctc tctccccagg 2400
ccagtgggtc tccattgccc agctcctgcc cactctccc cctgttgccc tgaccagagt 2460
catcatgcct cttgagcaga ggagtcagca ctgcaagcct gaagaaggcc ttgaggcccg 2520
aggagaggcc ctgggccttg tgggtgcgca ggtcctgct actgaggagc aggaggtgc 2580
ctcctcctct tctactctag ttgaagtcac cctgggggag gtgcctgctg ccgagtcacc 2640

```

```

agatcctccc cagagtcctc agggagcctc cagcctcccc actaccatga actaccctct 2700
ctggagccaa tcctatgagg actccagcaa ccaagaagag gaggggcca gcaccttccc 2760
tgacctggag tccgagttcc aagcagcact cagtaggaag gtggccgagt tggttcattt 2820
tctgctcctc aagtatcgag ccagggagcc ggtcacaaag gcagaaatgc tggggagtg 2880
cgtcggaaat tggcagatatt tctttcctgt gatcttcagc aaagcttcca gttccttgca 2940
gctgggtcttt ggcatcgagc tgatggaagt ggaccccatc ggccacttgt acatctttgc 3000
cacctgcctg ggccctcctc acgatggcct gctgggtgac aatcagatca tgcccaaggc 3060
aggcctcctg ataatcgtcc tggccataat cgcaagagag ggcgactgtg ccctgagga 3120
gaaaatctgg gaggagctga gtgtgttaga ggtgtttgag gggagggaag acagtatctt 3180
gggggatccc aagaagctgc tcaccaaca tttcgtgcag gaaaactacc tggagtaccg 3240
gcaggtcccc ggcatgata ctgcatgtta tgaattcctg tggggtccaa gggccctcgt 3300
tgaaaccagc tatgtgaaag tcctgcacca tatggtaaag atcagtggag gacctacat 3360
ttcctaccca ccctgcctg agtgggtttt gagagagggg gaagagtga tctgagcacg 3420
agttgcagcc agggccagtg ggaggggggtc tgggccaagt cacttccgg ggccgcatcc 3480
cttagtttcc actgcctcct gtgacgtgag gccattctt cactctttga agcagcagt 3540
cagcattctt agtagtgggt ttctgttctg ttggatgact ttgagattat tctttgtttc 3600
ctgttgaggt tttcaaatg ttctttttaa cggatgggtt aatgagcgtc agcatccagg 3660
tttatgaatg acagtatgca cacatagtgc tgtttatata gtttaggagt aagagtcttg 3720
ttttttactc aaattgggaa atccattcca ttttgtgaat tgtgacataa taatagcagt 3780
ggtaaaagta tttgcttaaa attgtgagcg aattagcaat aacatacatg agataactca 3840
agaaatcaaa agatagttag ttcttgcctt gtacctcaat ctattctgta aaattaaaca 3900
aatatgcaaa ccaggatttc cttgacttct ttgagaatgc aagcgaaatt aaatctgaat 3960
aaataattct tcctcttcac tggctcgttt cttttccgtt cactcagcat ctgctctgtg 4020
ggaggccctg ggtagtagt ggggatgcta aggtaaagcca gactcacgcc taccatagg 4080
gctgtagagc ctaggacctg cagtcatata attaaggtgg tgagaagtcc tgtaagatgt 4140
agaggaaatg taagagaggg gtgaggggtg ggcgtcccg gtgagagtag tggagtgtca 4200
gtgc 4204

```

<210> 84

<211> 752

<212> DNA

<213> Homo sapiens

<400> 84

```

atcctcgtgg gccctgacct tctctctgag agccggggcag aggcctccgga gccatgcagg 60
ccgaaggccg gggcacaggg ggttcgacgg gcgatgctga tggcccagga ggccctggca 120
ttcctgatgg ccaggggggc aatgctggcg gccaggaga ggcggtgccc acgggcggca 180
gaggtccccg gggcgagggg gcagcaaggg cctcggggcc gggaggaggc gcccgcggg 240
gtccgcatgg cggcgcggtc tcagggctga atggatgctg cagatgcggg gccagggggc 300
cggagagccg cctgcttgag ttctacctcg ceatgccttt cgcgacaccc atggaagcag 360
agctggcccc caggagcctg gcccaggatg cccacccgct tcccgtgcca ggggtgcttc 420
tgaaggagtt cactgtgtcc ggcaacatac tgactatccg actgactgct gcagaccacc 480
gccaactgca gctctccatc agctcctgtc tccagcagct ttccctgttg atgtggatca 540
cgcagtgttt tctgcccgtg tttttggctc agcctccctc agggcagagg cgctaagccc 600
agcctggcgc cccttcttag gtcattgcctc ctccctagg gaatgggtccc agcacgagt 660
gccagttcat tgtgggggcc tgattgtttg tcgctggagg aggacggctt acatgtttgt 720
ttctgtagaa aataaaactg agctacgaaa aa 752

```

<210> 85

<211> 2148

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(2)

<223> n = A,T,C or G

<400> 85

```

gcttcagggt acagctcccc cgcagccaga agccgggcct gcagcccctc agcaccgctc 60
cgggacaccc caccgccttc ccaggcgtga cctgtcaaca gcaacttcgc ggtgtggtga 120
actctctgag gaaaaacccat ttgtattatt actctcagac gtgcgtggca acaagtgact 180
gagacctaga aatccaagcg ttggaggtcc tgaggccagc ctaagtcgct tcaaatgga 240
acgaaggcgt ttgtgggggt ccattcagag ccgatacatc agcatgagtg tgtggacaag 300
cccacggaga cttgtggagc tggcagggca gagcctgctg aaggatgagg ccctggccat 360
tgccgcccctg gagggtgctgc ccaggagcct cttcccgcga ctcttcattg cagcctttga 420
cgggagacac agccagaccc tgaaggcaat ggtgcaggcc tggcccttca cctgectccc 480
tctgggagtg ctgatgaagg gacaacatct tcacctggag accttcaaag ctgtgcttga 540
tggacttgat gtgctccttg ccaggaggt tgcctccagg aggtggaaac ttcaagtgtc 600
ggattttacgg aagaactctc atcaggactt ctggactgta tggctctggaa acagggccag 660
tctgtactca tttccagagc cagaagcagc tcagcccatg acaaagaagc gaaaagttaga 720
tggtttgagc acagaggcag agcagccctt cattccagta gagggtgctcg tagacctgtt 780
cctcaaggaa ggtgcctgtg atgaattgtt ctctacctc attgagaaag tgaagcgaag 840
gaaaaatgta ctacgcctgt gctgtaagaa cctgaagatt tttgcaatgc ccatgcagga 900
tatcaagatg atcctgaaaa tgggtgcagc ggactctatt gaagatttgg aagtgacttg 960
tacctggaag ctaccaccc tggcgaaatt ttctccttac ctgggcccaga tgattaatct 1020
gcgtagactc ctctctctcc acatccatgc atcttcttac atttcccccg agaaggaaga 1080
gcagtatatc gcccagttca cctctcagtt cctcagtcct cagtgcctgc aggtctctta 1140
tgtggactct ttatttttcc ttagaggccg cctggatcag ttgctcaggc acgtgatgaa 1200
ccccttgga accctctcaa taactaactg ccggctttcg gaaggggatg tgatgcatct 1260
gtcccagagt ccagcgtca gtcagctaag tgtcctgagt ctaagtgggg tcatgctgac 1320
cgatgtaagt ccgagcccc tccaagctct gctggagaga gcctctgcca ccctccagga 1380
cctggtcttt gatgagtgtg ggatcacgga tgatcagctc cttgccctcc tgccttccct 1440
gagccactgc tcccagctta caaccttaag cttctacggg aattccatct ccatatctgc 1500
cttgacagat ctctgcagc acctcatcgg cctgagcaat ctgacccacg tgetgtatcc 1560
tgtccccctg gagagttatg aggacatcca tggtaacctc cacctggaga ggcttgccca 1620
tctgcatgcc aggtcaggg agttgctgtg tgagttgggg cggcccagca tggctctggc 1680
tagtgccaac ccctgtctc actgtgggga cagaaccttc tatgaccggg agcccatcct 1740
gtgcccctgt ttcattgecta actagctggg tgcacatatc aaatgcttca ttctgcatac 1800
ttggacacta aagccaggat gtgcatgcat ctgaagcaa caaagcagcc acagtttcag 1860
acaaatgttc agtgtgagt aggaaaaacat gttcagttag gaaaaaacat tcagacaaat 1920
gttcagttag gaaaaaaagg ggaagtggg gataggcaga tgttgacttg aggagttaat 1980
gtgatctttg gggagataca tcttatagag ttagaaatag aatctgaatt tctaaaggga 2040
gattctggct tgggaagtac atgtaggagt taatccctgt gtagactgtt gtaaagaaac 2100
tgttgaaaat aaagagaagc aatgtgaagc aaaaaaaaa aaaaaaaa 2148

```

<210> 86

<211> 1466

<212> DNA

<213> Homo sapiens

<400> 86

```

agccccaagc ttaccacctg caccgggaga gctgtgtgtc accatgtggg tcccggttgt 60
cttctcacc ctgtccgtga cgtggattgg tgctgcacc ctcatoctgt ctcgattgt 120
gggaggctgg gagtgcgaga agcattccca acctggcag gtgcttgtgg cctctcgtgg 180
cagggcagtc tgcggcgggtg ttctgggtga ccccagtggt gtcctcacag ctgcccactg 240
catcagggaac aaaaagcgtga tcttgctggg tcggcacagc ctgtttcatc ctgaagacac 300
aggccaggta tttcagggtc gccacagctt cccacacccg ctctacgata tgagcctcct 360
gaagaatcga ttctcaggc cagggtgatga ctccagccac gacctcatgc tgctccgcct 420
gtcagagcct gccgagctca cggatgctgt gaaggctcat gacctgcca cccaggagcc 480
agcactgggg accacctgct acgcctcagg ctggggcagc attgaaccag aggagtcttt 540
gaccccaaag aaacttcagt gtgtggacct ccatgttatt tccaatgacg tgtgtgcgca 600
agttcaccc cagaagggtga ccaagttcat gctgtgtgct ggacgctgga cagggggcaa 660
aagcacctgc tgggtgatt ctggggggcc acttgtctgt aatgggtgtc ttcaagggtat 720

```

```

cacgtcatgg ggcagtgaac catgtgccct gcccgaaagg ccttcctctgt acaccaaggt 780
ggtgcattac cgggaagtga tcaaggacac catcgtggcc aaccctctgag caccctctatc 840
aaccctctat tgtagtaaac ttggaacctt ggaaatgacc aggccaagac tcaagcctcc 900
ccagttctac tgacctttgt ccttaggtgt gaggtccagg gttgctagga aaagaaatca 960
gcagacacag gtgtagacca gagtgtttct taaatgggtgt aattttgtcc tctctgtgtc 1020
ctggggaata ctggccatgc ctggagacat atcactcaat ttctctgagg acacagatag 1080
gatgggggtgt ctgtgttatt tgtgggttac agagatgaaa gaggggtggg atccacactg 1140
agagagtggg gagtgcacatg tgctggacac tgtccatgaa gcactgagca gaagctggag 1200
gcacaacgca ccagacactc acagcaagga tggagctgaa aacataaccc actctgtcct 1260
ggaggcactg ggaagcctag agaaggctgt gagccaagga gggagggtct tcctttggca 1320
tgggatgggg atgaagtaag gagaggact ggacccctg gaagctgatt cactatgggg 1380
ggaggtgtat tgaagtcctc cagacaaccc tcagatttga tgatttccta gtagaactca 1440
cagaaataaa gagctgttat actgtg                                     1466

```

<210> 87

<211> 990

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(990)

<223> n = A,T,C or G

<400> 87

```

agggagaggc agtgaccatg aaggctgtgc tgcttgccct gttgatggca ggcttgggcc 60
tgacgccagg cactgccctg ctgtgctact cctgcaaagc ccaggtagc aacgaggact 120
gcctgcaggg gggaactgac acccagctgg gggagcagtg ctggaccgag cgcacccgag 180
cagttggcct cctgaccgtc atcagcaaag gctgcagctt gaactgcgtg gatgactcac 240
aggactacta cgtgggcaag aagaacatca cgtgctgtga caccgacttg tgcaacgcca 300
gcggggccca tgccctgcag ccggctgccc ccacccctgc gctgctccct gcactcggcc 360
tgctgctctg gggaccgggc cagctatagg ctctgggggg ccccgctgca gccacactg 420
gggtgtggtg cccaggcctt tgtgccactc ctcacagaac ctggcccagt gggagcctgt 480
cctggttctt gaggcacatc ctaacgcaag tttgaccatg tatgtttgca ccccttttcc 540
ccnaaccctg accttcccat gggccttttc caggattccn accnggcaga tcagttttag 600
tganacanat ccgcntgcag atggcccctc caacnntttn tgttgntgtt tccatggccc 660
agcattttcc acccttaacc ctgtgttcag gcacttnttc ccccaggaag ccttcctctg 720
ccacccattt tatgaattga gccaggtttg gtccgtgggtg tccccgcac ccagcagggg 780
acaggcaatc aggagggccc agtaaaggct gagatgaagt ggactgagta gaactggagg 840
acaagagttg acgtgagttc ctgggagttt ccagagatgg ggcttgagg cctggaggaa 900
ggggccaggc ctcacatttg tggggntccc gaatggcagc ctgagcacag cgtaggccct 960
taataaacac ctgttggata agccaaaaaa                                     990

```

<210> 88

<211> 9

<212> PRT

<213> Homo sapiens

<400> 88

Leu Pro His Ser Ser Ser His Trp Leu

1

5

<210> 89

<211> 10

<212> PRT

<213> Homo sapiens

<400> 89
Gln Leu Pro His Ser Ser Ser His Trp Leu
1 5 10

<210> 90
<211> 9
<212> PRT
<213> Homo sapiens

<400> 90
Leu Ile Tyr Arg Arg Arg Leu Met Lys
1 5

<210> 91
<211> 10
<212> PRT
<213> Homo sapiens

<400> 91
Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys
1 5 10

<210> 92
<211> 8
<212> PRT
<213> Homo sapiens

<400> 92
Ile Tyr Arg Arg Arg Leu Met Lys
1 5

<210> 93
<211> 9
<212> PRT
<213> Homo sapiens

<400> 93
Leu Pro His Ser Ser Ser His Trp Leu
1 5

<210> 94
<211> 10
<212> PRT
<213> Homo sapiens

<400> 94
Gln Leu Pro His Ser Ser Ser His Trp Leu
1 5 10

<210> 95

<211> 8
<212> PRT
<213> Homo sapiens

<400> 95
Glu Ser Leu Phe Arg Ala Val Ile
1 5

<210> 96
<211> 10
<212> PRT
<213> Homo sapiens

<400> 96
Ile Leu Glu Ser Leu Phe Arg Ala Val Ile
1 5 10

<210> 97
<211> 9
<212> PRT
<213> Homo sapiens

<400> 97
Ile Leu Glu Ser Leu Phe Arg Ala Val
1 5

<210> 98
<211> 10
<212> PRT
<213> Homo sapiens

<400> 98
Cys Ile Leu Glu Ser Leu Phe Arg Ala Val
1 5 10

<210> 99
<211> 9
<212> PRT
<213> Homo sapiens

<400> 99
Cys Ile Leu Glu Ser Leu Phe Arg Ala
1 5

<210> 100
<211> 9
<212> PRT
<213> Homo sapiens

<400> 100
Glu Phe Leu Trp Gly Pro Arg Ala Leu
1 5

<210> 101
<211> 8
<212> PRT
<213> Homo sapiens

<400> 101
Phe Leu Trp Gly Pro Arg Ala Leu
1 5

<210> 102
<211> 10
<212> PRT
<213> Homo sapiens

<400> 102
Phe Leu Trp Gly Pro Arg Ala Leu Ala Glu
1 5 10

<210> 103
<211> 10
<212> PRT
<213> Homo sapiens

<400> 103
Leu Trp Gly Pro Arg Ala Leu Ala Glu Thr
1 5 10

<210> 104
<211> 9
<212> PRT
<213> Homo sapiens

<400> 104
Pro Arg Ala Leu Ala Glu Thr Ser Tyr
1 5

<210> 105
<211> 10
<212> PRT
<213> Homo sapiens

<400> 105
Gly Pro Arg Ala Leu Ala Glu Thr Ser Tyr
1 5 10

<210> 106
<211> 9
<212> PRT
<213> Homo sapiens

<400> 106
Arg Ala Leu Ala Glu Thr Ser Tyr Val
1 5

<210> 107
<211> 9
<212> PRT
<213> Homo sapiens

<400> 107
Leu Ala Glu Thr Ser Tyr Val Lys Val
1 5

<210> 108
<211> 10
<212> PRT
<213> Homo sapiens

<400> 108
Ala Leu Ala Glu Thr Ser Tyr Val Lys Val
1 5 10

<210> 109
<211> 9
<212> PRT
<213> Homo sapiens

<400> 109
Ala Glu Thr Ser Tyr Val Lys Val Leu
1 5

<210> 110
<211> 10
<212> PRT
<213> Homo sapiens

<400> 110
Leu Ala Glu Thr Ser Tyr Val Lys Val Leu
1 5 10

<210> 111
<211> 9
<212> PRT
<213> Homo sapiens

<400> 111
Thr Ser Tyr Val Lys Val Leu Glu Tyr
1 5

<210> 112
<211> 10

<212> PRT
<213> Homo sapiens

<400> 112
Glu Thr Ser Tyr Val Lys Val Leu Glu Tyr
1 5 10

<210> 113
<211> 9
<212> PRT
<213> Homo sapiens

<400> 113
Lys Val Leu Glu Tyr Val Ile Lys Val
1 5

<210> 114
<211> 10
<212> PRT
<213> Homo sapiens

<400> 114
Ser Tyr Val Leu Val Thr Cys Leu Gly Leu
1 5 10

<210> 115
<211> 9
<212> PRT
<213> Homo sapiens

<400> 115
Tyr Val Leu Val Thr Cys Leu Gly Leu
1 5

<210> 116
<211> 8
<212> PRT
<213> Homo sapiens

<400> 116
Val Leu Val Thr Cys Leu Gly Leu
1 5

<210> 117
<211> 9
<212> PRT
<213> Homo sapiens

<400> 117
Thr Gln Asp Leu Val Gln Glu Lys Tyr
1 5

<210> 118
<211> 10
<212> PRT
<213> Homo sapiens

<400> 118
Leu Thr Gln Asp Leu Val Gln Glu Lys Tyr
1 5 10

<210> 119
<211> 9
<212> PRT
<213> Homo sapiens

<400> 119
Tyr Gly Glu Pro Arg Lys Leu Leu Thr
1 5

<210> 120
<211> 9
<212> PRT
<213> Homo sapiens

<400> 120
Leu Val Gln Glu Lys Tyr Leu Glu Tyr
1 5

<210> 121
<211> 10
<212> PRT
<213> Homo sapiens

<400> 121
Asp Leu Val Gln Glu Lys Tyr Leu Glu Tyr
1 5 10

<210> 122
<211> 9
<212> PRT
<213> Homo sapiens

<400> 122
Ser Ala Tyr Gly Glu Pro Arg Lys Leu
1 5

<210> 123
<211> 9
<212> PRT
<213> Homo sapiens

<400> 123

Lys Val Leu Glu Tyr Val Ile Lys Val
1 5

<210> 124
<211> 10
<212> PRT
<213> Homo sapiens

<400> 124
Val Lys Val Leu Glu Tyr Val Ile Lys Val
1 5 10

<210> 125
<211> 9
<212> PRT
<213> Homo sapiens

<400> 125
Tyr Val Lys Val Leu Glu Tyr Val Ile
1 5

<210> 126
<211> 9
<212> PRT
<213> Homo sapiens

<400> 126
Thr Ser Tyr Val Lys Val Leu Glu Tyr
1 5

<210> 127
<211> 10
<212> PRT
<213> Homo sapiens

<400> 127
Glu Thr Ser Tyr Val Lys Val Leu Glu Tyr
1 5 10

<210> 128
<211> 9
<212> PRT
<213> Homo sapiens

<400> 128
Val Ile Lys Val Ser Ala Arg Val Arg
1 5

<210> 129
<211> 10
<212> PRT

<213> Homo sapiens

<400> 129

Tyr Val Ile Lys Val Ser Ala Arg Val Arg
1 5 10

<210> 130

<211> 8

<212> PRT

<213> Homo sapiens

<400> 130

Glu Leu Val His Phe Leu Leu Leu
1 5

<210> 131

<211> 10

<212> PRT

<213> Homo sapiens

<400> 131

Met Val Glu Leu Val His Phe Leu Leu Leu
1 5 10

<210> 132

<211> 8

<212> PRT

<213> Homo sapiens

<400> 132

Ile Ser Arg Lys Met Val Glu Leu
1 5

<210> 133

<211> 9

<212> PRT

<213> Homo sapiens

<400> 133

Ala Ile Ser Arg Lys Met Val Glu Leu
1 5

<210> 134

<211> 10

<212> PRT

<213> Homo sapiens

<400> 134

Ala Ala Ile Ser Arg Lys Met Val Glu Leu
1 5 10

<210> 135
<211> 9
<212> PRT
<213> Homo sapiens

<400> 135
Lys Met Val Glu Leu Val His Phe Leu
1 5

<210> 136
<211> 9
<212> PRT
<213> Homo sapiens

<400> 136
Ile Ser Arg Lys Met Val Glu Leu Val
1 5

<210> 137
<211> 10
<212> PRT
<213> Homo sapiens

<400> 137
Ala Ile Ser Arg Lys Met Val Glu Leu Val
1 5 10

<210> 138
<211> 9
<212> PRT
<213> Homo sapiens

<400> 138
Leu Val His Phe Leu Leu Lys Tyr
1 5

<210> 139
<211> 10
<212> PRT
<213> Homo sapiens

<400> 139
Glu Leu Val His Phe Leu Leu Leu Lys Tyr
1 5 10

<210> 140
<211> 9
<212> PRT
<213> Homo sapiens

<400> 140
Arg Lys Met Val Glu Leu Val His Phe

1 5

<210> 141
<211> 9
<212> PRT
<213> Homo sapiens

<400> 141
Leu Gln Leu Val Phe Gly Ile Glu Val
1 5

<210> 142
<211> 10
<212> PRT
<213> Homo sapiens

<400> 142
Tyr Leu Gln Leu Val Phe Gly Ile Glu Val
1 5 10

<210> 143
<211> 9
<212> PRT
<213> Homo sapiens

<400> 143
Gln Leu Val Phe Gly Ile Glu Val Val
1 5

<210> 144
<211> 10
<212> PRT
<213> Homo sapiens

<400> 144
Leu Gln Leu Val Phe Gly Ile Glu Val Val
1 5 10

<210> 145
<211> 9
<212> PRT
<213> Homo sapiens

<400> 145
Ile Glu Val Val Glu Val Val Pro Ile
1 5

<210> 146
<211> 10
<212> PRT
<213> Homo sapiens

<400> 146
Gly Ile Glu Val Val Glu Val Val Pro Ile
1 5 10

<210> 147
<211> 9
<212> PRT
<213> Homo sapiens

<400> 147
Phe Gly Ile Glu Val Val Glu Val Val
1 5

<210> 148
<211> 9
<212> PRT
<213> Homo sapiens

<400> 148
Ala Ser Glu Tyr Leu Gln Leu Val Phe
1 5

<210> 149
<211> 10
<212> PRT
<213> Homo sapiens

<400> 149
Lys Ala Ser Glu Tyr Leu Gln Leu Val Phe
1 5 10

<210> 150
<211> 8
<212> PRT
<213> Homo sapiens

<400> 150
Glu Glu Lys Ile Trp Glu Glu Leu
1 5

<210> 151
<211> 10
<212> PRT
<213> Homo sapiens

<400> 151
Ala Pro Glu Glu Lys Ile Trp Glu Glu Leu
1 5 10

<210> 152

<211> 8
<212> PRT
<213> Homo sapiens

<400> 152
Ala Pro Glu Glu Lys Ile Trp Glu
1 5

<210> 153
<211> 9
<212> PRT
<213> Homo sapiens

<400> 153
Lys Ile Trp Glu Glu Leu Ser Met Leu
1 5

<210> 154
<211> 10
<212> PRT
<213> Homo sapiens

<400> 154
Glu Lys Ile Trp Glu Glu Leu Ser Met Leu
1 5 10

<210> 155
<211> 8
<212> PRT
<213> Homo sapiens

<400> 155
Phe Leu Trp Gly Pro Arg Ala Leu
1 5

<210> 156
<211> 9
<212> PRT
<213> Homo sapiens

<400> 156
Phe Leu Trp Gly Pro Arg Ala Leu Ile
1 5

<210> 157
<211> 9
<212> PRT
<213> Homo sapiens

<400> 157
Leu Ile Glu Thr Ser Tyr Val Lys Val
1 5

<210> 158
<211> 10
<212> PRT
<213> Homo sapiens

<400> 158
Ala Leu Ile Glu Thr Ser Tyr Val Lys Val
1 5 10

<210> 159
<211> 9
<212> PRT
<213> Homo sapiens

<400> 159
Arg Ala Leu Ile Glu Thr Ser Tyr Val
1 5

<210> 160
<211> 9
<212> PRT
<213> Homo sapiens

<400> 160
Ile Glu Thr Ser Tyr Val Lys Val Leu
1 5

<210> 161
<211> 10
<212> PRT
<213> Homo sapiens

<400> 161
Leu Ile Glu Thr Ser Tyr Val Lys Val Leu
1 5 10

<210> 162
<211> 8
<212> PRT
<213> Homo sapiens

<400> 162
Phe Leu Trp Gly Pro Arg Ala Leu
1 5

<210> 163
<211> 9
<212> PRT
<213> Homo sapiens

<400> 163

Glu Phe Leu Trp Gly Pro Arg Ala Leu
1 5

<210> 164

<211> 9

<212> PRT

<213> Homo sapiens

<400> 164

Phe Leu Trp Gly Pro Arg Ala Leu Val
1 5

<210> 165

<211> 9

<212> PRT

<213> Homo sapiens

<400> 165

Arg Ala Leu Val Glu Thr Ser Tyr Val
1 5

<210> 166

<211> 9

<212> PRT

<213> Homo sapiens

<400> 166

Leu Trp Gly Pro Arg Ala Leu Val Glu
1 5

<210> 167

<211> 10

<212> PRT

<213> Homo sapiens

<400> 167

Phe Leu Trp Gly Pro Arg Ala Leu Val Glu
1 5 10

<210> 168

<211> 10

<212> PRT

<213> Homo sapiens

<400> 168

Leu Trp Gly Pro Arg Ala Leu Val Glu Thr
1 5 10

<210> 169

<211> 9

<212> PRT

<213> Homo sapiens

<400> 169

Gly Pro Glu Ser Arg Leu Leu Glu Phe
1 5

<210> 170

<211> 9

<212> PRT

<213> Homo sapiens

<400> 170

Pro Glu Ser Arg Leu Leu Glu Phe Tyr
1 5

<210> 171

<211> 10

<212> PRT

<213> Homo sapiens

<400> 171

Gly Pro Glu Ser Arg Leu Leu Glu Phe Tyr
1 5 10

<210> 172

<211> 9

<212> PRT

<213> Homo sapiens

<400> 172

Glu Ser Arg Leu Leu Glu Phe Tyr Leu
1 5

<210> 173

<211> 9

<212> PRT

<213> Homo sapiens

<400> 173

Arg Leu Leu Glu Phe Tyr Leu Ala Met
1 5

<210> 174

<211> 9

<212> PRT

<213> Homo sapiens

<400> 174

Leu Glu Phe Tyr Leu Ala Met Pro Phe
1 5

<210> 175
<211> 10
<212> PRT
<213> Homo sapiens

<400> 175
Leu Leu Glu Phe Tyr Leu Ala Met Pro Phe
1 5 10

<210> 176
<211> 10
<212> PRT
<213> Homo sapiens

<400> 176
Ala Met Pro Phe Ala Thr Pro Met Glu Ala
1 5 10

<210> 177
<211> 9
<212> PRT
<213> Homo sapiens

<400> 177
Met Pro Phe Ala Thr Pro Met Glu Ala
1 5

<210> 178
<211> 9
<212> PRT
<213> Homo sapiens

<400> 178
Pro Leu Pro Val Pro Gly Val Leu Leu
1 5

<210> 179
<211> 10
<212> PRT
<213> Homo sapiens

<400> 179
Pro Pro Leu Pro Val Pro Gly Val Leu Leu
1 5 10

<210> 180
<211> 8
<212> PRT
<213> Homo sapiens

<400> 180

Leu Pro Val Pro Gly Val Leu Leu
1 5

<210> 181
<211> 10
<212> PRT
<213> Homo sapiens

<400> 181
Glu Leu Ala Arg Arg Ser Leu Ala Gln Asp
1 5 10

<210> 182
<211> 9
<212> PRT
<213> Homo sapiens

<400> 182
Val Pro Gly Val Leu Leu Lys Glu Phe
1 5

<210> 183
<211> 10
<212> PRT
<213> Homo sapiens

<400> 183
Pro Val Pro Gly Val Leu Leu Lys Glu Phe
1 5 10

<210> 184
<211> 8
<212> PRT
<213> Homo sapiens

<400> 184
Leu Pro Val Pro Gly Val Leu Leu
1 5

<210> 185
<211> 9
<212> PRT
<213> Homo sapiens

<400> 185
Thr Val Ser Gly Asn Ile Leu Thr Ile
1 5

<210> 186
<211> 10
<212> PRT

<213> Homo sapiens

<400> 186

Phe Thr Val Ser Gly Asn Ile Leu Thr Ile
1 5 10

<210> 187

<211> 9

<212> PRT

<213> Homo sapiens

<400> 187

Gly Val Leu Leu Lys Glu Phe Thr Val
1 5

<210> 188

<211> 10

<212> PRT

<213> Homo sapiens

<400> 188

Val Leu Leu Lys Glu Phe Thr Val Ser Gly
1 5 10

<210> 189

<211> 9

<212> PRT

<213> Homo sapiens

<400> 189

Leu Leu Lys Glu Phe Thr Val Ser Gly
1 5

<210> 190

<211> 9

<212> PRT

<213> Homo sapiens

<400> 190

Val Pro Gly Val Leu Leu Lys Glu Phe
1 5

<210> 191

<211> 10

<212> PRT

<213> Homo sapiens

<400> 191

Pro Val Pro Gly Val Leu Leu Lys Glu Phe
1 5 10

<210> 192
<211> 9
<212> PRT
<213> Homo sapiens

<400> 192
Ala Ala Asp His Arg Gln Leu Gln Leu
1 5

<210> 193
<211> 9
<212> PRT
<213> Homo sapiens

<400> 193
Ser Ile Ser Ser Cys Leu Gln Gln Leu
1 5

<210> 194
<211> 10
<212> PRT
<213> Homo sapiens

<400> 194
Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu
1 5 10

<210> 195
<211> 10
<212> PRT
<213> Homo sapiens

<400> 195
Thr Ala Ala Asp His Arg Gln Leu Gln Leu
1 5 10

<210> 196
<211> 9
<212> PRT
<213> Homo sapiens

<400> 196
Trp Ile Thr Gln Cys Phe Leu Pro Val
1 5

<210> 197
<211> 9
<212> PRT
<213> Homo sapiens

<400> 197
Ser Leu Leu Met Trp Ile Thr Gln Cys

1 5

<210> 198
<211> 9
<212> PRT
<213> Homo sapiens

<400> 198
Ser Ser Cys Leu Gln Gln Leu Ser Leu
1 5

<210> 199
<211> 9
<212> PRT
<213> Homo sapiens

<400> 199
Gln Gln Leu Ser Leu Leu Met Trp Ile
1 5

<210> 200
<211> 9
<212> PRT
<213> Homo sapiens

<400> 200
Ser Cys Leu Gln Gln Leu Ser Leu Leu
1 5

<210> 201
<211> 10
<212> PRT
<213> Homo sapiens

<400> 201
Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu
1 5 10

<210> 202
<211> 9
<212> PRT
<213> Homo sapiens

<400> 202
Thr Gln Cys Phe Leu Pro Val Phe Leu
1 5

<210> 203
<211> 10
<212> PRT
<213> Homo sapiens

<400> 203
Ile Thr Gln Cys Phe Leu Pro Val Phe Leu
1 5 10

<210> 204
<211> 9
<212> PRT
<213> Homo sapiens

<400> 204
Pro Met Gln Asp Ile Lys Met Ile Leu
1 5

<210> 205
<211> 10
<212> PRT
<213> Homo sapiens

<400> 205
Met Pro Met Gln Asp Ile Lys Met Ile Leu
1 5 10

<210> 206
<211> 9
<212> PRT
<213> Homo sapiens

<400> 206
Gln His Leu Ile Gly Leu Ser Asn Leu
1 5

<210> 207
<211> 10
<212> PRT
<213> Homo sapiens

<400> 207
Leu Gln His Leu Ile Gly Leu Ser Asn Leu
1 5 10

<210> 208
<211> 8
<212> PRT
<213> Homo sapiens

<400> 208
His Leu Ile Gly Leu Ser Asn Leu
1 5

<210> 209

<211> 9
<212> PRT
<213> Homo sapiens

<400> 209
Ile Gly Leu Ser Asn Leu Thr His Val
1 5

<210> 210
<211> 10
<212> PRT
<213> Homo sapiens

<400> 210
Leu Ile Gly Leu Ser Asn Leu Thr His Val
1 5 10

<210> 211
<211> 9
<212> PRT
<213> Homo sapiens

<400> 211
Val Leu Val His Pro Gln Trp Val Leu
1 5

<210> 212
<211> 10
<212> PRT
<213> Homo sapiens

<400> 212
Gly Val Leu Val His Pro Gln Trp Val Leu
1 5 10

<210> 213
<211> 9
<212> PRT
<213> Homo sapiens

<400> 213
Gly Val Leu Val His Pro Gln Trp Val
1 5

<210> 214
<211> 9
<212> PRT
<213> Homo sapiens

<400> 214
Trp Val Leu Thr Ala Ala His Cys Ile
1 5

<210> 215
<211> 10
<212> PRT
<213> Homo sapiens

<400> 215
Leu Val His Pro Gln Trp Val Leu Thr Ala
1 5 10

<210> 216
<211> 10
<212> PRT
<213> Homo sapiens

<400> 216
Val Leu Val His Pro Gln Trp Val Leu Thr
1 5 10

<210> 217
<211> 9
<212> PRT
<213> Homo sapiens

<400> 217
Leu Val His Pro Gln Trp Val Leu Thr
1 5

<210> 218
<211> 8
<212> PRT
<213> Homo sapiens

<400> 218
Cys Ile Arg Asn Lys Ser Val Ile
1 5

<210> 219
<211> 9
<212> PRT
<213> Homo sapiens

<400> 219
His Cys Ile Arg Asn Lys Ser Val Ile
1 5

<210> 220
<211> 9
<212> PRT
<213> Homo sapiens

<400> 220

His Pro Gln Trp Val Leu Thr Ala Ala
1 5

<210> 221

<211> 10

<212> PRT

<213> Homo sapiens

<400> 221

Ala Ala His Cys Ile Arg Asn Lys Ser Val
1 5 10

<210> 222

<211> 8

<212> PRT

<213> Homo sapiens

<400> 222

Leu Leu Trp Gly Pro Gly Gln Leu
1 5

<210> 223

<211> 9

<212> PRT

<213> Homo sapiens

<400> 223

Leu Leu Leu Trp Gly Pro Gly Gln Leu
1 5

<210> 224

<211> 10

<212> PRT

<213> Homo sapiens

<400> 224

Gly Leu Leu Leu Trp Gly Pro Gly Gln Leu
1 5 10

<210> 225

<211> 9

<212> PRT

<213> Homo sapiens

<400> 225

Ala Leu Gln Pro Ala Ala Ala Ile Leu
1 5

<210> 226

<211> 10

<212> PRT

<213> Homo sapiens

<400> 226

His Ala Leu Gln Pro Ala Ala Ala Ile Leu
1 5 10

<210> 227

<211> 10

<212> PRT

<213> Homo sapiens

<400> 227

Ala Pro Glu Lys Asp Lys Phe Phe Ala Tyr
1 5 10

<210> 228

<211> 9

<212> PRT

<213> Homo sapiens

<400> 228

Pro Glu Lys Asp Lys Phe Phe Ala Tyr
1 5

<210> 229

<211> 9

<212> PRT

<213> Homo sapiens

<400> 229

Glu Lys Asp Lys Phe Phe Ala Tyr Leu
1 5

<210> 230

<211> 8

<212> PRT

<213> Homo sapiens

<400> 230

Lys Asp Lys Phe Phe Ala Tyr Leu
1 5

<210> 231

<211> 9

<212> PRT

<213> Homo sapiens

<400> 231

Pro Ala Phe Leu Pro Trp His Arg Leu
1 5

<210> 232
<211> 10
<212> PRT
<213> Homo sapiens

<400> 232
Ala Pro Ala Phe Leu Pro Trp His Arg Leu
1 5 10

<210> 233
<211> 10
<212> PRT
<213> Homo sapiens

<400> 233
Phe Leu Leu Arg Trp Glu Gln Glu Ile Gln
1 5 10

<210> 234
<211> 9
<212> PRT
<213> Homo sapiens

<400> 234
Arg Leu Phe Leu Leu Arg Trp Glu Gln
1 5

<210> 235
<211> 10
<212> PRT
<213> Homo sapiens

<400> 235
Gly Ser Glu Ile Trp Arg Asp Ile Asp Phe
1 5 10

<210> 236
<211> 9
<212> PRT
<213> Homo sapiens

<400> 236
Ser Glu Ile Trp Arg Asp Ile Asp Phe
1 5

<210> 237
<211> 9
<212> PRT
<213> Homo sapiens

<400> 237

Arg Ile Trp Ser Trp Leu Leu Gly Ala
1 5

<210> 238
<211> 9
<212> PRT
<213> Homo sapiens

<400> 238
Ser Trp Leu Leu Gly Ala Ala Met Val
1 5

<210> 239
<211> 10
<212> PRT
<213> Homo sapiens

<400> 239
Trp Leu Leu Gly Ala Ala Met Val Gly Ala
1 5 10

<210> 240
<211> 9
<212> PRT
<213> Homo sapiens

<400> 240
Leu Leu Gly Ala Ala Met Val Gly Ala
1 5

<210> 241
<211> 9
<212> PRT
<213> Homo sapiens

<400> 241
Leu Leu His Glu Thr Asp Ser Ala Val
1 5

<210> 242
<211> 9
<212> PRT
<213> Homo sapiens

<400> 242
Ala Thr Ala Arg Arg Pro Arg Trp Leu
1 5

<210> 243
<211> 9
<212> PRT

<213> Homo sapiens

<400> 243

Thr Pro Lys His Asn Met Lys Ala Phe
1 5

<210> 244

<211> 10

<212> PRT

<213> Homo sapiens

<400> 244

Glu Leu Lys Ala Glu Asn Ile Lys Lys Phe
1 5 10

<210> 245

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (7)...(7)

<223> Xaa= His or Tyr

<400> 245

Asn Ile Lys Lys Phe Leu Xaa Asn Phe
1 5

<210> 246

<211> 10

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (8)...(8)

<223> Xaa = His or Tyr

<400> 246

Glu Asn Ile Lys Lys Phe Leu Xaa Asn Phe
1 5 10

<210> 247

<211> 9

<212> PRT

<213> Homo sapiens

<400> 247

Ala Gly Ala Lys Gly Val Ile Leu Tyr
1 5

<210> 248
<211> 10
<212> PRT
<213> Homo sapiens

<400> 248
Pro Leu Met Tyr Ser Leu Val His Asn Leu
1 5 10

<210> 249
<211> 9
<212> PRT
<213> Homo sapiens

<400> 249
Leu Met Tyr Ser Leu Val His Asn Leu
1 5

<210> 250
<211> 9
<212> PRT
<213> Homo sapiens

<400> 250
Arg Val Asp Cys Thr Pro Leu Met Tyr
1 5

<210> 251
<211> 9
<212> PRT
<213> Homo sapiens

<400> 251
Asp Cys Thr Pro Leu Met Tyr Ser Leu
1 5

<210> 252
<211> 9
<212> PRT
<213> Homo sapiens

<400> 252
Ser Gly Met Pro Arg Ile Ser Lys Leu
1 5

<210> 253
<211> 10
<212> PRT
<213> Homo sapiens

<400> 253
Phe Ser Gly Met Pro Arg Ile Ser Lys Leu

1 5 10

<210> 254
 <211> 28
 <212> PRT
 <213> Homo sapiens

<400> 254
 Arg Leu Thr Ala Ala Asp His Arg Gln Leu Gln Leu Ser Ile Ser Ser
 1 5 10 15
 Cys Leu Gln Gln Leu Ser Leu Leu Met Trp Ile Thr
 20 25

<210> 255
 <211> 28
 <212> PRT
 <213> Homo sapiens

<400> 255
 Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met Trp Ile Thr Gln Cys
 1 5 10 15
 Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser Gly
 20 25

<210> 256
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 256
 Lys Ala Glu Met Leu Glu Ser Val
 1 5

<210> 257
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 257
 Thr Lys Ala Glu Met Leu Glu Ser Val
 1 5

<210> 258
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 258
 Val Thr Lys Ala Glu Met Leu Glu Ser Val
 1 5 10

<210> 259
<211> 9
<212> PRT
<213> Homo sapiens

<400> 259
Met Leu Glu Ser Val Ile Lys Asn Tyr
1 5

<210> 260
<211> 10
<212> PRT
<213> Homo sapiens

<400> 260
Glu Met Leu Glu Ser Val Ile Lys Asn Tyr
1 5 10

<210> 261
<211> 9
<212> PRT
<213> Homo sapiens

<400> 261
Lys Ala Glu Met Leu Glu Ser Val Ile
1 5

<210> 262
<211> 8
<212> PRT
<213> Homo sapiens

<400> 262
Lys Ala Ser Glu Ser Leu Gln Leu
1 5

<210> 263
<211> 9
<212> PRT
<213> Homo sapiens

<400> 263
Gly Lys Ala Ser Glu Ser Leu Gln Leu
1 5

<210> 264
<211> 9
<212> PRT
<213> Homo sapiens

<400> 264
Ala Ser Glu Ser Leu Gln Leu Val Phe

1 5

<210> 265
<211> 9
<212> PRT
<213> Homo sapiens

<400> 265
Leu Val Phe Gly Ile Asp Val Lys Glu
1 5

<210> 266
<211> 8
<212> PRT
<213> Homo sapiens

<400> 266
Leu Leu Lys Tyr Arg Ala Arg Glu
1 5

<210> 267
<211> 8
<212> PRT
<213> Homo sapiens

<400> 267
Val Ala Asp Leu Val Gly Phe Leu
1 5

<210> 268
<211> 9
<212> PRT
<213> Homo sapiens

<400> 268
Lys Val Ala Asp Leu Val Gly Phe Leu
1 5

<210> 269
<211> 9
<212> PRT
<213> Homo sapiens

<400> 269
Ala Asp Leu Val Gly Phe Leu Leu Leu
1 5

<210> 270
<211> 10
<212> PRT
<213> Homo sapiens

<400> 270
Val Ala Asp Leu Val Gly Phe Leu Leu Leu
1 5 10

<210> 271
<211> 10
<212> PRT
<213> Homo sapiens

<400> 271
Leu Leu Lys Tyr Arg Ala Arg Glu Pro Val
1 5 10

<210> 272
<211> 9
<212> PRT
<213> Homo sapiens

<400> 272
Leu Val Glu Thr Ser Tyr Val Lys Val
1 5

<210> 273
<211> 10
<212> PRT
<213> Homo sapiens

<400> 273
Ala Leu Val Glu Thr Ser Tyr Val Lys Val
1 5 10

<210> 274
<211> 9
<212> PRT
<213> Homo sapiens

<400> 274
Lys Val Leu His His Met Val Lys Ile
1 5

<210> 275
<211> 9
<212> PRT
<213> Homo sapiens

<400> 275
Tyr Val Lys Val Leu His His Met Val
1 5

<210> 276

<211> 9
<212> PRT
<213> Homo sapiens

<400> 276
Pro Arg Ala Leu Val Glu Thr Ser Tyr
1 5

<210> 277
<211> 10
<212> PRT
<213> Homo sapiens

<400> 277
Gly Pro Arg Ala Leu Val Glu Thr Ser Tyr
1 5 10

<210> 278
<211> 10
<212> PRT
<213> Homo sapiens

<400> 278
Leu Val Glu Thr Ser Tyr Val Lys Val Leu
1 5 10

<210> 279
<211> 9
<212> PRT
<213> Homo sapiens

<400> 279
Thr Ile Ile Pro Glu Val Pro Gln Leu
1 5

<210> 280
<211> 10
<212> PRT
<213> Homo sapiens

<400> 280
Asp Thr Ile Ile Pro Glu Val Pro Gln Leu
1 5 10

<210> 281
<211> 10
<212> PRT
<213> Homo sapiens

<400> 281
Glu Val Pro Gln Leu Thr Asp Leu Ser Phe
1 5 10

<210> 282
<211> 8
<212> PRT
<213> Homo sapiens

<400> 282
Thr Pro Leu Asn Ser Ser Thr Ile
1 5

<210> 283
<211> 8
<212> PRT
<213> Homo sapiens

<400> 283
Ile Gly Leu Arg Trp Thr Pro Leu
1 5

<210> 284
<211> 9
<212> PRT
<213> Homo sapiens

<400> 284
Ser Ile Gly Leu Arg Trp Thr Pro Leu
1 5

<210> 285
<211> 9
<212> PRT
<213> Homo sapiens

<400> 285
Leu Asn Ser Ser Thr Ile Ile Gly Tyr
1 5

<210> 286
<211> 10
<212> PRT
<213> Homo sapiens

<400> 286
Pro Leu Asn Ser Ser Thr Ile Ile Gly Tyr
1 5 10

<210> 287
<211> 9
<212> PRT
<213> Homo sapiens

<400> 287

Thr Pro Leu Asn Ser Ser Thr Ile Ile
1 5

<210> 288

<211> 8

<212> PRT

<213> Homo sapiens

<400> 288

Ile Gly Tyr Arg Ile Thr Val Val
1 5

<210> 289

<211> 9

<212> PRT

<213> Homo sapiens

<400> 289

Ile Ile Gly Tyr Arg Ile Thr Val Val
1 5

<210> 290

<211> 10

<212> PRT

<213> Homo sapiens

<400> 290

Thr Ile Ile Gly Tyr Arg Ile Thr Val Val
1 5 10

<210> 291

<211> 9

<212> PRT

<213> Homo sapiens

<400> 291

Ile Gly Tyr Arg Ile Thr Val Val Ala
1 5

<210> 292

<211> 10

<212> PRT

<213> Homo sapiens

<400> 292

Ile Ile Gly Tyr Arg Ile Thr Val Val Ala
1 5 10

<210> 293

<211> 8

<212> PRT

<213> Homo sapiens

<400> 293

Ser Leu Pro Val Ser Pro Arg Leu

1 5

<210> 294

<211> 9

<212> PRT

<213> Homo sapiens

<400> 294

Gln Ser Leu Pro Val Ser Pro Arg Leu

1 5

<210> 295

<211> 8

<212> PRT

<213> Homo sapiens

<400> 295

Pro Val Ser Pro Arg Leu Gln Leu

1 5

<210> 296

<211> 9

<212> PRT

<213> Homo sapiens

<400> 296

Leu Pro Val Ser Pro Arg Leu Gln Leu

1 5

<210> 297

<211> 10

<212> PRT

<213> Homo sapiens

<400> 297

Ser Leu Pro Val Ser Pro Arg Leu Gln Leu

1 5 10

<210> 298

<211> 8

<212> PRT

<213> Homo sapiens

<400> 298

Leu Pro Val Ser Pro Arg Leu Gln

1 5

<210> 299
<211> 9
<212> PRT
<213> Homo sapiens

<400> 299
Gln Leu Ser Asn Gly Asn Arg Thr Leu
1 5

<210> 300
<211> 10
<212> PRT
<213> Homo sapiens

<400> 300
Leu Gln Leu Ser Asn Gly Asn Arg Thr Leu
1 5 10

<210> 301
<211> 9
<212> PRT
<213> Homo sapiens

<400> 301
Trp Val Asn Asn Gln Ser Leu Pro Val
1 5

<210> 302
<211> 9
<212> PRT
<213> Homo sapiens

<400> 302
Pro Val Ser Pro Arg Leu Gln Leu Ser
1 5

<210> 303
<211> 8
<212> PRT
<213> Homo sapiens

<400> 303
Ser Leu Pro Val Ser Pro Arg Leu
1 5

<210> 304
<211> 9
<212> PRT
<213> Homo sapiens

<400> 304

Gln Ser Leu Pro Val Ser Pro Arg Leu
1 5

<210> 305
<211> 8
<212> PRT
<213> Homo sapiens

<400> 305
Pro Val Ser Pro Arg Leu Gln Leu
1 5

<210> 306
<211> 9
<212> PRT
<213> Homo sapiens

<400> 306
Leu Pro Val Ser Pro Arg Leu Gln Leu
1 5

<210> 307
<211> 10
<212> PRT
<213> Homo sapiens

<400> 307
Ser Leu Pro Val Ser Pro Arg Leu Gln Leu
1 5 10

<210> 308
<211> 8
<212> PRT
<213> Homo sapiens

<400> 308
Leu Pro Val Ser Pro Arg Leu Gln
1 5

<210> 309
<211> 9
<212> PRT
<213> Homo sapiens

<400> 309
Gln Leu Ser Asn Asp Asn Arg Thr Leu
1 5

<210> 310
<211> 10
<212> PRT

<213> Homo sapiens

<400> 310

Leu Gln Leu Ser Asn Asp Asn Arg Thr Leu
1 5 10

<210> 311

<211> 9

<212> PRT

<213> Homo sapiens

<400> 311

Trp Val Asn Asn Gln Ser Leu Pro Val
1 5

<210> 312

<211> 9

<212> PRT

<213> Homo sapiens

<400> 312

Asn Gln Ser Leu Pro Val Ser Pro Arg
1 5

<210> 313

<211> 8

<212> PRT

<213> Homo sapiens

<400> 313

Ser Leu Pro Val Ser Pro Arg Leu
1 5

<210> 314

<211> 9

<212> PRT

<213> Homo sapiens

<400> 314

Gln Ser Leu Pro Val Ser Pro Arg Leu
1 5

<210> 315

<211> 8

<212> PRT

<213> Homo sapiens

<400> 315

Pro Val Ser Pro Arg Leu Gln Leu
1 5

<210> 316
<211> 9
<212> PRT
<213> Homo sapiens

<400> 316
Leu Pro Val Ser Pro Arg Leu Gln Leu
1 5

<210> 317
<211> 10
<212> PRT
<213> Homo sapiens

<400> 317
Ser Leu Pro Val Ser Pro Arg Leu Gln Leu
1 5 10

<210> 318
<211> 8
<212> PRT
<213> Homo sapiens

<400> 318
Leu Pro Val Ser Pro Arg Leu Gln
1 5

<210> 319
<211> 9
<212> PRT
<213> Homo sapiens

<400> 319
Gln Leu Ser Asn Gly Asn Arg Thr Leu
1 5

<210> 320
<211> 10
<212> PRT
<213> Homo sapiens

<400> 320
Leu Gln Leu Ser Asn Gly Asn Arg Thr Leu
1 5 10

<210> 321
<211> 9
<212> PRT
<213> Homo sapiens

<400> 321
Trp Val Asn Gly Gln Ser Leu Pro Val

1 5

<210> 322
<211> 9
<212> PRT
<213> Homo sapiens

<400> 322
Leu Trp Trp Val Asn Gly Gln Ser Leu
1 5

<210> 323
<211> 10
<212> PRT
<213> Homo sapiens

<400> 323
Tyr Leu Trp Trp Val Asn Gly Gln Ser Leu
1 5 10

<210> 324
<211> 9
<212> PRT
<213> Homo sapiens

<400> 324
Gly Gln Ser Leu Pro Val Ser Pro Arg
1 5

<210> 325
<211> 8
<212> PRT
<213> Homo sapiens

<400> 325
Asp Met Lys Leu Arg Leu Pro Ala
1 5

<210> 326
<211> 10
<212> PRT
<213> Homo sapiens

<400> 326
Gly Thr Asp Met Lys Leu Arg Leu Pro Ala
1 5 10

<210> 327
<211> 8
<212> PRT
<213> Homo sapiens

<400> 327

His Leu Asp Met Leu Arg His Leu
1 5

<210> 328

<211> 9

<212> PRT

<213> Homo sapiens

<400> 328

Thr His Leu Asp Met Leu Arg His Leu
1 5

<210> 329

<211> 10

<212> PRT

<213> Homo sapiens

<400> 329

Glu Thr His Leu Asp Met Leu Arg His Leu
1 5 10

<210> 330

<211> 8

<212> PRT

<213> Homo sapiens

<400> 330

Pro Ala Ser Pro Glu Thr His Leu
1 5

<210> 331

<211> 9

<212> PRT

<213> Homo sapiens

<400> 331

Leu Pro Ala Ser Pro Glu Thr His Leu
1 5

<210> 332

<211> 10

<212> PRT

<213> Homo sapiens

<400> 332

Arg Leu Pro Ala Ser Pro Glu Thr His Leu
1 5 10

<210> 333

<211> 9
<212> PRT
<213> Homo sapiens

<400> 333
Ser Pro Glu Thr His Leu Asp Met Leu
1 5

<210> 334
<211> 10
<212> PRT
<213> Homo sapiens

<400> 334
Ala Ser Pro Glu Thr His Leu Asp Met Leu
1 5 10

<210> 335
<211> 9
<212> PRT
<213> Homo sapiens

<400> 335
His Leu Asp Met Leu Arg His Leu Tyr
1 5

<210> 336
<211> 10
<212> PRT
<213> Homo sapiens

<400> 336
Thr His Leu Asp Met Leu Arg His Leu Tyr
1 5 10

<210> 337
<211> 8
<212> PRT
<213> Homo sapiens

<400> 337
Glu Leu Arg Lys Val Lys Val Leu
1 5

<210> 338
<211> 9
<212> PRT
<213> Homo sapiens

<400> 338
Thr Glu Leu Arg Lys Val Lys Val Leu
1 5

<210> 339
<211> 10
<212> PRT
<213> Homo sapiens

<400> 339
Glu Thr Glu Leu Arg Lys Val Lys Val Leu
1 5 10

<210> 340
<211> 9
<212> PRT
<213> Homo sapiens

<400> 340
Leu Lys Glu Thr Glu Leu Arg Lys Val
1 5

<210> 341
<211> 10
<212> PRT
<213> Homo sapiens

<400> 341
Ile Leu Lys Glu Thr Glu Leu Arg Lys Val
1 5 10

<210> 342
<211> 9
<212> PRT
<213> Homo sapiens

<400> 342
Met Arg Ile Leu Lys Glu Thr Glu Leu
1 5

<210> 343
<211> 10
<212> PRT
<213> Homo sapiens

<400> 343
Gln Met Arg Ile Leu Lys Glu Thr Glu Leu
1 5 10

<210> 344
<211> 9
<212> PRT
<213> Homo sapiens

<400> 344

Glu Thr Glu Leu Arg Lys Val Lys Val

1 5

<210> 345

<211> 10

<212> PRT

<213> Homo sapiens

<400> 345

Lys Glu Thr Glu Leu Arg Lys Val Lys Val

1 5 10

<210> 346

<211> 9

<212> PRT

<213> Homo sapiens

<400> 346

Met Pro Asn Gln Ala Gln Met Arg Ile

1 5

<210> 347

<211> 10

<212> PRT

<213> Homo sapiens

<400> 347

Ala Met Pro Asn Gln Ala Gln Met Arg Ile

1 5 10

<210> 348

<211> 10

<212> PRT

<213> Homo sapiens

<400> 348

Met Pro Asn Gln Ala Gln Met Arg Ile Leu

1 5 10

<210> 349

<211> 8

<212> PRT

<213> Homo sapiens

<400> 349

Arg Pro Arg Phe Arg Glu Leu Val

1 5

<210> 350

<211> 9

<212> PRT

<213> Homo sapiens

<400> 350

Cys Arg Pro Arg Phe Arg Glu Leu Val
1 5

<210> 351

<211> 9

<212> PRT

<213> Homo sapiens

<400> 351

Arg Phe Arg Glu Leu Val Ser Glu Phe
1 5

<210> 352

<211> 10

<212> PRT

<213> Homo sapiens

<400> 352

Pro Arg Phe Arg Glu Leu Val Ser Glu Phe
1 5 10

<210> 353

<211> 9

<212> PRT

<213> Homo sapiens

<400> 353

Glu Cys Arg Pro Arg Phe Arg Glu Leu
1 5

<210> 354

<211> 9

<212> PRT

<213> Homo sapiens

<400> 354

Gly Ala Ala Ser Gly Leu Asn Gly Cys
1 5

<210> 355

<211> 9

<212> PRT

<213> Homo sapiens

<400> 355

Arg Ala Ser Gly Pro Gly Gly Gly Ala
1 5

<210> 356
<211> 9
<212> PRT
<213> Homo sapiens

<400> 356
Pro His Gly Gly Ala Ala Ser Gly Leu
1 5

<210> 357
<211> 10
<212> PRT
<213> Homo sapiens

<400> 357
Gly Pro His Gly Gly Ala Ala Ser Gly Leu
1 5 10

<210> 358
<211> 10
<212> PRT
<213> Homo sapiens

<400> 358
Ala Pro Arg Gly Pro His Gly Gly Ala Ala
1 5 10

<210> 359
<211> 8
<212> PRT
<213> Homo sapiens

<400> 359
Val Arg Pro Arg Arg Trp Lys Leu
1 5

<210> 360
<211> 9
<212> PRT
<213> Homo sapiens

<400> 360
Glu Val Arg Pro Arg Arg Trp Lys Leu
1 5

<210> 361
<211> 9
<212> PRT
<213> Homo sapiens

<400> 361

Arg Pro Arg Arg Trp Lys Leu Gln Val
1 5

<210> 362
<211> 9
<212> PRT
<213> Homo sapiens

<400> 362
Pro Arg Arg Trp Lys Leu Gln Val Leu
1 5

<210> 363
<211> 10
<212> PRT
<213> Homo sapiens

<400> 363
Arg Pro Arg Arg Trp Lys Leu Gln Val Leu
1 5 10

<210> 364
<211> 9
<212> PRT
<213> Homo sapiens

<400> 364
Arg Trp Lys Leu Gln Val Leu Asp Leu
1 5

<210> 365
<211> 10
<212> PRT
<213> Homo sapiens

<400> 365
Arg Arg Trp Lys Leu Gln Val Leu Asp Leu
1 5 10

<210> 366
<211> 9
<212> PRT
<213> Homo sapiens

<400> 366
Pro Val Glu Val Leu Val Asp Leu Phe
1 5

<210> 367
<211> 8
<212> PRT

<213> Homo sapiens

<400> 367

Val Lys Arg Lys Lys Asn Val Leu
1 5

<210> 368

<211> 9

<212> PRT

<213> Homo sapiens

<400> 368

Lys Val Lys Arg Lys Lys Asn Val Leu
1 5

<210> 369

<211> 10

<212> PRT

<213> Homo sapiens

<400> 369

Glu Lys Val Lys Arg Lys Lys Asn Val Leu
1 5 10

<210> 370

<211> 8

<212> PRT

<213> Homo sapiens

<400> 370

Lys Val Lys Arg Lys Lys Asn Val
1 5

<210> 371

<211> 8

<212> PRT

<213> Homo sapiens

<400> 371

Arg Lys Lys Asn Val Leu Arg Leu
1 5

<210> 372

<211> 9

<212> PRT

<213> Homo sapiens

<400> 372

Lys Arg Lys Lys Asn Val Leu Arg Leu
1 5

<210> 373
<211> 10
<212> PRT
<213> Homo sapiens

<400> 373
Val Lys Arg Lys Lys Asn Val Leu Arg Leu
1 5 10

<210> 374
<211> 8
<212> PRT
<213> Homo sapiens

<400> 374
Asp Glu Leu Phe Ser Tyr Leu Ile
1 5

<210> 375
<211> 9
<212> PRT
<213> Homo sapiens

<400> 375
Val Leu Arg Leu Cys Cys Lys Lys Leu
1 5

<210> 376
<211> 10
<212> PRT
<213> Homo sapiens

<400> 376
Asn Val Leu Arg Leu Cys Cys Lys Lys Leu
1 5 10

<210> 377
<211> 9
<212> PRT
<213> Homo sapiens

<400> 377
Tyr Leu Ile Glu Lys Val Lys Arg Lys
1 5

<210> 378
<211> 8
<212> PRT
<213> Homo sapiens

<400> 378
Gln Ala Trp Pro Phe Thr Cys Leu

1 5

<210> 379
<211> 9
<212> PRT
<213> Homo sapiens

<400> 379
Val Gln Ala Trp Pro Phe Thr Cys Leu
1 5

<210> 380
<211> 10
<212> PRT
<213> Homo sapiens

<400> 380
Met Val Gln Ala Trp Pro Phe Thr Cys Leu
1 5 10

<210> 381
<211> 8
<212> PRT
<213> Homo sapiens

<400> 381
Leu Pro Leu Gly Val Leu Met Lys
1 5

<210> 382
<211> 9
<212> PRT
<213> Homo sapiens

<400> 382
Cys Leu Pro Leu Gly Val Leu Met Lys
1 5

<210> 383
<211> 10
<212> PRT
<213> Homo sapiens

<400> 383
Thr Cys Leu Pro Leu Gly Val Leu Met Lys
1 5 10

<210> 384
<211> 9
<212> PRT
<213> Homo sapiens

<400> 384

Gly Val Leu Met Lys Gly Gln His Leu
1 5

<210> 385

<211> 9

<212> PRT

<213> Homo sapiens

<400> 385

Leu Pro Leu Gly Val Leu Met Lys Gly
1 5

<210> 386

<211> 10

<212> PRT

<213> Homo sapiens

<400> 386

Cys Leu Pro Leu Gly Val Leu Met Lys Gly
1 5 10

<210> 387

<211> 10

<212> PRT

<213> Homo sapiens

<400> 387

Trp Pro Phe Thr Cys Leu Pro Leu Gly Val
1 5 10

<210> 388

<211> 9

<212> PRT

<213> Homo sapiens

<400> 388

Glu Leu Phe Pro Pro Leu Phe Met Ala
1 5

<210> 389

<211> 9

<212> PRT

<213> Homo sapiens

<400> 389

Pro Arg Glu Leu Phe Pro Pro Leu Phe
1 5

<210> 390

<211> 10
<212> PRT
<213> Homo sapiens

<400> 390
Leu Pro Arg Glu Leu Phe Pro Pro Leu Phe
1 5 10

<210> 391
<211> 9
<212> PRT
<213> Homo sapiens

<400> 391
Arg Glu Leu Phe Pro Pro Leu Phe Met
1 5

<210> 392
<211> 10
<212> PRT
<213> Homo sapiens

<400> 392
Pro Arg Glu Leu Phe Pro Pro Leu Phe Met
1 5 10

<210> 393
<211> 8
<212> PRT
<213> Homo sapiens

<400> 393
Arg Pro Ser Leu Tyr Thr Lys Val
1 5

<210> 394
<211> 9
<212> PRT
<213> Homo sapiens

<400> 394
Glu Arg Pro Ser Leu Tyr Thr Lys Val
1 5

<210> 395
<211> 8
<212> PRT
<213> Homo sapiens

<400> 395
Leu Pro Glu Arg Pro Ser Leu Tyr
1 5

<210> 396
<211> 9
<212> PRT
<213> Homo sapiens

<400> 396
Ala Leu Pro Glu Arg Pro Ser Leu Tyr
1 5

<210> 397
<211> 9
<212> PRT
<213> Homo sapiens

<400> 397
Ser Leu Tyr Thr Lys Val Val His Tyr
1 5

<210> 398
<211> 10
<212> PRT
<213> Homo sapiens

<400> 398
Pro Ser Leu Tyr Thr Lys Val Val His Tyr
1 5 10

<210> 399
<211> 9
<212> PRT
<213> Homo sapiens

<400> 399
Arg Pro Ser Leu Tyr Thr Lys Val Val
1 5

<210> 400
<211> 8
<212> PRT
<213> Homo sapiens

<400> 400
Gly Asn Lys Val Lys Asn Ala Gln
1 5

<210> 401
<211> 8
<212> PRT
<213> Homo sapiens

<400> 401

Ile Ala Arg Tyr Gly Lys Val Phe
1 5

<210> 402

<211> 9

<212> PRT

<213> Homo sapiens

<400> 402

Ala Gln Leu Ala Gly Ala Lys Gly Val
1 5

<210> 403

<211> 9

<212> PRT

<213> Homo sapiens

<400> 403

Lys Val Phe Arg Gly Asn Lys Val Lys
1 5

<210> 404

<211> 9

<212> PRT

<213> Homo sapiens

<400> 404

Gly Asn Lys Val Lys Asn Ala Gln Leu
1 5

<210> 405

<211> 9

<212> PRT

<213> Homo sapiens

<400> 405

Thr Pro Gly Tyr Pro Ala Asn Glu Tyr
1 5

<210> 406

<211> 10

<212> PRT

<213> Homo sapiens

<400> 406

Leu Thr Pro Gly Tyr Pro Ala Asn Glu Tyr
1 5 10

<210> 407

<211> 9

<212> PRT
<213> Homo sapiens

<400> 407
Gly Tyr Pro Ala Asn Glu Tyr Ala Tyr
1 5

<210> 408
<211> 10
<212> PRT
<213> Homo sapiens

<400> 408
Pro Gly Tyr Pro Ala Asn Glu Tyr Ala Tyr
1 5 10

<210> 409
<211> 9
<212> PRT
<213> Homo sapiens

<400> 409
Asp Pro Leu Thr Pro Gly Tyr Pro Ala
1 5

<210> 410
<211> 9
<212> PRT
<213> Homo sapiens

<400> 410
Ser Leu Tyr Glu Ser Trp Thr Lys Lys
1 5

<210> 411
<211> 10
<212> PRT
<213> Homo sapiens

<400> 411
Lys Ser Leu Tyr Glu Ser Trp Thr Lys Lys
1 5 10

<210> 412
<211> 9
<212> PRT
<213> Homo sapiens

<400> 412
Glu Gly Phe Glu Gly Lys Ser Leu Tyr
1 5

<210> 413
<211> 10
<212> PRT
<213> Homo sapiens

<400> 413
Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr
1 5 10

<210> 414
<211> 9
<212> PRT
<213> Homo sapiens

<400> 414
Thr Lys Lys Ser Pro Ser Pro Glu Phe
1 5

<210> 415
<211> 10
<212> PRT
<213> Homo sapiens

<400> 415
Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe
1 5 10

<210> 416
<211> 10
<212> PRT
<213> Homo sapiens

<400> 416
Ser Leu Tyr Glu Ser Trp Thr Lys Lys Ser
1 5 10

<210> 417
<211> 8
<212> PRT
<213> Homo sapiens

<400> 417
Trp Gly Glu Val Lys Arg Gln Ile
1 5

<210> 418
<211> 9
<212> PRT
<213> Homo sapiens

<400> 418

Ala Trp Gly Glu Val Lys Arg Gln Ile
1 5

<210> 419
<211> 10
<212> PRT
<213> Homo sapiens

<400> 419
Lys Ala Trp Gly Glu Val Lys Arg Gln Ile
1 5 10

<210> 420
<211> 8
<212> PRT
<213> Homo sapiens

<400> 420
Lys Ala Trp Gly Glu Val Lys Arg
1 5

<210> 421
<211> 9
<212> PRT
<213> Homo sapiens

<400> 421
Ser Lys Ala Trp Gly Glu Val Lys Arg
1 5

<210> 422
<211> 9
<212> PRT
<213> Homo sapiens

<400> 422
Gln Ile Tyr Val Ala Ala Phe Thr Val
1 5

<210> 423
<211> 9
<212> PRT
<213> Homo sapiens

<400> 423
Tyr Val Ala Ala Phe Thr Val Gln Ala
1 5

<210> 424
<211> 9
<212> PRT

<213> Homo sapiens

<400> 424

Trp Gly Glu Val Lys Arg Gln Ile Tyr
1 5

<210> 425

<211> 9

<212> PRT

<213> Homo sapiens

<400> 425

Glu Val Lys Arg Gln Ile Tyr Val Ala
1 5

<210> 426

<211> 9

<212> PRT

<213> Homo sapiens

<400> 426

Thr Val Gln Ala Ala Ala Glu Thr Leu
1 5

<210> 427

<211> 10

<212> PRT

<213> Homo sapiens

<400> 427

Phe Thr Val Gln Ala Ala Ala Glu Thr Leu
1 5 10

<210> 428

<211> 9

<212> PRT

<213> Homo sapiens

<400> 428

Lys Arg Gln Ile Tyr Val Ala Ala Phe
1 5

<210> 429

<211> 9

<212> PRT

<213> Homo sapiens

<400> 429

Pro Ser Lys Ala Trp Gly Glu Val Lys
1 5

<210> 430
<211> 9
<212> PRT
<213> Homo sapiens

<400> 430
Lys Ala Trp Gly Glu Val Lys Arg Gln
1 5

<210> 431
<211> 9
<212> PRT
<213> Homo sapiens

<400> 431
Trp Lys Glu Phe Gly Leu Asp Ser Val
1 5

<210> 432
<211> 10
<212> PRT
<213> Homo sapiens

<400> 432
Gln Trp Lys Glu Phe Gly Leu Asp Ser Val
1 5 10

<210> 433
<211> 10
<212> PRT
<213> Homo sapiens

<400> 433
Glu Phe Gly Leu Asp Ser Val Glu Leu Ala
1 5 10

<210> 434
<211> 9
<212> PRT
<213> Homo sapiens

<400> 434
Glu Leu Arg Gln Lys Glu Ser Lys Leu
1 5

<210> 435
<211> 10
<212> PRT
<213> Homo sapiens

<400> 435
Ala Glu Leu Arg Gln Lys Glu Ser Lys Leu

1 5 10

<210> 436
<211> 9
<212> PRT
<213> Homo sapiens

<400> 436
Lys Leu Gln Glu Asn Arg Lys Ile Ile
1 5

<210> 437
<211> 8
<212> PRT
<213> Homo sapiens

<400> 437
Gln Leu Glu Glu Lys Thr Lys Leu
1 5

<210> 438
<211> 9
<212> PRT
<213> Homo sapiens

<400> 438
Asn Gln Leu Glu Glu Lys Thr Lys Leu
1 5

<210> 439
<211> 9
<212> PRT
<213> Homo sapiens

<400> 439
Leu Leu Glu Glu Ser Arg Asp Lys Val
1 5

<210> 440
<211> 10
<212> PRT
<213> Homo sapiens

<400> 440
Phe Leu Leu Glu Glu Ser Arg Asp Lys Val
1 5 10

<210> 441
<211> 9
<212> PRT
<213> Homo sapiens

<400> 441

Glu Ser Arg Asp Lys Val Asn Gln Leu
1 5

<210> 442

<211> 10

<212> PRT

<213> Homo sapiens

<400> 442

Glu Glu Ser Arg Asp Lys Val Asn Gln Leu
1 5 10

<210> 443

<211> 9

<212> PRT

<213> Homo sapiens

<400> 443

Glu Lys Glu Val His Asp Leu Glu Tyr
1 5

<210> 444

<211> 10

<212> PRT

<213> Homo sapiens

<400> 444

Arg Glu Lys Glu Val His Asp Leu Glu Tyr
1 5 10

<210> 445

<211> 9

<212> PRT

<213> Homo sapiens

<400> 445

Asp Leu Glu Tyr Ser Tyr Cys His Tyr
1 5

<210> 446

<211> 9

<212> PRT

<213> Homo sapiens

<400> 446

Glu Val His Asp Leu Glu Tyr Ser Tyr
1 5

<210> 447

<211> 10
<212> PRT
<213> Homo sapiens

<400> 447
Glu Val His Asp Leu Glu Tyr Ser Tyr Cys
1 5 10

<210> 448
<211> 8
<212> PRT
<213> Homo sapiens

<400> 448
Lys Leu Ser Ser Lys Arg Glu Leu
1 5

<210> 449
<211> 8
<212> PRT
<213> Homo sapiens

<400> 449
Glu Leu Lys Asn Thr Glu Tyr Phe
1 5

<210> 450
<211> 9
<212> PRT
<213> Homo sapiens

<400> 450
Arg Glu Leu Lys Asn Thr Glu Tyr Phe
1 5

<210> 451
<211> 8
<212> PRT
<213> Homo sapiens

<400> 451
Lys Arg Gly Gln Arg Pro Lys Leu
1 5

<210> 452
<211> 10
<212> PRT
<213> Homo sapiens

<400> 452
Leu Pro Lys Arg Gly Gln Arg Pro Lys Leu
1 5 10

<210> 453
<211> 9
<212> PRT
<213> Homo sapiens

<400> 453
Leu Lys Asn Thr Glu Tyr Phe Thr Leu
1 5

<210> 454
<211> 10
<212> PRT
<213> Homo sapiens

<400> 454
Glu Leu Lys Asn Thr Glu Tyr Phe Thr Leu
1 5 10

<210> 455
<211> 9
<212> PRT
<213> Homo sapiens

<400> 455
Lys Arg Glu Leu Lys Asn Thr Glu Tyr
1 5

<210> 456
<211> 9
<212> PRT
<213> Homo sapiens

<400> 456
Lys Leu Ser Ser Lys Arg Glu Leu Lys
1 5

<210> 457
<211> 9
<212> PRT
<213> Homo sapiens

<400> 457
Gly Gln Arg Pro Lys Leu Ser Ser Lys
1 5

<210> 458
<211> 10
<212> PRT
<213> Homo sapiens

<400> 458
Arg Gly Gln Arg Pro Lys Leu Ser Ser Lys
1 5 10

<210> 459
<211> 9
<212> PRT
<213> Homo sapiens

<400> 459
Arg Pro Lys Leu Ser Ser Lys Arg Glu
1 5

<210> 460
<211> 8
<212> PRT
<213> Homo sapiens

<400> 460
Leu Glu Tyr Val Arg Glu Glu Leu
1 5

<210> 461
<211> 9
<212> PRT
<213> Homo sapiens

<400> 461
Glu Leu Glu Tyr Val Arg Glu Glu Leu
1 5

<210> 462
<211> 10
<212> PRT
<213> Homo sapiens

<400> 462
Asn Glu Leu Glu Tyr Val Arg Glu Glu Leu
1 5 10

<210> 463
<211> 10
<212> PRT
<213> Homo sapiens

<400> 463
Glu Leu Lys Gln Lys Arg Glu Asp Glu Val
1 5 10

<210> 464
<211> 9

<212> PRT
<213> Homo sapiens

<400> 464
Tyr Val Arg Glu Glu Leu Lys Gln Lys
1 5

<210> 465
<211> 9
<212> PRT
<213> Homo sapiens

<400> 465
Gln Leu Asn Val Tyr Glu Ile Lys Val
1 5

<210> 466
<211> 9
<212> PRT
<213> Homo sapiens

<400> 466
Ser Lys Gln Leu Asn Val Tyr Glu Ile
1 5

<210> 467
<211> 9
<212> PRT
<213> Homo sapiens

<400> 467
Ala Glu Ser Lys Gln Leu Asn Val Tyr
1 5

<210> 468
<211> 10
<212> PRT
<213> Homo sapiens

<400> 468
Thr Ala Glu Ser Lys Gln Leu Asn Val Tyr
1 5 10

<210> 469
<211> 8
<212> PRT
<213> Homo sapiens

<400> 469
Ile Lys Val Asn Lys Leu Glu Leu
1 5

<210> 470
<211> 9
<212> PRT
<213> Homo sapiens

<400> 470
Glu Ile Lys Val Asn Lys Leu Glu Leu
1 5

<210> 471
<211> 10
<212> PRT
<213> Homo sapiens

<400> 471
Tyr Glu Ile Lys Val Asn Lys Leu Glu Leu
1 5 10

<210> 472
<211> 9
<212> PRT
<213> Homo sapiens

<400> 472
Lys Leu Glu Leu Glu Leu Glu Ser Ala
1 5

<210> 473
<211> 9
<212> PRT
<213> Homo sapiens

<400> 473
Val Tyr Glu Ile Lys Val Asn Lys Leu
1 5

<210> 474
<211> 10
<212> PRT
<213> Homo sapiens

<400> 474
Asn Val Tyr Glu Ile Lys Val Asn Lys Leu
1 5 10

<210> 475
<211> 9
<212> PRT
<213> Homo sapiens

<400> 475

Glu Leu Glu Ser Ala Lys Gln Lys Phe
1 5

<210> 476
<211> 9
<212> PRT
<213> Homo sapiens

<400> 476
Lys Leu Glu Leu Glu Leu Glu Ser Ala
1 5

<210> 477
<211> 9
<212> PRT
<213> Homo sapiens

<400> 477
Glu Leu Glu Ser Ala Lys Gln Lys Phe
1 5

<210> 478
<211> 8
<212> PRT
<213> Homo sapiens

<400> 478
Lys Glu Lys Leu Lys Arg Glu Ala
1 5

<210> 479
<211> 9
<212> PRT
<213> Homo sapiens

<400> 479
Glu Ala Lys Glu Asn Thr Ala Thr Leu
1 5

<210> 480
<211> 10
<212> PRT
<213> Homo sapiens

<400> 480
Arg Glu Ala Lys Glu Asn Thr Ala Thr Leu
1 5 10

<210> 481
<211> 10
<212> PRT

<213> Homo sapiens

<400> 481

Lys Leu Lys Arg Glu Ala Lys Glu Asn Thr
1 5 10

<210> 482

<211> 8

<212> PRT

<213> Homo sapiens

<400> 482

Glu Ala Glu Lys Ile Lys Lys Trp
1 5

<210> 483

<211> 9

<212> PRT

<213> Homo sapiens

<400> 483

Gly Leu Ser Arg Val Tyr Ser Lys Leu
1 5

<210> 484

<211> 10

<212> PRT

<213> Homo sapiens

<400> 484

Glu Gly Leu Ser Arg Val Tyr Ser Lys Leu
1 5 10

<210> 485

<211> 9

<212> PRT

<213> Homo sapiens

<400> 485

Lys Leu Tyr Lys Glu Ala Glu Lys Ile
1 5

<210> 486

<211> 9

<212> PRT

<213> Homo sapiens

<400> 486

Asn Ser Glu Gly Leu Ser Arg Val Tyr
1 5

<210> 487
<211> 10
<212> PRT
<213> Homo sapiens

<400> 487
Glu Asn Ser Glu Gly Leu Ser Arg Val Tyr
1 5 10

<210> 488
<211> 9
<212> PRT
<213> Homo sapiens

<400> 488
Leu Ser Arg Val Tyr Ser Lys Leu Tyr
1 5

<210> 489
<211> 10
<212> PRT
<213> Homo sapiens

<400> 489
Gly Leu Ser Arg Val Tyr Ser Lys Leu Tyr
1 5 10

<210> 490
<211> 10
<212> PRT
<213> Homo sapiens

<400> 490
Leu Glu Asn Ser Glu Gly Leu Ser Arg Val
1 5 10

<210> 491
<211> 10
<212> PRT
<213> Homo sapiens

<400> 491
Lys Leu Tyr Lys Glu Ala Glu Lys Ile Lys
1 5 10

<210> 492
<211> 8
<212> PRT
<213> Homo sapiens

<400> 492
Arg Glu Asp Arg Trp Ala Val Ile

1 5

<210> 493
<211> 9
<212> PRT
<213> Homo sapiens

<400> 493
Met Arg Glu Asp Arg Trp Ala Val Ile
1 5

<210> 494
<211> 10
<212> PRT
<213> Homo sapiens

<400> 494
Lys Met Arg Glu Asp Arg Trp Ala Val Ile
1 5 10

<210> 495
<211> 9
<212> PRT
<213> Homo sapiens

<400> 495
Lys Met Arg Glu Asp Arg Trp Ala Val
1 5

<210> 496
<211> 9
<212> PRT
<213> Homo sapiens

<400> 496
Thr Thr Pro Gly Ser Thr Leu Lys Phe
1 5

<210> 497
<211> 10
<212> PRT
<213> Homo sapiens

<400> 497
Leu Thr Thr Pro Gly Ser Thr Leu Lys Phe
1 5 10

<210> 498
<211> 8
<212> PRT
<213> Homo sapiens

<400> 498

Gly Ser Thr Leu Lys Gly Ala Ile
1 5

<210> 499

<211> 9

<212> PRT

<213> Homo sapiens

<400> 499

Ile Arg Lys Met Arg Glu Asp Arg Trp
1 5

<210> 500

<211> 8

<212> PRT

<213> Homo sapiens

<400> 500

Arg Leu Glu Met His Phe Lys Leu
1 5

<210> 501

<211> 9

<212> PRT

<213> Homo sapiens

<400> 501

Ser Arg Leu Glu Met His Phe Lys Leu
1 5

<210> 502

<211> 9

<212> PRT

<213> Homo sapiens

<400> 502

Lys Leu Lys Glu Asp Tyr Glu Lys Ile
1 5

<210> 503

<211> 9

<212> PRT

<213> Homo sapiens

<400> 503

Lys Ile Gln His Leu Glu Gln Glu Tyr
1 5

<210> 504

<211> 10
<212> PRT
<213> Homo sapiens

<400> 504
Glu Lys Ile Gln His Leu Glu Gln Glu Tyr
1 5 10

<210> 505
<211> 9
<212> PRT
<213> Homo sapiens

<400> 505
Glu Asn Ser Arg Leu Glu Met His Phe
1 5

<210> 506
<211> 10
<212> PRT
<213> Homo sapiens

<400> 506
Arg Leu Glu Met His Phe Lys Leu Lys Glu
1 5 10

<210> 507
<211> 8
<212> PRT
<213> Homo sapiens

<400> 507
Leu Glu Asp Ile Lys Val Ser Leu
1 5

<210> 508
<211> 9
<212> PRT
<213> Homo sapiens

<400> 508
Glu Leu Glu Asp Ile Lys Val Ser Leu
1 5

<210> 509
<211> 10
<212> PRT
<213> Homo sapiens

<400> 509
Lys Glu Leu Glu Asp Ile Lys Val Ser Leu
1 5 10

<210> 510
<211> 8
<212> PRT
<213> Homo sapiens

<400> 510
Leu Thr Lys Glu Leu Glu Asp Ile
1 5

<210> 511
<211> 9
<212> PRT
<213> Homo sapiens

<400> 511
His Leu Thr Lys Glu Leu Glu Asp Ile
1 5

<210> 512
<211> 9
<212> PRT
<213> Homo sapiens

<400> 512
Ser Leu Gln Arg Ser Val Ser Thr Gln
1 5

<210> 513
<211> 9
<212> PRT
<213> Homo sapiens

<400> 513
Thr Lys Glu Leu Glu Asp Ile Lys Val
1 5

<210> 514
<211> 10
<212> PRT
<213> Homo sapiens

<400> 514
Leu Thr Lys Glu Leu Glu Asp Ile Lys Val
1 5 10

<210> 515
<211> 10
<212> PRT
<213> Homo sapiens

<400> 515
Asp Ile Lys Val Ser Leu Gln Arg Ser Val
1 5 10

<210> 516
<211> 8
<212> PRT
<213> Homo sapiens

<400> 516
Lys Met Lys Asp Leu Thr Phe Leu
1 5

<210> 517
<211> 9
<212> PRT
<213> Homo sapiens

<400> 517
Asn Lys Met Lys Asp Leu Thr Phe Leu
1 5

<210> 518
<211> 10
<212> PRT
<213> Homo sapiens

<400> 518
Glu Asn Lys Met Lys Asp Leu Thr Phe Leu
1 5 10

<210> 519
<211> 9
<212> PRT
<213> Homo sapiens

<400> 519
Leu Leu Glu Glu Ser Arg Asp Lys Val
1 5

<210> 520
<211> 10
<212> PRT
<213> Homo sapiens

<400> 520
Phe Leu Leu Glu Glu Ser Arg Asp Lys Val
1 5 10

<210> 521
<211> 9

<212> PRT
<213> Homo sapiens

<400> 521
Glu Ser Arg Asp Lys Val Asn Gln Leu
1 5

<210> 522
<211> 10
<212> PRT
<213> Homo sapiens

<400> 522
Glu Glu Ser Arg Asp Lys Val Asn Gln Leu
1 5 10

<210> 523
<211> 9
<212> PRT
<213> Homo sapiens

<400> 523
Glu Lys Glu Asn Lys Met Lys Asp Leu
1 5

<210> 524
<211> 10
<212> PRT
<213> Homo sapiens

<400> 524
Thr Glu Lys Glu Asn Lys Met Lys Asp Leu
1 5 10

<210> 525
<211> 9
<212> PRT
<213> Homo sapiens

<400> 525
Glu Asn Lys Met Lys Asp Leu Thr Phe
1 5

<210> 526
<211> 8
<212> PRT
<213> Homo sapiens

<400> 526
Ile Glu Lys Met Ile Thr Ala Phe
1 5

<210> 527
<211> 9
<212> PRT
<213> Homo sapiens

<400> 527
Asn Ile Glu Lys Met Ile Thr Ala Phe
1 5

<210> 528
<211> 10
<212> PRT
<213> Homo sapiens

<400> 528
Ser Asn Ile Glu Lys Met Ile Thr Ala Phe
1 5 10

<210> 529
<211> 8
<212> PRT
<213> Homo sapiens

<400> 529
Thr Ala Phe Glu Glu Leu Arg Val
1 5

<210> 530
<211> 9
<212> PRT
<213> Homo sapiens

<400> 530
Ile Thr Ala Phe Glu Glu Leu Arg Val
1 5

<210> 531
<211> 10
<212> PRT
<213> Homo sapiens

<400> 531
Met Ile Thr Ala Phe Glu Glu Leu Arg Val
1 5 10

<210> 532
<211> 9
<212> PRT
<213> Homo sapiens

<400> 532

Lys Met Ile Thr Ala Phe Glu Glu Leu
1 5

<210> 533
<211> 10
<212> PRT
<213> Homo sapiens

<400> 533
Glu Lys Met Ile Thr Ala Phe Glu Glu Leu
1 5 10

<210> 534
<211> 9
<212> PRT
<213> Homo sapiens

<400> 534
Glu Leu Arg Val Gln Ala Glu Asn Ser
1 5

<210> 535
<211> 10
<212> PRT
<213> Homo sapiens

<400> 535
Asp Leu Asn Ser Asn Ile Glu Lys Met Ile
1 5 10

<210> 536
<211> 8
<212> PRT
<213> Homo sapiens

<400> 536
Trp Thr Ser Ala Lys Asn Thr Leu
1 5

<210> 537
<211> 9
<212> PRT
<213> Homo sapiens

<400> 537
Thr Pro Leu Pro Lys Ala Tyr Thr Val
1 5

<210> 538
<211> 10
<212> PRT

<213> Homo sapiens

<400> 538

Ser Thr Pro Leu Pro Lys Ala Tyr Thr Val
1 5 10

<210> 539

<211> 9

<212> PRT

<213> Homo sapiens

<400> 539

Leu Ser Thr Pro Leu Pro Lys Ala Tyr
1 5

<210> 540

<211> 10

<212> PRT

<213> Homo sapiens

<400> 540

Thr Leu Ser Thr Pro Leu Pro Lys Ala Tyr
1 5 10

<210> 541

<211> 9

<212> PRT

<213> Homo sapiens

<400> 541

Asn Thr Leu Ser Thr Pro Leu Pro Lys
1 5

<210> 542

<211> 10

<212> PRT

<213> Homo sapiens

<400> 542

Lys Asn Thr Leu Ser Thr Pro Leu Pro Lys
1 5 10

<210> 543

<211> 8

<212> PRT

<213> Homo sapiens

<400> 543

Ile Ser Lys Asp Lys Arg Asp Tyr
1 5

<210> 544
<211> 10
<212> PRT
<213> Homo sapiens

<400> 544
His Gly Ile Ser Lys Asp Lys Arg Asp Tyr
1 5 10

<210> 545
<211> 9
<212> PRT
<213> Homo sapiens

<400> 545
Lys Arg Asp Tyr Leu Trp Thr Ser Ala
1 5

<210> 546
<211> 10
<212> PRT
<213> Homo sapiens

<400> 546
Ser Lys Asp Lys Arg Asp Tyr Leu Trp Thr
1 5 10

<210> 547
<211> 8
<212> PRT
<213> Homo sapiens

<400> 547
Glu Asn Lys Met Lys Asp Leu Thr
1 5

<210> 548
<211> 9
<212> PRT
<213> Homo sapiens

<400> 548
Glu Ile Asn Asp Lys Glu Lys Gln Val
1 5

<210> 549
<211> 9
<212> PRT
<213> Homo sapiens

<400> 549
Gln Ile Thr Glu Lys Glu Asn Lys Met

1 5

<210> 550
<211> 9
<212> PRT
<213> Homo sapiens

<400> 550
Ser Leu Leu Leu Ile Gln Ile Thr Glu
1 5

<210> 551
<211> 8
<212> PRT
<213> Homo sapiens

<400> 551
Phe Glu Lys Ile Ala Glu Glu Leu
1 5

<210> 552
<211> 9
<212> PRT
<213> Homo sapiens

<400> 552
Gln Phe Glu Lys Ile Ala Glu Glu Leu
1 5

<210> 553
<211> 10
<212> PRT
<213> Homo sapiens

<400> 553
Lys Gln Phe Glu Lys Ile Ala Glu Glu Leu
1 5 10

<210> 554
<211> 8
<212> PRT
<213> Homo sapiens

<400> 554
Asp Asn Lys Gln Phe Glu Lys Ile
1 5

<210> 555
<211> 9
<212> PRT
<213> Homo sapiens

<400> 555

Tyr Asp Asn Lys Gln Phe Glu Lys Ile
1 5

<210> 556

<211> 10

<212> PRT

<213> Homo sapiens

<400> 556

Leu Tyr Asp Asn Lys Gln Phe Glu Lys Ile
1 5 10

<210> 557

<211> 8

<212> PRT

<213> Homo sapiens

<400> 557

Leu Gly Glu Lys Glu Thr Leu Leu
1 5

<210> 558

<211> 9

<212> PRT

<213> Homo sapiens

<400> 558

Val Leu Gly Glu Lys Glu Thr Leu Leu
1 5

<210> 559

<211> 10

<212> PRT

<213> Homo sapiens

<400> 559

Lys Val Leu Gly Glu Lys Glu Thr Leu Leu
1 5 10

<210> 560

<211> 9

<212> PRT

<213> Homo sapiens

<400> 560

Leu Leu Arg Thr Glu Gln Gln Arg Leu
1 5

<210> 561

<211> 10
<212> PRT
<213> Homo sapiens

<400> 561
Glu Leu Leu Arg Thr Glu Gln Gln Arg Leu
1 5 10

<210> 562
<211> 9
<212> PRT
<213> Homo sapiens

<400> 562
Thr Glu Gln Gln Arg Leu Glu Asn Tyr
1 5

<210> 563
<211> 10
<212> PRT
<213> Homo sapiens

<400> 563
Arg Thr Glu Gln Gln Arg Leu Glu Asn Tyr
1 5 10

<210> 564
<211> 9
<212> PRT
<213> Homo sapiens

<400> 564
Glu Asp Gln Leu Ile Ile Leu Thr Met
1 5

<210> 565
<211> 10
<212> PRT
<213> Homo sapiens

<400> 565
Arg Leu Glu Asn Tyr Glu Asp Gln Leu Ile
1 5 10

<210> 566
<211> 8
<212> PRT
<213> Homo sapiens

<400> 566
Lys Ala Arg Ala Ala His Ser Phe
1 5

<210> 567
<211> 9
<212> PRT
<213> Homo sapiens

<400> 567
Val Val Thr Glu Phe Glu Thr Thr Val
1 5

<210> 568
<211> 10
<212> PRT
<213> Homo sapiens

<400> 568
Phe Val Val Thr Glu Phe Glu Thr Thr Val
1 5 10

<210> 569
<211> 9
<212> PRT
<213> Homo sapiens

<400> 569
Val Thr Glu Phe Glu Thr Thr Val Cys
1 5

<210> 570
<211> 10
<212> PRT
<213> Homo sapiens

<400> 570
Val Val Thr Glu Phe Glu Thr Thr Val Cys
1 5 10

<210> 571
<211> 9
<212> PRT
<213> Homo sapiens

<400> 571
Asp Leu Gln Ile Ala Thr Asn Thr Ile
1 5

<210> 572
<211> 9
<212> PRT
<213> Homo sapiens

<400> 572
Ile Ala Thr Asn Thr Ile Cys Gln Leu
1 5

<210> 573
<211> 10
<212> PRT
<213> Homo sapiens

<400> 573
Gln Ile Ala Thr Asn Thr Ile Cys Gln Leu
1 5 10

<210> 574
<211> 9
<212> PRT
<213> Homo sapiens

<400> 574
Val Met Thr Lys Leu Gly Phe Lys Tyr
1 5

<210> 575
<211> 9
<212> PRT
<213> Homo sapiens

<400> 575
Leu Asn Tyr Glu Val Met Thr Lys Leu
1 5

<210> 576
<211> 10
<212> PRT
<213> Homo sapiens

<400> 576
Lys Leu Asn Tyr Glu Val Met Thr Lys Leu
1 5 10

<210> 577
<211> 9
<212> PRT
<213> Homo sapiens

<400> 577
Thr Leu Pro Pro Phe Met Arg Ser Lys
1 5

<210> 578
<211> 9

<212> PRT
<213> Homo sapiens

<400> 578
Lys Ile Met Pro Lys Lys Pro Ala Glu
1 5

<210> 579
<211> 10
<212> PRT
<213> Homo sapiens

<400> 579
Ser Leu Gln Arg Ile Phe Pro Lys Ile Met
1 5 10

<210> 580
<211> 9
<212> PRT
<213> Homo sapiens

<400> 580
Tyr Ile Lys Ser Tyr Leu Glu Gln Ala
1 5

<210> 581
<211> 9
<212> PRT
<213> Homo sapiens

<400> 581
Ser Phe Gln Asp Tyr Ile Lys Ser Tyr
1 5

<210> 582
<211> 10
<212> PRT
<213> Homo sapiens

<400> 582
Asp Ser Phe Gln Asp Tyr Ile Lys Ser Tyr
1 5 10

<210> 583
<211> 8
<212> PRT
<213> Homo sapiens

<400> 583
Leu Pro Glu Glu Lys Gln Pro Leu
1 5

<210> 584
<211> 9
<212> PRT
<213> Homo sapiens

<400> 584
Gln Leu Pro Glu Glu Lys Gln Pro Leu
1 5

<210> 585
<211> 10
<212> PRT
<213> Homo sapiens

<400> 585
Lys Gln Leu Pro Glu Glu Lys Gln Pro Leu
1 5 10

<210> 586
<211> 9
<212> PRT
<213> Homo sapiens

<400> 586
Leu Pro Glu Glu Lys Gln Pro Leu Leu
1 5

<210> 587
<211> 10
<212> PRT
<213> Homo sapiens

<400> 587
Gln Leu Pro Glu Glu Lys Gln Pro Leu Leu
1 5 10

<210> 588
<211> 9
<212> PRT
<213> Homo sapiens

<400> 588
Ser Leu Leu Cys Arg His Lys Arg Lys
1 5

<210> 589
<211> 91
<212> PRT
<213> Homo sapiens

<400> 589

Glu Val Pro Gln Leu Thr Asp Leu Ser Phe Val Asp Ile Thr Asp Ser
 1 5 10 15
 Ser Ile Gly Leu Arg Trp Thr Pro Leu Asn Ser Ser Thr Ile Ile Gly
 20 25 30
 Tyr Arg Ile Thr Val Val Ala Ala Gly Glu Gly Ile Pro Ile Phe Glu
 35 40 45
 Asp Phe Val Asp Ser Ser Val Gly Tyr Tyr Thr Val Thr Gly Leu Glu
 50 55 60
 Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile Asn Gly Gly
 65 70 75 80
 Glu Ser Ala Pro Thr Thr Leu Thr Gln Gln Thr
 85 90

<210> 590

<211> 147

<212> PRT

<213> Homo sapiens

<400> 590

Cys Thr Phe Asp Asn Leu Ser Pro Gly Leu Glu Tyr Asn Val Ser Val
 1 5 10 15
 Tyr Thr Val Lys Asp Asp Lys Glu Ser Val Pro Ile Ser Asp Thr Ile
 20 25 30
 Ile Pro Glu Val Pro Gln Leu Thr Asp Leu Ser Phe Val Asp Ile Thr
 35 40 45
 Asp Ser Ser Ile Gly Leu Arg Trp Thr Pro Leu Asn Ser Ser Thr Ile
 50 55 60
 Ile Gly Tyr Arg Ile Thr Val Val Ala Ala Gly Glu Gly Ile Pro Ile
 65 70 75 80
 Phe Glu Asp Phe Val Asp Ser Ser Val Gly Tyr Tyr Thr Val Thr Gly
 85 90 95
 Leu Glu Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile Asn
 100 105 110
 Gly Gly Glu Ser Ala Pro Thr Thr Leu Thr Gln Gln Thr Ala Val Pro
 115 120 125
 Pro Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg
 130 135 140
 Val Thr Trp
 145

<210> 591

<211> 2823

<212> DNA

<213> Homo sapiens

<400> 591

ctgcactttt gataacctga gtcccgccct ggagtacaat gtcagtgttt acactgtcaa 60
 ggatgacaag gaaagtgtcc ctatctctga taccatcatc ccaggtaata gaaaataagc 120
 tgctatcctg agagtgcacat tccaataaga gtggggatta gcatcttaat cccagatgc 180
 ttaaggggtg caactatatt tgggatttaa ttccgatctc ccagctgcac ttccaaaac 240
 caagaagtca aagcagcgat ttggacaaaa tgcttgctgt taacactgct ttactgtctg 300
 tgcttcactg ggatgctgtg tggtgcagcg agtatgtaat ggagtggcag ccatggcctt 360
 aactctgtat tgtctgctca catggaagta tgactaaaac actgtcacgt gtctgtactc 420
 agtactgata ggctcaaagt aatatggtaa atgcatccca tcagtacatt tctgcccgat 480
 ttacaatcc atatcaattt ccaacagctg cctatttcat cttgcagttt caaatccttc 540

```

tttttgaaaa ttggatttta aaaaaaagtt aagtaaaagt cacacettca ggggtgttct 600
ttcttgtggc cttgaaagac aacattgcaa aggctgtcc taaggatagg cttgtttgtc 660
cattgggtta taacataatg aaagcattgg acagatcgtg tccccctttg gactcttcag 720
tagaatgctt ttactaacgc taattacatg ttttgattat gaatgaacct aaaatagtg 780
caatggcctt aacctaggcc tgtctttcct cagcctgaat gtgcttttga atggcacatt 840
tcacaccata cattcataat gcattagcgt tatggccatg atgttgtcat gagttttgta 900
tgggagaaaa aaaatcaatt tatcacccat ttattatttt ttccggttgt tcatgcaagc 960
ttatttttcta ctaaaacagt tttggaatta ttaaaagcat tgctgatact tacttcagat 1020
attatgtcta ggctctaaga atggttttca catcctaaac agccatataga tttttaggaa 1080
tctgaacagt tcaaattgta ccttttaagg atgttttcaa aatgtaaaaa atatatatat 1140
atatatatat tccctaaaaa aatattcctg tttattcttc tagggaagca aactgttcat 1200
gatgcttagg aagtcttttc agagaattta aaacagattg catattacca tcattgtctt 1260
aacattccac caattttact actagtaacc tgatatacac tgctttattt tttcctcttt 1320
ttttccctct attttccttt tgctccccc tccctttgct ttgtaactca atagaggtgc 1380
cccaactcac tgacctaaagc tttgttgata taaccgattc aagcatcggc ctgaggtgga 1440
ccccgctaaa cctttccacc attattgggt accgcatcac agtagttgag gcaggagaag 1500
gtatccctat ttttgaagat tttgtggact cctcagtagg atactacaca gtcacagggc 1560
tggagccggg cattgactat gatatcagcg ttatcactct cattaatggc ggcgagagtg 1620
cccctactac actgacacaa caaacgggtg aattttgaaa acttctgogt ttgagacata 1680
gatggtgttg catgtgccca ccagttactc cgggttaaata tggatgtttc atgggggaag 1740
tcagcaattg gccaaagatt cagataggtg gaattggggg gataaggaat caaatgcac 1800
tgctaaactg attggagaaa aacacatgca atattctcag tacactctca tttaaaccac 1860
aagtagatat aaagcctaga gaaatacaga tgtctgctct gttaaatata aaatagcaaa 1920
tgttcattca atttgaagac ctagaatttt tcttcttaaa taccaaacac gaataccaaa 1980
ttgcgtaagt accaattgat aagaatatat caccaaaatg taccatcatg ctcttccttc 2040
taccctttga taaactctac catgctcctt ctttgtagct aaaaacccat caaaatttag 2100
ggtagagtgg atgggcattg ttttgaggta ggagaaaaag aaacttggga ccattctagg 2160
ttttgttgct gtcactaggt aaagaaacac ctctttaacc acagtctggg gacaagcatg 2220
caacatttta aaggttctct gctgtgcatg ggaaaagaaa catgctgaga accaatttgc 2280
atgaacatgt tcacttgtaa gtagaattca ctgaatggaa ctgtagctct agatatctca 2340
catgggggga agtttaggac cctcttgtct ttttgtctgt gtgcatgtat ttctttgtaa 2400
agtactgcta tgtttctctt tgctgtgtgg caacttaagc ctcttcggcc tgggataaaa 2460
taatctgcag tggatttaat aatgtacata aagtcaacat atttgaagat agattaaaa 2520
cttttttaaa tatatcaatg atggcaaaaa gggttaaagg ggccaaacag tactgtgtgt 2580
agtgttttat ttttaacagt agtacactat aacttaaaat agacttagat tagactgttt 2640
gcatgattat gattctgttt cctttatgca tgaaatattg attttacctt tccagctact 2700
tcgttagctt taattttaaa atacattaac tgagctctcc ttcttggtcg aaaccagctg 2760
ttcctcctoc cactgacctg cgattcacca acattgggtc agacaccatg cgtgtcacct 2820
ggg

```

<210> 592

<211> 702

<212> PRT

<213> Homo sapiens

<400> 592

```

Met Glu Ser Pro Ser Ala Pro Pro His Arg Trp Cys Ile Pro Trp Gln
1          5          10          15
Arg Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr
20          25          30
Thr Ala Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly
35          40          45
Lys Glu Val Leu Leu Leu Val His Asn Leu Pro Gln His Leu Phe Gly
50          55          60
Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Ile
65          70          75          80
Gly Tyr Val Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Tyr Ser

```


124

```

Pro Arg Leu Gln Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn
545                               550                               555                               560
Val Thr Arg Asn Asp Ala Arg Ala Tyr Val Cys Gly Ile Gln Asn Ser
                               565                               570                               575
Val Ser Ala Asn Arg Ser Asp Pro Val Thr Leu Asp Val Leu Tyr Gly
                               580                               585                               590
Pro Asp Thr Pro Ile Ile Ser Pro Pro Asp Ser Ser Tyr Leu Ser Gly
                               595                               600                               605
Ala Asn Leu Asn Leu Ser Cys His Ser Ala Ser Asn Pro Ser Pro Gln
                               610                               615                               620
Tyr Ser Trp Arg Ile Asn Gly Ile Pro Gln Gln His Thr Gln Val Leu
625                               630                               635                               640
Phe Ile Ala Lys Ile Thr Pro Asn Asn Asn Gly Thr Tyr Ala Cys Phe
                               645                               650                               655
Val Ser Asn Leu Ala Thr Gly Arg Asn Asn Ser Ile Val Lys Ser Ile
                               660                               665                               670
Thr Val Ser Ala Ser Gly Thr Ser Pro Gly Leu Ser Ala Gly Ala Thr
                               675                               680                               685
Val Gly Ile Met Ile Gly Val Leu Val Gly Val Ala Leu Ile
690                               695                               700

```

<210> 593

<211> 2974

<212> DNA

<213> Homo sapiens

<400> 593

```

ctcagggcag agggaggaag gacagcagac cagacagtca cagcagcctt gacaaaacgt 60
tcctggaact caagctcttc tccacagagg aggacagagc agacagcaga gaccatggag 120
tctccctcgg cccctcccca cagatgggtgc atccccctggc agaggctcct gctcacagcc 180
tcactttctaa ccttctggaa cccgcccacc actgccaaagc tcactattga atccacgccg 240
ttcaatgtcg cagaggggaa ggaggtgctt ctacttgtcc acaatctgcc ccagcatctt 300
tttggctaca gctgttaca aggtgaaaga gtggatggca accgtcaaat tataggatat 360
gtaataggaa ctcaacaagc taccacaggg cccgcataca gtggtcgaga gataatatac 420
cccaatgcac ccctgctgat ccagaacatc atccagaatg acacaggatt ctacacccta 480
cacgtcataa agtcagatct tgtgaatgaa gaagcaactg gccagttccg ggtatacccg 540
gagctgcccc agcctcccat ctccagcaac aactccaaac cegtggagga caaggatgct 600
gtggccttca cctgtgaacc tgagactcag gacgcaacct acctgtggtg ggtaaacaat 660
cagagcctcc cggtcagtc caggctgcag ctgtccaatg gcaacaggac cctcactcta 720
ttcaatgtca caagaaatga cacagcaagc taaaaatgtg aaaccagaa cccagttagt 780
gccaggcgca gtgattcagt catcctgaat gtctctatg gcccgatgc cccaccatt 840
tcccctctaa acacatctta cagatcaggg gaaaatctga acctctcctg ccacgcagcc 900
tctaaccac ctgcacagta ctcttggtt gtcaatggga ctttccagca atccaccaa 960
gagctcttta tcccaacat cactgtgaat aatagtggat cctatacgtg ccaagcccat 1020
aactcagaca ctggcctcaa taggaccaca gtcacgacga tcacagtcta tgcagagcca 1080
cccaaaccct tcatcaccag caacaactcc aaccctgtg aggatgagga tgetgtagcc 1140
ttaacctgtg aacctgagat tcagaacaca acctacctgt ggtgggtaaa taatcagagc 1200
ctcccggtca gtcccaggct gcagctgtcc aatgacaaca ggacctcac tctactcagt 1260
gtcacaagga atgatgtagg accctatgag tgtggaatcc agaacgaatt aagtgttgac 1320
cacagcgacc cagtcatcct gaatgtcctc tatggcccag acgacccac catttcccc 1380
tcatacacct attaccgtcc aggggtgaac ctacgcctct cctgccatgc agcctctaac 1440
ccacctgcac agtattcttg gctgattgat gggaacatcc agcaacacac acaagagctc 1500
tttatctcca acatcactga gaagaacagc ggactctata cctgccaggc caataatca 1560
gccagtggcc acagcaggac tacagtcaag acaatcacag tctctgcgga gctgcccag 1620
ccctccatct ccagcaacaa ctccaaaccc gtggaggaca aggatgctgt ggccttcacc 1680
tgtgaacctg aggtcagaa cacaacctac ctgtggtggg taaatggtca gagcctccca 1740

```

```

gtcagtcacca ggetgcagct gtccaatggc aacaggaccc tcactctatt caatgtcaca 1800
agaaatgacg caagagccta tgtatgtgga atccagaact cagtgagtgc aaaccgcagt 1860
gaccagtcga ccctggatgt cctctatggg ccggacaccc ccatcatttc cccccagac 1920
tcgtcttacc ttctgggagc gaacctcaac ctctcctgcc actcggcctc taacccatcc 1980
ccgcagtatt cttggcgat caatgggata ccgcagcaac acacacaagt tctctttatc 2040
gccaaaatca cgccaaataa taacgggacc tatgcctggt ttgtctctaa cttggctact 2100
ggccgcaata attccatagt caagagcatc acagtctctg catctggaac ttctcctggt 2160
ctctcagctg gggccactgt cggcatcatg attggagtgc tggttggggt tgctctgata 2220
tagcagccct ggtgtagttt cttcatttca ggaagactga cagttgtttt gcttcttcct 2280
taaagcattt gcaacagcta cagtctaaaa ttgcttcttt accaaggata ttacagaaa 2340
agactctgac cagagatcga gaccatccta gccaacatcg tgaacccca tctctactaa 2400
aaatacaaaa atgagctggg cttgggtggc cgcacctgta gtcccagtta ctcgggaggc 2460
tgaggcagga gaatcgcttg aaccgggag gtggagattg cagtgagccc agatcgacc 2520
actgcactcc agtctggcaa cagagcaaga ctccatctca aaaagaaaag aaaagaagac 2580
tctgacctgt actcttgaat acaagtttct gataccactg cactgtctga gaatttccaa 2640
aactttaatg aactaactga cagcttcatg aaactgtcca ccaagatcaa gcagagaaaa 2700
taattaattt catgggacta aatgaactaa tgaggattgc tgattcttta aatgtcttgt 2760
ttcccagatt tcaggaaact ttttttcttt taagctatcc actcttacag caatttgata 2820
aaatatactt ttgtgaacaa aaattgagac atttacattt tctccctatg tggtcgctcc 2880
agacttggga aactattcat gaataattat attgtatggg aatatagtta ttgcacaagt 2940
tcaataaaaa tctgctcttt gtataacaga aaaa 2974

```

<210> 594

<211> 1255

<212> PRT

<213> Homo sapiens

<400> 594

```

Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
 1          5          10          15
Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys
 20          25          30
Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
 35          40          45
Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
 50          55          60
Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
 65          70          75          80
Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
 85          90          95
Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
100          105          110
Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
115          120          125
Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
130          135          140
Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
145          150          155          160
Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
165          170          175
Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
180          185          190
His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
195          200          205
Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
210          215          220
Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys

```

```

225          230          235          240
Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
          245          250          255
His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
          260          265          270
Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg
          275          280          285
Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu
          290          295          300
Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
305          310          315          320
Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
          325          330          335
Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu
          340          345          350
Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys
          355          360          365
Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp
          370          375          380
Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe
385          390          395          400
Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro
          405          410          415
Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg
          420          425          430
Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu
          435          440          445
Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly
          450          455          460
Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val
465          470          475          480
Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr
          485          490          495
Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His
          500          505          510
Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys
          515          520          525
Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys
          530          535          540
Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys
545          550          555          560
Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys
          565          570          575
Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp
          580          585          590
Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu
          595          600          605
Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln
          610          615          620
Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys
625          630          635          640
Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Val Ser
          645          650          655
Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly
          660          665          670
Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg
          675          680          685

```

```

Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly
690                               695                               700
Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu
705                               710                               715                               720
Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys
725                               730                               735
Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile
740                               745                               750
Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu
755                               760                               765
Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg
770                               775                               780
Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu
785                               790                               795                               800
Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg
805                               810                               815
Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly
820                               825                               830
Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala
835                               840                               845
Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe
850                               855                               860
Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp
865                               870                               875                               880
Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg
885                               890                               895
Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val
900                               905                               910
Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala
915                               920                               925
Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro
930                               935                               940
Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met
945                               950                               955                               960
Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe
965                               970                               975
Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu
980                               985                               990
Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu
995                               1000                               1005
Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu
1010                               1015                               1020
Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Ala Gly
1025                               1030                               1035                               1040
Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg Ser Gly Gly
1045                               1050                               1055
Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg
1060                               1065                               1070
Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly
1075                               1080                               1085
Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His
1090                               1095                               1100
Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu
1105                               1110                               1115                               1120
Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln
1125                               1130                               1135
Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro

```

1140	1145	1150
Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu		
1155	1160	1165
Arg Ala Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val		
1170	1175	1180
Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln		
1185	1190	1195
Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala		
1205	1210	1215
Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala		
1220	1225	1230
Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr		
1235	1240	1245
Leu Gly Leu Asp Val Pro Val		
1250	1255	

<210> 595

<211> 4530

<212> DNA

<213> Homo sapiens

<400> 595

```

aattctcgag ctcgtcgacc ggtcgacgag ctcgaggggtc gacgagctcg agggcgcgcg 60
ccccgcccc acccctcgca gcaccccgcg ccccgcgccc tcccagccgg gtccagccgg 120
agccatgggg ccggagccgc agtgagcacc atggagctgg cggccttggt ccgctggggg 180
ctcctctctcg ccatcttgcc ccccgagcc gcgagcacc aagtgtgcac cggcacagac 240
atgaagctgc ggctccctgc cagtcccgag acccacctgg acatgctccg ccacctctac 300
cagggtctgc aggtggtgca gggaaacctg gaactcacct acctgcccac caatgccagc 360
ctgtccttcc tgcaggatat ccaggaggtg cagggtacg tgctcatcgc tcacaaccaa 420
gtgaggcagg tcccactgca gaggtctcgg attgtgcgag gcacccagct ctttgaggac 480
aactatgccc tggccgtgct agacaatgga gaccgctga acaataccac ccctgtcac 540
ggggcctccc caggaggcct gcgggagctg cagcttcgaa gcctcacaga gatcttgaaa 600
ggagggggtct tgatccagcg gaacccccag ctctgctacc aggacacgat tttgtggaag 660
gacatcttcc acaagaacaa ccagctggct ctcacactga tagacaccaa ccgctctcgg 720
gcctgccacc cctgttctcc gatgtgtaag ggctcccgt gctggggaga gagttctgag 780
gattgtcaga gcctgacgcg cactgtctgt gccggtggct gtgcccgtg caaggggcca 840
ctgcccactg actgctgcca tgagcagtg gctgccggct gcacgggccc caagcactct 900
gactgcctgg cctgcctcca cttcaaccac agtggcatct gtgagctgca ctgcccagcc 960
ctggtcacct acaacacaga cacgtttgag tccatgcca atcccagggg ccggtataca 1020
ttcggcgcca gctgtgtgac tgctgtccc tacaactacc tttctacgga cgtgggatcc 1080
tgacccctcg tctgccccct gcacaaccaa gaggtgacag cagaggatgg aacacagcgg 1140
tgtgagaagt gcagcaagcc ctgtgcccga gtgtgctatg gtctgggcat ggagcacttg 1200
cgagagggtga gggcagttac cagtgcctaat atccaggagt ttgctggctg caagaagatc 1260
tttgggagcc tggcatttct gccggagagc tttgatgggg acccagcctc caacactgcc 1320
ccgctccagc cagagcagct ccaagtgttt gagactctgg aagagatcac aggttaccta 1380
tacatctcag catggcggga cagcctgcct gacctcagcg tcttcagaa cctgcaagta 1440
atccggggac gaattctgca caatggcgcc tactcgctga ccctgcaagg gctgggcatc 1500
agctggctgg ggctgcgctc actgagggaa ctgggcagtg gactggccct catccaccat 1560
aacacccacc tctgcttctg gcacacggtg ccctgggacc agctcttctg gaacccgac 1620
caagctctgc tccacactgc caacggcca gaggacgagt gtgtgggcca gggcctggcc 1680
tgccaccagc tgtgcgccc agggcactgc tggggtccag ggccaccca gtgtgtcaac 1740
tgcagccagt tccttcgggg ccaggagtgc gtggaggaat gccagtagt gcaggggctc 1800
cccaggagat atgtgaatgc caggcactgt ttgccgtgcc accctgagtg tcagccccag 1860
aatggctcag tgacctgttt tggaccggag gctgaccagt gtgtggcctg tgcccactat 1920
aaggaccctc ccttctgcgt ggcccgtgc cccagcgggtg tgaaacctga cctctctac 1980
atgcccatct ggaagtttcc agatgaggag ggcgcatgcc agccttgccc catcaactgc 2040

```

```

accactcct gtgtggacct ggatgacaag ggctgccccg ccgagcagag agccagccct 2100
ctgacgtcca tcgtctctgc ggtggttggc attctgctgg tcgtggtcct gggggtgggc 2160
tttgggatcc tcatcaagcg acggcagcag aagatccgga agtacacgat gcggagactg 2220
ctgcaggaaa cggagctggt ggagccgctg acacctagcg gagcgatgcc caaccaggcg 2280
cagatgcgga tcctgaaaga gacggagctg aggaaggtga aggtgcttgg atctggcgct 2340
tttggcacag tctacaaggg catctggatc cctgatgggg agaattgtgaa aattccagt 2400
gccatcaaag tgttgaggga aaacacatcc cccaaagcca acaaagaaat cttagacgaa 2460
gcatacgtga tggctggtgt gggctcccca tatgtctccc gccttctggg catctgcctg 2520
acatccacgg tgcagctggt gacacagctt atgccctatg gctgcctcct agaccatgtc 2580
cgggaaaacc gcggagcgct gggctcccag gacctgctga actggtgtat gcagattgcc 2640
aaggggatga gtacctgga ggatgtgcgg ctctacaca gggacttggc cgctcggaac 2700
gtgctgggtc agagtcccaa ccatgtcaaa attacagact tcgggctggc tcggctgctg 2760
gacattgacg agacagagta ccatgcagat gggggcaagg tgcccatcaa gtggatggcg 2820
ctggagtcga ttctccgccc gcggttcacc caccagagtg atgtgtggag ttatggtgtg 2880
actgtgtggg agctgatgac ttttggggcc aaaccttacg atgggatccc agcccgggag 2940
atccctgacc tgctggaaaa gggggagcgg ctgcccagc ccccatctg caccattgat 3000
gtctacatga tcatgggtcaa atgttggatg attgactctg aatgtcggcc aagattccgg 3060
gagttggtgt ctgaattctc ccgcatggcc agggaccccc agcgctttgt ggtcatccag 3120
aatgaggact tgggcccagc cagtcccttg gacagcacct tctaccgctc actgctggag 3180
gacgatgaca tgggggacct ggtggatgct gaggagtatc tggtagccca gcagggtctc 3240
ttctgtccag accctgcccc gggcgctggg ggcattggtc accacaggca ccgcagctca 3300
tctaccagga gtggcggtgg ggacctgaca ctaggctgg agccctctga agaggaggcc 3360
cccaggtctc cactggcacc ctccgaaggg gctggctccg atgtatttga tggtagacct 3420
ggaatggggg cagccaaggg gctgcaaagc ctcccacac atgaccccag ccctctacag 3480
cgtacagtg aggacccac agtaccctg ccctctgaga ctgatggcta cgttgcctcc 3540
ctgacctgca gccccagcc tgaatatgtg aaccagccag atgttcggcc ccagccccct 3600
tcgccccgag agggccctct gctgtctgcc cgacctgtg gtgccactct ggaaagggcc 3660
aagactctct cccagggaa gaatggggtc gtcaaagacg tttttgcctt tgggggtgcc 3720
gtggagaacc ccgagtactt gacaccccag ggaggagctg cccctcagcc ccacctcct 3780
cctgccttca gccagcctt cgacaacctc tattactggg accaggacce accagagcgg 3840
ggggtccac ccagcacctt caaagggaca cctacggcag agaaccaga gtacctgggt 3900
ctggacgtgc cagtgtgaac cagaaggcca agtccgcaga agccctgatg tgtcctcagg 3960
gagcagggaa ggctgactt ctgctggcat caagagtgga gagggccctc cgaccattc 4020
caggggaacc tgccatgcca ggaacctgtc ctaagggaacc ttcttctctg cttgagttcc 4080
cagatggctg gaaggggtcc agcctcgttg gaagaggaa agcactgggg agtctttgtg 4140
gattctgagg ccctgccc aa tgagactcta ggggtccagt gatgccacag ccagcttgg 4200
ccctttcctt ccagatcctg ggtactgaaa gccttaggga agctggcctg agaggggaa 4260
cggccctaag ggagtgtcta agaacaaaag cgaccattc agagactgtc cctgaaacct 4320
agtactgccc cccatgagga aggaacagca atggtgtcag tatccaggct ttgtacagag 4380
tgcttttctg tttagttttt actttttttt ttttgtttt ttaaagacga aataaagacc 4440
caggggagaa tgggtgttgt atggggaggc aagtgtgggg ggtccttctc cacaccact 4500
ttgtccattt gcaaatatat tttgaaaac 4530

```

<210> 596

<211> 976

<212> PRT

<213> Homo sapiens

<400> 596

```

Met Glu Lys Gln Lys Pro Phe Ala Leu Phe Val Pro Pro Arg Ser Ser
 1              5              10              15
Ser Ser Gln Val Ser Ala Val Lys Pro Gln Thr Leu Gly Gly Asp Ser
              20              25              30
Thr Phe Phe Lys Ser Phe Asn Lys Cys Thr Glu Asp Asp Leu Glu Phe
              35              40              45
Pro Phe Ala Lys Thr Asn Leu Ser Lys Asn Gly Glu Asn Ile Asp Ser
 50              55              60

```

```

Asp Pro Ala Leu Gln Lys Val Asn Phe Leu Pro Val Leu Glu Gln Val
65          70          75          80
Gly Asn Ser Asp Cys His Tyr Gln Glu Gly Leu Lys Asp Ser Asp Leu
      85          90          95
Glu Asn Ser Glu Gly Leu Ser Arg Val Phe Ser Lys Leu Tyr Lys Glu
      100        105        110
Ala Glu Lys Ile Lys Lys Trp Lys Val Ser Thr Glu Ala Glu Leu Arg
      115        120        125
Gln Lys Glu Ser Lys Leu Gln Glu Asn Arg Lys Ile Ile Glu Ala Gln
      130        135        140
Arg Lys Ala Ile Gln Glu Leu Gln Phe Gly Asn Glu Lys Val Ser Leu
145          150        155        160
Lys Leu Glu Glu Gly Ile Gln Glu Asn Lys Asp Leu Ile Lys Glu Asn
      165        170        175
Asn Ala Thr Arg His Leu Cys Asn Leu Leu Lys Glu Thr Cys Ala Arg
      180        185        190
Ser Ala Glu Lys Thr Lys Lys Tyr Glu Tyr Glu Arg Glu Glu Thr Arg
      195        200        205
Gln Val Tyr Met Asp Leu Asn Asn Asn Ile Glu Lys Met Ile Thr Ala
210          215        220
His Gly Glu Leu Arg Val Gln Ala Glu Asn Ser Arg Leu Glu Met His
225          230        235        240
Phe Lys Leu Lys Glu Asp Tyr Glu Lys Ile Gln His Leu Glu Gln Glu
      245        250        255
Tyr Lys Lys Glu Ile Asn Asp Lys Glu Lys Gln Val Ser Leu Leu Leu
      260        265        270
Ile Gln Ile Thr Glu Lys Glu Asn Lys Met Lys Asp Leu Thr Phe Leu
      275        280        285
Leu Glu Glu Ser Arg Asp Lys Val Asn Gln Leu Glu Glu Lys Thr Lys
290          295        300
Leu Gln Ser Glu Asn Leu Lys Gln Ser Ile Glu Lys Gln His His Leu
305          310        315        320
Thr Lys Glu Leu Glu Asp Ile Lys Val Ser Leu Gln Arg Ser Val Ser
      325        330        335
Thr Gln Lys Ala Leu Glu Glu Asp Leu Gln Ile Ala Thr Lys Thr Ile
      340        345        350
Cys Gln Leu Thr Glu Glu Lys Glu Thr Gln Met Glu Glu Ser Asn Lys
      355        360        365
Ala Arg Ala Ala His Ser Phe Val Val Thr Glu Phe Glu Thr Thr Val
370          375        380
Cys Ser Leu Glu Glu Leu Leu Arg Thr Glu Gln Gln Arg Leu Glu Lys
385          390        395        400
Asn Glu Asp Gln Leu Lys Ile Leu Thr Met Glu Leu Gln Lys Lys Ser
      405        410        415
Ser Glu Leu Glu Glu Met Thr Lys Leu Thr Asn Asn Lys Glu Val Glu
      420        425        430
Leu Glu Glu Leu Lys Lys Val Leu Gly Glu Lys Glu Thr Leu Leu Tyr
      435        440        445
Glu Asn Lys Gln Phe Glu Lys Ile Ala Glu Glu Leu Lys Gly Thr Glu
450          455        460
Gln Glu Leu Ile Gly Leu Leu Gln Ala Arg Glu Lys Glu Val His Asp
465          470        475        480
Leu Glu Ile Gln Leu Thr Ala Ile Thr Thr Ser Glu Gln Tyr Tyr Ser
      485        490        495
Lys Glu Val Lys Asp Leu Lys Thr Glu Leu Glu Asn Glu Lys Leu Lys
500          505        510
Asn Thr Glu Leu Thr Ser His Cys Asn Lys Leu Ser Leu Glu Asn Lys

```


515				520				525							
Glu	Leu	Thr	Gln	Glu	Thr	Ser	Asp	Met	Thr	Leu	Glu	Leu	Lys	Asn	Gln
530				535				540							
Gln	Glu	Asp	Ile	Asn	Asn	Asn	Lys	Lys	Gln	Glu	Glu	Arg	Met	Leu	Lys
545	550				555				560						
Gln	Ile	Glu	Asn	Leu	Gln	Glu	Thr	Glu	Thr	Gln	Leu	Arg	Asn	Glu	Leu
565				570				575							
Glu	Tyr	Val	Arg	Glu	Glu	Leu	Lys	Gln	Lys	Arg	Asp	Glu	Val	Lys	Cys
580				585				590							
Lys	Leu	Asp	Lys	Ser	Glu	Glu	Asn	Cys	Asn	Asn	Leu	Arg	Lys	Gln	Val
595				600				605							
Glu	Asn	Lys	Asn	Lys	Tyr	Ile	Glu	Glu	Leu	Gln	Gln	Glu	Asn	Lys	Ala
610				615				620							
Leu	Lys	Lys	Lys	Gly	Thr	Ala	Glu	Ser	Lys	Gln	Leu	Asn	Val	Tyr	Glu
625	630				635				640						
Ile	Lys	Val	Asn	Lys	Leu	Glu	Leu	Glu	Leu	Glu	Ser	Ala	Lys	Gln	Lys
645				650				655							
Phe	Gly	Glu	Ile	Thr	Asp	Thr	Tyr	Gln	Lys	Glu	Ile	Glu	Asp	Lys	Lys
660				665				670							
Ile	Ser	Glu	Glu	Asn	Leu	Leu	Glu	Glu	Val	Glu	Lys	Ala	Lys	Val	Ile
675				680				685							
Ala	Asp	Glu	Ala	Val	Lys	Leu	Gln	Lys	Glu	Ile	Asp	Lys	Arg	Cys	Gln
690	695				700				705						
His	Lys	Ile	Ala	Glu	Met	Val	Ala	Leu	Met	Glu	Lys	His	Lys	His	Gln
705	710				715				720						
Tyr	Asp	Lys	Ile	Ile	Glu	Glu	Arg	Asp	Ser	Glu	Leu	Gly	Leu	Tyr	Lys
725				730				735							
Ser	Lys	Glu	Gln	Gln	Ser	Ser	Leu	Arg	Ala	Ser	Leu	Glu	Ile	Glu	
740				745				750							
Leu	Ser	Asn	Leu	Lys	Ala	Glu	Leu	Leu	Ser	Val	Lys	Lys	Gln	Leu	Glu
755				760				765							
Ile	Glu	Arg	Glu	Glu	Lys	Glu	Lys	Leu	Lys	Arg	Glu	Ala	Lys	Glu	Asn
770	775				780				785						
Thr	Ala	Thr	Leu	Lys	Glu	Lys	Lys	Asp	Lys	Lys	Thr	Gln	Thr	Phe	Leu
785	790				795				800						
Leu	Glu	Thr	Pro	Glu	Ile	Tyr	Trp	Lys	Leu	Asp	Ser	Lys	Ala	Val	Pro
805				810				815							
Ser	Gln	Thr	Val	Ser	Arg	Asn	Phe	Thr	Ser	Val	Asp	His	Gly	Ile	Ser
820				825				830							
Lys	Asp	Lys	Arg	Asp	Tyr	Leu	Trp	Thr	Ser	Ala	Lys	Asn	Thr	Leu	Ser
835				840				845							
Thr	Pro	Leu	Pro	Lys	Ala	Tyr	Thr	Val	Lys	Thr	Pro	Thr	Lys	Pro	Lys
850				855				860							
Leu	Gln	Gln	Arg	Glu	Asn	Leu	Asn	Ile	Pro	Ile	Glu	Glu	Ser	Lys	Lys
865	870				875				880						
Lys	Arg	Lys	Met	Ala	Phe	Glu	Phe	Asp	Ile	Asn	Ser	Asp	Ser	Ser	Glu
885				890				895							
Thr	Thr	Asp	Leu	Leu	Ser	Met	Val	Ser	Glu	Glu	Glu	Thr	Leu	Lys	Thr
900				905				910							
Leu	Tyr	Arg	Asn	Asn	Asn	Pro	Pro	Ala	Ser	His	Leu	Cys	Val	Lys	Thr
915				920				925							
Pro	Lys	Lys	Ala	Pro	Ser	Ser	Leu	Thr	Thr	Pro	Gly	Pro	Thr	Leu	Lys
930				935				940							
Phe	Gly	Ala	Ile	Arg	Lys	Met	Arg	Glu	Asp	Arg	Trp	Ala	Val	Ile	Ala
945	950				955				960						
Lys	Met	Asp	Arg	Lys	Lys	Lys	Leu	Lys	Glu	Ala	Glu	Lys	Leu	Phe	Val
965				970				975							

<210> 597
 <211> 3393
 <212> DNA
 <213> Homo sapiens

<400> 597
 gccctcatag accgtttgtt gtagttcgcg tgggaacagc aaccacacggt ttcccgatag 60
 ttcttcaaaag atattttacaa ccgtaacaga gaaaatggaa aagcaaaaagc cttttgcatt 120
 gttcgtacca ccgagatcaa gcagcagtcg ggtgtctgcg gtgaaacctc agaccctggg 180
 aggcgattcc actttcttca agagtttcaa caaatgtact gaagatgatt tggagtttcc 240
 atttgcгааг actaatctct ccaaaaatgg ggaaaacatt gattcagatc ctgctttaca 300
 aaaagttaat ttcttgcccc tgcttgagca ggttggtaat tctgactgtc actatcagga 360
 aggactaaaa gactctgatt tggagaattc agagggattg agcagagtgt tttcaaaact 420
 gtataaggag gctgaaaaga taaaaaatg gaaagtaagt acagaagctg aactgagaca 480
 gaaagaaagt aagttgcaag aaaacagaaa gataattgaa gcacagcgaa aagccattca 540
 ggaactgcaa tttggaaatg aaaaagtaag tttgaaatta gaagaaggaa tacaagaaaa 600
 taaagattta ataaaagaga ataatgccac aaggcattta tgtaatctac tcaaagaaac 660
 ctgtgctaga tctgcagaaa agacaaagaa atatgaatat gaacgggaag aaaccaggca 720
 agtttatatg gatctaaata ataacattga gaaaatgata acagctcatg gggaacttcg 780
 tgtgcaagct gagaattcca gactggaaat gcattttaag ttaaaggaag attatgaaaa 840
 aatccaacac cttgaacaag aatacaagaa ggaaataaat gacaaggaaa agcaggtatc 900
 actactattg atccaaatca ctgagaaaaga aaataaaatg aaagatttaa cttttctgct 960
 agaggaatcc agagataaag ttaatcaatt agaggaaaag acaaaattac agagtgaaaa 1020
 cttaaaacaa tcaattgaga aacagcatca tttgactaaa gaactagaag atattaaagt 1080
 gtcattacaa agaagtgtga gtactcaaaa ggcttttagag gaagatttac agatagcaac 1140
 aaaaacaatt tctcagctaa ctgaagaaaa agaaactcaa atggaagaat ctaataaagc 1200
 tagagctgct cattcgtttg tggttactga atttgaaact actgtctgca gcttggaaaga 1260
 attattgaga acagaacagc aaagattgga aaaaaatgaa gatcaattga aaatacttac 1320
 catggagctt caaaagaaat caagtgcgct ggaagagatg actaagctta caaataacaa 1380
 agaagttaga cttgaagaat tgaaaaaagt cttgggagaa aaggaaaacac ttttatatga 1440
 aaataaaciaa tttgagaaga ttgctgaaga attaaaagga acagaacaag aactaattgg 1500
 tcttctccaa ccagagagaga aagaagtaca tgatttgga atacagttaa ctgccattac 1560
 cacaagtga cagtattatt caaaagaggt taaagatcta aaaactgagc ttgaaaacga 1620
 gaagcttaag aatactgaat taacttcaca ctgcaacaag ctttacttag aaaacaaaga 1680
 gctcacacag gaaacaagt atatgacctt agaactcaag aatcagcaag aagatattaa 1740
 taataacaaa aagcaagaag aaaggatgtt gaaacaata gaaaatcttc aagaaacaga 1800
 aaccaatta agaaatgaac tagaatatgt gagagaagag ctaaaacaga aaagagatga 1860
 agttaaatgt aaattggaca agagtgaaga aaattgtaac aatttaagga aacaagttga 1920
 aaataaaaac aagtatattg aagaacttca gcaggagaat aaggccttga aaaaaaaagg 1980
 tacagcagaa agcaagcaac tgaatgttta tgagataaag gtcaataaat tagagttaga 2040
 actagaaagt gccaaacaga aatttgagaa aatcacagac acctatcaga aagaaattga 2100
 ggacaaaaag atatcagaag aaaatctttt ggaagagggt gagaaagcaa aagtaatagc 2160
 tgatgaagca gtaaaattac agaaagaaat tgataagcga tgtcaacata aaatagctga 2220
 aatggttagc cttatggaaa aacataagca ccaatatgat aagatcattg aagaaagaga 2280
 ctcaagaatta ggactttata agagcaaaga acaagaacag tcatcactga gagcatcttt 2340
 ggagattgaa ctatccaatc tcaaagctga acttttgtct gttagaagac aacttgaaat 2400
 agaaagagaa gagaaggaaa aactcaaaag agaggcaaaa gaaaacacag ctactcttaa 2460
 agaaaaaaa gacaagaaaa cacaacatt tttattggaa acacctgaaa tttattggaa 2520
 attggattct aaagcagttc cttcacaaac tgtatctoga aatttcacat cagttgatca 2580
 tggcatatcc aaagataaaa gagactatct gtggacatct gccaaaaata ctttatctac 2640
 accattgcca aaggcatata cagtgaagac accaacaata ccaaaactac agcaaagaga 2700
 aaacttgaat ataccattg aagaaagtta aaaaagaga aaaatggcct ttgaatttga 2760
 tattaattca gatagttcag aaactactga tcttttgagc atggtttcag aagaagagac 2820
 attgaaaaca ctgtatagga acaataatcc accagcttct catctttgtg tcaaaacacc 2880
 aaaaaaggcc cttcatctc taacaacccc tggacctaca ctgaagtttg gagctataag 2940

```

aaaaatgCGG gagGaccgtt gggctgtaat tgctaaaatg gatagaaaaa aaaaactaaa 3000
agaagctgaa aagttatttg ttttaatttca gagaatcagt gtagttaagg agcctaataa 3060
cgtgaaactt atagttaata ttttgttctt atttgccaga gccacatttt atctggaagt 3120
tgagacttaa aaaatacttg catgaatgat ttgtgtttct ttatatattt agcctaaatg 3180
ttaactacat attgtctgga aacctgtcat tgtattcaga taattagatg attatatatt 3240
gttggttactt tttcttgat tcatgaaaac tgtttttact aagttttcaa atttgtaaag 3300
ttagcctttg aatgctagga atgcattatt gagggtcatt ctttattctt tactattaaa 3360
atattttgga tgcaaaaaaa aaaaaaaaaa aaa 3393

```

<210> 598

<211> 188

<212> PRT

<213> Homo sapiens

<400> 598

```

Met Asn Gly Asp Asp Ala Phe Ala Arg Arg Pro Arg Asp Asp Ala Gln
1          5          10          15
Ile Ser Glu Lys Leu Arg Lys Ala Phe Asp Asp Ile Ala Lys Tyr Phe
20        25        30
Ser Lys Lys Glu Trp Glu Lys Met Lys Ser Ser Glu Lys Ile Val Tyr
35        40        45
Val Tyr Met Lys Leu Asn Tyr Glu Val Met Thr Lys Leu Gly Phe Lys
50        55        60
Val Thr Leu Pro Pro Phe Met Arg Ser Lys Arg Ala Ala Asp Phe His
65        70        75        80
Gly Asn Asp Phe Gly Asn Asp Arg Asn His Arg Asn Gln Val Glu Arg
85        90        95
Pro Gln Met Thr Phe Gly Ser Leu Gln Arg Ile Phe Pro Lys Ile Met
100       105       110
Pro Lys Lys Pro Ala Glu Glu Glu Asn Gly Leu Lys Glu Val Pro Glu
115       120       125
Ala Ser Gly Pro Gln Asn Asp Gly Lys Gln Leu Cys Pro Pro Gly Asn
130       135       140
Pro Ser Thr Leu Glu Lys Ile Asn Lys Thr Ser Gly Pro Lys Arg Gly
145       150       155       160
Lys His Ala Trp Thr His Arg Leu Arg Glu Arg Lys Gln Leu Val Val
165       170       175
Tyr Glu Glu Ile Ser Asp Pro Glu Glu Asp Asp Glu
180       185

```

<210> 599

<211> 576

<212> DNA

<213> Homo sapiens

<400> 599

```

atgaacggag acgacgcctt tgcaaggaga cccaggggatg atgctcaa atcagagaag 60
ttacgaaagg ccttogatga tattgccaaa tacttctcta agaaagagtg ggaaaagatg 120
aaatcctcgg agaaaatcgt ctatgtgtat atgaagctaa actatgaggt catgactaaa 180
ctaggtttca aggtcaccct cccaccttct atgcgtagta aacgggctgc agacttccac 240
gggaatgatt ttggtaacga tcgaaaccac aggaatcagg ttgaacgtcc tcagatgact 300
ttcggcagcc tccagagaat cttcccgaag atcatgcccc agaagccagc agaggaagaa 360
aatggtttga aggaagtgcc agaggcatct ggccccaaaa atgatgggaa acagctgtgc 420
cccccgggaa atccaagtac cttggagaag attacaaga catctggacc caaaaggggg 480
aaacatgcct ggaccacag actgcgtgag agaaagcagc tgggtggttta tgaagagatc 540
agcgaccctg aggaagatga cgagtaactc ccctcg 576

```

<210> 600
 <211> 262
 <212> PRT
 <213> Homo sapiens

<400> 600
 Met Trp Phe Leu Val Leu Cys Leu Ala Leu Ser Leu Gly Gly Thr Gly
 1 5 10 15
 Ala Ala Pro Pro Ile Gln Ser Arg Ile Val Gly Gly Trp Glu Cys Glu
 20 25 30
 Gln His Ser Gln Pro Trp Gln Ala Ala Leu Tyr His Phe Ser Thr Phe
 35 40 45
 Gln Cys Gly Gly Ile Leu Val His Arg Gln Trp Val Leu Thr Ala Ala
 50 55 60
 His Cys Ile Ser Asp Asn Tyr Gln Leu Trp Leu Gly Arg His Asn Leu
 65 70 75 80
 Phe Asp Asp Glu Asn Thr Ala Gln Phe Val His Val Ser Glu Ser Phe
 85 90 95
 Pro His Pro Gly Phe Asn Met Ser Leu Leu Glu Asn His Thr Arg Gln
 100 105 110
 Ala Asp Glu Asp Tyr Ser His Asp Leu Met Leu Leu Arg Leu Thr Glu
 115 120 125
 Pro Ala Asp Thr Ile Thr Asp Ala Val Lys Val Val Glu Leu Pro Thr
 130 135 140
 Gln Glu Pro Glu Val Gly Ser Thr Cys Leu Ala Ser Gly Trp Gly Ser
 145 150 155 160
 Ile Glu Pro Glu Asn Phe Ser Phe Pro Asp Asp Leu Gln Cys Val Asp
 165 170 175
 Leu Lys Ile Leu Pro Asn Asp Glu Cys Glu Lys Ala His Val Gln Lys
 180 185 190
 Val Thr Asp Phe Met Leu Cys Val Gly His Leu Glu Gly Gly Lys Asp
 195 200 205
 Thr Cys Val Gly Asp Ser Gly Gly Pro Leu Met Cys Asp Gly Val Leu
 210 215 220
 Gln Gly Val Thr Ser Trp Gly Tyr Val Pro Cys Gly Thr Pro Asn Lys
 225 230 235 240
 Pro Ser Val Ala Val Arg Val Leu Ser Tyr Val Lys Trp Ile Glu Asp
 245 250 255
 Thr Ile Ala Glu Asn Ser
 260

<210> 601
 <211> 269
 <212> PRT
 <213> Homo sapiens

<400> 601
 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser
 1 5 10 15
 Cys Gly Asp Pro Thr Tyr Pro Pro Tyr Val Thr Arg Val Val Gly Gly
 20 25 30
 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr
 35 40 45
 Ser Ser Asn Gly Lys Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala
 50 55 60

```

Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Arg Thr
65          70          75          80
Tyr Arg Val Gly Leu Gly Arg His Asn Leu Tyr Val Ala Glu Ser Gly
          85          90          95
Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn
          100          105          110
Ser Asn Gln Ile Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala
          115          120          125
Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro
          130          135          140
Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp
145          150          155          160
Gly Arg Leu Gln Thr Asn Gly Ala Val Pro Asp Val Leu Gln Gln Gly
          165          170          175
Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Ala Trp Trp
          180          185          190
Gly Ser Ser Val Lys Thr Ser Met Ile Cys Ala Gly Gly Asp Gly Val
          195          200          205
Ile Ser Ser Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala
          210          215          220
Ser Asp Gly Arg Trp Gln Val His Gly Ile Val Ser Phe Gly Ser Arg
225          230          235          240
Leu Gly Cys Asn Tyr Trp His Lys Pro Ser Val Phe Thr Arg Val Ser
          245          250          255
Asn Tyr Ile Asp Trp Ile Asn Ser Val Ile Ala Asn Asn
          260          265

```

<210> 602

<211> 269

<212> PRT

<213> Homo sapiens

<400> 602

```

Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser
1          5          10          15
Cys Gly Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly
          20          25          30
Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr
          35          40          45
Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala
          50          55          60
Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Arg Ile
65          70          75          80
Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly
          85          90          95
Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn
          100          105          110
Ser Asn Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala
          115          120          125
Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro
          130          135          140
Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp
145          150          155          160
Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly
          165          170          175
Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp

```

137

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081646 A3

(51) International Patent Classification⁷: **A61K 38/02**,
38/16, 39/00, 45/00, 47/00, 39/395, C07K 1/00, 16/00,
C12N 15/00, 15/70, C07H 21/04

(21) International Application Number: PCT/US02/11101

(22) International Filing Date: 4 April 2002 (04.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/282,211 6 April 2001 (06.04.2001) US
60/337,017 7 November 2001 (07.11.2001) US
60/363,210 7 March 2002 (07.03.2002) US

(71) Applicant: **MANKIND CORPORATION** [US/US];
9340 DeSoto Avenue, Chatsworth, CA 91311 (US).

(72) Inventors: **SIMARD, John, J.L.**; 11918 Laughton Way,
Northridge, CA 91326 (US). **DIAMOND, David, C.**;
23135 Schoenborn Street, West Hills, CA 91304 (US).
LIU, Liping; 22228 Victory Blvd., H-111, Woodland
Hills, CA 91367 (US). **XIE, Zhidong**; 22228 Victory
Blvd., H-111, Woodland Hills, CA 91367 (US).

(74) Agent: **REISMAN, Joseph, M.**; Knobbe, Martens, Olson
& Bear, LLP, 16th Floor, 620 Newport Center Drive, New-
port Beach, CA 92660 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-
ity model), DE, DK, DM, DZ, EC, EE (utility model), EE,
ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility
model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
17 July 2003

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/081646 A3

(54) Title: EPITOPE SEQUENCES

(57) Abstract: Disclosed herein are polypeptides, including epitopes, clusters, and antigens. Also disclosed are compositions that include said polypeptides and methods for their use.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/11101

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/02, 38/16, 39/00, 45/00, 47/00, 39/395; C07K 1/00, 16/00; C12N 15/00, 15/70; C07H 21/04
 US CL : 424/93.71, 130.1, 185.1, 278.1, 193.1; 435/7.1, 252.3, 320.1, 326; 530/324, 328, 387.1; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.71, 130.1, 185.1, 278.1, 193.1; 435/7.1, 252.3, 320.1, 326; 530/324, 328, 387.1; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,487,974 A (BOON-FALLEUR et al) 30 January 1996 (30.01.1996), entire document.	1-74, 76-82
Y	US 5,744,316 A (LETHE et al) 28 April 1998 (28.04.1998), entire document.	1-74, 76-82
Y	RAMMENSEE et al. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995, Vol. 41, pages 178-228, entire article, especially page 193.	1-74, 76-82
Y	WO 97/41440 A1 (RIJKSUNIVERSITEIT TE LEIDEN) 06 November 1997 (06.11.1997), entire document.	1-82
Y	WO 99/45954 A1 (EPIMMUNE INC.) 16 September 1999 (16.09.1999), entire document.	1-82

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

28 February 2003 (28.02.2003)

Date of mailing of the international search report

26 MAR 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Felicia D. Roberts for
 Marianne DiBrino, Ph.D.

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

PCT/US02/11101

Continuation of B. FIELDS SEARCHED Item 3:

WEST 2.1, STN(EMBASE, BIOSIS, MEDLINE, CAPLUS, SCISEARCH)

search terms: inventors' names, tyrosinase, hla-a2, apc, housekeeping, ctl, antibodies, nucleic, ires, iss, nis, ubiquitin, flpwhrlfl
protein databases (SPTREMBL_21, A_GENESEQ_101002, PIR_73, SWISSPROT_40)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.